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Abstract 
 
The classical actions of vitamin D are to maintain bone health but vitamin D receptors are 
also expressed in several other tissues including the vascular system. The epidemiological 
evidence supports the associations between vitamin D status and vascular health but it is still 
uncertain whether the inadequate vitamin D status represents a risk factor for cardiovascular 
diseases (CVD). Nitric oxide (NO) is a soluble gas synthesized from the amino acid L-
arginine and plays an important role in maintaining vascular homeostasis. A reduced NO 
availability is an important hallmark of endothelial dysfunction, which is closely linked to the 
development of atherosclerosis and is an independent risk factor for cardiovascular events. 
Vitamin D may be involved in the maintenance of endothelial function (EF) through 
regulation of endothelium nitric oxide synthase (eNOS) activity which enhanced NO 
synthesis. This PhD project investigated the association between vitamin D intake and status, 
endothelial function and biomarkers of NO availability. In the first phase of the PhD, a 
systematic review and meta-analysis of randomized clinical trials was conducted to 
investigating the effects of vitamin D supplementation on EF. Overall, this showed no 
improvement of EF after vitamin D supplementation but there was evidence of positive 
effects in obese individuals and in diabetic patients. Next, a cross sectional study in post-
menopausal overweight and obese women was conducted to evaluate the associations 
between vitamin D status and physiological and circulating biomarkers of EF. The study 
revealed increased pulse wave velocity (PWV), a marker of arterial stiffness, and higher 
concentrations of asymmetric dimethylarginine (ADMA, a marker of NO availability) in 
those women with vitamin D concentrations < 30 nmol/L. Detailed laboratory experiments 
were also conducted as part of this project to improve the measurement of concentrations of 
NO3
- and NO2
- in plasma and urine using ozone-based chemiluminescence. The final phase 
of the project investigated the association between whole-body NO availability (measured by 
a non-invasive stable-isotopic method), PWV, ADMA and vitamin D status and whether 
these associations were modified by age. The study did not find a significant association of 
NO production with vitamin D. However, NO production was significantly lower in older 
individuals and was significantly associated with systolic blood pressure and PWV. 
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Structure of the Thesis 
 
The first chapter of this thesis provides an introduction to the physiological role of endothelial 
function (EF) and vitamin D in health and diseases, and contribution to the pathogenesis of 
cardiovascular disease (CVD). I also discussed about the function of nitric oxide (NO) and 
the mechanistic link between vitamin D and NO pathway and how they influence vascular 
health. 
In the second chapter, I conducted a systematic review and meta-analysis of randomised 
controlled clinical trials which examined the effects of vitamin D supplementation on 
physiological measures of EF (flow mediated dilatation, forearm blood flow, microvascular 
blood flow, pulse wave velocity and augmentation index). 
In the third chapter, I discussed about various methods of measurements of NO production, 
and the advantage and disadvantages of each method. I also discussed about the measurement 
of biomarkers of EF in biological samples including the methods to measure nitrate 
concentrations using three methods (chemiluminescence, Griess and Gas Chromatography 
Mass Spectrometry (GCMS).  The last part of this chapter was dedicated for the comparison 
of chemiluminescence vs griess methods for the measurement of nitrate/nitrite in biological 
samples. A validation study was also done for the analysis of serum vitamin D using dry 
blood spots (DBS) and conventional methods (assays on serum collected by venepuncture). 
In chapter four, I reported the results of a cross sectional study on the association of vitamin 
D with physiological and biochemical markers of endothelial function in overweight and 
obese post-menopausal women. 
In the fifth chapter, I report the result on the association between whole-body NO production 
with vitamin D. In this study, I investigated the association between age, whole-body NO 
production and vascular health in healthy young and old men and women. In addition, I 
investigated for the first time the association between whole-body NO production and vitamin 
D status measured by a novel, non-invasive method using stable isotope tracers.  
In the final chapter, I provide a synthesis and a general discussion of the main findings, 
highlight the strengths and limitations of the current work and the recommendations for future 
research. 
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Chapter 1. Introduction 
1.1 Cardiovascular disease  
Cardiovascular disease (CVD) is a term used to describe problems related to the functions of 
the heart and circulation. CVD emerged as a major public health concern in economically-
developed countries in the 20th century (Dalen et al., 2014),  and remain associated with an 
enormous burden of mortality and morbidity worldwide (Frayn and Stanner, 2008). It is 
estimated that in 2030, there will be 23.6 million deaths due CVD (Cannon, 2013). CVD can 
be divided into four main types, depending on the location of the main deterioration in the 
vascular system which affects blood supply to the heart [coronary heart disease (CHD)], brain 
[stroke] and peripheral arteries [peripheral arterial disease, (PAD)] or aorta [aortic 
aneurysm](Cannon, 2013). 
1.1.1 Coronary heart disease  
CHD and coronary artery disease (CAD) are two terms that are often used interchangeably. 
However, CHD is a result of CAD, which is related to the accumulation of plaque in the walls 
of the coronary arteries that result in the thickening in the walls and limitation of the blood 
flow to the heart which leads to CHD (Figure 1. 1) (Dahlof, 2010).  
 
Figure 1. 1: The accumulation of plaque causes narrowing of the artery, limiting the 
blood flow to the heart, and leads to CHD. 
Taken from (National Heart and Lung and Blood Institute, 2016a) 
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The process of vascular wall thickening is called atherosclerosis. Atherosclerosis is the 
hardening of the innermost layer of the artery, the intima, and results from the accumulation of 
cells, connective-tissue elements, lipids and debris which forms an atheromatous plaque (Lavie 
et al., 2013). This plaque may obstruct blood supply to the myocardium causing symptoms of 
pain on exertion (angina). Occasionally, the plaque may rupture and thrombosis may lead to 
complete blockage of blood supply to, and death of the corresponding cardiac muscle 
(myocardial infarction) (Dahlof, 2010).                           
1.1.2 Cerebrovascular disease 
Cerebrovascular disease is caused by insufficient supply of blood to the brain as the 
consequence of obstruction in, or rupture of, the relevant blood vessels (Elesber et al., 2006).  
There are a number of different types of cerebrovascular disease and the four most well-known 
are: 
1) Stroke – the condition where one part of the brain is damaged by the lack of blood 
supply or bleeding into the brain from a burst blood vessel. 
2) Transient ischaemic attack (TIA) – the condition where blood supply to one part of 
brain has failed temporarily and which results in similar symptoms to stroke.   
3) Subarachnoid haemorrhage – a type of stroke where blood leaks out of the brain's 
blood vessels on to the surface of the brain.  
4) Vascular dementia – characterised as persistent impairment in mental (cognitive) 
ability as a consequence of stroke or other problems related with blood circulation 
to the brain. 
1.1.3 Peripheral arterial disease  
Peripheral arterial disease (PAD), also known as peripheral vascular disease, is the condition 
where the accumulation of fatty deposits in the arteries results in insufficient blood supply to 
tissues other than the heart and brain and, most frequently, affects the leg muscles (Figure 1. 
2). It appears as pain in the leg muscle during ambulation and the symptoms can be treated by 
exercise, smoking cessation and pharmacotherapy. The risk factors for PAD are the same as 
those for other atherosclerotic diseases and include older age and being male. Smokers have 
three times greater risk of PAD compared with non-smokers (Kannel and McGee, 1979; 
National Heart and Lung and Blood Institute, 2016b). 
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Figure 1. 2: Illustration of the occurrence of PAD. 
Starting from the normal artery with normal blood flow (Figure A). The image shows a cross-section 
of the normal artery, which is clear from any fatty substances. Figure B shows an artery with plaque 
build-up that is partially blocking blood flow. The image shows a cross-section of the narrowed artery, 
which restricts blood supply to the leg. Taken from (National Heart and Lung and Blood Institute, 
2016b). 
1.1.4 Aortic aneurysm disease  
Aortic aneurysm disease is the condition where enlarged area occurs in the aorta, the body’s 
main artery. This is caused by weakness in the wall of the artery, which can lead to rupture or 
dissection of the aorta (National Heart and Lung and Blood Institute, 2016b). There are two 
most common aortic aneurysms depending on the location of the disease; thoracic aortic 
aneurysm (occurs in the chest) and abdominal aortic aneurysm (occurs in the abdominal area) 
(Figure 1.3). Many risk factors contribute to the occurrence of aortic aneurysm including male 
gender, aging, smoking, high blood pressure and family history. However, the most common 
risk factor is atherosclerosis, which narrows the arteries and increases the force of blood 
pushing against the walls of an artery (Dahlof, 2010).  
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Figure 1. 3: Illustration of the occurrence of aortic aneurysm 
Starting from the normal aorta exiting the heart (Figure A). The image shows a normal aorta. Figure B 
shows an aorta with bulging that is located behind the heart (thoracic aortic aneurysm).  Figure C shows 
abdominal aortic aneurysm, which is located below the arteries that supply blood to the kidneys. Taken 
from (National Heart and Lung and Blood Institute, 2016b). 
 
1.2 Epidemiology of cardiovascular disease 
1.2.1 The burden of cardiovascular disease globally and in the UK 
CVD are the leading cause of death worldwide, accounting for around 1/3 of all-cause mortality 
(Cannon, 2013). Approximately 7.4 million deaths are due to CHD and 6.7 million deaths to 
stroke (World Health Organization, 2016b). 
 
Cardiovascular mortality varies between countries. Low CVD mortality rates are observed in 
Japan and Mediterranean countries such as France, Spain, Portugal and Italy, while eastern 
European countries such as Ukraine, Russia and Latvia experience high CVD prevalence. 
These differing geographical trends are probably due to differences in lifestyle including 
smoking patterns, nutritional transitions and changes in physical activity/ sedentary behaviour, 
which are important determinants of CVD risk (Institute of Medicine, 2010). According to 
WHO (2016), globally around 45% of CVD deaths are due to CHD (Figure 1.4).  
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Figure 1. 4: The global distribution of CVD mortality rates (age standardized, per 
100000). 
Taken from (World Health Organization, 2016a). 
 
In the UK in 2014, CVD were the second most common cause of death after cancer and 
accounted for 19% and 28% of premature deaths among women and men, respectively. CHD 
is the biggest single cause of death in the UK with one in five men and one in ten women dying 
from CHD. This is followed by stroke and 25% of CVD deaths are from stroke. It has been 
estimated that 1.5 million of the UK population have survived a heart attack and 2.6 million 
are currently affected by CHD (British Heart Foundation, 2015) .  
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1.2.2 Variation in cardiovascular disease in the UK 
In the UK, CVD death rate is higher in urban and northern populations, particularly in Scotland, 
and lower in the south of England (Figure 1.5). This geographical patterning is probably due 
to differences in socioeconomic status which drive differences in physical activity, smoking 
and dietary behaviours that are major determinants of CVD risk (British Heart Foundation, 
2015).  
 
Figure 1. 5: Aged-standardized death rates from CVD in men and women of all ages, per 100 
000 by local authority, United Kingdom, 2011/2013. 
Taken from (British Heart Foundation, 2015) 
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1.2.3 Risk factors for CVD 
There are many risk factors for CVD (Table 1. 1), some of which are non-modifiable (such as 
age, sex and family history of CVD), whereas others are modifiable (such as abnormal blood 
lipids, smoking, diabetes, elevated blood pressure, abdominal obesity, lack of physical activity, 
diet, stress and overconsumption of alcohol). Modifiable factors are the major contributors to 
cardiovascular morbidity and mortality and account for > 90% of all myocardial infarctions 
(Dahlof, 2010).  
Table 1. 1: Risk Factors for CVD-(World Health Organization, 2016a) 
Modifiable (lifestyle) Potentially modifiable 
(Biochemical and physiological) 
 
Non-
modifiable 
 Cigarette smoking 
 Diet rich in saturated 
fats and energy with low 
intake of fruits and 
vegetables. 
 Physical inactivity  
 Excess alcohol intake  
 Psychosocial stress 
 Obesity  
 Dyslipidaemias (high plasma 
cholesterol, low plasma HDL, 
high triglycerides) 
 High blood pressure 
 Diabetes mellitus  
 Thrombotic factors 
 LVH/LV mass 
 Lp(A) 
 Haematological - Reductions in 
hematocrit and 
polymorphonuclear leukocytes 
(Jenkins et al., 2007) 
 Oxidized lipids 
 Age  
 Gender  
 Genetic factors 
Lp(A), lipoprotein (A); LVH, Left ventricular hypertrophy; HDL, high density lipoprotein 
1.3 Atherosclerosis 
1.3.1 Definitions 
Atherosclerosis is a multifactorial, progressive lesion of the arterial wall due to the 
accumulation of connective tissue components, cholesterol, macrophages, proliferation of 
smooth muscle cells (SMC) and the formation of thrombus (Whayne, 2011). The clinical 
outcomes of coronary heart, cerebrovascular, and peripheral vascular diseases are largely 
attributed to atherosclerotic lesions. Endothelial cells, leukocytes and intimal smooth muscle 
cells are the key roles of the development of atherosclerosis. Plaque causes affected arteries 
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to harden and narrow which is potentially dangerous due to restricted blood flow which can 
damage organs and cause malfunction. The atherosclerotic process may commence silently in 
late adolescence with the clinical manifestations usually becoming obvious after the age of 45 
years (Wilson, 2004).   
1.3.1.1 Pathogenesis and Stages of Atherosclerosis 
 
One of the earliest stages of the atherosclerosis process is deterioration of endothelial function 
(EF) (Figure 1.6). It has been suggested that reduced nitric oxide (NO) bioavailability is one 
of the factor responsible for this deterioration (Bondonno et al., 2016). The process may begin 
in childhood or early adulthood. The accumulation of lipoproteins in foam cells that leads to 
the formation of yellow- white fatty streaks in the major arteries is the first step into 
atherosclerosis. Fatty streaks are composed mainly of smooth muscle cells, saturated with 
cholesterol and monocyte-derived macrophage-like foam cells (Libby et al., 2002; Weber and 
Noels, 2011). The development of fatty streak starts when the accumulation of oxidised LDL 
in the vascular wall activates inflammatory reactions, which in turn, leads to secretion of 
cytokines. These cytokines then attract T cells and leukocytes to the site of injury, and lead to 
the accumulation of fat in macrophages which form lipid-laden foam cells and serve as the 
hallmark of early stage atherosclerotic lesion formation (Rosenfeld, 2013). Although fatty 
streaks per se do not cause any major problems related to heart function they can develop into 
atherosclerosis in the long term. 
 
Figure 1. 6: The process of atherosclerosis 
Modified from (Libby et al., 2011) 
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The formation of fibrous plaque in the walls of the arteries is the second stage of 
atherosclerosis. Plaque is composed of a large number of macrophages, smooth muscle cells 
and lymphocytes (Libby et al., 2002) and narrows the artery lumen and hardens the artery wall. 
Atherosclerotic plaques can be classified into two forms, depending on how they progress in 
the arteries. The slowly progressing plaques tend to be more stable and are not prone to rupture. 
On the other hand, more rapidly growing plaques have a thin fibrin cap and are more 
susceptible to rupture, which increases the risk of thrombotic events (Figure 1.7).  
 
 
Figure 1. 7: Stable and unstable plaque 
Taken from (Libby et al., 2011) 
The final stage of atherosclerosis begins when a fibrous plaque ruptures, revealing the 
cholesterol exposed to injury or stress, thereby provoking intense reactions of blood clotting 
and resulting the formation of thrombus. Depending on the location of thrombus, this condition 
will lead to heart attack or stroke if the thrombus is large enough to block the coronary blood 
vessel or cerebral blood vessel, respectively (Rosenfeld, 2013). Approximately 76% of all fatal 
cases related to coronary thrombi are caused by the plaque ruptured (Falk et al, 2006). 
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1.3.2 Endothelial function in health and disease 
1.3.2.1 Functions of the endothelium 
 
The endothelium is the single inner layer of squamous cells lining the blood vessel which 
separate the vascular lumen from the rest of the blood vessel. It is believed to be the key vessel 
wall component in the initiation of the atherogenic process. The endothelium  can be considered 
as one of the major organs of the human body with surface area extending about 350m2 and 
weighing approximately of 110g (Pries et al., 2000).  
Endothelial cells line the entire vascular system, from the heart to the smallest capillaries 
(Alberts et al., 2002). The structure of the endothelial cell is important in the maintenance and 
integrity of the circulatory function and vessel wall. The semi-permeable characteristic of these 
cells controls the passage of materials into and out of the blood vessels. Endothelial cells secrete 
several vasoactive agents including the vasodilators nitric oxide (NO), prostacyclin and 
Endothelium-Derived Hyperpolarizing Factor (EDHF) and the vasoconstrictors endothelin-1 
(ET-1), angiotensin II (AngII), and thromboxane A2.   Perturbation of endothelial structure or 
function will lead to haemodynamic instability, which can result in endothelial injury and 
dysfunction. These events may initiate many pathological process such as atherosclerosis, 
increase the risk of thrombosis and disturb permeability of the blood vessel (Sumpio et al., 
2002).  
1.3.2.2 Factors affecting endothelial function 
 
1. Nitric oxide (NO) 
NO is a water soluble gas which is produced continuously in endothelial cells from its 
precursor L-arginine via the enzymatic action of endothelial NO synthase (eNOS). It is 
a highly diffusible molecule with a very short half-life (~6-30 sec) (Palmer et al., 1988). 
An alternative source of NO is the non-enzymatic reduction of dietary inorganic nitrate 
to nitrite by oral bacteria; nitrite can then be further reduced to NO in the gastric lumen 
(in the presence of low oxygen tension and low pH) and in the blood vessels (reaction 
with deoxygenated haemoglobin or other enzymes with reductase activity e.g. xanthine 
oxido-reductase or aldehyde dehydrogenese). NO is considered to be the key mediator 
produced by the endothelial cell for the control of vascular tone and plays a pivotal role 
in maintaining vascular homeostasis. The functions of NO in endothelial cells include: 
relax blood vessels, inhibit platelet aggregation and adhesion, limit oxidation of low 
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density lipoprotein (LDL) cholesterol, inhibit proliferation of vascular smooth muscle 
cells and decrease inflammatory responses (Forstermann, 2010). Decreased production 
of NO and/or increased NO inactivation  leads to endothelial dysfunction (Higashi et 
al., 2009), and this precedes the development of atherosclerotic disease. 
 
2. Oxidative stress 
Oxidative stress contributes to the development of cardio-metabolic diseases including 
atherosclerosis, hypertension, dyslipidemia, diabetes, myocardial infarction, heart 
failure and angina pectoris (Schächinger et al., 2000). Atherosclerosis may occur  as a 
result of reduced endothelium-derived NO and from increased production and/or 
impaired inactivation of reactive oxygen species (ROS) (Lavie et al., 2013). ROS are 
essential for normal cell function (Sena and Chandel, 2012), but adequate levels of 
antioxidant defences are required to avoid the harmful effects of excessive ROS 
production. An imbalance of NO and ROS, so-called oxidative stress, contributes to 
endothelial dysfunction through the inactivation of NO (Hsieh et al., 2014). Elevated 
levels of ROS reduce the availability of NO by reacting with NO to form peroxynitrite, 
which leads to many pro-atherogenic events (Schulz et al., 2011; Hsieh et al., 2014).  
 
3. Ageing 
Advancing age is a major risk factor for CVD due to age-related impairment of EF 
(North and Sinclair, 2012). Decreased availability of NO occurs during ageing due to 
greater ROS production (e.g. superoxide) without a compensatory increase in 
antioxidant defenses and this lower NO contributes to reduced peripheral artery 
endothelium dependent dilation (EDD) (Palmer et al., 1988).  
 
4. Health status 
The ability of the endothelium to maintain the integrity of the vessel wall can be 
affected by the biochemical and pathophysiological state of the body due to both 
exogenous and endogenous factors including: 
 
Chronic smoking: Active and passive smoking may deteriorate EF due to decreased 
formation of NO, increased NO degradation via generation of oxygen free radicals, 
increased formation of asymmetric dimethylarginine (ADMA) and greater ROS 
(Toda and Toda, 2010).  
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Obesity: The reduced NO encountered in obesity arises either because of enhanced 
degradation (oxidative stress) or impairment of endothelial NO synthase activity 
(eNOS inactivation). This leads to impaired EF due to increased vasoconstrictor 
factors, such as endothelin-1, and sympathetic nerve activation (Toda and Okamura, 
2013).  
 
 Hypercholesterolemia: In hypercholesterolemia, impaired NO activity has been 
associated with increased NO degradation by oxygen radicals (Kuwai and Hayashi, 
2006). Hypercholesterolemia increases production of the superoxide anion, which 
may be responsible for an impairment of the balance between vasorelaxant and 
vasoconstrictor factors in the endothelium (Katusic, 1996; Perrault et al., 2000). 
Elevated ADMA is observed in people with hypercholesterolaemia (Böger et al., 
1998; Landim et al., 2009; Sydow and Böger, 2012). ADMA is well known as an 
endogenous competitive inhibitor of NO synthase, and thus may cause endothelial 
dysfunction by reducing availability of NO (Sibal et al., 2010). 
 
 Hyperglycaemia: Transient and prolonged hyperglycaemia impair EF. 
Hyperglycaemia is associated with increased oxidative stress, uncoupling of eNOS, 
LDL oxidation, and increased concentrations of vasoconstrictor mediators e.g. 
endothelin, angiotensin, and prostanoids (Sena et al., 2013) - all of which impair 
endothelium-dependent vasodilation. 
 
High blood pressure: Hypertensive patients have impaired EF (Puddu et al., 2000). 
This dysfunction may be due to reduce NO availability (increased degradation by 
oxidative stress and reduced production by eNOS inactivation) and abundance of 
vasoconstrictor agents in the circulation, such as angiotensin II and prostaglandins 
(Tang and Vanhoutte, 2010), which causes an imbalance between vasodilation and 
vasoconstriction.  
 
Homocysteinaemia: Homocysteinaemia (HHcy) is a pathological condition 
characterized by raised plasma concentration of total homocysteine (Clarke et al., 
1991). Homocysteine is a thiol amino acid synthesized during the metabolic 
conversion of methionine to cysteine by the demethylation pathway (Lai and Kan, 
2015). Possible mechanisms by which raised homocysteine concentration causes 
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endothelial dysfunction include NO inhibition, endothelin-1 (ET-1) induction, 
EDHF inhibition, proliferation of smooth muscle cells, increased oxidative stress 
and promoting inflammation (Pushpakumar et al., 2014).  
 
Hormones: Hormones that increase NO production include estrogen, progesterone, 
insulin, and growth hormone. In contrast, other hormones, including 
glucocorticoids, progesterone, and prolactin, decrease NO availability (Duckles and 
Miller, 2010). Long-term exposure to aldosterone  reduced the production of 
tetrahydrobiopterin (BH4) and increased oxidative stress (Hashikabe et al., 2006). 
Elevated aldosterone concentrations lead to the development of hypertension due 
to oxidative stress (Queisser and Schupp, 2012). Oestrogen modulates NO release 
by the endothelial cell (Vanhoutte et al., 2009) by up regulating eNOS activity via 
a receptor-mediator system (Hayashi et al., 1995).  
 
1.4 The Production of Nitric Oxide in humans  
NO is considered to be the key mediator produced by the endothelial cell for the control of 
vascular tone by activating guanylyl cyclase and, therefore, is one of the most important 
molecules secreted by the endothelium (Forstermann, 2010). There are two NO synthase-
dependent pathway in humans; either it can arise as an end product of the L-arginine-NO 
pathway or be produced from dietary nitrate as summarised in Figure 1.8. 
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NO, nitric oxide; NO2ˉ, nitrite; NO3ˉ, nitrate; BH4, tetrahydrobiopterin 
Figure 1. 8: NO synthase-dependent pathway in human 
NO synthase-dependent pathway in human from (A) L-arginine-NO pathway or (B) Enterosalivary 
nitrate-nitrite-NO pathway  - figure adapted from (Gilchrist et al., 2011)  
1.4.1 L-arginine - NO pathway 
NO can be generated endogenously by three isoforms of the enzyme NO synthase: endothelial 
(eNOS), neuronal (nNOS) and inducible (iNOS) (Forstermann and Sessa, 2012). eNOS is a 
homodimeric enzyme which is expressed constitutively in endothelial cells. It oxidizes and 
converts the amino acid L-arginine into L-citrulline and NO (Michiels, 2003). There are two 
steps required in the production of NO. The first step is the hydroxylation of L-arginine to Nω-
hydroxy-L-arginine by NOS. In the second step, NOS oxidizes Nω-hydroxy-L-arginine to L-
citrulline and NO (Stuehr et al., 2001; Bruckdorfer, 2005; Forstermann and Sessa, 2012). This 
process requires molecular oxygen and nicotinamide-adenine-dinucleotide phosphate 
(NADPH) as co-substrates. Many cofactors are needed in this process including calmodulin-
calcium, tetrahydrobiopterin (BH4), haem, flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD) (Forstermann and Sessa, 2012).         
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1.4.2. Entero-salivary nitrate-nitrite-NO pathway  
NO can also be produced by the entero-salivary nitrate-nitrite-NO pathway which includes the 
conversion of nitrate (NO3ˉ) to nitrite (NO2ˉ) to NO (Bondonno et al., 2016). Rich dietary 
sources of NO3ˉ include vegetables such as cress, celery, lettuce, red beetroot, chervil, spinach 
or rocket (Hord et al., 2009). Nitrate from the diet or endogenous sources is reduced to NO2ˉ 
by the commensal bacteria in the oral cavity and gastrointestinal tract (Figure 1.9). After the 
formation of NO2ˉ, there are innumerable pathways in the body for its further reduction to NO 
because of the acidity environment in the stomach, involving enzymatic and non-enzymatic 
pathways such as haemoglobin, myoglobin, xanthine oxidoreductase, ascorbate, polyphenols 
and protons (Lundberg et al., 2008). It is well recognized that nitrate and nitrite act as storage 
pools for NO, and can be recycled back to NO, especially under hypoxic conditions where the 
NOS enzymes may be dysfunctional (Lundberg et al., 2008). 
 
 
Figure 1. 9: The entero-salivary pathway in humans. 
The entero-salivary pathway in human. Ingested NO3ˉ (a) from dietary sources such as green leafy 
vegetables are swallowed and rapidly absorbed in the gastrointestinal tract (1) into the systemic 
circulation (2), where it mixes with endogenous nitrate. Most NO3¯ is excreted by the kidney (70%), 
(3) while a small portion is taken up by the salivary glands (25%) (c). Nitrate-rich saliva is secreted into 
the oral cavity (4) where facultative anaerobic bacteria (E. coli, Salmonella enterica serovar 
Typhimurium and Paracoccus pantotrophus) reduce nitrate to NO2ˉ (d) via the action of nitrate 
reductase enzymes. Nitrite-rich saliva is then swallowed (5) and further metabolized to nitric oxide 
(NO) non-enzymatically because of the acidic condition in the stomach (e). NO exerts various 
biological effects in the body (6-7). Figure adapted from (Monaco, 2016). 
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1.5 Vitamin D 
1.5.1 Chemical structure, preforms and metabolites of vitamin D  
Vitamin D is classified as one of the fat soluble vitamins, together with vitamin A, E and K. It 
is also known as the sunshine vitamin that  can be synthesized in the skin epidermis as a 
prohormone from the cholesterol-like precursor, 7-dehydrocholesterol (7-DHC) in response to 
ultraviolet light (290 -315 nm) (Bouillon et al., 2008). Also classified as a secosteroid, vitamin 
D comes in two forms: vitamin D2 (ergocalciferol) that is derived from plants and fungi such 
as mushrooms and vitamin D3 (cholecalciferol) that is derived from animal sources – the latter 
is considered the most important source of vitamin D in most human diets (Holick, 2007) 
(Kassi et al., 2013).  
 
Vitamin D2 differs structurally from vitamin D3 in the side chain attached to the secosteroid 
skeleton. Vitamin D2  contains an additional methyl group on  carbon atom 24 and a double 
bond between carbon atoms 22 and 23 (Norman, 2008) (Figure 1.10). Supplemental vitamin 
D3 was more effective at raising serum 25(OH)D levels than supplemental vitamin D2 
(Tripkovic, 2013). This may be because  the conversion of vitamin D3 to 25(OH)D3 is five 
times faster than that of vitamin D2 to form 25(OH)D2 (Houghton and Vieth, 2006; Tripkovic 
et al., 2012).  
 
                                         
a) Vitamin D3 (cholecalciferol)           b) Vitamin D2 (ergocalciferol) 
Figure 1. 10: Chemical structure of vitamin D 
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1.5.2 Metabolism of vitamin D 
At higher latitudes, vitamin D stores are produced during summer, and in the winter, vitamin 
D status depends on vitamin D storage in the body (largely in liver and adipose tissue) and on 
vitamin D supplied by foods (Vaidya, 2013). In the UK, the action of UVB from the sunlight 
on skin is the main source of 25(OH)D concentration during spring and summer (late March/ 
early April to September). However, in autumn and winter season (October and early March), 
when the sunshine is limited, there is no ambient ultraviolet sunlight of the appropriate 
wavelength for skin synthesis of 25(OH)D concentration (NICE, 2016). Storage of sufficient 
25(OH)D concentration in the adipose tissues and liver is very important during the winter to 
prevent deficiency of 25(OH)D concentration if the dietary intake of this vitamin is insufficient 
(O'Connor, 2011). 
 
The skin synthesis of 25(OH)D concentration begins when the sunlight containing UVB 
radiation strikes the epidermis of the skin, which contains 7-DHC, to produce previtamin D3. 
Prolonged UVB exposure results in conversion of previtamin D3 to lumisterol and tachysterol 
which are biologically inactive (Holick et al., 1980). Previtamin D3 then undergoes 
spontaneous thermal rearrangement to cholecalciferol i.e. vitamin D3. 25(OH)D concentration 
(from skin synthesis or after absorption from the gut) is transported to the liver bound to vitamin 
D binding protein (DBP) (Bhan, 2014), where the enzyme 25-hydroxylase (cytochrome P450 
2R1 [CYP2R1]) catalyses hydroxylation at position 25 and the production of 25-
hydroxyvitamin D [25(OH)D] or calcidiol, the most commonly used index of vitamin D status 
and the major circulating form of vitamin D (Haddad, 1995). From the liver, 25(OH)D is 
transported to kidney, again bound to DBP. In the kidney, the enzyme 1-α-hydroxylase 
(CYP27B1) converts serum 25(OH)D to serum 1,25-dihydroxyvitamin D [1,25(OH)2D] or 
calcitriol, which is the active metabolite of vitamin D (Figure 1.11)   (Christakos et al., 2012). 
The biological half-life of serum 25(OH)D3 is 20-30 days and for 1,25(OH)2D is 4-6 hours 
(Haddad et al., 1993), and this explains why serum 25(OH)D is a better indicator for assessing 
vitamin D status than is 1,25(OH)2D (Holick, 1996). 
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Figure 1. 11: Overview of metabolism of vitamin D. 
Figure adapted from (SACN, 2016) 
 
1.5.3 Absorption and transport of vitamin D 
The absorption of vitamin D from the gut requires three organs; the liver (which synthesises 
bile acids), the pancreas (which produces lipases and colipase) and the small intestine  
(Christakos et al., 2011). Ingested vitamin D is absorbed from the jejunum and ileum and 
transported together with lipoproteins in chylomicron via the lymphatic system. Therefore, 
partial gastrectomy, chronic pancreatic insufficiency, intrinsic small bowel disease, disorders 
of the biliary tract, and surgical bypass procedures of the jejunum and ileum can all affect the 
absorption of vitamin D (Bikle, 2007).  
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1.5.4 Functions and mechanisms of action of vitamin D 
In addition to its classical actions in the regulation of serum calcium and phosphorus 
concentrations (mineral homeostasis), 1,25 dihydroxyvitamin D (1,25 (OH)D) also participates 
in non-classical actions, i.e. control of metabolism, cellular growth and immune function (non-
skeletal functions). These effects of 1,25 (OH) D are exerted by both genomic and non-genomic 
mechanisms. Genomic mechanisms are responsible for long-term modulation of gene 
expression which is mediated through vitamin D receptor (VDR), dependent transcriptional 
effects in the cell nucleus (Jurutka et al., 2001). Non genomic mechanisms include short term 
activation of intracellular signalling pathways, when the VDR induces rapid signalling, situated 
on the cell membrane and/or cytoplasm (Trochoutsou et al., 2015) .  
 
The genomic actions of vitamin D are mediated by the VDR which, on binding the hormone, 
interacts with the DNA to induce or inhibit gene expression and, ultimately, new protein 
synthesis (Figure 1.15). When vitamin D gets into the cell nucleus, it binds to VDR and induces 
a conformational modification that allows it to form a complex with the retinoic acid X receptor 
(RXR). Then, the VDR-RXR heterodimers bind with specific enhancer elements in DNA, 
known as vitamin D response elements (VDRE), a pre-defined promoter DNA sequence. The 
type of the co-regulatory protein (whether co-activators or co-repressor) that bind to the VDR-
RXR-VDRE determine whether gene transcription is repressed or initiated (Haussler et al., 
2011). Because of the complexity of the signalling and transcription process related to the VDR 
signalling, genomic functions of vitamin D can take several hours to produce their effects 
(Trochoutsou et al., 2015).  
 
The non-genomic actions of vitamin D are mediated by the VDR located within caveolae (small 
invaginations) in the plasma membranes (mVDR), in specific locations involved in the signal 
transduction pathways (Pusceddu et al., 2015) (Figure 1.12). These are ‘rapid response 
pathways’ which are mediated within seconds to minutes compared with genomic actions 
which may take hours. The signalling induced by non-genomic action includes the opening of 
ion channels, the induction of second messenger molecules (e.g. mitogen activated protein 
kinases (MAPK)), and secretion of certain hormones such as estrogen, progesterone, 
testosterone, corticosteroids, and thyroid hormone (Haussler et al., 1995; Bikle, 2014). The 
genomic and non-genomic pathways operates in several cell types, suggesting that ‘cross talk’ 
might happen between these two pathways (Haussler et al., 2011; Dalan et al., 2014). 
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VDR is an intracellular receptor protein, which ligand-activated transcription factor binding to 
vitamin D response elements in the promoter region of target genes (Andrukhova et al., 2014).  
The VDR gene is expressed in more than 30 tissues including smooth muscle cells, pancreatic 
β-cells, monocytes, keratinocytes, suggesting that VDR may be involved in modulating 
numerous metabolic processes beyond regulation of mineral homeostasis (Nagpal et al., 2005), 
supporting a role of vitamin D in delineating healthy trajectories of ageing.    
                        
 
Figure 1. 12: 1,25(OH)2D exerts its biological functions via non-genomic and genomic 
actions. 
Modified from (Pusceddu et al., 2015) 
DNA Pol II, DNA polymerase II; IP3/DAG, inositol triphosphate/diacylglycerol; PKC, protein kinase C; PLC, 
phospholipase C; RXR, retinoid X receptors; VDR, vitamin D receptor; VDREs, vitamin D response elements. 
  
1.5.5 Daily requirement and dietary sources of vitamin D  
Vitamin D is absorbed from the gastrointestinal tract from dietary sources such as fatty fish, 
red meat, fortified margarines and egg yolk.  In addition, other meats, chicken, inner organs, 
dairy products and some wild mushrooms contain small amounts of vitamin D (Campos-
Outcalt, 2013). The absorption of vitamin D from supplements in humans varies between 60-
90%, but it has been suggested that the absorption of vitamin D from natural sources is less 
efficient (van den Berg, 1997). 
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Defining adequacy of 25(OH)D concentration status is challenging as there is no consensus 
among researchers as to which cut-off levels of serum 25(OH)D should be applied (Palacios 
and Gonzalez, 2014). The discrepant opinion of the terms used for classification such as 
‘suboptimal’, hypovitaminosis’, ‘deficiency’, ‘insufficiency’ on the 25(OH)D concentration 
status has bring uncertainties and confusion surrounding the dietary reference intake (DRI), 
estimated average requirement (EAR) and recommended nutrient intake (RNI) values as well 
as to identify threshold effects and possible adverse effects of excessive consumption. The 
Institute of Medicine (IOM) used bone health as a parameter for developing the Recommended 
Dietary Allowances (RDAs) of 25(OH)D concentration, and proposed that for optimum health, 
serum 25(OH)D should be at least 50 nmol/L (Dietary Reference Intakes for Calcium and 
Vitamin D, 2011; Ross et al., 2011) . Individuals with the serum 25(OH)D <30 nmol/L are 
classified as deficiency, and those with 25(OH)D concentrations of 50 nmol/L and above were 
classified as sufficient. The Endocrine Society Task Force on  serum 25 (OH)D concluded that 
50 nmol/L of serum 25(OH)D is the cut-off level for 25(OH)D concentration sufficiency and 
in addition for the maximum benefits of 25(OH)D concentration on calcium, bone and muscle 
metabolism, serum 25(OH)D concentrations should exceed 75 nmol/L (Holick et al., 2011). 
Concentrations of 25(OH)D below 25 nmol/L are considered deficient while concentrations 
less than 50 nmol/L are considered insufficient by the UK’s Scientific Advisory Committee on  
Nutrition (SACN, 2016). 
In the UK, the Reference Nutrient Intake (RNI) was developed for specific group at risk of 
insufficient sunshine exposure: infants and children aged 0-3y (UK Department of Health, 
1998). However, in their more recent report, SACN have set the RNI of 10 micrograms vitamin 
D per day, throughout the year for everyone in the general population aged 4 years and older 
(SACN, 2016). Recommended intakes for vitamin D are presented in Table 1. 2. Intakes in 
this section are compared with the RDA IOM for other population groups. 
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Table 1.2: Vitamin D requirements by age category 
Age category 
 
IOM RDA1 UK RNI2 
0 – 6 months * 340 IU 
(8.5 mcg) 
 
7 months – 3 years 
 
 
600 IU 
(15 mcg) 
280 IU 
(7 mcg) 
14-18 years 600 IU 
(15 mcg) 
 
400 IU  
(10 mcg) 
19-50 years 600 IU 
(15 mcg) 
 
400 IU  
(10 mcg) 
51 – 70 years 600 IU 
(15 mcg) 
 
400 IU  
(10 mcg) 
>70 years 800 IU 
(20 mcg) 
 
400 IU  
(10 mcg) 
Pregnant and breast-
feeding women 
   
600 IU (15 mcg) 400 IU 
(10 mcg) 
RDA= Recommended Dietary Allowance, RNI = Reference Nutrient Intake. IOM= Institute of Medicine,  
1(Dietary Reference Intakes for Calcium and Vitamin D, 2011); 2(SACN, 2016) 
 
1.5.6 Global vitamin D status 
High prevalence of vitamin D deficiency even those residing near the equator, has been a major 
public health problem (Figure 1.13)  (Palacios and Gonzalez, 2014). Despite of having 
adequate sunshine all around the year, high prevalence of 25(OH)D concentration insufficiency 
(<50 nmol/L) was found  in the Asian continent and majority of countries were found to have 
less than the optimum level of 25(OH)D concentration (75 nmol/L) (Wahl et al., 2012). 
However, due to the unavailability of relevant data, the prevalence of vitamin D deficiency is 
not known in certain region such as Central America, South America (with the exception of 
Brazil) and much of Africa. This information gap needs attention in view of the importance of 
vitamin D for health. 
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Figure 1. 13: Map of global Vitamin D status (serum 25(OH)D [nmol/L]) in adults 
(18+yrs). 
Mean 25(OH)D values calculated from winter measurements. Taken from (Wahl et al., 2012) 
 
1.5.7 Vitamin D status in the UK  
There have been concerns in recent years that vitamin D deficiency is becoming more common 
in Western countries including the UK. A typical normal range of serum 25(OH)D in adults 
living in UK is 47.4 ± 23.8 nmol/L (National Diet and Nutrition Survey, 2011). Located at 
latitudes >50° N, most  of the UK land mass receives insufficient UVB rays from sunlight 
especially during October to March to allow adequate dermal synthesis of 25(OH)D 
concentration (Webb, 2009) thus increasing the reliance on dietary sources of the vitamin. 
Dietary intakes of vitamin D are low in the UK particularly in children aged 1.5 to years 3 
years, and adults over 65 years old. Moreover, most adults failed to meet the UK RNI of 
10 μg/day (SACN, 2016).  
A cross sectional study done by (Hypponen and Power, 2007) revealed that prevalence of 
hypovitaminosis D in the general population in the UK was alarmingly high especially in 
winter and spring, where limited sunshine occurs which prevents synthesis of 25(OH)D 
concentration (Figure 1.14).  Even during the remainder of the year, cloud cover can block up 
to 99% of 25(OH)D concentration production. Furthermore, dietary intake of vitamin D may 
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be low in Great Britain. Obese participants and those living in Scotland were at the highest risk 
of hypovitaminosis D. 
 
Figure 1. 14: Seasonal and geographical variation in the prevalence of hypovitaminosis 
D (25-hydroxyvitamin D <40 nmol/L) in Great Britain. 
Taken from (Hypponen and Power, 2007). 
 
1.5.8 Vitamin D determinants  
The concentration of 25(OH)D concentration in the blood is depends strongly on sunlight 
exposure as well as dietary intake of vitamin D and on vitamin D supplementation. 25(OH)D 
concentration synthesis in the skin depends on latitude and season and also on other factors 
such as:  
i. Adiposity 
Recent evidence suggests that obese individuals have lower circulating 25(OH)D 
concentrations than age and sunlight exposure-matched normal weight persons (Kevin 
McKinney, 2008; Ardawi et al., 2012; Samuel and Borrell, 2013; Walsh et al., 2016). 
This inverse relationship between vitamin D status and adiposity has been observed in 
multiple countries and in different age groups (Alyahya, 2017; Greene-Finestone et al., 
2017). The lower 25(OH)D concentrations in obese people may be explained by 
adipose tissue sequestration and/ or volumetric dilution of 25(OH)D (Blum et al., 2008; 
Drincic et al., 2012) and/or negative feedback from higher circulating concentration of 
25(OH)D (Pourshahidi, 2015). 
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ii. Skin pigmentation  
Darker skin contains more melanin in the epidermal layer, which provides greater 
protection against ultraviolet radiation but reduces the skin’s ability to produce vitamin 
D from sunlight (Bonilla et al., 2014). Because of this protective effect, people with 
darker skin require more UVB exposure than those with lighter skin colors (Norman 
and Powell, 2014). The efficiency of cutaneous 25(OH)D concentration synthesis is 
lower in people with dark skin, as the high concentration of melanin absorbs and 
scatters the UVB rays, resulting in less efficient synthesis of 7-DHC  to previtamin D3 
(SACN, 2016).  
 
iii. Use of sunscreen and clothes style 
Sunscreen prevents sunburn and skin cancer by blocking UVB light. However  concerns 
have been raised that the application of sunscreen may prevent 25(OH)D concentration 
synthesis in the skin (SACN, 2016). The evidence supporting this concern is very 
limited and the published studies are insufficient to draw a concrete conclusion on the 
effects of sunscreen on 25(OH)D concentration synthesis (Springbett et al., 2010). 
Clothing styles that prevent skin exposure to direct sunlight - may block the sun's rays, 
resulting in reduced 25(OH)D concentration synthesis (Mithal et al., 2009; Nemerovski 
et al., 2009; Bassil et al., 2013). 
 
iv. Indoor environments and institutionalized older persons 
The elderly are especially at risk of 25(OH)D concentration deficiency as they are more 
likely than younger people to stay indoors, to use sunscreen (Gloth, 1995; Janssen et 
al., 2002), to cover more of the skin with clothing whilst outside and to consume diets 
with less vitamin D (Gillespie et al., 2012). The elderly cannot synthesize 25(OH)D 
concentration in the skin when exposed to the sun as well as when younger due to 
atrophic skin alterations with greater availability of the precursor 7-DHC (Hill et al., 
2016). Another factor that may contribute to age-related increased risk of vitamin D 
deficiency is reduced 1,25(OH)D synthesis due to lower renal function with ageing 
(Mosekilde, 2005). As renal function declines with age, the activity of the renal enzyme 
1-α hydroxylase that converts 25(OH)D into 1,25(OH)D falls (Gallagher, 2013). 
Vitamin D receptor (VDR), as its name implies, function as the receptor for vitamin D, 
which decreased with advancing age. This condition can worsen the problems and put 
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the institutionalized elderly at a very high risk of low 25(OH)D concentration status 
(Mosekilde, 2005) in the absence of supplementation with vitamin D.  
 
v. Air pollution 
Carbon particulates in the air from the burning of fossil fuels, wood, and other materials 
scatter, and ozone absorbs UVB rays which may reduce dermal synthesis of 25(OH)D 
(Mithal et al., 2009). A study done among 200, free-living, housewives, aged between 
20 to 55 years, from Tehran (high polluted area) and Ghazvin (low polluted area) found 
that living in a polluted area plays a significant independent role in the aetiology of 
vitamin D deficiency (Hosseinpanah et al., 2010). Another study in Belgian 
postmenopausal women also confirmed the positive correlation between air pollution 
and 25(OH)D deficiency (Manicourt and Devogelaer, 2008). 
 
vi. Pregnancy and lactation 
Exclusively breast fed infants are at risk of insufficiency of 25(OH)D concentration, 
because human milk provides approximately 25 IU of vitamin D per liter, which is not 
enough for an infant if it is the sole source of vitamin D (Oberhelman et al., 2013). 
Most cases of rickets occur in exclusively breastfed infants who lack sunshine exposure 
and are not supplemented with vitamin D (Majid Molla et al., 2000; Dawodu and 
Wagner, 2007). Vitamin D supply in breastmilk is reduced if the vitamin D status of 
the mother is low, the baby has darker pigmentation, they are living at higher latitudes, 
and in the winter season, so it is suggested that exclusively breastfed infants receive 
daily supplements of 400 IU of vitamin D when sunshine exposure is low or maternal 
25(OH)D concentration status is inadequate (Holick, 1998; Pettifor, 2004; Wagner and 
Greer, 2008). 
vii. Liver and Kidney Disease 
As both liver and kidney are involved in the conversion of 25(OH)D concentration into 
its active form; i.e. the liver produces 25(OH)D, and kidney produced metabolically 
active 1,25(OH)D, the impairment of either of these two organs may result in vitamin 
D deficiency due to impaired synthesis. (Nair, 2010; Putz-Bankuti et al., 2012).  
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1.6 Cardiovascular effects of vitamin D  
Classically, vitamin D is important for calcium and phosphorus homeostasis which is essential 
for bone mineralisation and related musculoskeletal outcomes (Jones et al., 1998). However, 
the expression of the vitamin D receptor in multiple tissues suggests other potential functions 
of vitamin D in non-musculoskeletal health outcomes. There is growing evidence that vitamin 
D may plays role in determining risk of cardio-metabolic outcomes, particularly metabolic 
syndrome (MetS), type 2 diabetes mellitus, and systemic hypertension (Lavie et al., 2013) and 
that adequate 25(OH)D concentration status help to prevent CVD (Holick, 2008).  
 
A systematic review by Pittas et al (2010) reported that in longitudinal observational studies, 
there is a significant negative relationship between 25(OH)D concentrations and risk of major 
cardiovascular events and related chronic diseases, including hypertension, myocardial 
infarction (MI), stroke and type 2 diabetes.  In contrast, in randomized controlled trials, there 
was no significant effect of vitamin D supplementation on blood pressure, glycaemic, or 
cardiovascular outcomes including MI, stroke and other cardiac and cerebrovascular outcomes 
(Pittas et al., 2010). In a further systematic review, Elamin et al (2011) reported that  vitamin 
D supplementation had no significant effect on death (RR, 0.96; 95% CI, 0.93, 1.00; P=0.08; 
I2  =0%), stroke (RR,1.05; 95% CI, 0.88, 1.25; P=0.59; I2 = 15%), MI ( RR, 1.02; 95% CI, 0.88, 
1.25; P = 0.59; I2=15%) , lipid fractions, blood pressure, and blood glucose concentration  in 
randomized controlled trials (Elamin et al., 2011).  
 
i. Vitamin D and EF 
There are several possible mechanisms by which higher 25(OH)D concentration status could 
improve EF. 25(OH)D concentration is involved in the regulation of endothelial cell-dependent 
vasodilation. The effect may be mediated by the link of 25(OH)D concentration with renin 
angiotensin-aldosterone system (RAAS), a hormonal system that regulates blood pressure and 
fluid balance (Figure 1.15). Elevated RAAS activity can contribute to hypertension and 
cardiovascular risk (Vaidya and Forman, 2012). Deficiency of 25(OH)D concentration 
predisposes to the up-regulation RAAS, hypertrophy of smooth muscle and a pro-inflammatory 
state which can increase the risk of hypertension and left ventricle hypertrophy (Wu et al., 
2010).  
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In addition, through its role in determining calcium homeostasis, 25(OH)D concentration may 
affect vascular smooth muscle cell function and, specifically the release of inflammatory 
cytokines such as such as IL-6, TNF-α and IFNγ which may influence vascular contractility 
(Polly and Tan, 2014) . Initial evidence suggested that VDR knockout mice are characterized 
by lower NO availability due to reduced expression of eNOS, leading to endothelial 
dysfunction, independent of changes in the renin-angiotensin system (Andrukhova et al., 
2014).  
 
 
Figure 1. 15: Conceptual model of major pathways through which vitamin D deficiency 
may lead to increased CVD risk 
(Artaza et al., 2009) 
 
The VDR activates a wide variety of genes including vascular endothelial growth factor 
(VEGF) which in turn, promotes NO synthesis by endothelial cells (Ahmed et al., 2013) 
(Figure 1.16). Vascular smooth muscle and endothelial cells express VDR as well as 1α-
hydroxylase (Somjen et al., 2000) which enables autocrine production of 1,25(OH) D. This 
1,25(OH)2D may act locally to modulate the effects of inflammatory cytokines on the 
vasculature, such as decreasing endothelial adhesion molecules, increasing NO production 
(Molinari et al., 2011) and reducing platelet aggregation (Aihara et al., 2006). Despite this 
mechanistic evidence suggesting a role for 25(OH)D concentration in EF, a recent systematic 
review and meta-analysis found no consistent evidence that vitamin D supplementation in 
humans improves measures of arterial stiffness (Rodríguez et al., 2016) 
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Figure 1. 16: Mechanisms by which vitamin D deficiency may increase cardiovascular 
disease risk. 
Potential effects of vitamin D metabolism on the cardiovascular system are divergent, but share 
common initial steps of nuclear and plasma membrane VDR activation. VDR, vitamin D receptor; 1, 
25-OH D2, 1, 25-dihydroxyvitamin D; RXR, retinoid-X receptor; Ca+, calcium cation; ANP, atrial 
natriuretic peptide; MMP, matrix metalloproteinases; VDRE, vitamin D response elements (promoter 
region of target genes); RAS, renin–angiotensin system; VEGF, vascular endothelial growth factor; 
VSMC, vascular smooth muscle cells. Taken from (Al Mheid et al., 2013). 
 
ii. Vitamin D and insulin sensitivity 
Vitamin D status has been linked with the regulation of insulin secretion by the pancreatic beta 
cells. Deficiency of 25(OH)D concentration predisposes to insulin resistance and increased risk 
of type 2 diabetes (Lavie et al., 2013), as calcitriol, via the VDR, regulates genes involved in 
insulin production in the pancreas (Lee et al., 2008). 
 
In addition, the 1- α – hydroxylase in pancreatic β-cells catalyses the conversion of 25(OH)D 
to 1,25(OH)2D which activates transcription of the insulin receptor gene (Maestro et al., 2002), 
and enhances insulin mediated glucose transport in vitro (Maestro et al., 2000). 25(OH)D 
concentration has a close mechanistic link with the insulin signalling pathway (Figure 1.17). 
Since insulin secretion is a calcium-dependent process, 25(OH)D deficiency may affect insulin 
secretion and sensitivity via alteration of extracellular and intracellular β-cell calcium pools 
and so interfere with normal insulin release (Nagpal et al., 2005). Sustained elevation of 
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intracellular calcium concentration may inhibit insulin-target cells from sensing the brisk 
intracellular calcium fluxes necessary for insulin action, such as glucose transport (Worrall and 
Olefsky, 2002).  
 
 
Figure 1. 17: Mechanistic link between vitamin D, insulin and NO pathway 
 
1.7 Hypothesis, Aims and Objectives 
Hypothesis 
The hypothesis of this PhD programme was based on assumption that 25(OH)D concentration 
is involved in the regulation of EF via NO production. It is well established that NO initiates 
and maintains vasodilation in the endothelium, and 25(OH)D concentration may have an 
important role in regulating eNOS activity, which enhances the availability of NO.  
Vitamin D is involved in vascular smooth muscle (VSM) function by modulating the regulation 
of growth and proliferation of VSM cells. Fat mass and ageing also modulate these 
physiological processes. Individuals with excess body weight tend to have lower vitamin D 
concentrations probably due to the sequestration of 25(OH)D in adipose tissue and/or 
volumetric dilution of 25(OH)D. Ageing is associated with decreased NO generation mediated 
by the reduction of the eNOS activity. Lower NO availability may increase the likelihood of 
endothelial cell senescence which may make the endothelium less responsive to hemodynamic 
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shear stress.  As a consequences, as vessels age, blood flow may be reduced as resulted by less 
infective heart function (North and Sinclair, 2012).   
It is postulated that 25(OH)D concentration status is positively associated with EF and with 
biomarkers of NO activity. In addition, fat mass is hypothesized to be a significant modulator 
of this association and it is anticipated that there will be stronger associations in lean compared 
with obese individuals. Similarly, ageing is predicted to be a significant modulating factor in 
the relationships between 25(OH)D concentration, EF and NO production and it is anticipated 
that stronger associations will be observed in older compared to younger individuals.  
Aims 
The aims of this PhD project were to investigate whether 25(OH)D status was a significant 
predictor of EF and in vivo whole body NO production, EF and cardiovascular biomarkers in 
two separate cohorts of individuals:  
Project 1: Overweight and obese, post-menopausal women. 
Project 2: Young and old, healthy male and female individuals to explore the association 
between age, whole-body NO production and vascular health in both men and women. 
Objectives 
The specific objectives of this PhD programme were to: 
1. Conduct a systematic review of the effects of vitamin D supplementation on EF in 
randomized clinical trials (RCTs). 
2. Test the accuracy of different methods for measuring nitrate, nitrite and 25(OH)D 
concentration in biological samples. 
3. Test whether deproteination of plasma samples influences estimates of the plasma 
concentration of nitrate and nitrite using chemiluminescence. 
4. Compare the estimates of circulating 25(OH)D concentrations using a conventional 
method (assays on plasma collected by venepuncture) and using a dry blood spot (DBS) 
method. 
5. Conduct a cross-sectional study to evaluate the association of 25(OH)D concentration 
with biomarkers of EF in obese postmenopausal women.  
6. Explore the association between ageing, 25(OH)D concentration and whole-body NO 
production. 
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Chapter 2. Effects of Vitamin D Supplementation on Endothelial Function: 
An Updated Systematic Review and Meta-Analysis 
 
2.1 Introduction  
Cardiovascular diseases (CVDs) are a major public health concern and contribute >30% of 
overall mortality worldwide (Dahlof, 2010). The pathogenesis of CVDs is multifactorial, and 
a critical step in the onset and advancement of CVDs is the formation of atherosclerotic lesions 
(Hansson, 2005). One of the earliest stages of the atherosclerosis process is the impairment of 
endothelial function (EF) (Higashi et al., 2009).  
 
The pathophysiology of endothelial dysfunction is complex and involves multiple mechanisms 
including over-production of reactive oxidative species (ROS), inflammatory cytokines and 
pro-atherogenic lipoproteins together with an imbalance between vasodilating and 
vasoconstricting molecules such as nitric oxide (NO), prostacyclin, Endothelium-Derived 
Hyperpolarizing Factor (EDHF), endothelin-1 (ET-1), angiotensin II (AngII), and 
thromboxane A2. Impairment of vasodilatation may be due to reduced availability of NO, 
which is produced by the endothelial cells and which is involved in multiple physiological 
processes including vasodilation, inflammation and platelet aggregation (Endemann and 
Schiffrin, 2004).  
 
Vitamin D is a pro-hormone which plays well-established roles in the regulation of calcium 
homeostasis and in bone remodelling (Lips, 2006). However, vitamin D is also essential for 
several non-musculoskeletal functions including regulation of vascular tone, gluco-insular 
homeostasis and immunity (Lips, 2006). Vitamin D receptors (VDRs) are expressed in several 
tissues including endothelial cells, vascular smooth muscle cells and cardiomyocytes 
(Brandenburg et al., 2012) so providing a plausible basis for a role of vitamin D in 
cardiovascular function. In addition, the active form of vitamin D (1α,25-dihydroxyvitamin D3, 
1,25(OH)2D3) is a direct transcriptional regulator of endothelial NO synthase (Dalan et al., 
2014). A study has shown that VDR mutant mice have lower NO availability due to lower 
circulating of NO concentrations, leading to endothelial dysfunction, increased arterial 
stiffness, increased aortic impedance, structural remodelling of the aorta and impaired systolic 
and diastolic heart function (Andrukhova et al., 2014). However, observational studies 
evaluating the association of vitamin D with CVD risk have reported mixed results. A 
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significant inverse relationship between vitamin D status, as assessed by circulation of serum 
25-hydroxy vitamin D (25(OH)D) and risk of major cardiovascular events and chronic diseases 
such as myocardial infarction (MI), stroke, hypertension and type 2 diabetes has been reported 
(Liu et al., 2005; Pittas et al., 2006; Knekt et al., 2008), but this has not been confirmed in 
other cohorts (Bajaj et al., 2014; Sollid et al., 2014). These discrepant results may be ascribed 
to the differences in study designs and to heterogeneity in the phenotypic characteristics of 
each study or of study participants including (1) duration of follow up, (2) cut-off values for 
the definition of deficient vitamin D status, (3) diagnostic criteria for the identification and 
classification of cardiovascular outcomes, (4) confounding factors (i.e., diet, sun exposure, 
seasonality, physical activity) and (5) health status of the participants in the cohorts (Pittas et 
al., 2010).  
 
Randomised controlled trials (RCTs) examining the effects of vitamin D supplementation on 
EF have also reported contradictory results; whilst some studies have reported improvement in 
EF (Sugden et al., 2008; Harris et al., 2011a; Breslavsky et al., 2013) others have observed no 
effect of vitamin D supplementation (Witham et al., 2010; Gepner et al., 2012; Larsen et al., 
2012; Longenecker et al., 2012; Marckmann et al., 2012; Sokol et al., 2012; Stricker et al., 
2012; Witham et al., 2012; Beveridge and Witham, 2013; Hewitt et al., 2013; Witham et al., 
2013b; Witham et al., 2013c; Yiu et al., 2013). A meta-analysis found a non-significant effect 
of vitamin D supplementation on changes in flow-mediated dilation measured by ultrasound 
after post-occlusion hyperaemia. The study showed that effects were greater in short studies 
(<16 weeks) and in participants with raised systolic and diastolic blood pressure (BP) 
(Stojanovic and Radenkovic, 2015).   
 
The method selected for the assessment of EF in humans depends on the availability of 
resources and equipment, technical and research expertise and, most importantly, by the 
research question under investigation. The most commonly used methods to measure dynamic 
vascular responses are: 1) ultrasound to assess the increase in diameter of large arteries 
following post-occlusive hyperaemia, 2) plethysmography to asses changes in forearm blood 
flow during infusion of pharmacological agents targeting endothelial-related mechanisms (e.g. 
acetylcholine or sodium nitroprussiate)  and 3) applanation tonometry by measuring pulse wave 
velocity (PWV) of peripheral arteries (Siervo et al., 2011c).  
 
 34 
 
In this chapter, the result of systematic review and meta-analysis of RCTs investigating the 
effect of supplemental vitamin D on EF were reported. The secondary aim of the study was to 
determine whether the effect size was modified by health status, study duration, dose, route of 
vitamin D administration, baseline vitamin D status and changes in 25(OH)D after 
supplementation, body mass index (BMI), age and type of vitamin D (vitamin D2 or vitamin 
D3).  
2.2 Methods 
The present systematic review was conducted according to the Cochrane guidelines (Higgins 
and Green, 2008) and it is reported according to PRISMA guidelines (Liberati et al., 2009). 
This systematic review has been registered in the International Prospective Register of 
Systematic Reviews (PROSPERO) (Registration No: CRD42014009668). 
2.2.1 Literature search 
This chapter is an update of previous systematic review and meta-analysis performed by our 
group (Hussin et al., 2017) which was published in the European Journal of Nutrition 
(Appendix 2.1).  Four databases (Medline, Embase, Scopus, and Cochrane Library) were used 
to search for articles from inception until March 2015. These databases were chosen as they 
are the ones used most widely for publications of research in medical, biomedical and life 
sciences and, therefore, are likely to contain reference to most relevant publications for this 
systematic review. In addition, they have easy-to-use search functions and allow the export of 
reference to Endnote (a widely used reference management system). Additionally, for the 
current update, eligible studies were searched in the articles from March 2015 until March 2017 
to identify any additional relevant publications.  
 
A manual search of reference lists of relevant reviews and articles included in the systematic 
review was performed.  The search was conducted based on pre-defined search terms 
[Ergocalciferol OR Cholecalciferol OR vitamin D OR Vitamin D2 OR vitamin D3 OR 
25(OH)D] And [Endotheli* OR Endotheli* dysfunction OR FMD or Hyperaemia OR 
Plethysmography OR Flow mediated OR Endothelial-dependent  OR Vasomotor or Vasoacti* 
OR Blood flow OR Brachial OR Vasodilat* OR Dilat* OR Vascular resistance OR Pulse Wave 
OR Augmentation index OR Arterial stiffness OR Digital volume pulse OR Pulse amplitude 
tonometry OR Arterial compliance]. 
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2.2.2 Study selection  
The following criteria were applied to identify articles to be included in this systematic review 
and meta-analysis: (1) RCTs; (2) studies involving adults aged 18 years or more, and no 
exclusion criteria were applied for health status, smoking history or body size; (3) vitamin D 
administered alone i.e. not combined with other drugs or nutritional interventions; studies were 
not excluded on the basis of the dose, duration of follow up, route of administration of vitamin 
D or type of administration (i.e. tablet, capsule, solution or as fortified food) and type of assay 
used for the determination of 25(OH)D concentrations; (4) studies reporting changes in EF 
measured by ultrasound, venous-occlusion phlethysmography, photo phlethysmography, 
PWV, pulse amplitude tonometry, laser Doppler flowmetry; (5) no language or time 
restrictions were applied in searching the databases.  
 
Two investigators (AMH and MS) independently screened the titles and abstracts of the articles 
to evaluate eligibility for inclusion. If consensus was reached, articles were either excluded or 
moved to the next stage (full text). If consensus was not reached, the articles were moved to 
the full-text stage. The full texts of the selected articles were appraised critically to determine 
eligibility for inclusion in the systematic review. Disagreements were resolved by discussion 
between the investigators until consensus was reached. 
2.2.3 Data extraction and quality assessment 
The following information was extracted from the eligible articles: (1) authors, journal details 
and year of publication; (2) participants (total number, male/female ratio, age, health status); 
(3) study characteristics (country, design, inclusion/exclusion criteria, description of 
measurement protocols; (4) vitamin D intervention (type, formulation, dose, duration of follow 
up, route of administration); (5) EF measurement (instrument, position, duration of cuffing) 
and (6) circulating concentrations of vitamin D before and after intervention. 
 
In addition, the modified Jadad score was adopted to assess the risk of bias of the included 
studies; possible scores ranged from 0 to 5 and a score of ≤ 3 indicates high risk while a score 
of > 3 indicates low risk of bias (Crowther et al., 2010). 
2.2.4 Statistical analysis 
Serum concentrations of 25(OH)D given in ng/mL were converted to nmol/L (1 ng/mL=2.46 
nmol/L)(Dietary Reference Intakes for Calcium and Vitamin D, 2011). Several methods were 
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used to assess EF in the included studies including flow mediated dilation (FMD), forearm 
blood flow (FBF), pulse wave analysis (PWA) and laser Doppler (LD) with the results obtained 
from these methods reported on different scales. Therefore, to allow comparison of effect sizes 
between studies, standardised mean differences (SMDs) were used as a summary statistic. 
SMD is estimated from the difference between the mean outcome values of the intervention 
and control groups divided by the pooled standard deviation (SD) of the outcome values; this 
converts the estimated effect to SD units. SMD of 0.2, 0.5 and 0.8 represent small, medium 
and large effect sizes, respectively (Cummings, 2011). In addition, different methods were 
frequently used in the same trial to assess EF, as shown in Table 2.1, and therefore this lack of 
independence of the EF measurement in each trial was taken into consideration in the 
derivation of the pooled effect size. Statistical analyses were performed by using 
Comprehensive meta-analysis software (version 2, Biostat, Englewood, New Jersey, USA). 
Data synthesis, including calculation of effect sizes with 95% confidence intervals, was 
accomplished by employing a random-effects model using inverse variance weighting. Forest 
plots were generated for graphical presentation of the effect of supplemental vitamin D on EF. 
For this purpose, the mean and SD of the EF measure before and after the intervention period 
(for both vitamin D intervention and control) were extracted and used in the analysis. For 
studies that reported changes in EF at two or more time-points (e.g. acute and chronic effects 
of vitamin D supplementation), the last EF measurement (chronic effect) was used in the meta-
analysis. Data not provided in the main text or tables were extracted from the figures.  
 
Subgroup analyses were undertaken to investigate the variables which may have influenced the 
effects of supplementation on EF. These factors included: health status, type (vitamin D2 or 
D3) and the frequency of administration (single dose, daily-weekly or monthly) of vitamin D 
supplementation. Random effect meta-regression analyses were used to determine whether 
participant baseline characteristics (age, BMI, systolic and diastolic blood pressure, baseline 
concentration of 25-OHD) influenced the effect of vitamin D supplementation (vitamin D2 or 
D3) on EF. Furthermore, meta-regression analyses were conducted to investigate the influence 
of other factors including vitamin D dose, baseline 25(OH)D, change in 25(OH)D 
concentration after supplementation, duration of interventions, sample size and quality score 
(Jadad score) on the effect of vitamin D supplementation on EF.  
 
 37 
 
Heterogeneity between studies was evaluated using Cochrane Q statistics; p > 0.1 indicates 
significant heterogeneity. The I2 test was also used to evaluate consistency between studies 
where a value <25% indicates low risk of heterogeneity, 25-75% indicates moderate risk of 
heterogeneity and >75% indicates high risk of heterogeneity (Higgins et al., 2003). The 
evidence of publication bias was assessed by visual inspection of the funnel plots and by 
Egger’s regression test (Egger et al., 1997). 
2.3. Results 
2.3.1 Search results 
The process of screening and selection of studies is summarised in Figure 2.1. The original 
primary search of the four databases produced 4159 articles after removal of duplicates. After 
title and abstract screening, 22 full-text papers were retrieved for further evaluation. 
Additionally, one study was found by manual searching references of the relevant reviews and 
studies. Examination of the full text of 23 articles yielded 16 studies which were eligible to be 
included in this systematic review and meta-analysis. One trial (Witham et al., 2010) included 
two independent arms supplementing different vitamin D doses, which resulted in 17 
independent interventions entered in the meta-analysis. The article describing that original 
analysis was published by (Hussin et al., 2017). For the work reported in this chapter, the 
reviews were then extended to accommodate any more recently published papers and four 
additional articles (Dalan et al., 2014; Pilz et al., 2015; Witham et al., 2015; Borgi et al., 2017) 
published within the time frame (March 2015 to March 2017) were found and are included in 
this review. Therefore, the final number of articles included in this review is 20. 
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N, number of subjects; T2D, Type 2 Diabetes; OW, overweight; CKD, Chronic Kidney Disease; Ht, Hypertension; HIV, Human Immunodeficiency Virus; CHD, Coronary Heart Disease; PAD, 
Peripheral Arterial Disease; MI, Myocardial Infarction; ISH, Isolated systolic Hypertension ; CFS/ME, Chronic fatigue syndrome/<myalgic encephalomyelitis; AI; Augmentation Index; PWV, 
Pulse Wave Velocity; FMD, Flow Mediated Dilatation; RH-PAT, Reactive Hyperaemia Peripheral Arterial Tonometry; LD-ION: Laser Doppler Iontophoresis; RHI, Reactive Hyperaemia Index; 
EDV; Endothelial-dependent vasodilation; Group 1: 100 000 IU , Group 2: 200 000 IU; IU, International Unit; D,  daily; w, weeks; WK, weekly; M, monthly; SD, single dose; 2M, every 2 
months; 3M,  every 3 months. Δ= changes in vitamin D concentrations after supplementation.; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; IA, Immunoassay; LC-MS,  
Liquid chromatography–mass spectrometry
Table 2. 1: Summary of findings from 20 publications included in systematic review and meta-analysis 
 
Author Country Health 
Status 
Outcome Sample 
Size 
Male 
(N) 
Age  
(years) 
BMI 
(kg/m2) 
SBP/DBP 
(mmHg) 
Vit D Dose 
(IU) 
Duration 
(Frequency) 
Formulation 
(Route) 
Baseline Vit 
D (Assay)  
Δ Vit D 
(nmol/L) 
Jadad  
Score 
Breslavsky et al. 2013 (Breslavsky et al., 
2013) 
Israel T2D AI 47 22 67 29 153/74 1000  52w 
(D) 
Capsule 
(Oral) 
29 (IA) 17 3 
Gepner et al. 2012 (Gepner et al., 2012) US Healthy PWV, 
FMD,AI 
109 0 64 26 122/72 2500  16w 
(D) 
Biscuits 
(Oral) 
78 (LC-MS) 39 5 
Harris et al. 2011 (Harris et al., 2011a) US OW FMD 45 21 29 30 123/74 60,000  16w 
(M) 
Capsule 
(Oral) 
36 (IA) 66 4 
Hewitt et al. 2013 (Hewitt et al., 2013) Australia CKD PWV, 
FMD 
60 29 60 29 131/76 50,000  8w 
(WK) 
Solution 
(Oral) 
42 (IA) 42 4 
Larsen et al. 2012 (Larsen et al., 2012) Denmark Ht AI, PWV 130 35 60 28 131/77 3000  20w 
(D) 
Tablet 
(Oral) 
57 (IA) 52 5 
Longenecker et al. 2012(Longenecker et al., 
2012) 
US HIV FMD 45 35 47 27 118/80 4000  12w 
(D) 
Capsule 
(Oral) 
19 (IA) 12 5 
Marckmann et al. 2012 (Marckmann et al., 
2012) 
Denmark CKD PWV, 
FMD 
52 39 71 25 135/72 40,000  8w 
(WK) 
Capsule 
(Oral) 
28 (LC-MS) 118 4 
Sokol et al. 2012 (Sokol et al., 2012) US CHD RH-PAT 90 66 55 30 133/76 50,000 12w 
(WK) 
Tablet 
(Oral) 
84 (LC-MS) 67 3 
Stricker et al. 2012 (Stricker et al., 2012) Switzerland PAD AI 62 38 73 27 136/74 100,000  4w 
(SD) 
Solution 
(Oral) 
41 (IA) 19 4 
Sugden et al. 2008 (Sugden et al., 2008) UK T2D FMD 34 18 65 31 141/80 100,000  8w 
(SD) 
Solution 
(Oral) 
38 (IA) 23 3 
Witham et al. 2010 (Witham et al., 2010) UK T2D FMD 61 41 G1:65 
G2:63 
G1:31  
G2:32 
G1:141/76 
G2:128/72 
G1:100000 
G2:200000 
16w 
(SD) 
Solution 
(Oral) 
G1: 46  (IA) 
G2: 43 (IA) 
G1:28 
G2:18 
5 
Witham et al. 2012 (Witham et al., 2012) UK Stroke FMD 58 42 66 27 129/72 100000 16w 
(SD) 
Solution 
(Oral) 
38 (IA) 12 3 
Witham et al. 2013 (Beveridge and Witham, 
2013) 
UK-South 
Asian 
Healthy  FMD, 
PWV, AI,  
LD-ION  
50 0 41 27 121/78 100000 8w 
(SD) 
Solution 
(Oral) 
27 (IA) 10 5 
Witham et al. 2013 (Witham et al., 2013b) UK MI RHI 75 52 64 27 128/72 100000 24w 
(2M) 
Solution 
(Oral) 
47 (IA) 13 4 
Witham et al.2013 (Witham et al., 2013c) UK ISH FMD, 
PWV 
159 82 77 28 163/78 100000 52w 
(3M) 
Solution 
(Oral) 
45 (IA) 25 5 
Yiu et al. 2012 (Yiu et al., 2013) China T2D FMD, 
PWV 
100 66 50 25 146/81 5000 12w 
(D) 
Tablet 
(Oral) 
54 (IA) 92 3 
Dalan et al. 2016 (Dalan et al., 2016a)  Singapore T2D RHI, AI 61 33 54 28 139/77 1000 16w (D)                                       Tablet (Oral) 43(IA) 35 5 
Pilz et al 2015 (Pilz et al., 2015) Austria Ht PWV 200 106 60 30 143/86 2800 8w (D) Oily drops 
(Oral) 
52(IA) 28 5 
Witham et al 2015 (Witham et al., 2015) UK CFS/ME PWV,FMD 50 12 49 29 128/78 100,000 24w (2M) Oily drops 
(Oral) 
46(IA) 18 3 
Borgi et al 2016 (Borgi et al., 2017) US OW, 
obese 
EDV 93 30 37 34 118/78 50000 8w (WK) Tablet (Oral) 37(IA) 71 3 
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Figure 2. 1: Flow diagram of the selection process of the randomised clinical trials 
included in the systematic review and meta-analysis.  
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2.3.2 Studies characteristics 
The total number of participants from the 20 studies included in this systematic review was 
1581 (814 females; 767 males) with median of 79 (range 34 -200) participants per study. The 
median age was 57.6 (range 37-77) years. All RCTs included in the meta-analysis were parallel, 
double-blind, placebo-controlled trials. The duration of the trials ranged from 4 weeks to 52 
weeks (Table 2.1).  
 
Four studies investigated the effect of vitamin D in healthy participants (Harris et al., 2011a; 
Witham et al., 2013a; Gepner et al., 2015; Borgi et al., 2017), two studies were conducted in 
patients with chronic kidney disease (Marckmann et al., 2012; Hewitt et al., 2013), five studies 
in diabetics (Sugden et al., 2008; Witham et al., 2010; Breslavsky et al., 2013; Yiu et al., 2013; 
Dalan et al., 2016b), seven studies in patients with CVDs (Larsen et al., 2012; Sokol et al., 
2012; Stricker et al., 2012; Witham et al., 2012; Witham et al., 2013b; Witham et al., 2013c; 
Pilz et al., 2015), one study in patients with chronic fatigue syndrome/myalgic 
encephalomyelitis (Witham et al., 2015) and one study in patients with HIV (Longenecker et 
al., 2012). In all trials, participants were supplemented orally with vitamin D. Trials however 
utilised different forms of supplementation including tablets (Larsen et al., 2012; Sokol et al., 
2012; Yiu et al., 2013; Dalan et al., 2016b; Borgi et al., 2017), solution (Sugden et al., 2008; 
Witham et al., 2010; Stricker et al., 2012; Witham et al., 2012; Hewitt et al., 2013; Witham et 
al., 2013a; Witham et al., 2013b), capsules (Harris et al., 2011a; Longenecker et al., 2012; 
Marckmann et al., 2012; Breslavsky et al., 2013), fortified biscuits (Gepner et al., 2012) and 
oil drops (Pilz et al., 2015; Witham et al., 2015). The majority of the trials utilised vitamin D3 
with daily doses varying from 1000 IU/day (Breslavsky et al., 2013; Dalan et al., 2016a) to 
5000 IU/day (Yiu et al., 2013).  
 
Several methods were used to assess EF in the included trials. The most commonly used 
methods were flow-mediated dilation (FMD) (Sugden et al., 2008; Witham et al., 2010; Harris 
et al., 2011a; Gepner et al., 2012; Longenecker et al., 2012; Marckmann et al., 2012; Hewitt 
et al., 2013; Witham et al., 2013c; Yiu et al., 2013), pulse wave velocity (PWV) (Gepner et 
al., 2012; Larsen et al., 2012; Marckmann et al., 2012; Hewitt et al., 2013; Witham et al., 
2013a; Witham et al., 2013c; Yiu et al., 2013; Pilz et al., 2015) and augmentation index (AIx) 
(Gepner et al., 2012; Larsen et al., 2012; Stricker et al., 2012; Breslavsky et al., 2013; Gepner 
et al., 2015; Dalan et al., 2016b). Other methods include laser Doppler flowmetry (Witham et 
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al., 2013a), digital volume pulse (Witham et al., 2013b) and endothelial-dependent 
vasodilation (Borgi et al., 2017) (Table 2.1). 
2.3.3 Qualitative analysis 
Three of the studies included in the present systematic review reported a significant 
improvement in EF in response to vitamin D administration (Sugden et al., 2008; Harris et al., 
2011b; Breslavsky et al., 2013) whereas the other 17 studies reported no effect of 
supplementation (Witham et al., 2010; Gepner et al., 2012; Larsen et al., 2012; Longenecker 
et al., 2012; Marckmann et al., 2012; Sokol et al., 2012; Stricker et al., 2012; Witham et al., 
2012; Hewitt et al., 2013; Witham et al., 2013b; Witham et al., 2013c; Yiu et al., 2013; Gepner 
et al., 2015; Pilz et al., 2015; Witham et al., 2015; Dalan et al., 2016b; Borgi et al., 2017). 
Fifteen studies described the methods of randomisation (Witham et al., 2010; Gepner et al., 
2012; Larsen et al., 2012; Longenecker et al., 2012; Marckmann et al., 2012; Sokol et al., 
2012; Beveridge and Witham, 2013; Hewitt et al., 2013; Witham et al., 2013b; Yiu et al., 2013; 
Gepner et al., 2015; Pilz et al., 2015; Witham et al., 2015; Dalan et al., 2016b; Borgi et al., 
2017), and five studies stated the methods of allocation concealment (Witham et al., 2010; 
Larsen et al., 2012; Longenecker et al., 2012; Beveridge and Witham, 2013; Witham et al., 
2013b). The drug history of the participants was reported by all except three studies (Harris et 
al., 2011a; Beveridge and Witham, 2013; Breslavsky et al., 2013). With the exception of two 
studies (Harris et al., 2011a; Hewitt et al., 2013), all other studies reported, and described, 
participant dropout. The quality of the included studies ranged from 3 to 5 (Jadad score) and 
thirteen studies had a low risk of bias (Jadad score ≥4) (Table 2.1).   
 2.3.4 Meta-analysis 
Meta-analysis of the 20 studies (1581 participants) showed that, overall, there was a non-
significant trend for vitamin D supplementation improve EF (SMD: 0.10, 95% CI: -0.01, 0.20, 
p=0.08) (Figure 2.2). There was no overall effect of supplemental vitamin D on post-occlusive 
vasodilation of the brachial artery (FMD %, N=11, +0.09 %, 95 % CI: -0.08, 0.27, p=0.30) 
(Table 2.2). 
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Figure 2. 2: Forest plot showing the effect of vitamin D supplementation on endothelial 
function.  
T2D, type 2 diabetes; CVD, cardiovascular disease; CKD, chronic kidney disease; CFS/ME, Chronic 
Fatigue Syndrome/Myalgic Encephalomyelitis; HIV, Human Immunodeficiency Virus. Relative weight 
for a random model allows for small size studies contributing in a similar magnitude to the pooled 
estimate. The marker may be vary in size according to the weights assigned to the different studies. The 
pooled effect is represented using a diamond. 
 
Heterogeneity between studies was not significant (Q=22.8, I2=12.5%, P=0.29). However, 
subgroup analysis showed that vitamin D supplementation improved EF significantly in 
participants with type 2 diabetes (N=5, SMD: 0.24, 95 % CI: 0.06, 0.42, P=0.003) (Table 2.3). 
This was also confirmed by the significant effect of vitamin D supplementation in type 2 
diabetics on changes in FMD % (N=4, +0.28 %, 95 % CI: 0.00, 0.55, p=0.04 (Table 2.2). The 
response of EF to vitamin D supplementation was not significantly modified by baseline health 
status of the participants, method of administration, baseline 25(OH)D concentrations or type 
of vitamin D (Table 2.3). Meta-regression analyses demonstrated a significant effect of BMI 
(β: 0.04, SE: 0.01, P=0.03) and there was a trend of significant association of baseline diastolic 
blood pressure (β: 0.02, SE: 0.01, p=0.06) with the effect size on EF of vitamin D 
supplementation (Table 2.4). 
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Table 2. 2: Effect of vitamin D supplementation on endothelial function measured by flow 
mediated dilation (FMD) of brachial artery in the total samples and in subjects with type 2 
diabetes 
 
 Number Studies Point estimate (%)a Standard error ±95%CI P-value 
Total Sample 11 0.09 0.09 -0.08 0.27 0.30 
Type 2 Diabetes 4 0.28 0.13 0.00 0.55 0.04 
aPoint estimate is the post-occlusive percent dilation of brachial artery 
 
 
Table 2. 3: Sensitivity analysis to evaluate the influence of health status, frequency of 
administration of vitamin D and type of vitamin D dose and baseline 25(OH)D 
concentration on the effect of vitamin D supplementation on endothelial function 
 
Group No of trials or 
subgroup 
Effect size 95% CI p p between 
groups 
Health status 
 Healthy 
 HIV 
 T2D 
 CKD  
 CVD 
 CFS/ME 
 
4 
1 
5 
2 
7 
1 
 
0.05 
0.00 
0.24 
-0.07 
-0.00 
0.16 
 
-0.10 0.21 
-0.61 0.62 
0.06 0.42 
-0.40 0.25 
-0.12 0.11 
-0.23 0.55 
 
0.47 
0.97 
0.003 
0.64 
0.95 
0.41 
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Frequency of Dose 
Administration 
 1-2 months 
 1-3 month 
 Daily-Weekly 
 Single dose 
 
 
2 
5 
8 
5 
 
 
0.16 
      0.08 
-0.02 
0.10 
 
 
-0.23 0.55 
-0.09 0.25 
-0.13 0.08 
-0.07 0.27 
 
 
0.41 
0.38 
0.69 
0.26 
 
 
 
0.12 
Baseline 25-OHD 
concentration  
Normal 
(≥50nmol/L) 
Deficient 
(<50nmol/L) 
 
 
 
5 
 
15 
 
 
 
0.01 
 
-0.00 
 
 
 
0.00 0.20 
 
-0.12 0.12 
 
 
 
0.04 
 
0.98 
 
 
 
 
0.12 
Vitamin D type 
 D2 
 D3 
 
3 
17 
 
-0.09 
0.08 
 
-0.33 0.14 
-0.00 0.16 
 
0.42 
0.05 
 
0.12 
HIV, Human Immunodeficiency Virus; T2D, type 2 diabetes; CVD, cardiovascular disease; CKD, chronic kidney 
disease; CFS/ME, Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis; D2, ergocalciferol; D3, cholecalciferol; 
25(OH)D, 25 hydroxy vitamin D.  
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Table 2. 4: Meta-regression analysis to evaluate the association of potential modifiers of 
the effects of vitamin D supplementation on endothelial function 
 
Covariates Slope SE Q (df=1) P Value 
Baseline Systolic BP (mmHg) 0.002 0.003 0.35 0.55 
Baseline Diastolic BP (mmHg) 0.02 0.01 3.38 0.06 
Vitamin D concentration at baseline (nmol/L) -0.003 0.002 3.12 0.07 
Change in 25(OH)D concentration after 
supplementation (nmol/L) 
 
-0.001 0.001 0.83 0.35 
Study Duration (weeks) 0.001 0.003 0.01 0.90 
Vitamin D Dose (IU) 0.0001 0.00001 0.00 0.96 
Age (years) -0.003 0.004 2.25 0.13 
BMI (kg/m2) 0.04 0.01 4.39 0.03 
Study Sample Size (N) -0.001 0.001 0.69 0.40 
Jadad Score -0.02 0.04 0.30 0.57 
BP, blood pressure; BMI, body mass index; N, number of study participants; 25(OH)D, 25 hydroxy vitamin D. 
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BMI did not modify the association between type 2 diabetes and EF (N=8, β: 0.04, SE: 0.03, 
p=0.23) (Appendix 2.2) whereas lower baseline 25(OH)D concentrations were associated with 
larger effect sizes in type 2 diabetic participants (N=8, β: -0.02, SE: 0.01, p=0.04) (Figure 2.3). 
The dose of vitamin D was not associated with significant changes in EF (Table 2.4 and Figure 
2.4). 
 
Figure 2. 3: Meta-regression analysis to evaluate the influence of baseline vitamin D 
concentration on the effects of vitamin D supplementation on endothelial function in type 2 
diabetic patients 
 
 
 
Figure 2. 4: Meta-regression analysis to evaluate the association between daily dose of vitamin 
D and the effects of vitamin D supplementation on endothelial function (P = 0.96). 
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2.3.5 Publication bias 
Visual inspection of the funnel plot showed modest evidence of asymmetric distribution of 
the effect size (Figure 2.5), which was confirmed formally by the lack of significance of the 
Egger’s test (p=0.06).  
 
Figure 2. 5: Funnel plot examining the presence of publication bias in the meta-analysis of the 
effects of vitamin D supplementation on endothelial function. 
 
2.4. Discussion 
Overall, this meta-analysis demonstrated no effect of vitamin D supplementation on EF. In 
addition, changes in vitamin D concentration after supplementation were not associated with 
effects of vitamin D supplementation on EF. However, vitamin D supplementation resulted in 
a significant improvement in EF in patients with diabetes, and there was a significant, positive 
trend towards greater effects of vitamin D on EF with increasing baseline BMI and an almost 
significant association with baseline diastolic blood pressure.  
 
Contrary to this meta-analysis, a recent systematic review and meta-analysis including 12 RCT 
conducted by (Mazidi et al., 2017) reported a positive effect of vitamin D supplementation on 
endothelial function. In the latter analysis, flow mediated dilation alone was chosen as the 
method for measuring endothelial function. In addition, the RCT included in this review 
supplemented with both vitamin D2 and D3, and one study provided paricalcitol (an analogue 
of 1,25-dihydroxyergocalciferol, the active form of vitamin D2) as the form of vitamin D 
supplementation in chronic kidney disease patients. 
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In contrast, the systematic review reported in this chapter was more inclusive and included 
studies regardless of the method used for measuring endothelial function. This resulted in the 
inclusion of articles using Augmentation Index, Pulse Wave Velocity, Flow Mediated 
Dilatation, Reactive Hyperaemia Peripheral Arterial Tonometry; Laser Doppler Iontophoresis, 
Reactive Hyperaemia Index and Endothelial-dependent vasodilation. The diversity of the 
methods for measuring endothelial function in this chapter might have contributed to the 
contrasts findings when compared with the systematic review and meta-analysis done by 
(Mazidi et al., 2017).  
 
Several putative mechanisms could explain the positive effects of vitamin D on EF in some 
population groups, particularly in those at higher cardiovascular risk. Vitamin D is involved in 
the regulation of endothelial cell-dependent vasodilation, which may be mediated by the effect 
of vitamin D metabolites on the renin angiotensin-aldosterone system, a hormonal system that 
regulates blood pressure and fluid balance. A low plasma 25(OH)D predisposes to up-
regulation of the renin-angiotensin system, smooth muscle proliferation and favours a pro-
inflammatory state, which can increase the risk of hypertension and left ventricle hypertrophy 
(Wu et al., 2010). The improvement in EF through vitamin D supplementation could also be 
mediated by the local effects of vitamin D metabolites on calcium metabolism in vascular 
smooth muscle cells and on the release of inflammatory cytokines, which may affect vascular 
contractility (Kassi et al., 2013). Vascular smooth muscle and endothelial cells express VDR 
as well as 1α-hydroxylase (Somjen et al., 2000), allowing for autocrine production of 
1,25(OH)2D, which may act at the local level to modulate the effects of inflammatory cytokines 
on the vasculature, such as decreasing endothelial adhesion molecules, increasing NO 
production (Molinari et al., 2011) and reducing platelet aggregation (Aihara et al., 2006). 
Binding of 1,25(OH)D2 and activation of the VDR induces the transcription of a wide range of 
genes including those coding for vascular endothelial growth factor, which in turn promotes 
NO synthesis by endothelial cells (Ahmed et al., 2013). In addition, 1,25(OH)2D is a direct 
regulator of endothelial NO synthase (Andrukhova et al., 2014).  
 
Vitamin D may also have beneficial effects on cardio-metabolic health in those with 
hypertension (Bednarski et al., 2007; Almirall et al., 2010; Cosenso-Martin and Vilela-Martin, 
2011; Chai et al., 2013), type 2 diabetes (Borissova et al., 2003; Knekt et al., 2008; Yiu et al., 
2013) and CVD (Grandi et al., 2010; Nadir et al., 2010; Al Mheid et al., 2011). A meta-analysis 
of data from 21 prospective studied showed  an inverse association between vitamin D status 
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and risk of type 2 diabetes (Song et al., 2013). In addition, cardiovascular disease is the main 
cause of premature mortality and morbidity in patients with CKD (Marckmann et al., 2012). 
These cardiovascular complications may be related to hypovitaminosis  (Williams et al., 2009), 
which may be linked to the inability of renal mass to convert 25(OH)D to the active form of 
vitamin D, 1, 25-dihydroxyvitamin (Ruggiero and Pacini, 2009). However, this analysis did 
not show a significant effect of vitamin D supplementation on EF in patients with CKD, which 
could be explained by several factors including the small number of studies (only two trials), 
the short duration of supplementation (8 weeks), the inadequacy of the vitamin D dose or the 
advanced stage of endothelial dysfunction. Alternatively, such vitamin D supplementation may 
be ineffective in improving EF in CKD patients. 
   
In the present meta-analysis, vitamin D supplementation was observed to produce a significant 
improvement in vascular function in individuals with type 2 diabetes. While the small number 
of trials included in the analyses (n=5) calls for cautious and objective interpretation of the 
finding, this is supported by a robust mechanistic rationale. This apparent disease-specific 
effect may be explained by several mechanisms including the link between low 25(OH)D 
concentrations and (1) deterioration of β-cell function, (2) dysregulation of peripheral insulin 
signalling and (3) altered glucose disposal which are characteristic features in the pathogenesis 
of type 2 diabetes (Pittas et al., 2007b; Knekt et al., 2008; Pittas et al., 2010). These effects 
appear to be supported by the greater effect of vitamin D supplementation on EF in type 2 
diabetic patients with insufficient vitamin D status. Vitamin D receptors and 1-α-hydroxylase 
are expressed in pancreatic β-cells and therefore, an involvement of vitamin D in the regulation 
of insulin secretion may be expected (Borissova et al., 2003; Talaei et al., 2013; Al-Shoumer 
and Al-Essa, 2015). In turn, 1,25(OH)2D activates transcription of the human insulin receptor 
gene, stimulates expression of the insulin receptor (Maestro et al., 2002) and enhances insulin-
mediated glucose transport in vitro (Maestro et al., 2000). In addition, insulin secretion is a 
calcium-dependent process and vitamin D metabolites have been linked to the regulation β-cell 
calcium pools, which promotes insulin release (Nagpal et al., 2005). The putative beneficial 
effects of vitamin D metabolites on EF may also be explained by the mechanistic 
interconnection between the insulin and NO pathways. The activation of the insulin receptor 
on the endothelial cells induces a vasodilatory response via the activation of the 
phosphoinositol-3-phosphate-Akt pathway which increases NO production by the enzyme 
endothelial nitric oxide synthase (Siervo et al., 2011a). 
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The meta-regression analysis showed a significant improvement of EF in response to vitamin 
D supplementation in participants with high BMI. There is a growing evidence of an inverse 
association between plasma 25(OH)D concentrations and BMI (Wortsman et al., 2000; 
Rodríguez-Rodríguez et al., 2009). Decreased vitamin D status was found in obese subjects 
(Wortsman et al., 2000; Vilarrasa et al., 2007; Rodríguez-Rodríguez et al., 2009), which may 
be explained by adipose tissue sequestration and/ or volumetric dilution of 25(OH)D (Blum et 
al., 2008). In turn, this may explain the tendency towards a greater effect of supplemental 
vitamin D on EF in subjects with greater adiposity. In addition, obesity and excess visceral 
adiposity are closely associated with insulin resistance and development of type 2 diabetes, 
which may explain the significant effect of vitamin D supplementation on EF in obese subjects. 
These findings support the idea that the effect size of vitamin D on EF may be correlated with 
the degree of metabolic derangement of the insulin signalling pathway.   
 
Results may have been affected by the choice of the method used to measure vitamin D status 
i.e. by estimation 25(OH)D concentrations. Unlike chromatographic methods, immunoassays 
do not measure vitamin D3 and vitamin D2 independently, and this is a well-recognised 
limitation of immunoassays. The importance of being able to quantify both metabolites of 
vitamin D independently is becoming increasingly important with the evidence that vitamin D3 
is more biologically active than vitamin D2 (Tripkovic et al., 2012) as well as emerging 
evidence that 25(OH)D2 concentrations are in the range of 1.5-10.0nmol/L in several RCT and 
population-based studies and thus, may contribute significantly to total 25(OH)D status 
(Cashman et al., 2014). It is also important to point out that results of 25(OH)D estimation 
using chromatographic methods show significant variation, mainly due to extraction and 
calibration problems associated with these methods. Such assay variation reinforces the need 
for all users of vitamin D assays to have appropriate quality control and standardisation 
protocols in place. 
 
This meta-analysis has some limitations. First, the available trials had relatively small sample 
sizes with samples sizes of <100 in about 75% of the trials included in the meta-analysis. 
Second, the variability in duration, dose and type of vitamin D supplementation, the different 
methods used to assess EF and the diversity in participant characteristics (age, sex and health 
status) may have introduced significant heterogeneity and have militated against observation 
of the true overall effects of vitamin D supplementation on EF in our meta-analysis. Third, not 
all studies adjusted for potential confounding factors that may have influenced the effect of 
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vitamin D on EF such as sun exposure, seasonality, physical activity or dietary patterns. Most 
of the study participants were aged between 40 to 77 years old, thus limiting the applicability 
of the findings to other life stages. Finally, studies have used different assays to measure 
25(OH)D concentrations (Immuno-Assay, N=16; Liquid Chromatography Mass Spectrometry, 
N=3), which may have introduced a measurement bias (Appendix 2.3). However, the 
exclusion of the three studies using LC-MS from the analysis did not modify the results, which 
provides support to the importance of vitamin D status in influencing the efficacy of vitamin 
D supplementation on vascular outcomes. 
 
The current evidence base is believed to be inadequate to draw firm conclusions about any 
protective role of supplemental vitamin D on EF and as a pharmaco-nutritional strategy for 
CVD prevention. However, this study provides important information on the effects of vitamin 
D supplementation on EF and shows that benefit may be anticipated in diabetics and those with 
higher BMI. This may indicate a potential role of insulin resistance in modulating the effects 
of vitamin D on vascular function and a greater effect of supplemental vitamin D on EF in 
subjects with greater adiposity. This hypothesis remains to be tested in future studies.
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Chapter 3: Methodology 
 
3.1 Measurement of nitric oxide (NO) production  
Reduced NO availability, through reduction of NO generation or NO inactivation, is an 
important hallmark of endothelial dysfunction, which is closely linked to the development of 
atherosclerosis and is an independent risk factor for cardiovascular events (van Eijk et al., 
2007).  As a potent endogenous vasodilator, NO plays a crucial role in maintaining the 
homeostasis of the endothelium. However, because of the short life span of NO (t ½ = 3-6 s), 
the assessment of NO production can be a challenging analytical problem in humans 
(Kleinbongard et al., 2006). This is due to its rapid chemical reaction with a wide range of 
molecules, e.g. NO disappears rapidly after it binds with oxyheme proteins such as 
oxyhaemoglobin (Hakim et al., 1996) and it is also oxidized to nitrite and nitrate which have 
circulating half-lives of 110 seconds  and 5-8 hours respectively (Bryan and Grisham, 2007).  
Due to the extremely short physiological half-life of NO, the quantification of NO metabolites 
(nitrate (NO3ˉ) and nitrite (NO2ˉ)) have been used as surrogates to calculate in vivo NO 
production i.e., circulating NO2ˉ can be used for the estimation of endothelial NO formation, 
and NO3ˉ was used in estimating overall NO turnover (Kelm, 1999). However, NO can be 
determined using several sophisticated assays and techniques which are is not suitable for the 
in vivo setting, and are not available/ applicable for routine clinical use (Bryan and Grisham, 
2007).  
The methods of measurement NO production can be classified as direct methods (the target of 
measuring in vivo NO concentration itself) and indirect methods. Direct methods include the 
use of chemiluminescence methods to measure the real estimation of NO directly in the blood 
stream or in exhaled air (Siervo et al., 2011c). For indirect methods, the concepts of 
measurements are more to the estimation of NO production rate (Mair and Puschendorf, 1998; 
Kleinbongard et al., 2006). This involves the measurement of the concentration of NO-derived 
nitrite and nitrate in the blood/plasma or in urine. Indirect methods are then further classified 
as isotopic (van Eijk et al., 2007) and non-isotopic methods, depending on whether the protocol 
include stable isotope tracer or not. Non-isotopic methods are then further classified into 
laboratory and clinical methods. Laboratory methods estimate the availability of NO by 
measuring the concentrations of specific substance in plasma/urine (Ahren et al., 1999; Cui et 
al., 2007). Clinical methods estimate the production of NO by measuring the vasodilatory 
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response of an artery which is assumed to be proportional to NO availability (Wilkinson et al., 
2002). The methods of measurement NO production are summarized in Figure 3.1. The 
technical characteristics, advantages and disadvantages of each method are described in Table 
3.1. 
 
 
Figure 3. 1: The methods of measurement of in vivo NO production in humans 
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Table 3. 1: Description of the non-isotopic protocols used for the determination of in vivo NO production in human 
 
 Method Description Advantages Disadvantages 
1.Direct method 
 
 
1) Intra-vascular 
Porphirinic Probe 
(Vallance et al., 1995) 
 
 
This method was invented in 1995. 
However, it has not been re-used in 
other studies for the measurement of 
NO. The procedure involved the 
insertion of a porphyrinic microsensor 
into a hand vein, where the vessel was 
then stimulated with pharmacological 
stimuli (acetylcholine or bradykinin). 
 
Able to measure in vivo NO 
production in the blood vessels 
 
Invasive and requires a high 
skilled operator. The estimation of 
in vivo NO production depends on 
the location of the infusion of 
acetylcholine or bradykinin and 
the results are site-specific, and do 
not apply necessarily to other parts 
of the vasculature. 
 
 
2) Chemiluminescence 
(Kharitonov et al., 1997) 
 
 
The measurement of in vivo NO 
concentration in exhaled breath. The 
principle of this method is based on the 
measurement of light generated by the 
gas-phase titration of NO and the 
amount light produced by this 
procedure is equal to the NO 
concentration in the air sample. 
 
 
 
 
 
 
 
 
 
Non-invasive and convenient for 
use in vulnerable groups such as 
children and patients. 
Repeatable procedures 
 
It does not give the whole 
estimation of NO concentration 
and require calibration curves to 
acquire the quantitative 
measurement. The estimation of in 
vivo NO production is dependent 
on the site of the measurement 
(respiratory system) and thus does 
not reflect necessarily the whole 
systemic NO production. 
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 Method Description Advantages Disadvantages 
2. Indirect method 
   Laboratory methods 
 1. Nitrate or Nitrite 
(Griess, Ozone-based 
chemiluminescence, Mass 
Spectrometry) 
(Metzger et al.,   2006;   
Tsikas, 2007) 
 
Nitrate and NO2
- are the relatively 
stable metabolites of NO found in the 
circulation. The concentrations of NO3ˉ 
and NO2ˉ  in plasma and urinary NO3ˉ  
can be determined using colorimetric 
assays based on the Griess reaction, 
ozone-based chemiluminescence and 
Mass Spectrometry. 
 
Minimally invasive. The Griess 
assay is commercially available 
and ‘ready to use’ kit, which is 
convenient for the measurement of 
NO2ˉ/NO3ˉ. Mass spectrometry 
and chemiluminescence are 
characterised by high accuracy. 
 
It does not provide an estimate of 
the rate of NO synthesis. 
Measurements can be influenced 
by confounding factors such as 
dietary NO3ˉ intake and renal NO3ˉ 
clearance. 
 
 2. Cyclic Guanosine  
Monophosphate 
(cGMP)(Mair and 
Puschendorf, 1998; 
Rybalkin et al., 2003) 
 
Plasma or urine cyclic Guanosine 
Monophosphate (cGMP) may act as a 
marker of NO production. This is 
because cGMP is involved in the 
stimulation of cell proliferation and 
increases permeability of the vascular 
endothelium, inhibits cell proliferation 
and mediates vasorelaxation which 
leads to vasodilation and increased 
blood flow (Smolenski et al., 2000; 
Kook et al., 2003). 
 
Minimally invasive cGMP may be 
quantified by ELISA which is 
characterised by high accuracy. 
 
cGMP is a proxy for NO and not a 
direct measurement of NO 
concentration. 
 
 3. N[omega] hydroxyl-L- 
arginine (NOHA) 
 
The principle of this method is that the 
compound N(omega)-hydroxy-L-
arginine (NOHA) is a product of the 
reaction between arginine and citrulline 
which leads to NO production. 
 
 
Minimally invasive. This metabolite 
is measured using high-pressure 
liquid chromatography (HPLC) 
which is characterised by high 
accuracy 
 
It does not provide an estimate of 
the rate of NO synthesis. 
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 Method Description Advantages Disadvantages 
Clinical methods 
4. Flow Mediated 
Dilation (FMD) 
(Corretti et al., 2002; 
Harris et al., 2010) 
 
FMD test characterised by the 
occurrence of vasodilation after the 
acute increase in the blood flow (shear 
stress resulted from the cuff occlusion 
in the upper arm). This leads to 
increases in diameter of the arterial 
vessel that are proportional to NO 
release. 
 
Non-invasive measurement of 
endothelial function 
Repeatable measurements 
 
Expensive equipment and highly 
skilled operators are required to 
perform the test. Confounding 
factors (temperature, food, drugs 
and sympathetic stimuli) might 
affect the measurement. The 
accuracy of the measurement is 
highly dependent on the quality of 
ultrasound images. 
 
 5. Forearm blood flow 
(FBF) (Wilkinson and 
Webb, 2001) 
 
Also known as venous occlusion 
plethysmography. The principle of this 
measurement is that when the outflow 
of blood via the venous system is 
blocked, arterial inflow is unaltered i.e. 
blood can enter the forearm but cannot 
escape. 
 
Accurate, reproducible and 
convenient method 
Minimally invasive 
 
Requires expensive equipment and 
highly skilled operators. 
Does not provide a quantitative 
measure of NO concentration. 
 
 6. Pulse Wave Analysis 
(Wilkinson et al., 
2002) 
 
The principle of this measurement 
involves the assumption that arterial 
stiffness depends on the smooth muscle 
tone. Provides the estimation of 
augmentation index (AIx) 
measurement which can be used to 
assess vascular stiffness and 
cardiovascular risk. 
 
Simple, repeatable, non-invasive 
means of assessing endothelial 
function in vivo. Accurate and 
convenient method. 
 
The measurement of NO 
bioactivity is local as 
measurements are performed in 
the peripheral arterial circulation. 
Does not provide a quantitative 
measure of NO concentration. 
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3.1.1 Isotopic methods 
Stable isotope tracers have been used for 20 years for the determination of in-vivo whole body 
NO production. Such approaches, are considered as indirect because they use precursor-end-
product paradigms to characterize the pharmacokinetics of the metabolic pathway (Siervo et 
al., 2011c).  The most common protocol used in investigating NO production are summarized 
briefly in Table 3.2. Depending on the type of the protocols, estimates of the rate of NO 
production may differ due to differences in the route of administration, dose and rate of infusion 
of the tracer and the duration of the infusion protocol.  
Detailed descriptions of individual protocols are beyond the scope of this PhD program, which 
principally focused on vitamin D, NO and vascular health. A more detailed description of the 
Nitrate-Nitrate Protocol is provided in Chapter 5 where it was used in the third phase of this 
PhD project, which explored the physiological connection between ageing, vitamin D 
metabolism and whole-body NO production. 
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Table 3. 2: Description of the isotopic protocols used for the determination of in vivo NO production in human 
 Method Description Advantages Disadvantages 
1. Arginine-Citrulline Protocol 
(Leaf et al., 1989) 
 
The principle of this measurement 
involved the assumption that L-
arginine was the precursor for 
endogenously synthesized nitrate 
in humans. 
- Collection of total urine volume 
is not required in this protocol. 
- Confounding factors from NO3ˉ 
dietary intake can be omitted in 
this protocol. 
-The procedures in this protocol 
can estimate information on NO 
synthesis. 
- Requires expensive equipment 
and highly skilled operators 
- The measurement of NO 
production is general and not 
organ-specific measures. 
- Invasive procedure involved the 
intravenous infusion ranged from 
3 to 12 hours. 
2. Arginine-Nitrate Protocol 
(Castillo et al., 1996) 
This protocol uses an intravenous 
tracer administration (labelled 
arginine) as a bolus or constant 
infusion. Urinary NO3ˉ  acted as 
the parameter that have to be 
measured for the solution of the 
model. 
 
- The information on NO synthesis 
and fractional rate of conversion of 
arginine into NO can be obtained 
from this protocol. 
- The assessment of NO 
production is less analytical 
challenging compared to 
Arginine-Citrulline protocol  
- Requires total urine output 
collection (between 12 and 48 
hours) 
- Restriction of dietary NO3
-   
intake during the study. 
- Requires expensive equipment 
and highly skilled operators. 
3. Arginine-Nitrate Protocol - 
Oral Arginine Dose (Forte et 
al., 2006) 
This protocol is suitable to use in 
paediatric population as it is less 
invasive. It is based on the 
principles that oral dose of labelled 
arginine can be absorbed 
immediately in the GI tract and 
mixes with endogenous arginine 
pool. 
- Less invasive procedure. 
-The information on NO synthesis 
and fractional rate of conversion of 
arginine into NO can be obtained 
from this protocol. 
- Required collection of total urine 
output (36 hours). 
- Restriction of dietary NO3ˉ   
intake during the study. 
- Requires expensive equipment 
and highly skilled operators. 
4. Arginine-Nitrate Protocol - A 
Compartmental Modelling 
Approach (Avogaro et al., 
2003) 
This protocol is based on the 
principle of the two-compartment 
model can have  inferences on the 
pharmacokinetics on the arginine-
NO-nitrate pathway 
- It provides estimates of the 
production of NO from arginine,  
NO production from other sources 
than arginine. 
 
- Required frequent blood 
sampling (18 blood samples) and 
collection of total urine output for 
48 hours. 
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 Method Description Advantages Disadvantages 
- Requires expensive equipment 
and highly skilled operators. 
- Requires the reduction of 
dietaryNO3ˉ intake during the 
study 
5. The Oxygen Inhalation-
Nitrate Protocol (Sakinis et 
al., 1999) 
 
This protocol is based on the 
principle that in order to synthesis 
NO, oxygen is required as it will 
be incorporated into the NO 
molecule. In this protocol, subject 
is required to breathe a mixture of 
air contained in an air tight system 
for 30 minutes. 
- Less time consuming (~30 
minutes). 
-   It provides estimates of the 
production of NO rate. 
- Requires expensive equipment 
and highly skilled operators. 
- Requires the reduction of 
dietaryNO3ˉ intake during the 
study 
-Blood samples are needed. 
6. The Nitrate-Nitrate Protocol 
(Šantak et al., 1997) 
 
This protocol has been tested in 
pig and demonstrated the first 
application of an isotopic dilution 
approach for the measurement of 
NO production  
 
- The information of NO synthesis 
can be obtained. 
- The protocol is less analytically 
challenging compared to the 
arginine-citrulline method 
- Requires the restriction of dietary 
NO3ˉ  intake during the study. 
- Requires expensive equipment 
and highly skilled operators. 
- Long duration procedure (~9 
hours). 
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3.2 Assessment of endothelial function 
Many methodological approaches have been developed to assess the physiological function of 
endothelial function in human. The assessment of endothelial function can be classified as 
invasive and noninvasive method (Flammer et al., 2010). Invasive method mainly involved the 
insertion of pharmacological stimuli to the forearm circulation. Noninvasive method is mainly 
involved the occlusion of venous drainage from the arm by placing a pressure cuff around the 
upper arm. The basic principle of the methods to assess vascular function (regardless invasive 
or non-invasive) is that healthy arteries dilate in response to pharmacological stimuli (e.g. 
acetylcholine, bradykinin, or serotonin) via release of NO and/or other endothelium-derived 
vasoactive substances, or in response to the reactive hyperemia (Flammer et al., 2012). The 
details about each of the methods are described below. The advantages and disadvantages of 
the methods are summarized briefly in Table 3.3. 
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 Method Description Advantages Disadvantages 
1. Invasive methods    
 i.Intra-coronary artery 
infusion of vasoactive 
agents  
 
 
This method involves the infusion of acetylcholine into the 
coronary artery. However, acetylcholine has dual effects on 
coronary artery tone depending on the condition of 
endothelium and the presence of coronary atheroma. In intact 
endothelium, the infusion of acetylcholine dilates normal 
arteries, through  receptor mediated stimulation of NO 
production by endothelial cells (Tousoulis et al., 1998). 
However, in endothelial dysfunction, acetylcholine decreases 
the vasodilatory response or vasoconstriction of the coronary 
artery due to the absence of NO release. This is because of its 
direct action on the smooth muscle cells where the constrictor 
effects of smooth muscle cells are dominant compared with the 
endothelial vasodilator effects.  
 
The procedures in this 
protocol can estimate 
information on NO 
synthesis. 
This method has the 
disadvantage as it cannot be 
used as a screening test in the 
general population due to its 
invasiveness and relative 
expense. 
 
 ii. Intra-branchial 
infusion of vasoactive 
agents 
The principle of this method is similar to the intra-coronary 
infusion of vasoactive agents. It involves the infusion of 
vasoactive substances (acetylcholine and nitroprusside) into 
the brachial arteries. A cannula is inserted to the branchial 
artery and the blood pressure and heart rate of the patients are 
monitored continuously. Forearm blood flow (FBF) is 
measured using gauge-strain plethysmography. The infusion 
of acetylcholine is used to evaluate the vasodilatory effect in 
the endothelium and changes in FBF during acetylcholine 
infusion reflect endothelium dilation (Virdis et al., 2001).  
 
 
Reliable, reproducible 
and easily to apply. 
It has potential dangers and 
complications as it involves 
arterial cannulation 
(Tousoulis et al., 2005). 
 
Table 3. 3: Methods, advantages and disadvantages of various assessment of endothelial function  
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 Method Description Advantages Disadvantages 
2. Non-invasive methods    
 i.Gauge-strain 
plethysmography 
 
This technique evaluates changes in FBF during reactive 
hyperaemia. The principle of this method is the occlusion of 
venous drainage from the arm by placing a pressure cuff 
around the upper arm. The FBF output signal is transmitted to 
a computer. EF is evaluated after release of the pressure cuff 
by measuring maximum blood flow - in the artery and the 
percentage change from the baseline to the maximum flow. 
This results in a linear increase in forearm volume in the area 
under the curve, which represents the overall dilatory capacity 
of resistance arteries (Virdis et al., 2001).   
 
This method is simple, 
repeatable and the results 
are less observer 
dependent when 
compared with 
ultrasound-based 
approaches (Tousoulis et 
al., 2005). 
 
Requires highly skilled 
operators. 
 ii.Flow Mediated 
Dilation (FMD) 
 
This method is based on the increased of the blood flow in 
peripheral as the result of the changes of the diameter in the 
artery, after being obstructed for a certain period. This 
condition increased shear stress, which can reflect the ability 
of vascular endothelium to produce NO (Kelm, 2002). The 
method involves the transient ischemia in the conduit artery 
after a cuff is placed on the forearm and inflated for five 
minutes (Laclaustra et al., 2007). When the cuff is deflated, 
the increased blood flow results in shear stress which activates 
eNOS and results in NO production via the L-arginine 
pathway. The NO released acts on the smooth muscle cells, 
resulting in vasodilation. FMD is measured as the percentage 
change in branchial diameter from the baseline to the 
maximum increase in diameter (Al-Qaisi et al., 2008).  A 
small FMD response is interpreted as indicating a low NO 
availability and possibly an associated increased risk of 
Advantages of FMD 
includes being safe, non-
invasive and reproducible 
and the results obtained 
relate closely to EF in the 
coronary arteries. 
 
FMD measurement varies 
between assessors i.e. it is 
observer-dependent 
(Anderson and Mark, 1989). 
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 Method Description Advantages Disadvantages 
vascular disease or cardiac events (Pyke and Tschakovsky, 
2005).  
 iii.Laser Doppler 
flowmetry and 
iontophoresis 
 
This technique measures the increases in blood flow after 
either the transdermal application of acetylcholine by 
iontophoresis, or the release of transient arterial occlusion 
(reactive hyperemia).  
 
Sensitivity in detecting 
and quantifying relative 
changes in skin blood 
flow in response to a 
given stimulus (Kubli et 
al., 2000). 
 
Requires expensive 
equipment and highly skilled 
operators. 
 iv.Pulse wave velocity 
(PWV)  
 
PWV is an indicator of arterial stiffness (Al-Qaisi et al., 2008). 
Arterial PWV, especially in the aorta, has emerged as an 
important independent predictor of vascular damage and 
cardiovascular events (Oliver and Webb, 2003). Arterial pulse 
waves can be detected using pressure-sensitive transducers 
(Asmar et al., 1995), doppler ultrasound (the pressure pulse 
and the flow pulse propagate at the same velocity) (Sutton-
Tyrrell et al., 2001), or applanation tonometry (Wilkinson et 
al., 1998).  
 
Simple and non-invasive, 
the major advantage of 
this technique is that it 
can be used to screen for 
vascular damage in large 
populations. 
Does not provide a 
quantitative measure of NO 
concentration. 
 
 
 
 63 
 
3.3 Measurement of biomarkers of endothelial function in biological samples 
Endothelium-derived NO is an important molecule in maintaining the integrity of EF. 
Insufficient NO production will lead to endothelial dysfunction, which precedes cardiovascular 
events (Tousoulis et al., 2012). In addition to measurement of NO production for assessing EF, 
biomarkers of endothelial activation and dysfunction may be used.  
Several biochemical markers have been used as indicators of EF: The details about each of the 
biomarkers are described in Table 3.4. 
Table 3.4: Biomarkers of Endothelial Function 
 Biomarkers of Endothelial 
Function 
Description 
1. Plasma concentration of NO Circulating concentrations of nitrites and nitrosylated proteins in 
part reflect endothelial generation of NO, but are difficult to 
measure and do not always represent endothelial NO production 
(Rassaf et al., 2004). Many direct and indirect methods have been 
used to assess the production of NO (Mair and Puschendorf, 1998; 
Kleinbongard et al., 2006) but in vivo NO production using stable-
based techniques is arguably the best global measure that reflects 
the underlying EF in health and disease (Siervo et al., 2011c). 
 
2. Asymmetric dimethylarginine 
(ADMA) 
ADMA is an endogenous inhibitor of nitric oxide synthase, and 
increased concentrations of ADMA are associated with increased 
cardiovascular risk and endothelial L-arginine/NO pathway 
dysfunction (Davis et al., 2011). Plasma ADMA concentration is 
increased in humans with hypercholesterolemia, atherosclerosis, 
hypertension, chronic renal failure, and chronic heart failure 
(Boger, 2004). Higher concentrations of ADMA are associated with 
reduced NO availability in both animal and clinical studies 
(Vallance and Leiper, 2004). 
 
3. E-selectin It is probably the most specific marker of endothelial cell 
activation. Higher E-selectin concentration is associated with 
cardiovascular risk factors, with structural and functional measures 
of atherosclerotic disease, as well as with adverse cardiovascular 
prognosis (Ridker et al., 2004). 
 
4. Cyclic Guanosine 
monophosphate (cGMP) 
cGMP is a second messenger that mediates physiological changes 
such as proliferation, differentiation, survival, migration and 
apoptosis in endothelial cells. Increased cGMP is associated with 
vascular smooth muscle relaxation (Rapoport and Murad, 1983; 
Surks, 2007). 
 
5. Vascular Endothelial Growth 
Factor (VEGF) 
Also known as vascular permeability factor (VPF), VEGF is 
important for NO release and stimulation of endothelial cell 
proliferation and migration. VEGF is involved in angiogenesis and 
vascular permeability and plays a key role in maintaining the 
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 Biomarkers of Endothelial 
Function 
Description 
integrity of the endothelium (Kliche and Waltenberger, 2001; 
Shibuya, 2011).  
 
6. Endothelin-1(ET-1) Whilst NO is an important vasodilator, ET-1 is a potent 
vasoconstrictor. Alteration or imbalance in ET-1 production has 
been implicated in the development of endothelial dysfunction and 
CVD.     
 
In this PhD project, several methods of measuring biomarkers of EF using immunoassay have 
been used and the protocols are described below. 
3.4 Methods of Assessing Biomarkers of Endothelial Function 
3.4.1 Asymmetric Dimethylarginine (ADMA) 
Asymmetric dimethylarginine (ADMA), an analogue of L-arginine, is a naturally occurring 
product of metabolism found in the human circulation. ADMA is produced by the methylation 
of arginine.  Elevated ADMA inhibits the production of NO by competing with L-arginine, 
which is important for the synthesis of NO. The impairment of NO production leads to 
endothelial dysfunction and, eventually cardiovascular events  (Sibal et al., 2010). The 
measurement of ADMA in this PhD project was done using a commercial kit (CUSABIO 
ELISA kit CSB-E09298h) in a 96-well format. Details of the ADMA analysis procedures can 
be found in Appendix 3.1.  
Principle of assay 
This assay used the technique of quantitative sandwich enzyme immunoassay. The microplate 
has been pre-coated with an antibody specific for ADMA, which reacted with any ADMA 
present after the standards and samples were pipetted into the wells. The procedures involved 
adding the biotin-conjugated antibody specific for ADMA, washing and adding the substrate 
solution to develop the colour in proportion to the amount of ADMA present. The intensity of 
the colour was measured using a microplate reader. 
3.4.2 Nitrotyrosine (3NT) 
NO is important for endothelium homeostasis but excessive concentrations of NO can cause 
adverse effects and tissue injury (Habib and Ali, 2011). 3NT is an indicator or marker of cell 
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damage, inflammation and over production of NO, which can exert cytotoxic effects (Halliwell, 
1997). 3NT is a well-established marker of protein damage by oxidative stress.  
Peroxynitrite (ONOOˉ) is the formation of highly reactive oxidant species, as the result of the 
reaction between excess NO and superoxide radical (O2ˉ) (Kaur and Halliwell, 1994). It 
involved in the pathology of a wide range of diseases and quantification of 3NT is one of the 
methods for measuring indirectly oxidative stress due to the excessive production of ONOOˉ 
(Nemirovskiy et al., 2009). The measurement of 3NT in this PhD project was done using a 
commercial kit (ABCAM ab113848) in a 96 well format. Details of the 3NT analysis 
procedures can be found in Appendix 3.2. 
Principle of assay 
This assay determined the concentration of 3NT modified protein in the sample. The microplate 
has been pre-coated with a 3NT responsive antigen. The principle of this assay is involving the 
amount of soluble 3NT modified protein present in the samples competes for binding by the 
anti-3NT detector antibody. The degree of competition is proportional to the concentration of 
3NT modified protein in the sample. Therefore, the signal in each well measured by the 
microplate reader has an inverse relationship to the amount of 3NT in each sample.  
3.4.3 Vascular Endothelial Growth Factor (VEGF) 
Vascular Endothelial Growth Factor (VEGF), as its name implies, plays an important role in 
the homeostasis of vascular health and cardiovascular system (Khurana et al., 2005). Also 
known as vascular permeability factor (VPF), VEGF is a signal protein produced by endothelial 
cell which induces endothelial cell proliferation, promotes cell migration, and inhibits 
apoptosis (Neufeld et al., 1999). In its vasculo-protective role, VEGF up-regulates NO synthase 
by enhancing eNOS expression, resulted in increased synthesis of NO (Lin and Sessa, 2006). 
The measurement of VEGF in this PhD project was done using a 96 well format commercial 
kit from R&D SystemTM Quantikine® ELISA. Details of the VEGF analysis procedures can be 
found in Appendix 3.3. 
Principle of the assay 
The assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for VEGF was pre-coated onto the microplate. When the standards or samples 
were pipetted into the wells, any VEGF presented was bounded by the immobilized antibody. 
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Any unbound substances were being washed, and an enzyme-linked polyclonal antibody 
specific for VEGF were added to the wells. The second washing was intended to remove any 
unbound antibody-enzyme reagent, and a substrate solution was added to the wells and colour 
were developed in proportion to the amount of VEGF bound in the initial step. The colour 
development was stopped by adding stop solution, and the intensity of the colour was 
measured. 
3.4.4 Endothelin-1 (ET-1) 
Contrary to NO which is well known as a vasodilator, ET-1 is a potent vasoconstrictor peptide 
isolated originally from endothelial cells. An imbalance between vasodilator (NO) and 
vasoconstrictor (ET-1) effects an important factor in the development of vascular dysfunction 
and may lead to the onset of cardiovascular disease (Agapitov and Haynes, 2002; Bourque et 
al., 2011). The measurement of ET-1 in this PhD project was done using a 96 well format 
commercial kit from Enzo Life Sciences, Inc (catalog #ADI-900-020A). Details of the ET-1 
analysis procedures can be found in Appendix 3.4. 
Principle of the assay 
Samples and standards were added to wells coated with a monoclonal antibody specific for ET-
1. The plate was then incubated for 30 minutes. Then, the plate was washed, leaving only bound 
ET-1 on the plate. A solution of HRP labelled monoclonal antibody to ET-1 was added. This 
binds the ET-1 captured on the plate. The plate was incubated again for 30 minutes. Then, the 
plate was washed to remove excess HRP labelled antibody and TMB substrate solution was 
added. The substrate generates a blue colour when catalysed by the HRP. Lastly, stop solution 
was added to stop the substrate reaction and the resulting yellow colour were read at 450 nm. 
3.4.5 Cyclic Guanosine Monophosphate (cGMP) 
Increased concentrations of cGMP produced by guanylate cyclase within vascular smooth 
muscle to allow blood vessels to relax and thus increase blood flow (Ignarro et al., 1986). The 
measurement of urinary and plasma cGMP can be an indicator for the NO production. This is 
because cGMP involved in the biological signalling of NO (Francis et al., 2010). The 
measurement of cGMP in this PhD project was done using a 96 well format commercial kit 
from Enzo Life Sciences, Inc (catalog #ADI-900-013). Details of the cGMP analysis 
procedures can be found in Appendix 3.5. 
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Principle of the assay 
The kit used a polyclonal antibody to cGMP to bind, in a competitive manner, the cGMP in the 
standard or sample which has cGMP covalently attached to it. After a simultaneous incubation 
at room temperature, the excess reagents were washed away and substrate was added. After a 
short incubation time, the enzyme reaction stopped and the yellow colours generated were read 
on a microplate reader at 405nm. The intensity of the bound yellow colour was inversely 
proportional to the concentration of cGMP in either standards or samples. 
3.5 Methods to measure nitrate concentrations in biological samples 
Various techniques are used in assessing nitrate and nitrite concentrations in biological samples 
including capillary electrophoresis, chemiluminescence, the Griess method and Gas 
Chromatography Mass Spectrometry (GCMS). Choosing the most appropriate method for 
measurement of NO and NO metabolites in biological systems depends on the background 
assay principle, specificity, sensitivity, advantages, disadvantages and financials  (Csonka et 
al., 2015). In this PhD study, chemiluminescence, Griess and GCMS methods were used for 
measuring plasma nitrate, plasma nitrite, urinary nitrate and salivary nitrate in humans. Below 
are the brief descriptions of the available techniques used in measuring NO3ˉ concentration. 
3.5.1 Chemiluminescence 
Although this method is more expensive due to its high capital cost and costs for instrument 
maintenance, this approach has been acknowledged to be the gold standard and the most 
sensitive technique available to measure NO and NO metabolites (Pinder et al., 2008).  In this 
study, the ozone-based chemiluminescence method was used to measure plasma and urine NO3
-
concentrations, and plasma NO2ˉ concentrations using Sievers gas-phase chemiluminescence 
nitric oxide analyser (NOA 280i, Analytix, UK). The main component of the NOA system 
include: 
1) NO chemiluminescence analyser 
This machine acted as the connector for gases (N2 and O2), the vacuum pump, 
computer, printer and analog signal from the output of the analyses.  
2) Purge vessel (Inert Carrier Gas) 
This custom designed glass purge vessel has an interchangeable reagent vessel (~10 ml 
maximum volume) with side arm injection port and a T shaped gas purging component, 
with a gas-tight fit to the reagent vessel (Figure 3.3). 
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Figure 3. 2: Setup for Nitrate Measurement 
Prior to the analysis, a standard curve was plotted for the calibration (Appendix 3.6). The area 
under the curve (AUC) was measured to calculate the total NO3
- concentrations. The Sievers® 
NOAnalysis™ Software Version 3.2 was used for data acquisition and data analysis. 
Principle of the analysis 
In the process of analysing the NO3ˉ concentrations, vanadium chloride solution was added to 
the purge vessel. This solution reacted with the NO3ˉ from the samples which were injected 
through the valve into the purge vessel using a glass Hamilton (Fisher) syringe. NO3ˉ released 
from this reaction and was measured by the NOA. Details of this procedure can be found in 
Appendix 3.7 and details of the NO2ˉ analysis using chemiluminescence can be found in 
Appendix 3.8. 
3.5.2 Griess method 
Developed in 1879 by Johann Peter Griess, the Griess assay is used to measure NO and 
metabolites of NO (Tsikas, 2007). This is the most popular method because of its simplicity, 
low cost and ease of use. The assay, can be purchased in ready-to-use format and has straight 
forward data analysis (Hetrick and Schoenfisch, 2009; Csonka et al., 2015). However, this 
method is more suitable for the measurement of nitrite.  
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Principle of assay 
The analysis of nitrate requires chemical or enzymatic reduction of the nitrate to nitrite prior to 
the diazotization reaction. The second step is the addition of Griess reagents which convert 
nitrite into a deep purple-coloured azo compound. The formation of the azo compound is then 
monitored spectroscopically at 540 nm (Figure 3.4). Details of the procedure can be found in 
Appendix 3.9. 
 
 
Figure 3. 3: The reaction of NO3ˉ with Griess assay reagents forms an azo compound 
that is detected by the spectrophotometer and used to calculate the NO3ˉ concentrations 
in the sample. 
 
3.5.3 Gas Chromatography Mass Spectrometry  
Gas Chromatography Mass Spectrometry (GCMS) has been used extensively to determine 
nitrate in biological samples. The first GCMS methods involved the nitration of aromatic 
compounds such as benzene, toluene and trimethyl-oxi-benzene (Green et al., 1981; Green et 
al., 1982; Rhodes et al., 1995) in the presence of sulphuric acid, which acted as a catalyst for 
the reaction (Gutzki et al., 1992). However, these methods, while accurate, were characterised 
by an important disadvantage in the utilisation of concentrated sulphuric acid which  is a 
hazardous reagent, and could artificially increase nitrate levels due to degradation of nitrated 
arginine analogues (Greenberg et al., 1995; Tsikas et al., 1998).  In this study, mesitylene 
(1,3,5-trimethylbenzene) was used as the aromatic electrophilic compound and trifluoroacetic 
anhydrate (TFAA) as the catalyst as proposed by (Jackson et al., 2008). The main advantage 
of this approach is the combination of milder acidic conditions derived from mesitylene and 
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less aggressive catalyst by using TFAA which are safer and result in less interference from 
other compounds compared with other methods. Details on the procedure can be found in 
Appendix 3.10. 
Principle of the analysis 
The analysis was done using an Agilent GCMS 5977E system (Agilent Technologies, 
Stockport, UK) comprising a HP 6820A GC with autosampler and split/splitless injector. The 
GCMS was operated in Electron Ionization (EI) mode. MassHunter Data Software was used 
for data acquisition and data analysis. The total run time for the analysis of one sample was 
seven minutes. The minimum oven temperature was 90ºC and the maximum was 270ºC and 
the oven temperature was ramped at an increment of 30 ºC per minute to reach the maximum 
temperature. The peak areas were determined at m/z 165 and 166. Detailed GCMS 
chromatogram graph can be found in Appendix 3.11. 
3.6 Comparison studies: Evaluation of different laboratory methods for the measurement 
of nitrate and nitrite concentrations in biological samples 
 
Currently, nitrite and nitrate can be quantified in plasma, serum and urine of humans by various 
methods based on different analytical principles such as chemiluminescence (CL), colorimetry, 
spectrophotometry, fluorescence, GCMS and electrophoresis (Tsikas, 2005a). However, these 
methods have produced differing estimates of the concentrations of nitrite and nitrate in the 
circulation of healthy humans (Hunter et al., 2013). One of the major reasons for these 
discrepancies seems to be methodological problems (Tsikas et al., 1997). 
This part of the chapter is dedicated to the comparison of different methods for the 
measurement of nitrate and nitrite in biological samples (plasma and urine). The methods used 
for the measurement of nitrate and nitrite are summarised in Figure 3.5. 
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Figure 3. 4: Experiments and methods used for the measurement of nitrate and nitrite 
in biological samples  
 
The following experiments were conducted to evaluate the agreement between the methods: 
 Plasma nitrate (deproteination: MTH vs ETH) using CL method (n=200) 
(EXPERIMENT 1) 
 Plasma nitrate (deproteination: MTH vs Griess) (n=80) (EXPERIMENT 2) 
 Plasma nitrate (deproteination: ETH vs Griess) (n=80) (EXPERIMENT 3) 
 Urinary nitrate (CL vs Griess method) (n=80) (EXPERIMENT 4) 
 Plasma nitrite (deproteination: ETH vs MTH) (n=120) (EXPERIMENT 5) 
 Plasma nitrite (non deproteination vs ETH) (n=120) (EXPERIMENT 6) 
 Plasma nitrite (non deproteination vs MTH) using CL method (n=120) (EXPERIMENT 
7) 
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EXPERIMENT 1: Comparison of the influence of different deproteination methods (MTH VS 
ETH) of plasma samples on nitrate and nitrite concentrations by ozone-based CL. 
 
Protein precipitation, or deproteination is the process of protein removal from the plasma/serum 
sample prior to the analysis of nitrate/nitrite. Proteins need to be precipitated and removed from 
the sample otherwise these can contribute to false reading due to turbidity (Romitelli et al., 
2007). In addition, this procedure can reduce the foaming that occurs during the procedure due 
to high concentrations of protein. 
For nitrate analysis in this study, deproteination methods was suggested in the 
chemiluminescence protocol of the GE Analytical Instrument © 2006 for Sievers NOA 280i, 
which are: 
a) Cold ethanol precipitation (ETH) 
b) Zinc Sulfate/Sodium Hydroxide precipitation (MTH) 
These deproteination procedures are described below. 
Cold ethanol precipitation (ETH) 
1. The glassware and tubes were rinsed with deionized water prior the experiments to 
avoid any contamination. 
2. The required ethanol was chilled to 0º C. 
3. 0.5 mL of the sample were placed in a 1.5 mL microcentrifuge tube, 1mL of cold 
ethanol was added and the tube was vortexed for 10 seconds. 
4. The sample was placed at 0º C for 30 minutes. 
5. The sample was centrifuged at 14,000 RPM for 5 minutes. 
6. The supernatant (about 1.8ml) was removed for the determination of nitrate (NB: The 
subsequent calculation accounted for the 3-fold dilution introduced by this 
deproteination method). 
 
Zinc Sulfate/Sodium Hydroxide precipitation (MTH)  
1. The glassware and tubes were rinsed with deionized water prior the experiments to 
avoid any contamination. 
2. 200 µL of sample was added to the microcentrifuge tube. 
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3. 400 µL of 0.5 N NaOH and 400 µL of 10% by weight aqueous ZnSO4 were added to 
the microcentrifuge tube. 
4. The microcentrifuge tube was vortexed for 30 seconds and let stand at room 
temperature for 15 minutes. 
5. The microcentrifuge tube was centrifuge at 14,000 RPM for 5 minutes. 
6. The supernatant was removed for the determination of nitrate (NB: The subsequent 
calculation accounted for the 5-fold dilution introduced by this deproteination method). 
 
For nitrite concentrations, the results of ETH and MTH were compared with non-deproteinised 
samples (Figure 3.4). 
1) Evaluation of the agreement between CL (reference method) and a commercially available 
colorimetric assay kit based on the Griess reaction (indirect method) for the measurement 
of nitrate in plasma and urine samples. 
 
The samples for the plasma nitrate/plasma nitrite/urinary nitrate analyses were obtained from 
two studies via: 
1) The cross sectional study used to evaluate the association of vitamin D with 
physiological and biochemical markers of endothelial function in overweight and obese 
post-menopausal women (described in detail in Chapter 4 of this thesis). The samples 
obtained from this study were used for the analysis of plasma nitrate (deproteination vs 
non deproteination) and urinary nitrate (80 samples). 
 
2) An intervention study with beetroot juice supplementation which was carried out in 
Leeds- Beckett University - The samples obtained from this study were used for the 
analysis of plasma nitrate and nitrite (120 samples). 
 
For the analysis of the effects of type of deproteination on estimates of plasma nitrate 
concentration, the samples from these two studies were combined to provide a total of 200 
samples. Analyses of method comparison described by CL and Griess (regression equation and 
r2) and by Bland Altman method (mean difference ± SD). The significance of differences 
between methods determined by paired t-test analysis is reported in Table 3.4. 
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Table 3. 4: Correlation and agreement parameters of nitrate and nitrite concentration in plasma and urine measured by the CL 
(deproteination and non deproteination) and Griess assay 
 
 N Overall mean 
concentration 
Mean 
Bias 
Regression 
equation 
r2 t-test (p) +2SD Min Max 
Nitrate-Deproteination (µM) - Chemiluminescence 
Plasma Nitrate 
Ethanol vs Methanol 
 
200 
 
163.08  
 
14.11 
 
y = 3.4 + 0.98x 
 
0.83 
 
p=0.89 
 
93.85 
 
-564 
 
273 
Griess vs Chemiluminescence (µM) 
Plasma Nitrate 
•  Griess vs Ethanol 
 
80 
 
29.22 
 
-10.92 
 
y = -7.11 + 0.89x 
 
0.77 
 
p<0.001 
 
10.22 
 
-38 
 
28 
•  Griess vs Methanol 80 29.18 -10.84 y = -6.85 + 0.88x 0.75 p<0.001 10.68 -40 37 
Urinary Nitrate 80 770 -229 y = 1.68 + 0.55x 0.74 p<0.001 604 -4670 919 
Nitrite-Non Deproteination (µM) - Chemiluminescence 
•  Ethanol vs Methanol 120 602 -58.37 y = 1.58 + 0.66x 0.37 p<0.05 229 -891 446 
•  Non deproteination vs ethanol 120 427 -292 y = -1.91 + 0.82x 0.38 p<0.001 120 -818 72 
•  Non deproteination vs methanol 120 456 -350 y = -1.04 + 0.61x 0.37 p<0.001 218 -1154 -60 
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Bland Altman analysis (B & A), developed by J. Martin Bland and Douglas G. Altman in 1986 
was used to assess the agreement between two quantitative methods of measurement. The 
principle of B & A is based on the evaluation of bias between the mean differences, and the 
estimation of an agreement interval. This is achieved by plotting the difference between the 
two methods of measurement against the average obtained with each of the two techniques 
(Bland and Altman, 1986). Good agreement between the two methods exists when the mean 
of the difference is close to zero and the individual differences are within the limits of 
agreements, i.e. within the range mean ± 1.96 SD. The regression line is drawn to evaluate bias 
between the two methods. Horizontal lines are drawn at the mean difference, and at the limits 
of agreement, which are defined as the mean difference plus and minus 1.96 times the standard 
deviation of the differences.  
In this study, the B & A method has been used to provide a visual representation of the 
agreement between the methods of measuring plasma nitrate/ plasma nitrite/urinary nitrate. 
The analysis was conducted in SPSS 22 for Windows (SPSS, USA) and Excel for Windows 
(Microsoft Corporation, USA). 
3.6.1 Estimation of Plasma Nitrate concentration 
1) CL (Deproteinisation: ETH vs MTH – Experiment 1 and Experiment 2) 
The results of the comparison between two methods of deproteination (ETH vs MTH) using 
CL are summarised in Figure 3.6. Figure 3.6 (A and B) showed a strong, significant 
association between plasma nitrate concentrations measured by the MTH and ETH 
deproteinisation methods (n=200, r=0.83, p<0.001). The BA plot showed that the majority of 
the data lie within the 95% CI. However, there are five clear outliers in the scatterplot and the 
removal of these points further improved the association between the two methods (n=196, 
r=0.97, p<0.001) (Appendix 3.12).  
The difference in estimates between MTH and ETH methods used for measurement of nitrate 
concentrations in plasma samples was small (mean bias = 0.84, p=0.89) (Table 3.4). In 
addition, B & A analysis confirmed this small difference between the two methods with 
majority of the points lying within the limits of agreements. However, the bias in estimates 
between the two methods increased as the concentration of nitrate increased at the average of 
200 µM (R2=0.33, p<0.01) Figure 3.6 (B).  
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(A) Regression analysis of plasma nitrate concentration (µM) estimated by CL after 
deproteination using the ETH and MTH methods   
 
 
 
(B) Bland-Altman analysis of estimates of plasma nitrate concentration after deproteination using 
the ETH and MTH methods 
 
Figure 3. 5: Comparison of CL for deproteination method using ETH and MTH. 
(A) Linear regression analysis between plasma nitrate concentration observed by the ETH and MTH. 
(B) B & A method was used to evaluate the agreement between the nitrate concentrations measured by 
the ETH and MTH. Black horizontal lines (bold) show the mean difference between ETH and MTH 
and the fine, grey line, are the limits of agreement (± 2SD). A regression line was fitted to the points 
(dashed black line) to evaluate differential bias.  
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Recommendation for practice: 
Given the negligible, non-significant difference (p=0.89) in estimates of plasma nitrate 
concentration after use of the two deproteination methods, it is suggested that either ETH or 
MTH method can be used for nitrate concentration measurement using the CL procedure. This 
procedure is suitable to be used for concentration of nitrate up to 200 µM. 
2) CL (deproteination: ETH) vs Griess (non-deproteination)- Experiment 3 
The objective of this experiment is to assess the comparison between the two methods of nitrate 
analysis by CL (samples were processed using the ETH method) and Griess method (Figure 
3.7 A and B). Linear regression analysis showed a strong significant association between the 
two methods (n=80, R2=0.772, p<0.001, Figure 3.7 A). The results from the B & A analysis 
showed that nitrate concentrations in plasma sample measured by the Griess method were 
significantly higher than the CL method (mean bias = -10.92, p <0.001) (Table 3.4). The BA 
plot showed that the majority of the data lie within the 95% CI. Most of the points lied within 
the limits of agreement and we found no evidence of differential bias with increasing nitrate 
concentrations (R2=0.001, p=0.90 Figure 3.7 B). Similar results between the two methods were 
seen if plasma samples, measured by CL, were processed by the MTH method (See figure – in 
Appendix 3.13). 
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(A) Regression analysis of plasma nitrate concentration (µM) estimated by CL and Griess 
 
 
(B) Bland-Altman analysis of estimates of mean plasma nitrate concentration using CL 
and Griess methods  
Figure 3. 6: Comparison of CL and Griess methods for the measurements of plasma 
concentrations in 80 subjects.  
(A), Linear regression analysis to evaluate the association between plasma nitrate concentration 
measured by the Griess and CL methods. (B), Agreement and differential bias between the two methods 
was evaluated by the Bland-Altman method. Black horizontal lines (bold) show the mean difference 
between CL and Griess methods and the fine, grey line are the limits of agreement (± 2SD). A regression 
line was fitted to the points (dashed black line) to evaluate differential bias. Plasma samples 
measured by CL were processed using the ETH method. 
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Recommendation for practice: 
Even though we found a strong significant association between the two methods, the Griess 
method over-estimated the nitrate concentrations compared to the CL approach. Therefore, 
results from Griess method should be interpreted cautiously. 
3.6.2 Estimation of Urinary Nitrate Concentration 
1) CL (non depoteination) vs Griess (non deproteination) –Experiment 4 
The objective of this experiment is to assess the agreement between the two methods of urinary 
nitrate analysis by CL and Griess method. Linear regression and B & A analyses were 
performed. 
The results for the comparison of the two methods were illustrated in Figure 3.8 A and B. 
Linear regression analysis of urinary nitrate concentrations (in µM, range 44-6977 µM) 
measured by Griess (y) versus those measured by CL (x) revealed a significant correlation 
between the two methods (n=80, R2= 0.74, p<0.001) (Figure 3.8 A). 
The B & A analysis showed a significant difference was found for the measurement of urinary 
nitrate concentrations as the Griess significantly overestimated nitrate concentrations 
compared to CL (mean bias= 228.94 nmol/L; p<0.001) (Table 3.4). The BA plot showed that 
the majority of the data lie within the 95% CI. In addition, a significant differential bias as the 
difference between the two methods increased as urinary nitrate concentration increased 
(R2=0.45, p<0.001) (Figure 3.8 B). 
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(A) Regression analysis of urinary nitrate concentration (µM) estimated by CL and Griess         
 
 
(B) Bland-Altman analysis of estimates of mean urinary nitrate concentration using CL and Griess 
methods 
 
Figure 3. 7: Comparison of CL and Griess methods for the measurements of urinary 
nitrate. 
(A), Linear regression analysis to evaluate association between Griess and CL methods. (B), B & A 
plot to assess the agreement between the Griess and CL methods for measuring the difference in nitrate 
concentrations. Black horizontal line shows the mean difference (bold) and the ± 2S.D. range (fine, grey 
line). A regression line was fitted to the points (dashed black line) to evaluate differential bias.
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Recommendation for Practice:  
Similar to plasma nitrate analysis, the Griess method over-estimated urinary nitrate 
concentration compared with the CL method. Furthermore, the difference between these two 
methods increased in line with the increased of urinary nitrate concentration. Therefore, it can 
be recommended that results from Griess method should be interpreted cautiously. 
3.6.3 Estimation of Plasma Nitrite concentration 
1) CL (deproteination: ETH vs MTH) – Experiment 5 
The objective of this experiment is to assess the correlation and agreement between the two 
methods of deproteination (ETH vs MTH) using CL. B & A method was performed to describe 
the agreement between the two methods.  
The results for the comparison of the two methods of deproteination are illustrated in Figure 
3.9. Figure 3.9 (A and B) and show the agreement in plasma nitrite concentration between the 
two methods. Linear regression analysis revealed a significant correlation between the two 
methods (n=120, R2=0.37, p<0.001, Figure 3.9 A). However, the B & A analysis showed a 
significant difference for the measurement of nitrite concentrations between the MTH and ETH 
nitrite methods (mean bias= 58.3nmol/L; p<0.05) (Table 3.4). 
The BA plot showed that the majority of the data lie within the 95% CI. The majority of the 
data points were between the limits of agreements, and no evidence of differential bias has 
been found with increasing nitrite concentrations (R2=0.008, p=0.317, Figure 3.9 B). 
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(A) Regression analysis of plasma nitrite concentration (µM) estimated by CL (ETH vs 
MTH) 
 
 
(B) Bland-Altman analysis of estimates of mean plasma nitrite concentration using CL 
(ETH and MTH) 
 
Figure 3. 8: Comparison of effects of ETH and MTH deproteination methods on the 
measurement of plasma nitrite by CL. 
 (A), Linear regression analysis to evaluate associations between the two methods. (B), B & A plot to 
assess agreement between ETH and MTH deproteination methods for the measurement of differences 
in nitrite concentrations. Black horizontal line shows the mean difference (bold) and the ± 2S.D. range 
(fine, grey line). A regression line was fitted to the points (dashed black line) to evaluate differential 
bias. 
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Recommendation for practice: 
Referring to the significant influence of plasma nitrite between the two deproteination methods, 
where a slightly higher of NO2ˉ concentration measured using MTH method, it is suggested 
that ETH method should be used for NO2ˉconcentration measurement using CL procedure. 
 
2) CL (deproteination: ETH and MTH) vs CL (non deproteination) –Experiment 6 
The objective of this experiment is to assess the agreement between the two ETH 
deproteination methods and untreated (non-deproteination) plasma samples for the 
measurement of nitrite by CL. The results for the comparison of the two methods were 
illustrated in Figure 3.10.  
 
Linear regression analysis of plasma nitrite concentrations (in µM, range 40-1398 µM) showed 
a significant correlation between the two methods (n=120, R2=0.80 p<0.001, Figure 3.10 A). 
However, there was a significant difference between the two methods and estimates of the 
nitrite concentrations from the non-deproteination method were significantly higher than those 
found using the ETH method (mean bias= 291.8 nmol/L; p<0.001) (Table 3.4 and Figure 3.10 
B). The BA plot showed that the majority of the data lie within the 95% CI. However, no 
evidence of a differential bias was found between the two methods (R2=0.03, p=0.05) (Figure 
3.10 B). Similar results were obtained from the application of the MTH deproteination method 
(Appendix 3.14). 
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(A)  Regression analysis of plasma nitrite concentration (µM) estimated by CL 
(untreated vs ETH)   
 
 
(B) Mean plasma nitrite by CL (untreated vs ETH) Bland-Altman analysis of 
estimates of mean plasma nitrite concentration using CL (untreated vs ETH) 
 
Figure 3. 9: Comparison of plasma nitrite concentration measured by CL in untreated 
samples and using the ETH deproteination method. 
(A), Linear regression analysis to evaluate the association between the two processing methods. (B), B 
& A method to assess agreement between the two methods and evaluate presence of differential bias. 
Black horizontal line shows the mean difference (bold) and the ± 2S.D. range (fine, grey line). A 
regression line was fitted to the points (dashed black line) to evaluate differential bias. 
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Recommendation for practice: 
It is suggested that the process of deproteination is crucial in analysing plasma nitrite. This is 
because it will reduce foaming formation and improves applicability of techniques.  Non-
deproteinised samples had higher nitrite concentrations than those that were deproteinised.  
3.6.4 Discussion  
These experiments were dedicated to explore the comparison of different methods for the 
quantitative analysis of nitrate and nitrite in biological samples (plasma and urine). As been 
discussed earlier in this chapter, there are various analytical methods based on different 
analytical principles, such as colorimetry, spectrophotometry, fluorescence, 
chemiluminescence, gas and liquid chromatography, electrophoresis and mass spectrometry 
(Tsikas, 2005a). The method for the assessment of nitrate and nitrite in humans depends on the 
availability of resources and equipment, technical and research expertise.  
 
In this study, CL (with and without deproteination) method and the Griess method were used 
for quantifying concentrations of nitrate and nitrite in plasma and urine. These methods were 
used based on the availability of the machine in the laboratory (ozone based CL) and the 
commercially available of ‘ready to use’ kits for the Griess method. In addition, the GCMS 
method was used for the analysis of saliva samples in the third phase of this PhD project (details 
in Chapter 5).  
 
In general, following comparison of the three techniques (CL, Griess and GCMS) used in 
measuring nitrate/nitrate in plasma, urine and saliva samples, the following conclusions have 
been made: 
 
1) Even though CL is the best technique for measuring nitrate (Piknova et al., 2016), extra 
precaution is required when using this method. Injecting the samples into the purge 
vessel resulting in excessive bubbles even though an antifoaming agent was used, and 
this was exacerbated with for non-deproteinised due to the protein present in the 
samples. The bubbles should be monitored by adjusting the needle valve so that the 
bubbles did not get into the inlet tube since that will damage the machine. At maximum 
of 10 injections of samples were done before the nitrate reducing agent solution in the 
bubble base needed to be changed. The cell pressure should be constantly monitored at 
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4 – 7 torr. The samples need to be deproteinised prior to the analysis, which may add 
considerable time and expense to the analysis. Due to tedious, time consuming and 
technically difficult, it can be suggested that CL method is only suitable to be used in 
research laboratory setting.  
 
2) The Griess method is practical for analysing large numbers of samples where the fast, 
cheaper and reproducible measurement is a considerable advantage. However, the 
presence of protein in the sample, can interfere in the outcome. Therefore, performing 
protein removal prior to the Griess procedure might be beneficial into reducing 
inaccuracy in the determination of nitrate/nitrite concentrations in samples (Hunter et 
al., 2013).  
 
3) GCMS, although quite cumbersome to performed, is considered the most accurate 
technique of measurement nitrate/nitrite in biological samples (Romitelli et al., 2007). 
In the study reported in the Chapter 5 of this thesis, the saliva samples have to 
undergone several steps of derivatisation before being analysed in the GCMS machine. 
Drying down, heating, washing and filtration were the procedures done before the 
sample were placed into the injection port of the GC device. Due to the multiple 
derivatisation procedures prior to the measurement, time consuming and expensive 
equipment, it can be suggested that GCMS is more suitable to be used in the clinical 
and research laboratory setting and performed by experienced personnel. 
 
Discrepancies and methodological problems on diverging values of nitrate/nitrite measured are 
depends on the analytical principles of the method (Tsikas, 2005b). Tsikas et al reported a 
relatively poor correlation (R= 0.8) between estimates of nitrate in human urine samples (n=33) 
when estimated using the Griess assay and by GCMS (Tsikas et al., 1997). This discrepancy 
may be due to the interference by free reduced thiols, proteins, and other plasma constituents 
in the Griess assay.  
There are various methods of deproteination available for treating plasma samples prior to 
nitrate/nitrite analysis such as acetonitrile-chloroform, ultrafiltration, zinc sulfate, zinc sulfate-
sodium hydroxide and methanol-diethyl ether. The complete removal of protein is essential 
because any remaining protein may cause turbidity and may lead to the inaccuracy in 
determination of nitrite and nitrate concentration. In this study, authors suggested that 
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acetonitrile-chloroform is the most efficient method for protein precipitation (Romitelli et al., 
2007).  
In the present PhD study, for nitrate analysis using CL method, there was no difference in the 
effects of MTH and ETH as deproteination agents prior to the measurement of nitrate 
concentrations in plasma samples (Figure 3.6). However, for nitrite analysis using CL method, 
nitrite concentrations were significantly higher after using the MTH than the ETH approach 
(Figure 3.9). However, both deproteination methods resulted in lower plasma nitrite 
concentrations than were observed when non-deproteinised samples were analysed. These 
results suggest that both ETH and MTH can be used as deproteination agents for nitrate 
measurements.  Deproteination using ETH method is adviced for the measurement of nitrite 
concentrations as it produced less foaming and shorter protocol for the processing of the 
samples. While non-deproteinised samples had higher nitrite concentrations, the formation of 
foam makes the analyses cumbersome and technically difficult. 
 
The comparison between the Griess method and the CL method showed relatively poor 
agreement for the measurement of nitrate in both plasma and urine. Both deproteination 
methods (ETH and MTH) showed a similar degree of under-estimation of plasma nitrate 
concentrations by the Griess compared with CL (Figure 3.7). Finally, the Griess method 
significantly over-estimated urinary nitrate concentrations (Figure 3.8). 
 
For the analysis using Griess method, we can conclude this method performs poorly in plasma 
and urine samples for the measurement of nitrate concentrations and its results should be 
interpreted cautiously. In the case of proportional difference variability between measurements, 
i.e. constant coefficient of variation across the range of concentration, the effect on the B & A 
revealed that in all experiments performed, all unit difference has a widening trend of the 
agreement range with increasing concentrations on nitrite/nitrate in urine/plasma.  
3.6.5 Conclusion 
In conclusion, even though analysis of nitrate/nitrite concentrations using the Griess method is 
tempting due to its simplicity, low cost and ease of use, results from the CL method are more 
reliable because it is one of the most sensitive methods to measure low nanomolar 
concentrations of metabolites. This study also found that there is no significant difference 
between the two methods of deproteination (ETH and MTH) when used for nitrate analysis, 
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suggested that these two methods can be used interchangeably.  However, when undertakings 
nitrite analysis, the ETH method is the preferred method of protein precipitation.  
3.7 Comparison studies: Evaluation of accuracy of laboratory methods for the 
measurement vitamin D concentration using a conventional method (assays on liquid 
serum collected by venepuncture) and using a dry blood spot (DBS) method  
 
In the cross sectional study entitled - "Association of vitamin D with physiological and 
biochemical markers of endothelial function in overweight and obese post-menopausal 
women" (described in detail in Chapter 4), the analysis of 25(OH)D concentration was done 
using two methods:  
1. A conventional method using chemiluminescence immunoassay (CLIA) on liquid 
serum collected by venepuncture.  
2. A more novel method based on analysis of dry blood spots (DBS). 
 
Below are brief descriptions of the analyses used with these two approaches. 
3.7.1 Analysing of 25(OH)D concentration using the conventional method. 
In this study, serum from use of plain blood collection vacutainer tubes was used for assay of 
25(OH)D using a competitive immunoassay utilizing CLIA technology at the Freeman 
Laboratories, Freeman Hospital, Newcastle upon Tyne NE7 7DN. Details of the procedure or 
analysing 25(OH)D concentration using this method can be found in Appendix 3.15. 
3.7.2 Analysing 25(OH)D concentration using DBS 
The use of DBS is a relatively new approach for collection and storage of blood samples for 
later measurement of a wide range of analytes including 25(OH)D concentration. The blood 
samples can be self-collected using a minimally invasive technique which has the advantages 
that it does not require a phlebotomist to perform the venepuncture, and the samples do not 
require centrifugation and low temperature storage, which are crucial in the traditional method 
to prevent the degradation of plasma or serum samples (Hoeller et al., 2016). The procedure 
involved using a small sterile lancet to prick the skin and to produce a drop of blood which is 
dropped on to a marked circle on a filter paper card (Chambers et al., 2015). The blood is 
allowed to dry at the room temperature and then the DBS card is stable at room temperature. 
This means that the DBS system can be used for blood sample collection in populations at 
remote locations or at home, and the shipment of frozen samples is unnecessary (Demirev, 
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2013). One explanation for this may be the presence of a specific vitamin D binding protein in 
blood that, together with serum albumin, bind >99 % of the circulating25(OH)D, thereby 
stabilizing the vitamin on the DBS cards (Hoeller et al. 2016). 
 
 For this study, five circles on the filter card (Whatman Protein Saver 903 card; GE Healthcare 
from DSM Nutritional Products Ltd. Switzerland) were required to be filled with blood. For 
the finger prick, 2.0-mm contact-activated lancets (BD Microtainer; becton, Dickinson and 
Company) were used. The DBS cards were then air dried for at least one hour but not more 
than four hours at room temperature before being stored in the laboratory at -80ºC. The analyses 
of DBS were done at City Assay, Clinical Biochemistry Sandwell and West Birmingham 
Hospitals NHS Trust, City Hospital, Dudley Road, Birmingham, B18 7QH.  Details of the 
procedure used can be found in Appendix 3.16. 
 
This part is dedicated to the comparison of results of 25(OH)D concentrations obtained after 
these two methods. For that purpose, Bland Altman method was performed to provide a visual 
representation of the agreement these two methods. 
The samples for the 25(OH)D were obtained from two studies; 
1) Study 1 - Cross sectional study to evaluate the association of vitamin D with physiological 
and biochemical markers of endothelial function in overweight and obese post-menopausal 
women (described in detail in Chapter 4 of this thesis).  
2) Study 2 - The effect of vitamin D and physical activity on knee osteoarthritis symptoms in 
older obese adults: a mixed methods study (PhD thesis, R Brown, Newcastle University 2017 
- Personal communication from JC Mathers). 
The results of the 25(OH)D analyses conducted using the two methods are summarised in 
Table 3.5. In the two studies, there was a significant difference between 25(OH)D 
concentrations derived by direct analysis on liquid serum after venepuncture and those derived 
using DBS method. On average, 25(OH)D concentrations derived from DBS were more than 
two fold higher compared with direct analysis of serum sample in both studies. 
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Table 3. 5: Mean 25(OH)D concentrations measured from serum sample and DBS in 
two independent studies 
 Mean (SD) 
 
Min - Max P value 
Study 1 (n=80) 
 
   
Serum sample 
 
44.84 (23.87) 12 - 125  
p<0.001 
DBS sample 
 
101.78 (40.02) 40.20 – 218.90 
Study 2 (n=20) 
 
   
Serum sample 
 
67.35 (29.52) 13.00 – 122.00  
p<0.001 
DBS sample 
 
147.98 (54.71) 23.40 – 218.40 
Significant p values are shown in bold. 
 
Table 3.6 summaries the correlation and agreement of 25(OH)D concentration obtained 
using the two methods. 
 
Table 3. 6: Correlation and agreement parameters of 25(OH)D concentration in serum 
measured by conventional and dry blood spot method 
 N Mean 
Bias 
Regression 
equation 
 
r2 t-test (p) +2SD Min Max 
Study 1 80 -56.94 y=-5.65+ 0.5x 0.691 p <0.001 
 
24.14 
 
-119.3 
 
-15.40 
 
Study 2 20 80.63 y=9.96 + 0.39x 0.47 p <0.001 39.28 
 
-41.60 
 
137.8 
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Study 1 (n=80) 
The results of B&A analysis for the comparison of the two methods are illustrated in Figure 
3.11. This showed that, whilst there was a strong and significant, positive correlation between 
25(OH)D concentrations measured by the conventional and DBS methods (n=80, r2=0.69, 
p<0.001), the DBS approached significantly and systematically overestimated 25(OH)D 
concentrations compared to the conventional method (mean bias= 56.94 nmol/L; p<0.001) 
(Table 3.6). The 95% limits of agreement are -9.62 nmol/L, -104.26 nmol/L and all of the 
points are within these limits apart except for 3 points. For these three points, which is outside 
the 95% limit, the 25(OH)D concentrations of DBS are much higher than that given by venous 
25(OH)D. In addition, a significant differential bias was found as the difference between the 
two methods increased with a rise in 25(OH)D concentrations (R2=0.486, p= <0.001) Figure 
3.11 B.  
 
A) Regression analysis of 25(OH)D concentration (nmol/L) by conventional and DBS 
method 
 92 
 
 
B) Bland-Altman analysis of estimates of mean 25(OH)D concentration (nmol/L) serum 
venous vs DBS 
Figure 3. 10: Comparison of 25(OH)D concentration using serum venous (conventional 
method) and DBS method. 
(A), linear regression analysis between venous 25(OH)D and DBS (B), Agreement and differential bias 
between the two methods was evaluated by the Bland Altman method. Black horizontal lines (bold) 
show the mean difference between conventional and DBS method and the fine, grey line are the limits 
of agreement (± 2SD). A regression line was fitted to the points (dashed black line) to evaluate 
differential bias. 
 
Recommendation for practice: 
In this study, the DBS method over-estimating 25(OH)D measurement compared with the 
conventional method. Furthermore, the difference between these two methods increased when 
the 25(OH)D concentration increased. Therefore, it can be recommended that results from DBS 
method should be interpreted cautiously. 
 
Study 2 (n=20) 
The findings from Study 2 were very similar to those from Study 1. As shown in Figure 3.12 
whilst estimates of 25(OH)D concentration obtained using the two methods were significantly 
and positively correlated (n=20, R2= 0.517, p<0.001), values from use of DBS were 
consistently higher that when using the conventional approach and there was evidence of 
differential bias (Figure 3.12 B) in results from use of the two methods. 
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A) Regression analysis of 25(OH)D concentration (nmol/L) by conventional and DBS 
method 
 
 
B) Bland-Altman analysis of estimates of mean 25(OH)D concentration (nmol/L) serum 
venous vs DBS 
 
Figure 3. 11 (A and B): Comparison of 25(OH)D concentration using serum venous 
(conventional method) and DBS method. 
 (A), linear regression analysis between venous 25(OH)D and DBS (B), Agreement and differential bias 
between the two methods was evaluated by the Bland Altman method. Black horizontal lines (bold) 
show the mean difference between conventional and DBS method and the fine, grey line are the limits 
of agreement (± 2SD). A regression line was fitted to the points (dashed black line) to evaluate 
differential bias. 
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Recommendation for practice: 
Similar in Study 1, the use of DBS method was found to be over-estimated 25(OH)D 
concentration compared with the conventional method. Furthermore, the difference between 
these two methods increased as the concentration of 25(OH)D increased. Therefore, results 
from use of the DBS method should be interpreted cautiously. 
3.7.3 Discussion  
In this study, large differences in 25(OH)D concentration were found between use of DBS and 
conventional analysis of serum samples. Analysis of DBS led to consistent over estimation of 
25(OH)D concentration. By using DBS method, it seems that none of the participants in either 
study had vitamin D deficiency, which is doubtful. 
 
In Study 1, the serum samples were collected with capillary blood spot at the same time from 
overweight and obese postmenopausal women aged 50 to 70 years old. The participants were 
not using vitamin D supplementation and not using artificial sunlamps (or taking sunny 
vacations before sampling), so we were expecting the 25(OH)D values for the participants to 
be in line with Northern England Data (SACN, 2016), where the seasonal 25(OH)D values are 
as follows: 
 
North England (n = 676)        Mean winter 25(OH)D (nmol/L)       = 41.2 (95% CI: 39.7, 42.7) 
North England (n = 1261)      Mean Summer 25(OH)D (nmol/L)    = 60.9 (95% CI: 59.5, 62.3) 
 
Study 1 revealed the mean 25(OH)D concentration of the women using the CLIA method is 
44.8 nmol/L whilst using the DBS method it is 101.8 nmol/L.    Interestingly using the DBS 
method, none of the women would be categorized as 'vitamin D deficient' (25(OH)D < 25 
nmol/L) (SACN, 2016) even though it is regularly observed that 30% of the UK population 
aged 50-65 and over  have vitamin D deficiency throughout the year.   Half of the participants 
have 25(OH)D > 100 nmol/L using the DBS method whereas only one participant had 
25(OH)D > 100 nmol/l using the CLIA method.  
 
In study 2, the participants were supplemented with 25 µg vitamin D for three months. The 
results revealed that mean 25(OH)D concentration from serum samples is 67.35 nmol/L, which 
is not surprising as it was as expected. However, the mean 25(OH)D concentration using DBS 
method was more than double (147.98 nmol/L).  
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A few studies have reported that use of the DBS method resulted in 25(OH)D concentrations 
that were substantially lower compared with venepuncture plasma/serum 25(OH)D (Eyles et 
al., 2009; Larkin et al., 2011; Heath et al., 2014; Sakhi et al., 2015), which is contrary to this 
study.  A longitudinal study among 109 mother-infant dyads in Tennessee conducted by Larkin 
et al., 2011 demonstrated good agreement between DBS and serum. The measurement of 
25(OH)D by DBS in this study were on average lower compared to serum measurement. 
Similarly, a cohort study done by Health et al., 2014 involving 62 participants from Melbourne 
Collaborative Cohort Study were done for a study calibrating 25(OH)D concentrations in DBS 
with plasma.  The result showed good agreement between 25(OH)D from DBS and plasma. 
However, in this PhD study, it seems likely that the results from use of DBS are imprecise and 
CLIA estimations are closer to the ‘true values’. 
 
Several reasons can be postulate from this dissimilarity finding.  DBS card in this study has 
been stored in -80ºC for about 6 months before being analysed. Even though (Heath et al., 
2014) in her study reported that measurements of 25(OH)D concentrations in archived DBS up 
to 19 years are reliable, the possibilities of some degradation of 25(OH)D might occur, which 
leads to inaccuracy of the results. The same condition can be observed during the drying phase 
of freshly spotted DBS prior to frozen storage.  
 
The blood collection procedures, transportation and storage may lead to variation in sample 
quality. The compounds need to be stable in the presence of oxygen at ambient temperature for 
at least the initial drying time and shipment time to the laboratory. Apart from these pre-
analytical procedures, biological factors such as sample viscosity and haematocrit level might 
be the additional challenges that lead to this discrepancy.  In addition, the importance of 
calibration of the machines (in this case; CLIA and LC-MS/MS) prior to the measurements of 
the samples are essential for the reliability of the analysis. As the analysis of serum samples 
and DBS were analysed in Freeman Hospital, Newcastle and Birmingham Hospital, 
respectively, this is beyond our control, even though each of the laboratories reported that they 
participate in the Vitamin D External Quality Assurance Scheme (DEQAS). However, DEQAS 
does not operate quality control for DBS, so in this case, although the Birmingham laboratory 
participate in DEQAS for venous sampling, it is not applicable for DBS.  
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3.7.4 Conclusion 
In conclusion, this study showed a large discrepancy between the measurement of 25(OH)D 
using conventional method (assays on liquid serum collected by venepuncture) and using a 
dried blood spot (DBS) method. Therefore, we ought to reject the DBS values for 25(OH)D in 
this study because the high results were not explained by the participant’s dietary vitamin D 
intake (which is low and non-users of vitamin D supplements – Study 1) or sun exposure (no 
sunbed use or sun holidays in the previous three months prior to sampling). Furthermore, the 
unusually high 25(OH)D results obtained by DBS (i.e. half of the participants had 25(OH)D > 
100 nmol/L) is atypical for North-East 50-70-year-old women (SACN, 2016).       
 
3.8 Limitations in comparison and clinical interpretation of serum-levels across 
different assay methods - Diversity of 25(OH)D analysis perspective 
In early 1970s, the first method of measuring 25(OH)D was developed using the competitive 
protein binding format with the vitamin D binding protein (DBP) as the binder (Wallace, 2010). 
Measuring serum 25(OH)D concentrations vary and it depends on the type of assay used and 
the specific laboratory undertaking the analysis, thus impairing the accurate assessment of 
vitamin D status (Lips et al., 1999).  
 
To date, there are several commercially analytical techniques have been widely used for 
25(OH)D analysis in serum or plasma, such as chemiluminescence immunoassays (CLIA), 
radioimmunoassay (RIA), high performance liquid chromatography (HPLC), liquid 
chromatography –tandem mass spectrometry (LC-MS/MS). The technical characteristics, 
advantages and disadvantages of each technique used for 25(OH)D analysis are described in 
Table 3.7. 
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Table 3. 7: The technical characteristics, advantages and disadvantages of each technique used for 25(OH)D analysis 
 Method & Description Advantages Disadvantages 
 
1. 
Chemiluminescence immunoassays (CLIA)  
The main principle of CLIA involved the generation 
of electromagnetic radiation as light by the release of 
energy from a chemical reaction. The light is then 
emitted in the ultraviolet, visible or infrared region, 
and measured by a photomultiplier as relative light 
units (RLU) (Wagner et al., 2009). 
 
 
More practical and easier method 
compared to another analytical technique 
for 25(OH)D analysis. Higher-throughput 
capacity and lower sample volume 
requirement. 
 
 
 
Required high skilled operator. Unable to 
measure 25(OH)D2 and 25(OH)D3 separately. 
 
 
2. 
Radioimmunoassay (RIA)  
This technique is more favour for laboratories in 
clinical monitoring. Developed by DiaSorin Liaison 
Corporation, this method was used by many 
reference laboratories and considered the gold 
standard in the past decades before the developing of 
LC-MS/ MS method (Hollis et al., 1996). 
 
 
 
Suitable for laboratories with a larger 
testing volume. More often used for 
clinical diagnosis due to its reliability and 
accuracy. Convenience and can providing 
fast output. Good comparability with other 
methods. 
 
 
 
 
Unable to measure 25(OH)D2 and 25(OH)D3 
separately. Involving multiple phase separation 
steps (washing steps), and requiring special 
instruments or manufacturer specific 
instruments to perform 
 
3. 
High performance liquid chromatography (HPLC)  
This type of assay was introduced in 1977 from the 
laboratory of Dr. Hector DeLuca determining 
25(OH)D2 and 25(OH)D3 in human plasma using 
high-pressure liquid chromatography and detection 
by ultraviolet absorbance. This technique is more 
favour for laboratories carrying out research (Eisman 
et al., 1977). 
 
 
 
 
Often referred to as the standard by which 
other methods are compared. It can 
measure the individual quantitation of 
25(OH)D2 and 25(OH)D3. High accuracy 
if validated and performed by experienced 
personnel. 
 
 
 
 
Requires expensive equipment and highly 
skilled operators. The output result needs to be 
cautiously interpreted. The procedure need 
large sample volume requirements, slow sample 
throughput. Technically difficult, not fully 
automated, and of low throughputs. Unsuitable 
for routine as the method is very time 
consuming and required extensive purification 
steps. 
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 Method & Description Advantages Disadvantages 
 
4. 
Liquid chromatography –tandem mass spectrometry 
(LC-MS/MS)  
This technique is more favour for laboratories 
carrying out research. This method is reported to be 
the ‘gold’ standard for 25(OH)D measurement, 
providing the most specific and sensitive results (van 
den Ouweland, 2016). 
 
 
 
 
 
It can measure the individual quantitation 
of 25(OH)D2 and 25(OH)D3. Highly 
precision and reliability. Most sensitive 
and specific for measuring serum 
25(OH)D concentrations. Minimal 
adaptation to standard method required. 
 
 
 
 
Need calibration to standardize the 
measurement. Not commonly available in 
clinical laboratories due to its high equipment 
costs. The procedure need large sample volume 
requirements. 
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3.9 Proficiency testing of 25(OH)D assays 
3.9.1 Vitamin D External Quality Assessment Scheme (DEQAS) 
It is well acknowledged that the measurement of 25(OH)D is challenging due to its 
physiological characteristic (highly lipophilic, bound strongly to DBP) (Wagner et al., 2009). 
Apart from that, 25(OH)D exists in two structurally similar forms, 25(OH)D3 and 25(OH)D2, 
which makes it difficult to measured. The large inconsistency and variability in 25(OH)D 
measurements between methods and laboratories has ignited the needs of establishment a 
quality assurance scheme to monitor the analytical reliability of 25(OH)D assays.  
 
To standardize the laboratory methodology and proficiency of vitamin D assay, the Vitamin D 
External Quality Assessment Scheme (DEQAS) has been established to monitor 25(OH)D 
assay performance since 1989. Mainly operated by Charing Cross Hospital, London, UK, 
DEQAS has regularly conducted and reported on a number of investigations into the 
performance of 25(OH)D methods within laboratories worldwide (Carter et al., 2010a). Since 
then, more than 35 countries has participated in this scheme, as it provides expertise in vitamin 
D field and proficiency testing schemes and biostatistics which is beneficial for the laboratories 
and manufacturers (Carter et al., 2010b).  
 
After 20 years of the establishment of this scheme, over 250 US laboratories have voluntarily 
registered with DEQAS and this indicates that the importance of standardization of techniques 
used for 25(OH)D analysis in serum or plasma has been accepted and acknowledged (Hollis, 
2008). In April 2013, DEQAS has been collaborated with US National Institute of Standards 
and Technology (NIST). From this collaboration, each of the DEQAS samples will have the 
values assigned by the NIST Reference Measurement Procedure (RMP) for the individual 
metabolites 25(OH)D3, 25(OH)D2 and additional 3-epi – 25(OH)D3, which is significant for 
laboratories using HPLC/UV and LC-MS/MS methods (Vitamin D External Quality 
Assessment Scheme, 2014).  
 
Apart from the collaboration with NIST, DEQAS is also mutually participating with Vitamin 
D Standardisation Program (VDSP). VDSP was established in 2010 by the US Office of 
Dietary Supplements (ODS) and the objectives are similar to DEQAS, which is focusing in the 
standardization of laboratory measurement of 25(OH)D. This scheme also conducting 
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international research programs which is committed to improve the quality of laboratory 
measurement of 25(OH)D (Vitamin D External Quality Assessment Scheme, 2014). 
 
The combination of these three quality assurance scheme (DEQAS, NIST and VDSP) has bring 
new important contribution for the analytical reliability of 25(OH)D assays, which is very 
important for the integrity of the laboratory performance (Vitamin D External Quality 
Assessment Scheme, 2014). 
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Chapter 4: Association of Vitamin D Status with Physiological and 
Biochemical Markers of Endothelial Function in Overweight and Obese 
Post-Menopausal Women 
 
4.1 Introduction 
Vitamin D, the ‘sunshine vitamin’, is currently the subject of controversy in relation to its role 
in cardiovascular disease (CVD) prevention. Primarily known for its key role in calcium 
homeostasis and in bone health, there has been increasing study of the actions of vitamin D on 
non-skeleton health. The latter studies have been stimulated by evidence from epidemiological 
studies (Judd et al., 2008; Anderson et al., 2010; Bajaj et al., 2014) and following the discovery 
that vitamin D regulates the expression of a very large number of genes involved in multiple 
cellular processes related to CVD (Dobnig et al., 2008; Jablonski et al., 2011; Wang et al., 
2013). 
 
Investigations of links between vitamin D intake/status and CVD risk have yielded 
heterogeneous results which appear to be related to the study methodology. Most observational 
studies suggest a positive link between higher vitamin D intake/status and cardiovascular 
health, e.g. risk of hypertension is increased in those with low serum 25(OH)D concentration 
in blood (Judd et al., 2008; Rueda et al., 2008; Chan et al., 2012). Similarly, a study from the 
US showed that lower serum 25(OH)D concentrations were associated with highly significant 
increases in the prevalence of diabetes, hypertension, hyperlipidaemia, and peripheral vascular 
disease (Anderson et al., 2010). This is in line with a study by Wang et al, 2008, which 
demonstrated that serum 25(OH)D concentrations were inversely associated with risk of 
coronary artery disease, myocardial infarction, heart failure and stroke (Wang et al., 2008). 
Details of the findings from observational studies on vitamin D and CVD related outcomes are 
summarised in Appendix 4.1. 
 
Results from randomized controlled trial (RCTs) demonstrated inconsistent results. Some 
RCTs reported a positive effect of vitamin D supplementation on surrogate markers of vascular 
disease. For example, when assessing effects of serum 25(OH)D concentration on endothelial 
function, some studies have seen improvements in endothelial function (Tarcin et al., 2009; 
Dong et al., 2010; Harris et al., 2011a) while other RCTs reported negative results (Witham et 
al., 2010; Gepner et al., 2012; Stricker et al., 2012). For blood pressure, some, but not all 
studies have reported a positive effect of vitamin D supplementation on blood pressure 
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(Margolis et al., 2008; Sugden et al., 2008; Nagpal et al., 2009; Zittermann et al., 2009). 
Several trials found that there were no effect of vitamin D supplementation on glycemia or 
incident of diabetes (Hsia et al., 2007; Pittas et al., 2007a; de Boer et al., 2008; Jorde and 
Figenschau, 2009; von Hurst et al., 2010). Therefore, the available data are insufficient to make 
a conclusion about the effects of vitamin D status (as assessed by 25(OH)D concentration) on 
risk of cardio metabolic outcomes.  
 
In Chapter 2, the findings from RCTs on effects of vitamin D supplementation on endothelial 
function have been discussed. The results of that systematic review and meta-analysis were 
mainly equivocal. In this chapter, the findings from a cross sectional study will be described 
and discussed which investigated the association of serum 25(OH)D status with endothelial 
function (EF) in older overweight and obese, postmenopausal women who are at higher CVD 
risk. Such an association may be explained by the link between serum 25(OH)D concentration 
and pathways involved in the regulation of nitric oxide (NO) signalling and EF.  
 
Serum 25(OH)D concentration may influence NO and EF indirectly by suppressing renin 
angiotensin aldosterone (RAS), a hormone that control the regulation of blood pressure (Li et 
al., 2002), and, in particular, low circulation of serum 25(OH)D may increase the expression 
of RAS. Reduction of PTH is also associated with high circulating concentrations of serum 
25(OH)D concentration (Yankouskaya and Snezhitskiy, 2014). Higher PTH concentrations are 
associated with increased risk of CVD events by increasing blood pressure, cardiac 
hypertrophy, and myocardial dysfunction (van Ballegooijen et al., 2013). Therefore, the 
rationale of the cross sectional study reported in this chapter is that those with higher serum 
25(OH)D concentrations group will have lower PTH. The vitamin D receptor (VDR) is 
expressed in smooth muscle cells (SMC) and endothelial cells, which strengthens the argument 
that serum 25(OH)D is involved in maintenance of the integrity of EF perhaps by enhancing 
the proliferation SMC and through expression of vascular endothelial growth factor (VEGF) 
(Kamen and Tangpricha, 2010; Ferder et al., 2013; Min, 2013). A stronger association between 
serum 25(OH)D concentration and physiological markers of EF (PORH and PWV) would be 
predicted as these markers provide an integrated assessment of various pathways involved in 
the control of vascular homeostasis. Therefore, we speculate that there will be an inverse 
association between serum 25(OH)D concentrations and measures of EF and blood pressure.  
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4.2 Hypothesis, aim and objectives 
The main hypothesis of the project was based on the occurrence of a higher prevalence of 
vitamin D deficiency in individuals with signs of endothelial dysfunction (Alyami et al., 2014). 
Specifically, we evaluated to test whether lower levels of serum 25(OH)D concentration were 
significantly associated with greater impairment of EF, assessed using physiological and 
biochemical biomarkers in older, overweight and obese postmenopausal women.  
 
The primary aim was to conduct a cross-sectional study including 80 middle-aged and older, 
overweight and obese post-menopausal women to investigate the association between serum 
25(OH)D concentration, physiological and biochemical markers of EF.  
 
The specific objectives of the study were: 
1. To collect socio-demographic, dietary, lifestyle information and assess body 
composition and resting blood pressure. 
2. To investigate the association between serum 25(OH)D concentrations and PORH and 
PWV, measured by laser Doppler and digital photopletysmography (PPG), 
respectively. 
3. To evaluate the association between serum 25(OH)D concentrations and biomarkers of 
EF including asymmetric dimethylarginine (ADMA), cyclic Guanosine 
Monophosphate (cGMP), Endothelin-1 (ET-1) and Vascular Endothelial Growth 
Factor (VEGF). 
4.3 Methods 
4.3.1 Study design 
This was a cross sectional study involving healthy, overweight and obese post-menopausal 
women living in Newcastle and nearby. The study was conducted in the Clinics for Research 
and Service in Themed Assessment (CRESTA) facility, Newcastle Biomedical Research 
Building on the Campus for Ageing and Vitality, Newcastle University. The study took place 
between December 2014 and August 2015. 
4.3.2 Participants recruitment 
This study was aimed to recruit volunteers from the general public. A total of 80 healthy (with 
no established medical diagnosis), non-smoking, overweight or obese, post-menopausal 
women with a BMI between 25.0 and 40.0kg/m2, and age range between 50 to 70 years old 
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were recruited from the general public in Newcastle through volunteer databases available at 
Newcastle University, circulation of emails to members of staff of Newcastle University and 
Newcastle NHS Hospitals, dissemination of posters and leaflets as well as advertisement in the 
local community in public places including the City Library and  local shops . We also sought 
support from Voice North (the regional research and engagement panel 
(http://www.ncl.ac.uk/iah/ageing/volunteer/voicenorth.htm). Each advertisement contained 
concise information on the study title, aims of the study, main inclusion criteria (age, BMI, 
gender, smoking status) and contact details of the study coordinators. 
 
Telephone screening 
Telephone screening was conducted to check participant eligibility. A standardised 
questionnaire was used to ensure the accurate evaluation of the inclusion and exclusion criteria 
as well as to collect information on sociodemographic status, GP practice, smoking behaviour 
and commitment and availability to complete the study. Participants were excluded if they have 
any of the following criteria: weight change more than 3.0 kg in the last three months; took 
nutritional supplements which provided calcium (dosage more than 500 mg/day) and vitamin 
D (dosage more than 10 mcg per day - this included those on vitamin D preparations for joint 
pain either prescribed by their GP or obtained over the counter ); diagnosis of cancer and any 
diagnosis of malignant cancer in the last five years; chronic and acute metabolic and 
inflammatory conditions which could interfere with the study outcomes; previous diagnosis of 
type 1 diabetes or type 2 diabetes treated with insulin; use of weight loss medication 
(sibutramine, orlistat or rimonabant) or history of bariatric surgery; use of specific drugs 
including: oral corticosteroids, anticoagulants, nitrate-derived agents, anti-cholinergic drugs; 
use of hormonal therapies (oestrogens, thyroxine, progesterone, oral hypoglycaemic agents), 
anti-hypertensive (diuretics, beta-blockers, calcium antagonists, ACE-inhibitors and 
angiotensin receptors inhibitors), statins and any other anti-dyslipidaemic agent and use of 
psychiatric drugs (antidepressants, sedatives, antipsychotics) if this use had started, or the dose 
had been changed, in the previous three months; haematological disorders including previous 
diagnosis of severe anaemia (Hb < 10 mg/dL); major surgical operations interfering with the 
study outcomes; alcohol intake >14 units/week; non English speakers or volunteers requiring 
translators or interpreters. 
 
During the telephone screening, the participants were asked about their contact details (home 
address, email address, telephone number (home/office/mobile), name and address of medical 
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practice, anthropometric measurements (weight and height), health status, medication that they 
consumed (prescribed or over the counter) smoking and drinking status. If they were eligible 
and willing to participate in the study, appointments were set up based on the availability of 
the potential participants to attend and the availability of the clinic. 
Study invitation 
 
An invitation email was sent to the potential participant for the confirmation about the study 
visit. The email contains the date, time and venue of the study visit. The participant information 
sheet also was send as an attachment in the email for them to read and have a brief idea about 
the study. For those without email address, an invitation letter was sent by mail. 
 
Two days before the study visits were held, a reminder email was sent to the participant and 
details of the route to the CRESTA clinic were attached. For those who needed transport to 
come to the clinic, a taxi was booked for them and details of the booking were sent by email. 
The participant was reminded to be fasting starting from 8.30 pm on the day before the study 
visit (water was allowed). Since they were required to lie down during the visit for the vascular 
measurement, the participant was advised to wear comfortable clothes (a short sleeve 
top/blouse and trousers rather than a long sleeves or a dress). 
 
From December 2014 to April 2015, we conducted one session of study visits every Monday, 
Tuesday and Friday (one participant per session). From May to August 2015, we conducted 
two sessions of study visits (two participants per day). For the latter, session one ran from 8.15 
am to 9.45 am and session two from 9.30 am to 11.00 am. 
Equipment set up 
 
Before the study visit, all the forms necessary for the participant’s visit were printed and 
organized in a folder (screening form, consent forms, study form, information sheet, study 
questionnaires, tracking form, reimbursement form and equipment manual). A request form 
was send to Clinical Ageing Research Unit (CARU) to assess the participant’s clinical note 
three days before the study visit was held. 
 
Labels and tubes for the collection of blood and urine samples were prepared a day before the 
study visit. This included labelling the tubes for storage of aliquots of blood and these tubes 
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were kept in the laboratory until required. The equipment for dry blood spot collection were 
prepared (lancet, Protein SaverTM 903TM card, alcohol swab, plaster). 
 
Equipment for vascular measurements (laser Doppler and PWV) were set up to ensure the 
effectiveness of the measurement during the study visit. The weighing scale and portable blood 
pressure device were tested for the battery efficiency. A breakfast voucher and honorarium 
voucher were prepared in an envelope for the participant. 
4.3.3 Sample size 
The calculation of the sample size was based on the results of a cross sectional study which 
investigated differences in FMD in middle aged/older men and women stratified by vitamin D 
status (deficient, normal). This study found a significant difference in FMD between the groups 
with the following results: Normal: 4.75±19.2%, n=22; Deficient: 3.33±1.87%, n=22 
(Jablonski et al., 2011). We used this information to estimate the sample size required to detect 
a significant effect in vascular measurement between obese post-menopausal women with 
normal and those with deficient vitamin D status. The calculations showed that 58 overweight 
and obese post-menopausal women will be required to detect a significant difference between 
the two groups with an  level of 0.05 and a power (1-β) of 0.80. We aimed to recruit 80 
participants for this study. The calculations were performed using G power 3.1 for Windows. 
FMD was used as the method to estimate sample size even though this study used PWV and 
PORH for the assessment of EF. This was because at the time of the design of the study, no 
study was conducted using PWV/PORH for the measurement of EF and association with serum 
25(OH)D concentration. Therefore, the magnitude of the difference in FMD observed by 
Jablonski et al, 2011 was assumed and applied to this study. 
4.3.4 Study sponsorship 
The Newcastle upon Tyne Hospitals NHS Foundation Trust acted as the research sponsor for 
this study, under the Department of Health’s guidelines for research in health and social care 
(Trust R&D Project No: 7074) (Appendix 4.2). 
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4.3.5 Ethical approval 
REC application 
Prior to recruiting any participants, ethical approval was sought and gained from NRES 
Committee East Midlands-Northampton (14/EM/1073) (Appendix 4.3). 
Substantial amendment 
A substantial amendment to the ethical approval was sought and obtained to amend the 
exclusion criteria about the permitted dosage of nutritional supplement (specifically vitamin D 
and calcium) consumed by the participants (Appendix 4.4). 
R&D application 
IRAS project ID: 152807 
Caldicott and Data Protection approval for storage of data was sought and gained from The 
Newcastle upon Tyne Hospitals NHS Foundation Trust (3331). 
4.3.6 Clinical assessment 
Participants arrived at Clinics for Research and Service in Themed Assessment (CRESTA) 
early in the morning (~8.30 am) after an overnight fast of about 12 hours and were asked to 
avoid caffeinated drinks before the visit. 
 
Participants were provided with a Participant Information Sheet which outlined the aim of the 
study and what they would be required to do. The potential risks and benefits of their 
participation were clearly explained in the information sheet and subjects were informed that, 
while their anonymity would be preserved and their data stored safely, the group data may be 
published in academic journals or presented at national/international conferences. Participants 
were told that they were free to withdraw from the study at any point with no disadvantage to 
themselves. Any additional questions or concerns that the participants had were answered 
before they provided written, informed consent to participate. 
Measurements 
Anthropometric measurements 
Height and weight were measured with a standard stadiometer and weight scale, with 
participants wearing light clothing and barefooted. Weight was measured in kilograms to the 
nearest 100g. Weight and height measurements were used to calculate BMI according to the 
following equation: 
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BMI= weight (kg) 
             height (m)2 
 
Waist circumference was measured with a standard non-stretchable tape, in the standing 
position, at the minimum circumference between iliac crest and the rib cage. Body composition 
was measured using a leg-to-leg bioelectrical impedance device (TANITA 300 MA). 
Blood pressure measurement 
Blood pressure measurement was done in triplicate at one minute intervals using an automated 
blood pressure monitor (model: Omron M3 [HEM-7200-E8(V)]) with the participant in the 
sitting position. Before the measurements, participants were invited to rest for a minimum of 
five minutes. An appropriate cuff size was used for each subject. 
Biochemical measurements 
A total of 20 ml fasting venous blood were drawn by venepuncture in the antecubital fossa and 
transferred into five different vacutainers (lithium heparin, serum gel, EDTA, plain tube, 
sodium fluoride). Blood samples were separated by centrifugation within two hours of being 
drawn and aliquots were stored at -80ºC until analysis. The EDTA vacutainer were sent to 
Clinical Biochemistry Laboratory (Freeman Hospital, UK) on the same day for the analysis of 
haematocrit. 
 
A finger prick capillary blood samples was obtained for vitamin D concentration using the 
dried blood spot approach. The blood drops then were transferred onto a specific filter paper 
(blood spot card) (Protein SaverTM 903TM Card, DSM). Blood spots were air dried for at least 
30 minutes before the flap was closed on the blood spot card. Fully dried samples were then 
stored at -80ºC until required for vitamin D assay. A spot urine sample was collected in urine 
plastic container.  
Vascular measurement 
The final part of the visit was the assessment of vascular health. During the measurements, 
participants were asked to lie on a bed for 30 minutes and to avoid any movement as this may 
affect the validity of the measurements. The first test was called “Pulse Wave Velocity” which 
measures how fast the heart beat travels in the arteries (Table 4.1). This test is simple, non-
invasive, validated and reproducible measurement of arterial stiffness (Laurent et al., 2006). 
The stiffer the arteries are, the faster the wave is returned, adding to the forward wave and 
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augmenting the systolic pressure (augmentation index (AI)) (Cho et al., 2013). Developed by 
the Medical Physics Department of Newcastle University, photoplethysmography (PPG) was 
developed to measure the PWV and distensibility coefficient (DC). The procedure involved the 
attachment of five electrodes using small adhesive gel pads to the ear lobe, fingertip, chest and 
abdominal area. The data were recorded and analysed by a computer (Fujitsu Lifebook S3020 
laptop, Japan). Single lead ECG was also recorded simultaneously (Figure 4.1). A series of 
two separate measurements were performed with different external cuff pressures (0 and 40 
mmHg) applied to the whole right arm through the long cuff, with a minute rest interval 
between each measurement. During the recording session, the arms were kept parallel to the 
body and as still as possible, with regular and gentle breathing. The measurement last 
approximately 15 minutes. The data, display, ECG and PPG signal acquisition were stored in 
software named ARD (Analogue Recorder and Display), developed by the Medical Physics 
Department. 
 
Table 4. 1: Photoplethysmography variables  
 Variables 
 
Definitions 
1. Pulse Transit Time (ms) The time it takes for the pulse pressure wave to go 
through an arterial tree in the arm, resulted from the 
ejection of blood after the release of the 40mmHg 
pressure applied to the arm. 
 
2. Pulse Wave Velocity (m/s) The distance travelled by the wave (Δx) divided by 
the time for the wave to travel for that distance (Δt) 
when 40mmHg pressure was applied to the arm. 
(Δx) 
(Δt) 
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Figure 4. 1: Example of pulse wave recording of study participant. 
 
At the end of the test, the electrodes were removed and the second test was performed, which 
is called Post- Occlusive Reactive Hyperaemia (PORH) (Table 4.2). This test was used to 
measure the cutaneous microvascular reactivity and based on the ability of the endothelium to 
release nitric oxide (NO) as a response to proximal arterial occlusion. After the end of the 
occlusion, when the peripheral perfusion is restored, the immediate reduction of vascular 
resistance results in an increase of the blood flow which is closely linked to NO release and 
integrity of endothelial function (Carasca et al., 2017).  The duration of the test was 
approximately 15 minutes. A laser Doppler probe was attached to the right forearm. The test 
involved the placement of a blood pressure cuff around the participants’ arms which were 
inflated for three minutes to 200mmHg to obstruct the blood flow in the brachial artery. After 
the deflation of the pressure cuff, the hyperaemic response was recorded using Moor VMS 
V3.1 software. PORH index was calculated as the ratio between Area Under Curve (AUC) a 
minute after the deflation of the cuff with AUC of a minute before the inflation of the cuff 
(Figure 4.2 and Figure 4.3). 
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Table 4. 2: Post-Reactive Occlusive Hyperaemia variables 
 
 Variables Definitions 
 
1. Resting level  (RL) The first three minutes of the procedure. 
 
2. Maximum level (ML) The maximum level of the graph of the blood flow after the 
release of the cuff at 200mmHg. 
 
3. Area of occlusion (AO) The area when the occlusion happens and blocks the blood 
flow (shown as blue area in the graph).  
 
4. Area of hyperemia (AH) Area under the curve after the release of the cuff (shown as 
pink area in the graph). 
 
5. Area of hyperemia (AH) / 
area of occlusion (AO) 
Area under the curve after the release of the cuff divided 
with area when the occlusion happens and block the blood 
flow. 
 
6. Time to recovery (TR) The first few second after the release of the cuff. 
 
7. Time to maximum (TM) The time taken to reach the peak of the graph of hyperemia. 
 
8. Time to half decay from 
maximum (TH) 
 
The time taken to reach the half of area of hyperemia. 
9. PORH Index Area under curve one minute after the deflation of the cuff 
Area under curve one minute before the inflation of the cuff   
 
 
 
 
Figure 4. 2: Graphical statistic of PORH analysis 
 (Taken from moorVMS recording and analysis software V4.0, Vascular Monitoring System Software 
Manual)
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Figure 4. 3: Laser Doppler Iontophoresis (LDI) recording from a participant during one 
of the study visits. 
 
Questionnaires 
 
Participants were asked to complete a battery of questionnaires regarding their general health, 
lifestyle and physical activity (Appendix 4.5). In addition, participants’ diets were assessed 
using a self-administered Food Frequency Questionnaire (FFQ) (Appendix 4.6) for the 
assessment of overall dietary and nitrate intake. The intakes of energy and nutrients were 
calculated using the MEDE FFQ Database. Short questionnaires on sun exposure were used to 
evaluate the participant’s overall sun exposure (Appendix 4.7). 
 
This completes the study visit. At the end of the visit participants were provided with an 
honorarium of £10, a £3 voucher for light refreshment at the cafeteria and reasonable travel 
expenses were also been paid to each participant. The quantitative measurements made on each 
participant during the study visit were summarised in Table 4.3. 
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Table 4. 3: Table summarising the measurement method, equipment and duration of the quantitative measurements taken during the 
cross-sectional study visit 
Outcome Equipment Procedure Approximate time 
taken to complete 
Weight (kg), BMI, 
Body Fat%, Fat Mass 
(kg) 
 
Bioelectrical impedance device 
(TANITA 300 MA). 
Participants were asked to stand barefoot on the scale. Age, 
body type, gender and height were imputed. Results for 
anthropometric measures are printed and recorded in the data 
collection sheet. 
 
5 minutes 
Height (cm) Stadiometer Participants were asked to stand straight with their back 
towards. Stadiometer ruler and the marker were brought down 
to the top of the head. Height was measured from the marker 
and measured 3 times. 
 
5 minutes 
Waist circumference 
(cm) 
Flexible measuring tape  
(marked in centimetres) 
Waist size was measured using a measuring tape halfway 
between the bottom rib and iliac crest. 
 
5 minutes 
Blood pressure 
measurement (mmHg) 
Automated blood pressure 
monitor  (Omron M3 (HEM-
7200-E8(V))) 
The participant’s upper arm was placed with the BP cuff and 
measured in triplicate. 
 
 
5 minutes 
Serum 25(OH)D 
concentration, Serum 
Calcium and 
Haematocrit 
1x Plain, 1x Serum Gel, 1x 
EDTA, 1x Sodium Fluoride, 1x 
Lithium Heparin Vacutainer 
Tubes, Butterfly needle, 
vacutainer tube holder, antiseptic 
wipe, tourniquet, gauze, plaster, 
pathology sample bag 
The participant’s arm is assessed and prepared before blood 
is taken from the vein, using a vacutainer blood collection 
system. 
 
 
 
 
 
 
10 minutes 
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Outcome Equipment Procedure Approximate time 
taken to complete 
Serum 25(OH)D 
concentration 
 
DBS (Dried Blood Spot) Kit: 
containing DBS card, Foil 
packaging, high flow lancet, 
plaster, antibacterial wipes and 
sterile gauze. 
The participants washed their hands thoroughly. The 
researcher disinfected finger before blood is obtained by 
finger prick. Blood drops are placed on a filter paper and dried 
at room temperature. 
 
 
5 minutes 
Vascular measurement  Participants were asked to lie on a bed for about 25-30 
minutes and avoid any movement. All the measurements were 
taken in a temperature controlled room (~23 ± 1C). 
 
 
 Pulse Wave Velocity Small adhesive gel pads, 
computer (Fujitsu Lifebook 
S3020 laptop, Japan), 5x optical 
probes, single lead ECG, long 
blood pressure cuff 
 
The procedure involved the attachment of five optical probes 
using small adhesive tape to earlobe, fingertip, chest and 
abdominal area. A long cuff was wrapped around the whole 
arm of the participants and a series of two separate 
measurements was performed with different external cuff 
pressures (0 and 40 mmHg) with a minute rest interval 
between each measurement.   Single lead ECG was recorded 
simultaneously. During the recording session, the arms were 
kept parallel to the body and as still as possible, with regular 
and gentle breathing. The information was recorded and 
analysed by a computer. 
 
15 minutes 
 Post-Reactive 
Occlusive 
Hyperaemia 
Laser Doppler probe, 
Computer, blood pressure cuff, 
Moor VMS V3.1 machine and 
software 
 
 
 
 
A small probe was attached to the forearm. The test involved 
the placement of a blood pressure cuff around the 
participant’s arm which was inflated for three minutes to 
200mmHg. 
 
 
 
15 minutes 
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Outcome Equipment Procedure Approximate time 
taken to complete 
Questionnaires 
 
 FFQ 
 Nitrate intake 
 IPAQ 
 Sunshine exposure 
questionnaires 
 
Participants were asked to complete a battery of 
questionnaires regarding their general health, dietary pattern, 
lifestyle and physical activity. 
30 minutes 
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4.3.7 Participant Feedback 
On conclusion of the study, each participant was mailed a letter thanking them for their 
participation in the study and an individual feedback sheet which provided data collected 
during their study visit. This included: 
• BMI (kg/m2) 
• Waist measurement (centimetres) 
• Blood Pressure- systolic and diastolic (mmHg) 
• Blood Vitamin D (25(OH)D) concentrations (nmol/L) 
• Blood Calcium concentrations (mmol/L – data were interpreted as normal, low 
and high) 
4.3.8 Sample storage 
Blood samples for serum or plasma collection were spun in a centrifuge (Jouan CR3i) at 
3000 rpm for 10 mins at 4°C. Using a Gilson pipette, plasma/ serum was taken off the spun 
samples, aliquoted into pre-labelled aliquot tubes and stored in the -80ºC freezed at the 
Human Nutrition Research Centre (HNRC) as quickly as possible for further analysis.  A 
fresh pipette tip was used for each sample tube. The labelling on each aliquot tube was 
checked to ensure that it matched the labelling on the sample tube. Used pipette tips and 
recapped discarded sample tubes were disposed in the biohazard bins. Plasma from serum 
gel and EDTA tube were transfer into aliquot tubes and were sent to the Freeman Hospital 
for 25(OH)D, PTH and calcium analysis. One EDTA tube was send to Freeman Hospital 
on same day for the haematocrit analysis. 
4.3.9 Statistical analyses 
Baseline characteristics of the participants are presented as arithmetic means ± SDs for 
numerical variables and counts and percentages for categorical variables. We tested the 
assumption of normality for all variables by testing the data graphically (visual inspection 
on the histogram) and numerically (by looking at the p-value for the Shapiro-Wilk, if the 
p-value < 0.05, the data are considered as not normally distributed, and vice versa). For 
non-normally distributed variables, we applied logarithmic transformations and data are 
presented as median (with 25th and 75th percentiles). Mean concentrations of serum 
25(OH)D were computed and aggregated into two groups i.e. below and above the cut-off 
for adequacy (<30 nmol/L and ≥30 nmol/L). Pearson correlation analysis was used to assess 
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correlations between pairs of variables. Independent sample t-test was used to compare 
between two groups of variables. Multiple linear regression models were used to examine 
the associations between PWV (independent variable) and various clinical measures (e.g. 
25(OH)D concentration, cGMP, ADMA, age, BMI and PAL) as dependent variables. We 
also derived the EF z-score as the mean of the following six standardized continuous 
indexes of NO3ˉ, cGMP, ADMA, 3NT, VEGF and ET-1. To calculate the z-score, the 
difference between values in the indexes and the mean were divided by the standard 
deviation. As the biomarkers carries different values (cGMP, VEGF and NO3ˉ  were 
considered as positive) and (ADMA, 3NT and ET-1 were considered as negative values) 
for the EF, a careful consideration was given to the direction of the association between 
biomarkers of EF. All statistical analyses were performed using the Statistical Package for 
the Social Sciences (SPSS) 22.0 program for Windows (SPSS Inc., Chicago, IL). Two sided 
p<0.05 was considered statistically significant in all cases.  
 
4.4 Results 
4.4.1 Participant recruitment 
Two hundred letters were sent out to potential participants obtained from the volunteer 
database. A total of 99 participants were contacted for the screening interview. After 
screening, 10 subjects did not meet the criteria (not eligible due to health condition: five 
subjects, BMI<25 kg/m2: three subjects, reluctant to draw blood: one subject, location too 
far from the research centre: one subject). Seven individuals dropped out after being given 
the appointment date due to change of mind and two individuals did not attend the research 
centre on the date of appointment.  Hence, 80 participants completed the study (Figure 
4.4). 
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Figure 4. 4: Recruitment flow chart 
 
 
Disseminating of study information via: 
1. Volunteer databases 
2. Flyers: 5000 pieces 
3. Voice North Website 
4. Circulation of email to: 
 Newcastle University  
o staff homepage 
o Human Nutrition 
Research Center 
(HNRC) webmail 
o Agriculture, Food and 
Rural Development 
(AFRD) webmail 
 Freeman Hospital 
 Women’s Institute, Newcastle 
 Northumbria University 
 City council 
o Staff homepage 
 General hospital 
 Royal Victoria Infirmary (RVI) 
o Staff homepage 
5. Diocese of Newcastle 
6. Posters 
 
Potential participants contacted through 
telephone interview: 99  
Potential participants excluded = 10 
 Not eligible due to: 
o Health condition: 5 
o BMI < 25kg/m2: 3 
 Reluctant to draw blood:1 
 Location (too far): 1 
 
 
Participant eligible for the study and who 
were invited to CRESTA clinic = 89 
Dropped out= 9 
 Changed mind: 7 
 Did not attend the appointment: 2 
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The duration of this study was eight months: recruitment started on 16th December 2014 and 
the last participant was recruited on 11th August 2015. Due to a protracted ethical approval 
process, this study which was designed to start in September 2014 was delayed until December 
2014. The eligibility requirements also contributed to the delay in completing the study because 
it was challenging to find potential participants in the appropriate age range (50 to 70 years 
old) who did not take nutritional supplements containing calcium and/or vitamin D. Therefore, 
a substantial amendment was submitted to the ethics committee to permit inclusion of those 
taking low doses of calcium (not more than 500 mg/day) and/ or vitamin D (not more than 10 
mcg per day). 
4.4.2 Baseline characteristics of participants 
The characteristics of the study participants are summarized in Table 4.4. Mean age of        
participants was aged 60.0 (IQR 57.0, 67.7) years, all were overweight or obese with mean 
BMI 28.9 (IQR 25.9, 32.0) kg/m2, and their mean BP was normal; mean systolic BP (SBP: 129 
IQR 121.0, 142.5 mmHg), mean diastolic BP (DBP: 74.6 ± 9.5 mmHg). However, when 
individual measures of BP were examined, 28.4% of the participants were categorised as 
having high blood pressure (SBP >140 mmHg and DBP > 90 mmHg), and three participants 
(3.7%) were having low blood pressure (DBP <60 mmHg).  
 
For the biochemical measurements, the mean 25(OH)D concentration was 42.5 nmol/L, the 
mean calcium concentration was 2.0 mmol/L, which is classified as  normal (range between 
2.0-2.6 mmol/L) and  the mean PTH concentration was 4.5 pmol/L (normal range of PTH 
between 1.2 - 5.8 pmol/L). The average age at menopause was 50.0 years and 10% (8/80) had 
an early menopause, defined as occurring before the age of 45 years. 
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Table 4. 4: Characteristics of study participants 
 Mean (SD) Min - Max 
Age (years)* 60.0 (57.0, 67.7) 50.0 - 70.0 
Weight (kg)* 73.1 (66.9, 83.7) 53.0 - 115.2 
Height (cm) 160.2 (6.3) 146.0 - 177.0 
BMI (kg/m2)* 28.9 (25.9, 32.0) 24.7 - 42.9 
FM (kg) 31.2 (10.3) 18.0 - 53.4 
SBP (mmHg)* 129.5 (121.0, 143.5) 96.0 - 212.0 
DBP (mmHg) 74.6 (9.5) 50.0 - 101.0 
HR (bpm) 65.9 (9.9) 43.6 - 92.3 
25(OH)D  (nmol/L)* 42.5 (26.2, 60.7) 12.0 - 125.0 
Calcium (mmol/L) 2.0 (0.1) 1.8 - 2.3 
PTH (pmol/L  )* 4.5 (4.0, 6.1) 2.0 - 13.0 
RBC (n x1012/L) 4.5 (0.3) 3.7 - 5.3 
WBC ((n x 109/L) 5.5 (1.6) 3.1 - 13.8 
Hb (g/L) 133.9 (9.5) 109.0 - 157.0 
Platelets (n x 109/L) 256.0 (50.0) 88.0 - 402.0 
Age at menopausal (years)* 50.0 (47.2, 52.0) 40.0 -  60.0 
*Reported as median (25th, 75th percentiles) 
BMI, Body Mass Index; FM, Fat Mass; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HR, Heart 
Rate; PTH, Parathyroid Hormone; RBC, Red Blood Cell; WBC, White Blood Cell; Hb, Hemoglobin. 
 
 
Most of the participants were recruited in summer (Jun to August; 46%), followed by spring 
(March to May; 36%) and winter (December to February; 18%). Almost 60% of the 
participants had a family history of heart disease, followed by stroke (46.3%), diabetes (41.3 
%) and lung disease (40.0%) (Figure 4.5). 
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Figure 4. 5: Family history of with diseases among participants 
 
When stratified by serum 25(OH)D concentration into two groups (<30 nmol/L and ≥30 
nmol/L), there was no significant difference in the proportion of the participants with lower 
vitamin D status who were recruited in winter and spring (December 2014 to March 2015) 
compared with those participants recruited in summer (April to August 2015). However, 
majority of the participants (65%) recruited in winter and spring had serum 25(OH)D 
concentration less than 30 nmol/L (Table 4.5). 
 
Table 4. 5: Relationship between season of recruitment and vitamin D status 
 
 Season 
 
 
25(OH)D 
concentration 
Winter and spring 
N (%) 
Summer 
N (%) 
 
P value 
 <30 nmol/L 28 (65) 26 (70) 0.75 
 ≥30 nmol/L 15 (35) 
 
11 (30) 
Analysis has been conducted using chi-square test. 
 
There was no significant difference in mean age, anthropometric measurements (weight, 
height, BMI, fat mass) and physical activity levels between the two groups of participants 
stratified by vitamin D status (Table 4.6). There was no significant difference in mean intakes 
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of nutrients between these two groups except for -  vitamin B12 and vitamin D intake (p<0.05). 
Those participants with higher vitamin D status (≥30 nmol/L 25(OH)D) had higher intakes of 
vitamin B12 (5.1 vs 3.7 mg/day) and for vitamin D (3.6 vs 2.7 µg/day). NB These intakes of 
vitamin D from all sources are considerably less than the recommended RNI (10 µg/day) 
(SACN, 2016).  
 
Table 4. 6: Dietary intake (amounts /d) and physical activity level (PAL) for 80 overweight 
and obese post-menopausal women stratified according to serum 25(OH)D concentration 
defined by (IOM), 2010. 
 
  (<30 nmol/L)  (≥30 nmol/L) P value 
N 27 (33.7%) 53 (66.2%)  
Age (years)* 59.0 (57.0, 68.0) 61.0 (56.5, 67.5) 0.80 
Weight (kg)* 77.0 (64.0, 93.5) 72.2 (67.4, 79.7) 0.24 
Height (cm) 161.5 (7.0) 159.5 (5.9) 0.18 
BMI (kg/m2)* 29.0 (26.0, 33.0) 28.8 (25.9, 31.3) 0.40 
FM (kg) 32.4 (13.0) 30.6 (8.7) 0.46 
PAL (METs/wk2)* 2079.0 (198.0, 3318.0) 1782.0 (720.0, 4039.0) 0.57 
Energy (Kcal/day)* 2358.1 (1856.2, 3215.6) 2562.0 (2049.5, 3357.1) 0.22 
Carbohydrate (g)* 286.5 (228.7,394.9) 298.7 (230.0,402.5) 0.44 
Calcium (mg)* 886.2 (809.8, 1149.4) 886.1 (728.2, 1216.0) 0.42 
Fat (g)* 85.5 (66.6, 123.6) 96.3 (73.1,139.3) 0.26 
Iron (mg)* 16.5 (13.6, 22.2) 17.8 (14.4, 21.3) 0.41 
MUFA (g)* 20.8 (16.2, 27.6) 25.4 (18.5,35.5) 0.11 
Sodium (mg)* 3355.8  (2767.7, 4451.6) 3876.9 (3050.7, 5061.7) 0.26 
PUFA (g)* 11.3 (7.8, 17.5) 13.5 (10.0, 20.8) 0.11 
Protein (g)* 92.6 (74.5, 118.9) 101.2 (77.7, 133.7) 0.25 
SFA (g)* 23.6 (17.0, 36.9) 29.2 (19.4, 40.0) 0.16 
Vitamin B12 (µg)* 3.7 (2.7, 5.4) 5.1 (4.1, 6.4) 0.01 
Vitamin B6 (mg)* 2.7 (1.7, 3.4) 2.9 (2.1, 3.5) 0.22 
Vitamin C (mg)* 201.7 (140.0, 267.0) 182.9 (129.4,257.8) 0.79 
Vitamin D (µg)* 2.7 (1.9, 3.9) 3.6 (2.4, 4.8) 0.02 
Vitamin E (mg)* 10.5 (7.7, 11.9) 10.8 (7.9, 15.3) 0.16 
Zinc (mg)* 11.4 (8.7, 13.6) 11.9 (9.2, 15.1) 0.32 
Nitrate Intake (mg/day)* 274.3 (131.7, 357.0) 200.3 (153.2, 331.0) 0.79 
*Reported as median (25th, 75th percentiles). t-test for independent samples has been used for the analyses. BMI, 
Body Mass Index; FM, Fat Mass; PAL, Physical Activity Level; MUFA, Monounsaturated Fatty Acid; PUFA, 
Polyunsaturated Fatty Acid; SFA, Saturated Fatty Acid. Significant p values are shown in bold. 
 
4.4.3 Blood pressure and assessment of vascular health 
Mean blood pressure (BP) measurements and EF measurements (PWV and PORH) were 
comparable for the two groups of participants stratified by serum 25(OH)D concentration. For 
BP measurement, subjects with serum 25(OH)D concentration less than 30 nmol/L had higher 
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SBP and DBP but these values were not significantly different when compared with those in 
the higher serum 25(OH)D concentration (≥30 nmol/L) group (Table 4.7).  
 
For the assessment of PWV, the reference value for PWV is 12 m/s has been proposed in the 
2007 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) 
hypertension guidelines (Mancia et al., 2007).  The finding reveals that PWV is significantly 
higher in the <30 nmol/L serum 25(OH)D concentration (p<0.05). However, the mean values 
for both groups (9.2 (5.0, 11.7) for <30 nmol/L group and 8.5 (7.5, 9.8) in ≥30 nmol/L group) 
are less than the reference value, which can be considered as normal PWV. Pulse transit time 
(PTT), an index of arterial stiffness, was significantly higher in the lower serum 25(OH)D 
concentration group (<30 nmol/L) (p<0.05). PTT is a direct indicator of arterial pressure, since 
arterial stiffness increases as arterial pressure increases (Sharwood-Smith et al., 2006).  
 
There were no significant differences in PORH variables between the two groups stratified by 
serum 25(OH)D concentration. A reactive hyperaemia index (RHI) score of less than 1.67 is 
correlates with endothelial dysfunction (Schoenenberger et al., 2012). In this study, the <30 
nmol/L and ≥30 nmol/L groups have median RHI indices of 3.2 (2.5, 4.4) and 3.6 (2.3, 5.2), 
respectively (reported as median (25th, 75th percentiles)), which can be considered as normal 
RHI. 
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Table 4. 7: Physiological measurements of vascular health in 80 overweight and obese 
post-menopausal women stratified according to serum 25(OH)D concentration (IOM 
2010) 
  (<30 nmol/L)  (≥30 nmol/L) P value 
N 27 (33.75%) 53 (66.25%)  
SBP* 134.0 (123.0, 144.0) 127.0 (121.0, 143.5) 0.70 
DBP 75.9 ( 9.1) 73.9 (9.7) 0.30 
HR 65.7 (8.3 66.0 (10.7) 0.90 
PORH variables 
 
 
 
 
 
 
 Resting level* 
 
10.6 (8.1, 13.7) 
 
10.0 (8.1, 13.0) 
 
0.60 
 ML* 
 
77.0 (60.1, 96.2) 
 
92.8 (67.5, 115.6) 
 
0.12 
 Area of occlusion* 
 
1064.7 (750.7, 1878.9) 
 
1160.7 (668.3, 1603.6) 
 
0.45 
 Area of hyperemia* 
 
1584.4 (1137.6, 1992.3) 
 
1696.0 (960.9, 2686.1) 
 
0.57 
 AH/AO* 
 
1.41 (0.7, 2.3) 
 
1.6 (0.9, 2.5) 0.29 
 Time to recovery* 0.6 (0.5, 1.0) 
 
0.8 (0.6, 1.0) 0.39 
 Time to maximum* 11.7 (8.7, 12.8) 10.4 (7.02, 14.9) 0.97 
 
 Time to half decay 
from maximum* 
 
22.6 (18.9, 26.1) 21.8 (16.9, 25.3) 0.72 
 RHI Index* 3.2 (2.5, 4.4) 3.6 (2.3, 5.2) 0.92 
 
Phothophlethysmopghy 
 
   
 PTT40mmHg (ms)* 
 
71.0 (65.0, 81.0) 66.0 (55.0, 73.5) <0.05 
 PWV40mmHg (m/s)* 
 
9.2 (8.0, 11.7) 8.5 (7.5, 9.8) <0.05 
*Reported as median (25th, 75th percentiles). t-test for independent samples has been used for the analyses.  
SBP; Systolic Blood Pressure, DBP; Diastolic Blood Pressure, HR; Heart Rate, PORH; Post Occlusive Reactive 
Hyperemia, ML; Maximum Level, AH/AO; Area of Hyperaemia/ Area of Occlusion, RHI; Reactive Hyperemia 
Index, PTT; Pulse Transit Time, PWV; Pulse Wave Velocity. Significant p values are shown in bold. 
 
4.4.4 Biomarkers of vitamin D and calcium status 
Table 4.8 summarises biomarkers of vitamin D and calcium status. Except for calcium, the 
data are reported as medians (25th, 75th percentiles) as the data were not normally distributed. 
As was expected, mean serum 25(OH)D was significantly (p<0.001) greater – almost three 
times higher – in the higher vitamin D status group. 
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Table 4. 8: Biomarkers of vitamin D and calcium status in 80 overweight and obese 
post-menopausal women stratified according to vitamin D status 
  (<30 nmol/L)  (≥30 nmol/L) P value 
N 27 (33.75%) 53 (66.25%)  
25(OH)D (nmol/L) * 21.0 (14.0, 27.0) 55.0 (42.5, 69.5) < 0.05 
PTH (pmol/L) * 4.9 (4.2, 6.1) 4.5 (3.7, 6.0) 0.13 
Calcium (mmol/L) 2.0 (0.13) 2.0 (1.8) 0.90 
    
*Reported as median (25th, 75th percentiles). t-test for independent samples has been used for the analyses. If 
needed, data were log-transformed prior to analysis. Significant p values are shown in bold. 
 
4.4.5 Sun exposure to measure the impact of dermal synthesis of serum 25(OH)D 
concentration  
To investigate the possible impact of dermal synthesis of serum 25(OH)D concentration, 
participants completed a sun exposure questionnaire which assessed their habitual sunshine 
exposure during weekdays and at the weekend. Those participants who spent less than one hour 
in outdoors activities during the sunny months were defined as low- moderate sun exposure 
and those spending more than one hour as high sunshine exposure. Interestingly, the finding 
revealed that more than 50% of the participants in serum 25(OH)D concentration ≥ 30 nmol/L 
group are in the category of low-moderate sunshine exposure Figure 4.6. 
 
 
Figure 4. 6: Stratification of serum 25(OH)D concentration according to the sun 
exposure 
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4.4.6 Nitroso-compounds, biomarkers of EF and NO activity 
Descriptive statistics for nitroso-compounds, biomarkers of EF and NO activity stratified 
according to the serum 25(OH)D concentration are presented in Table 4.9.  While the low 
serum 25(OH)D concentration group (<30 nmol/L 25(OH)D) had apparently higher serum 
levels of ET-1 (p=0.61), urinary nitrate (p=0.83) and VEGF (p=0.99), these differences were 
not significant. However, ADMA concentrations were 38% higher in the group with <30 
nmol/L serum 25(OH)D concentration and there was a non-significant trend of higher ADMA 
concentrations in the low vitamin D group (p=0.07). The current sample size provided a power 
of 36% to detect a significant difference between group and minimum total sample size of 160 
participants (1:1 distribution between groups) would be needed to detect a significant 
difference in ADMA levels between low and normal serum 25(OH)D groups. 
 
Table 4. 9: Descriptive of biomarkers of vascular health in 80 overweight and obese 
post-menopausal women stratified according to vitamin D status 
 (<30 nmol/L)  (≥30 nmol/L) P value 
Plasma nitrate  (µmol/L) * 27.3 (18.9, 38.1) 29.7 (22.9, 40.6) 0.67 
Urinary nitrate (mmol/L) * 6.3 (3.6, 8.8) 5.4 (3.8, 10.19) 0.83 
cGMP (pmol/mL)* 24.8 (18.5, 39.36) 25.8 (21.3, 35.1) 0.83 
VEGF (pg/ml)* 110.9 (80.3, 137.7) 106.5 (71.4, 160.2) 0.99 
ADMA (ng/mL)* 86.7 (54.7, 151.6) 54.3 (39.0, 128.2) 0.07 
ET-1 (pg/ml)* 7.6 (4.5, 10.5) 6.9 (4.2, 11.2) 0.61 
3NT (ng/mL)* 334.1 (85.4, 619.5) 382.5 (134.3, 894.8) 0.58 
*Reported as median (25th, 75th percentiles). t-test for independent samples has been used for the analyses. If 
needed, data were log-transformed prior to analysis. 
cGMP; cyclic guanosine monophosphate, VEGF; vascular endothelial growth factor, ADMA; asymmetric 
dimethylarginine, ET-1; endothelin-1, 3NT; nitrotyrosine 
 
4.4.7 Correlation between serum 25(OH)D concentration and cardio-metabolic biomarkers      
Table 4.10 reports correlations between serum 25(OH)D concentration and biomarkers of bone 
health, vitamin D and nitrate intake, blood pressure, vascular measurement and biomarkers of 
EF where significant correlations are highlighted in bold. 
 
There was a positive correlation between PTH with DBP (r= 0.32, p<0.01), BMI (r= 0.34, 
p<0.01) and WC (r= 0.33, p<0.01) and a negative correlation with ET-1 (r=-0.22, p<0.05). 
Calcium correlated positively with cGMP (r=0.30, p<0.01), VEGF (r=0.26, p<0.01) and 
ADMA (r=0.23, p<0.05). On the other hand, SBP correlated positively with DBP (r=0.56, 
p<0.01), PWV (r=0.41, p<0.01) and 3NT (r= 0.32, p<0.01). 
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Diastolic blood pressure was positively correlated with PWV (r=0.48, P<0.01), BMI (r=0.32, 
p<0.01) and WC (r= 0.33, P<0.01). Plasma nitrate correlated positively with urinary nitrate 
(r=0.52, p<0.01), VEGF (r=0.22, p<0.05), 3NT (r=0.26, p<0.01) and age (r=0.22, p<0.05). 
Urinary nitrate correlated positively with VEGF (r=0.31, p<0.01) and VEGF correlated 
positively with ADMA (r=0.28, P<0.01) and 3NT (r=0.26, P<0.01). 
 
Scatterplots were performed to observe the pattern of the correlations between the variables. 
Figure 4.7 (A) demonstrated the positive and almost significant (p= 0.06) relationship between 
BMI and PWV, while Figure 4.7 (B) shows the inverse association between BMI and plasma 
nitrate. On the other hand, Figure 4.7 (C) and Figure 4.7 (D) illustrated the positive 
correlations of age with ADMA, and of SBP with PWV, respectively. 
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Table 4. 10 Correlation between 25(OH)D and anthropometric measurements, biomarkers of bone health, vitamin D and nitrate intake, blood pressure, vascular 
measurement and biomarkers of endothelial function 
 
 
25(OH)
D 
PTH Calciu
m 
Vit D 
Intake 
NO3 
Intake 
SBP DBP PORH 
Index 
PWV Plasma 
nitrate 
Urinar
y 
nitrate 
cGMP ET-1 VEGF ADMA 3NT Age BMI WC 
25(OH)
D 
1 r=-0.16 
p=0.13 
r=0.01 
p=0.96 
r=0.17 
p=0.11 
r=-0.04 
p=0.69 
r=0.02 
p=0.98 
r=-0.13 
p=0.23 
r=-0.01 
p=0.95 
r=0.18 
p=0.11 
r=0.09 
p=0.41 
r=0.03 
p=0.73 
r=0.01 
p=0.92 
r=-0.18 
p=0.11 
r=-0.03 
p=0.77 
r=-0.11 
p=0.30 
r=0.12 
p=0.27 
r=0.11 
p=0.31 
r=-0.11 
p=0.29 
r=-0.12 
p=0.27 
PTH r=-0.16 
p=0.13 
1 r=0.13 
p=0.23 
r=-0.03 
p=0.76 
r=-0.01 
p=0.38 
r=0.15 
p=0.18 
r=0.32 
p<0.00 
r=0.01 
p=0.87 
r=0.13 
p=0.23 
r=0.00 
p=0.99 
r=0.06 
p=0.56 
r=-0.02 
p=0.80 
r=-0.22 
p<0.05 
r=0.04 
p=0.66 
r=0.10 
p=0.37 
r=0.02 
p=0.79 
r=0.10 
p=0.37 
r=0.34 
p<0.00 
r=0.33 
p<0.00 
Calciu
m 
r=0.01 
p=0.96 
r=0.13 
p=0.23 
1 r=-0.08 
p=0.47 
r=0.62 
p=0.59 
r=0.13 
p=0.24 
r=0.05 
p=0.65 
r=-0.09 
p=0.41 
r=0.00 
p=0.98 
r=0.14 
p=0.18 
r=0.15 
p=0.17 
r=0.30 
p<0.00 
r=0.13 
p=0.22 
r=0.26 
p<0.05 
r=0.23 
p<0.05 
r=0.16 
p=0.14 
r=0.12 
p=0.29 
r=0.06 
p=0.55 
r=0.01 
p=0.86 
Vit D 
Intake 
r=0.17 
p=0.11 
r=-0.03 
p=0.76 
r=-0.08 
p=0.47 
1 r=0.17 
p=0.12 
r=-0.17 
p=0.12 
r=-0.21 
p=0.05 
r=-0.07 
p=0.52 
r=0.05 
p=0.63 
r=0.14 
p=0.20 
r=-0.06 
p=0.56 
r=-0.06 
p=0.55 
r=0.05 
p=0.63 
r=-0.05 
p=0.61 
r=0.05 
p=0.61 
r=-0.10 
p=0.33 
r=-0.06 
p=0.58 
r=-0.06 
p=0.57 
r=-0.02 
p=0.81 
NO3 
Intake 
r=-0.04 
p=0.69 
r=-0.01 
p=0.87 
r=0.62 
p=0.59 
r=0.17 
p=0.12 
1 r=0.01 
p=0.86 
r=0.09 
p=0.42 
r=0.03 
p=0.74 
r=0.07 
p=0.53 
r=0.01 
p=0.88 
r=0.03 
p=0.78 
r=-0.04 
p=0.70 
r=0.08 
p=0.44 
r=0.02 
p=0.85 
r=0.05 
p=0.62 
r=0.08 
p=0.48 
r=-0.19 
p=0.08 
r=0.07 
p=0.49 
r=0.11 
p=0.31 
SBP r=0.02 
p=0.98 
r=0.15 
p=0.18 
r=0.13 
p=0.24 
r=-0.17 
p=0.12 
r=0.01 
p=0.86 
1 r=0.56 
p<0.00 
r=-0.09 
p=0.40 
r=0.41 
p<0.00 
r=0.00 
p=0.96 
r=-0.04 
p=0.67 
r=0.08 
p=0.44 
r=-0.04 
p=0.67 
r=-0.01 
p=0.88 
r=0.04 
p=0.70 
r=-0.01 
p=0.90 
r=0.32 
p<0.00 
r=0.19 
p=0.08 
r=0.17 
p=0.13 
DBP r=-0.13 
p=0.23 
r=0.32 
p<0.00 
r=0.05 
p=0.65 
r=-0.21 
p=0.05 
r=0.09 
p=0.42 
r=0.56 
p<0.00 
1 r=0.08 
p=0.43 
r=0.48 
p<0.00 
r=0.00 
p=0.97 
r=0.03 
p=0.77 
r=0.12 
p=0.26 
r=-0.03 
p=0.74 
r=-0.04 
p=0.69 
r=-0.09 
p=0.42 
r=-0.03 
p=0.75 
r=-0.01 
p=0.29 
r=0.32 
p<0.00 
r=0.33 
p<0.00 
PORH 
Index 
r=-0.01 
p=0.95 
r=0.01 
p=0.87 
r=-0.09 
p=0.41 
r=-0.07 
p=0.52 
r=0.03 
p=0.74 
r=-0.09 
p=0.40 
r=0.08 
p=0.43 
1 r=-0.02 
p=0.85 
r=0.05 
p=0.61 
r=-0.08 
p=0.44 
r=-0.16 
p=0.15 
r=-0.03 
p=0.74 
r=-0.19 
p=0.78 
r=-0.04 
p=0.67 
r=-0.16 
p=0.14 
r=-0.20 
p=0.07 
r=0.09 
p=0.42 
r=0.20 
p=0.07 
PWV r=0.18 
p=0.11 
r=0.13 
p=0.23 
r=0.00 
p=0.98 
r=0.05 
p=0.63 
r=0.07 
p=0.53 
r=0.41 
p<0.00 
r=0.48 
p<0.00 
r=-0.02 
p=0.85 
1 r=0.06 
p=0.58 
r=0.03 
p=0.74 
r=-0.02 
p=0.85 
r=-0.04 
p=0.71 
r=-0.18 
p=0.10 
r=-0.12 
p=0.25 
r=0.07 
p=0.52 
r=0.04 
p=0.69 
r=0.20 
p=0.06 
r=0.15 
p=0.17 
Plasma 
Nitrate 
r=0.09 
p=0.41 
r=0.00 
p=0.99 
r=0.14 
p=0.18 
r=0.14 
p=0.20 
r=0.01 
p=0.88 
r=0.00 
p=0.96 
r=0.00 
p=0.97 
r=0.05 
p=0.61 
r=0.06 
p=0.58 
1 r=0.52 
p<0.00 
r=0.12 
p=0.27 
r=0.15 
p=0.16 
r=0.22 
p<0.05 
r=0.00 
p=0.94 
r=0.26 
p<0.05 
r=0.22 
p<0.05 
r=-0.21 
p=0.05 
r=-0.08 
p=0.43 
Urinary 
Nitrate 
r=0.03 
p=0.73 
r=0.06 
p=0.56 
r=0.15 
p=0.17 
r=-0.06 
p=0.56 
r=0.03 
p=0.78 
r=-0.04 
p=0.67 
r=0.03 
p=0.77 
r=-0.08 
p=0.44 
r=0.03 
p=0.74 
r=0.52 
p<0.00 
1 r=0.20 
p=0.07 
r=0.02 
p=0.83 
r=0.31 
p<0.00 
r=0.08 
p=0.48 
r=0.08 
p=0.43 
r=0.16 
p=0.13 
r=-0.11 
p=0.31 
r=-0.07 
p=0.51 
cGMP r=0.01 
p=0.92 
r=-0.02 
p=0.80 
r=0.30 
p<0.00 
r=-0.06 
p=0.55 
r=-0.04 
p=0.70 
r=0.08 
p=0.44 
r=0.12 
p=0.26 
r=-0.16 
p=0.15 
r=-0.02 
p=0.85 
r=0.12 
p=0.27 
r=0.20 
p=0.07 
1 r=0.17 
p=0.12 
r=0.19 
p=0.08 
r=0.11 
p=0.33 
r=0.19 
p=0.08 
r=0.19 
p=0.07 
r=-0.04 
p=0.67 
r=0.01 
p=0.89 
ET-1 r=-0.18 
p=0.11 
r=-0.22 
p<0.05 
r=0.13 
p=0.22 
r=0.05 
p=0.63 
r=0.08 
p=0.44 
r=-0.04 
p=0.67 
r=-0.03 
p=0.74 
r=-0.03 
p=0.74 
r=-0.04 
p=0.71 
r=0.15 
p=0.16 
r=0.02 
p=0.83 
r=0.17 
p=0.12 
1 r=0.18 
p=0.09 
r=0.10 
p=0.38 
r=0.12 
p=0.27 
r=-0.01 
p=0.88 
r=-0.15 
p=0.17 
r=-0.18 
p=0.10 
VEGF r=-0.03 
p=0.77 
r=0.04 
p=0.66 
r=0.26 
p<0.05 
r=-0.05 
p=0.61 
r=0.02 
p=0.85 
r=-0.01 
p=0.88 
r=-0.04 
p=0.69 
r=-0.19 
p=0.78 
r=-0.18 
p=0.10 
r=0.22 
p<0.05 
r=0.31 
p<0.00 
r=0.19 
p=0.08 
r=0.18 
p=0.09 
1 r=0.28 
p<0.05 
r=0.26 
p<0.05 
r=0.17 
p=0.12 
r=0.03 
p=0.77 
r=0.03 
p=0.78 
ADMA r=-0.11 
p=0.30 
r=0.10 
p=0.37 
r=0.23 
p<0.05 
r=0.05 
p=0.61 
r=0.05 
p=0.62 
r=0.04 
p=0.70 
r=-0.09 
p=0.42 
r=-0.04 
p=0.67 
r=-0.12 
p=0.25 
r=0.00 
p=0.94 
r=0.08 
p=0.48 
r=0.11 
p=0.33 
r=0.10 
p=0.38 
r=0.28 
p<0.05 
1 r=0.06 
p=0.57 
r=0.21 
p=0.05 
r=-0.02 
p=0.80 
r=-0.02 
p=0.85 
3NT r=0.12 
p=0.27 
r=0.02 
p=0.79 
r=0.16 
p=0.14 
r=-0.10 
p=0.33 
r=0.08 
p=0.48 
r=0.08 
p=0.48 
r=-0.03 
p=0.75 
r=-0.16 
p=0.14 
r=0.07 
p=0.52 
r=0.26 
p<0.05 
r=0.08 
p=0.43 
r=0.19 
p=0.08 
r=0.12 
p=0.27 
r=0.26 
p<0.05 
r=0.06 
p=0.57 
1 r=0.11 
p=0.30 
r=-0.07 
p=0.51 
r=-0.07 
p=0.53 
Age r=0.11 
p=0.31 
r=0.10 
p=0.37 
r=0.12 
p=0.29 
r=-0.06 
p=0.58 
r=-0.19 
p=0.08 
r=0.32 
p<0.00 
r=-0.01 
p=0.29 
r=-0.20 
p=0.07 
r=0.04 
p=0.69 
r=0.22 
p<0.05 
r=0.16 
p=0.13 
r=0.19 
p=0.78 
r=-0.01 
p=0.88 
r=0.17 
p=0.12 
r=0.21 
p=0.05 
r=0.11 
p=0.30 
1 r=-0.11 
p=0.29 
r=-0.04 
p=0.66 
BMI r=-0.11 
p=0.29 
r=0.34 
p<0.00 
r=0.06 
p=0.55 
r=-0.06 
p=0.57 
r=0.07 
p=0.49 
r=0.19 
p=0.08 
r=0.32 
p<0.00 
r=0.09 
p=0.42 
r=0.20 
p=0.06 
r=-0.21 
p=0.05 
r=-0.11 
p=0.31 
r=-0.04 
p=0.67 
r=-0.15 
p=0.17 
r=0.03 
p=0.77 
r=-0.02 
p=0.80 
r=-0.07 
p=0.51 
r=-0.11 
p=0.29 
1 r=0.82 
p<0.00 
WC r=-0.12 
p=0.27 
r=0.33 
p<0.00 
r=0.01 
p=0.86 
r=-0.02 
p=0.81 
r=0.11 
p=0.31 
r=0.17 
p=0.13 
r=0.33 
p<0.00 
r=0.20 
p=0.07 
r=0.15 
p=0.17 
r=-0.88 
p=0.43 
r=-0.07 
p=0.51 
r=0.01 
p=0.89 
r=-0.18 
p=0.10 
r=0.03 
p=0.78 
r=-0.02 
p=0.85 
r=-0.07 
p=0.53 
r=-0.04 
p=0.66 
r=0.84 
p<0.00 
1 
BP; blood pressure, BMI; body mass index, WC; waist circumference, FM; fat mass, PTH; parathyroid hormone, PTT; pulse transit time, PWV; pulse wave velocity, PORH; post occlusive reactive hyperemia, cGMP; cyclic 
guanosine monophosphate, ADMA; asymmetric dimethylarginine, VEGF; vascular endothelial growth factor, ET-1; endothelin-1, 3-NT; nitrotyrosine. Significant p values are shown in bold (Pearson’s Correlation). 
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Figure 4. 7: Scatterplot of (A) BMI against PWV   (B) BMI against plasma nitrate   (C) Age against ADMA   (D) SBP against PWV
  
(A) 
 
 (B) 
 
 
 
 (C) 
 
 
 (D) 
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4.4.8 Mean biomarkers of endothelial functions composite score 
In this study, several biomarkers were assessed to measure endothelial functions including 
NO3ˉ, cGMP, ADMA, 3NT, VEGF and ET-1. These biomarkers were not expressed in the 
same unit of measure. Therefore, a composite score, also known as Z score, was used to 
standardize the means of these biomarkers and to enable them to be combined into a single 
measure (Figure 4.8). This approach has been described in detail in the method section. Whilst 
the mean EF composite score was lower in group with lower serum 25(OH)D concentration, 
the difference between groups was not significant (p = 0.31). 
 
 
Figure 4. 8: The mean endothelial function composite score 
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4.4.9 Multiple linear regression analysis 
Outcomes from the regression analysis model demonstrated that BMI was the most significant 
determinant of the arterial stiffness and that serum 25(OH)D concentration, cGMP, ADMA, 
age and PAL were not identified as independent predicting variables (Table 4.11). 
 
Table 4. 11: Results of multiple regression analysis for the dependent variable: Pulse 
Wave Velocity 
 Pulse Wave Velocity (m/s) 
 
 B (SE) (95% CI) P 
25(OH)D 
 
0.07 (0.75) -0.04 – 0.19 0.23 
cGMP 
 
0.01 (0.03) -0.05 – 0.07 0.75 
ADMA 
 
-0.02 (0.01) -0.06 – 0.01 0.23 
Age 
 
0.08 (0.15) -0.22 – 0.39 0.59 
BMI 
 
0.21 (0.10) -0.00 – 0.41 0.04 
PAL 0.008 (0.02) -0.07 – 0.06 0.76 
Significant p values are shown in bold. 
25(OH)D, 25-hydroxyvitamin D; cGMP, cyclic Guanosine Monophosphate; ADMA, Asymmetric 
Dimethylarginine; BMI, Body Mass Index; PAL, Physical Activity Level 
 
4.5 Discussion 
4.5.1 Main findings of the study 
The serum 25(OH)D concentration in this sample of 80 overweight or obese post-menopausal 
women ranged from 12.0 – 125.0 nmol/L. Using a cut-off <30 nmol/L to indicate vitamin D 
‘deficiency’ (Institute of Medicine Committee to Review Dietary Reference Intakes for 
Vitamin and Calcium, 2011), the study found that 27 participants (34%) were serum 25(OH)D 
concentration ‘deficient’. This finding was compared with the biomarkers of vascular health in 
this group with those in the other 53 participants who had adequate serum 25(OH)D 
concentration. This revealed limited evidence for effects of serum 25(OH)D concentration on 
vascular function; for most biomarkers, including BP, there were no significant (p>0.05) 
differences between serum 25(OH)D concentration groups. However, PWV was significantly 
higher in the low serum 25(OH)D concentration (<30 nmol/L) group (p<0.05), which may 
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indicate greater arterial stiffness. In addition, there was a non-significant trend for higher 
ADMA concentrations in the low vitamin D group (p=0.07). 
4.5.2 Interpretation of main findings 
Sunshine exposure and seasonality 
This study was conducted among women who live around Newcastle upon Tyne, Tyne and 
Wear. Situated in Northern England, with latitude 54-55ºN, the sunlight is too weak during the 
late autumn, winter and early spring (October to March) to produce cutaneous biosynthesis of 
vitamin D. A wide survey in the United Kingdom revealed that more than 50% of the adult 
population has insufficient circulating concentrations of vitamin D, and that the prevalence of 
insufficiency increased by 16% during winter and spring. The survey also demonstrated a 
gradient of prevalence across the UK, with highest rates in Scotland, northern England, and 
Northern Ireland (Hypponen and Power, 2007).  
 
Season plays an important role in determining serum 25(OH)D concentration because it 
determines whether sun exposure results in endogenous cutaneous synthesis of vitamin D as a 
result of ultraviolet (UV)B radiation (Kimlin, 2008). In general, populations living >30ºN and 
>30ºS receive no UVB during the winter time, therefore cutaneous synthesis of vitamin D is 
impossible in this season (Schoenmakers et al., 2016). This cross sectional study found that 
majority of the participants (65%) who are deficient for serum 25(OH)D were recruited during 
winter and spring. It is well acknowledged that the vitamin D supply during the absence of sun 
exposure is mainly through diet and supplementation.  
 
The present study collected some information on factors which may influence sun exposure 
and, therefore endogenous vitamin D synthesis. Regarding the type of clothing worn, the 
majority of participants (95%) reported that they usually wear short sleeves and long 
trousers/skirt when there are outdoors during the sunny months. However, 70% of participants 
reported that they use sunscreen when being outdoors. As majority of the participants are in 
retirement age (mean age 61 years old), almost all of the participants spend most of their time 
indoors or mixture.  Given that there is insufficient solar UVB to generate vitamin D in the skin 
at latitudes >50ºN, and that they spent limited time spent outdoors, the participants would not 
synthesis vitamin D especially during the winter/early spring months. 
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Anthropometric, physical activity and dietary intake 
Our study demonstrated that there is no significant difference between the two serum 25(OH)D 
concentration groups with respect to anthropometry, physical activity and most aspects of 
dietary intake. However, from the food frequency questionnaire, we found that the lower serum 
25(OH)D concentration group has significantly lower dietary intakes of vitamin B12 and 
vitamin D. There is no direct link between these two vitamins, but it might represents a common 
denominator as both vitamins needs a healthy intestine for the absorption (Mishra et al., 2015). 
Vitamin D and vitamin B12 are absorbed in ileum. Both of these vitamins need assistance in 
order to be absorb in the intestine. Vitamin B12 combines with a protein made by the stomach 
called intrinsic factor and vitamin D needs VDR in the intestine. In this study, both serum 
25(OH)D concentration groups have vitamin B12 intake more than the recommended RNI 
intake (RNI for vitamin B12 is 1.5 µg/day) (British Nutrition Foundation, 2016).  
 
Dietary sources of vitamin D are limited and were mainly obtained from natural sources such 
as fatty fish and eggs. Some sources of vitamin D can be found in fortified food such as milk 
and dairy product, breakfast cereals and fat spread (Spiro and Buttriss, 2014). Natural sources 
of vitamin B12 were mainly from meat, fish, dairy products, poultry, eggs and fortified 
breakfast cereals (O’Leary and Samman, 2010). Therefore, it can be postulated that the sources 
of vitamin D and vitamin B12 in dietary intake of the participants were mainly from eggs, fish 
and breakfast cereals. 
 
Biomarkers of bone health 
Participants in this study had normal concentrations of PTH and calcium. PTH and vitamin D 
share a reciprocal relationship that links the status of calcium level in the body, where serum 
25(OH)D concentration plays a main role in regulating calcium and PTH level. Normally, low 
blood calcium concentration triggers PTH release, which raises the circulating concentration 
of calcium. However, serum 25(OH)D concentration is essential for the absorption of calcium; 
vitamin D binds to VDR in enterocytes and stimulates active calcium transport from the 
intestine to the circulation which increases the concentration of calcium in blood (Lips, 2012). 
In this study, there was an inverse (negative) correlation between serum 25(OH)D 
concentration and PTH but this was not significant.  
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Physical activity 
Physical activity can be an important determinant of serum 25(OH)D concentration as it may 
act as a surrogate for sunshine exposure during the outdoor physical activity (Wanner et al., 
2015). However, in this study, there was no significant difference in PAL between the two 
vitamin D groups. A self-report PA questionnaire (IPAQ-SF) (which assess the frequency and 
type of activities performed along with duration – number of minutes per week) was used to 
estimate the level of PA among the participants. Designed to be used in population-level 
surveillance of PA among adults, this questionnaire was structured to provide separate scores 
for three PA domains (walking, moderate-intensity and vigorous intensity activity). In this 
study, there were no significant differences between the two serum 25(OH)D concentration 
group for the three sets of domains. 
 
Endothelial function measurements 
There are various methods of assessing EF in humans depending on the resources, equipment 
available and technical skill (discussed in Chapter 3). In this study, PWV and PORH were used 
for the assessment of EF.  
 
PWV was used to measure the arterial stiffness, and is inversely correlated with EF. Arterial 
stiffness is known as an early marker of systemic atherosclerosis. In this study, those who have 
lower serum 25(OH)D concentration were hypothesized to have higher PWV index, which 
reflect the higher arterial stiffness.  
 
This study demonstrated that the lower serum 25(OH)D concentration group has significantly 
higher mean PWV. A similar finding was reported by (Giallauria et al., 2012) who found a 
significant inverse association between PWV and serum 25(OH)D concentration (adjusted r2 
=0.27; β=-0.43; P=0.001). A recent cross sectional study among Korean adults found that 
arterial stiffness was higher in those with lower serum 25(OH)D concentration (Lee and Suh, 
2017). However, several previous cross sectional studies reported no significant association 
between serum concentration of 25(OH)D and PWV (Lim et al., 2012; Deleskog et al., 2013). 
 
PORH, measured as reactive hyperaemia index (RHI) was the second method of measuring EF 
in this study. Those who have lower serum 25(OH)D concentration were hypothesized to have 
lower RHI. Impaired endothelial function is defined as RHI < 1.67 (Syvänen et al., 2011). 
However, the results demonstrated that the RHI for both serum 25(OH)D concentration groups 
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was more than 1.67 (median 3.2 for < 30nmol/L serum 25(OH)D concentration and median 
3.6 for ≥ 30nmol/L serum 25(OH)D concentration). The finding also showed that there is no 
significant difference for the mean of RHI between the two serum 25(OH)D concentration 
groups. This is in line with a recent study done among premenopausal African American 
women which reported that serum 25(OH)D concentration did no associated with mean of RHI 
(p>0.05) (Moore and Ruppe, 2017). Contrary to this result, a study done by  (Ertek et al., 2012) 
revealed that the mean RHI  was significantly lower in serum 25(OH)D concentration deficient 
subjects than in those with normal serum 25(OH)D concentration group. 
 
Biomarkers of EF 
There are various biomarkers of EF including cGMP, ADMA, VEGF, ET-1, vascular cell 
adhesion molecule (VCAM-1), intercellular adhesion molecule (ICAM-1),  endothelial 
leucocyte adhesion molecule (ELAM-1) (Dessein et al., 2005), interleukin 6 (IL-6), 4-
hydroxynonenal (4-HNE), fibroblast growth factor-23 (FGF-23), e-selectin and p-selectin. In 
this study, the nitroso-compound biomarkers group (cGMP, ADMA, VEGF and ET-1) were 
measured as these four biomarkers are closely related to NO production. The role of these 
biomarkers has been discussed in Chapter 3.  
 
The results for nitroso-compounds demonstrated that those who in higher serum 25(OH)D 
concentration group had higher plasma nitrate and those who had lower serum 25(OH)D 
concentration had higher urinary nitrate. This study also showed that participants in the low 
vitamin D status group (<30 nmol/L) have higher ADMA concentration - this difference was 
almost statistically significant (p=0.07). As been described in Chapter 3, ADMA is closely 
related to endothelial dysfunction. Elevated levels of ADMA inhibit NO synthesis which leads 
to impairment of EF, resulting in atherosclerosis (Yilmaz et al., 2008).  
 
Increased arterial stiffness and endothelial dysfunction are strong predictors for future 
development of hypertension (Quyyumi and Patel, 2010). The majority of large cross-sectional 
studies have demonstrated an inverse relationship between serum 25(OH)D concentration and 
blood pressure, and the risk of future hypertension seems to be greater in those with vitamin D 
deficiency (Forman et al., 2007; Pilz et al., 2009). In this study, we observed a significant 
correlation between PWV with SBP and DBP (p<0.001). Similarly, a study done among 
normotensive and hypertensive Malay men demonstrated that PWV was significantly higher 
in  hypertensive compared with the normotensives (blood pressure 169/100 mm Hg +/- 14/7 
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vs. 120/80 mm Hg +/- 10/4, p < 0.001; PWV 11.69 m/s +/- 1.12 vs. 8.83 m/s +/- 1.35, p < 
0.001) (Ngim et al., 1999).  
 
There was a trend of positive correlation between BMI and PWV (p=0.06) and a significant 
correlation between BMI and DBP (p<0.001).  Obesity is an important risk factor for 
hypertension, with obese people having higher rates of hypertension than normal weight 
individuals (Mertens and van Gaal, 2000; Lakoski et al., 2011).  
 
A mechanism by which obesity might contribute to arterial stiffness has been proposed. In 
obese people, macrophages are accumulating in adipose tissue (Yudkin et al., 1999; Weisberg 
et al., 2003; Boutens and Stienstra, 2016).  This condition will leads to the chronic state 
vascular and systemic inflammation and leads to impaired endothelial function in obese people 
(Cancello et al., 2006; Strasser et al., 2015).  It is also well established that higher BMI is 
associated with higher SBP and DBP due to greater cardiac output, increased blood flow, 
vasodilation and vascular resistance with increased weight (Felber and Golay, 2002; Dua et al., 
2014). 
 
4.5.3 Public health implications of study 
This finding revealed that the average daily dietary intake of vitamin D among the study 
participants was 3.82 µg/day, which is much lower than the recommended daily dietary intake 
of vitamin D (10 µg/day) (Ashwell et al., 2010; SACN, 2016). This is in line with results from 
UK National Diet and Nutrition Survey which reported that the prevalence of inadequate 
dietary intakes of vitamin D among older adults in UK is high and that dietary vitamin D intake 
is approximately 2-3 µg/day (Smithers et al., 2000). Living in the northern hemisphere at 
latitudes greater than 40ºN, with restricted sunlight to produce cutaneous vitamin D synthesis, 
the UK population is at risk of vitamin D deficiency if dietary intake is low. Apart from 
supplementation, vitamin D can be obtained by consuming dietary vitamin D such as fatty fish, 
eggs, dairy products, fortified milk and breakfast cereals (Spiro and Buttriss, 2014).  
 
Therefore, there is a need to address these problems at national and regional level with aim of 
early identification and prevention of vitamin D deficiencies. Appropriate community based 
intervention program should be reinforced to increase the awareness of the community of the 
importance of vitamin D. 
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4.5.4 Strengths and limitations of the study 
This study has been conducted among 80 overweight and obese postmenopausal women in 
Newcastle, United Kingdom. This population group was chosen for the study because such 
women are at increased risk of vitamin D deficiency (Snijder et al., 2005) and because their 
vascular function will be more compromised than in younger and leaner women (Celermajer 
et al., 1994). In this sample, 1/3 of the participants had serum 25(OH)D concentration less than 
30 nmol/L (the cut-off for the deficiency as defined by the IOM (Institute of Medicine 
Committee to Review Dietary Reference Intakes for Vitamin and Calcium, 2011).  
 
A high variability in BP measurements were found among the participants. Although the mean 
BP was normal for both groups of participants stratified by serum 25(OH)D concentration, the 
inter-individual variation shows more than 1/3 of the participants were categorised as having 
high blood pressure (SBP >140 mmHg and DBP > 90 mmHg). The heterogeneity in serum 
25(OH)D concentration and biomarkers of vascular function also provided a foundation for 
further investigation whether serum 25(OH)D concentration was associated with better EF. 
Furthermore, all observations in this study were done by the same researcher, which may 
reduce the likelihood of confounding by inter-researcher differences in measurements. 
 
This study has a few limitations. The study was restricted to postmenopausal women aged 
between 50 to 70 years with BMI more than 24.9 kg/m2. Subjects were not randomly selected, 
but volunteered to participate, which may contribute to bias.  Since during ageing, men showed 
progression of endothelial dysfunction earlier than women (Celermajer et al., 1994), older men 
might be more sensitive to the effects of vitamin D compared to older women.  Furthermore, 
this study used a single measurement of serum 25(OH)D concentration as an indicator of 
vitamin D status and this may not be sufficient to reflect accurately long-term vitamin D status. 
This study also did not consider the seasonal variation of serum 25(OH)D concentrations, 
which is necessary to develop assessment of vitamin D deficiency and vitamin D 
supplementation strategies in the future study. 
4.5.5 Conclusion 
In this study, we found that there is no significant association between serum 25(OH)D 
concentration with biomarkers of EF, blood pressure, age and BMI. However, our study 
demonstrates that there is a significant difference in mean PWV between lower and higher 
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serum 25(OH)D concentration groups. Those participants with higher serum 25(OH)D 
concentration had lower mean value of PWV compared to lower serum 25(OH)D concentration 
(p<0.05). However, this study was restricted to women aged 50 to 70 years and it will be 
important to extend such studies to older women and to men before drawing definitive 
conclusions about the relationship between serum 25(OH)D concentration and vascular health. 
In addition, longer term (more than 12 months) vitamin D intervention studies in those with 
compromised vitamin D status will be necessary to provide causal evidence for a role for 
vitamin D in maintenance endothelial function and for cardio-metabolic health.  
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Chapter 5 – Ageing, Vitamin D and NO Production 
 
5.1 Introduction 
The normal function of the cardiovascular system is closely dependent on the integrity of the 
endothelium, a monolayer of cells lining in the lumen of blood vessels (Teixeira et al., 2014). 
The loss of integrity of the endothelial layer and consequent alteration of the function of 
endothelial cells may trigger critical mechanisms (e.g. increased monocyte and platelet 
adhesiveness, loss of laminar flow and vascular elasticity) involved in the pathogenesis of 
cardiovascular diseases (CVD) (Rajendran et al., 2013). These include coronary heart, 
cerebrovascular and peripheral vascular diseases, which are largely attributed to the 
atherosclerotic lesions (Widmer and Lerman, 2014).  
 
Ageing is one of the most important CVD risk factor, due to structural alterations and loss of 
function in the vasculature during the ageing process (Seals et al., 2011). These vascular 
changes affect both smooth muscle cells and intima layers. The mechanisms underlying 
vascular ageing are complex and involve multiple pathways and factors such as reduced 
peripheral artery endothelium-dependent dilation, arterial stiffness, impaired angiogenesis, 
increased vascular oxidative stress and increased superoxide production (Seals et al., 2011). 
Vascular function depends on availability of nitric oxide (NO), which is synthesised mainly by 
the activity of endothelial nitric oxide synthase (eNOS) on the substrate arginine (Förstermann 
& Sessa, 2012). NO helps keep blood vessels dilated, controls blood pressure, and has 
numerous other vasoprotective and anti-atherosclerotic effects (Förstermann & Sessa, 2012). 
Ageing is associated with impaired endothelial function which may be due to decreased 
synthesis of NO. Several studies have evaluated the association between ageing and 
physiological (e.g. flow mediated dilation) or biochemical (i.e., nitrate, nitrite) indirect markers 
of NO synthesis and have reported reduced synthesis of NO with ageing (Toprakçı et al., 2000). 
However, to date, no study in humans has quantified the relationship between ageing and 
whole-body NO production measured by stable isotopic tracers. There is evidence that 
concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS 
increase with ageing, which may contribute to lower whole body NO production and 
deterioration of endothelial function (Sverdlov et al., 2014). Siervo et al 2011 have reported a 
significant association between ADMA concentration and whole body NO production in obese 
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individuals (Siervo et al., 2011b) but no study has investigated whether there is an association 
with ageing. 
 
Vitamin D may play a key role in modifying the risk for adverse cardio-metabolic outcomes, 
particularly metabolic syndrome (MetS), type 2 diabetes mellitus, and systemic hypertension 
(Lavie et al, 2011). Whilst the mechanisms for these associations are not clear, these may relate 
to the role of vitamin D in modulating NO production (Andrukhova et al., 2014) . Vitamin D 
is involved in the regulation of endothelial cell-dependent vasodilation, an effect that may be 
mediated by the VDR, which cause the phosphorylation of p38, Akt and ERK (which play 
important roles in cell proliferation and survival). Activation of this MAPK signalling pathway 
leads to eNOS activation and, increased NO synthesis, which in turn, may improve the 
modulation of vasculature (Tousoulis et al., 2012; Dalan et al., 2014).  
 
Ageing may impact on 25(OH)D status. The formation of the active form of vitamin D 
((1,25[OH]2D; calcitriol) may be reduced as a result of age-related decline of renal function 
by, reducing the activity of the enzyme 1-α hydroxylase that converts 25(OH)D into 
1,25(OH)2D in the kidney (Gallagher, 2013). In addition, skin production of 25(OH)D may 
decrease in older people due to lower 7-DHC  activity in the epidermis (MacLaughlin and 
Holick, 1985; Kinyamu et al., 1997a; Kinyamu et al., 1997b; Gallagher, 2013).  
In this study, the association of whole-body NO production measured using a non-invasive 
stable isotopic method with age, gender and serum 25(OH)D concentration was investigated 
for the first time. Finally, the associations between serum 25(OH)D concentration and whole-
body NO production, PWV and plasma concentrations of nitrite and ADMA were explored. 
5.2 Aims and Objectives 
5.2.1 Hypothesis  
Ageing is one of the most important risk factors for endothelial dysfunction and impaired 
cardiovascular health which may be partially explained by an age-related decline in NO 
production. This study aims to test the hypothesis that whole-body NO production is reduced 
in older compared to younger individuals and test whether these differences could be explained 
by differences in circulating 25(OH)D concentrations. Previous research using stable isotopic 
methods (Forte et al., 1997) has indicated a greater production of NO in women compared to 
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men and this aims to confirm these previous findings and whether this gender-specific 
association with NO production may be modified by age (young vs old). 
Primary Objectives:  
To investigate the association between age and whole body NO synthesis. 
Secondary Objectives:  
To determine the association between whole body NO synthesis with: 
 Circulating 25(OH)D concentrations 
 Gender 
 Resting-clinic and home blood pressure measurements 
 Pulse wave velocity 
 Plasma ADMA, nitrate and nitrite concentrations 
5.3 Methods 
5.3.1 Study design 
This was a cross sectional study involving both younger (20-49 years) and older (50-75 years) 
with equal numbers (10 males and 10 females) within each age group. A telephone screening 
interview was conducted to check for participants’ eligibility according to the 
inclusion/exclusion criteria (see below). Potentially eligible individuals were invited to 
Newcastle University’s NU Food Research Facility to confirm eligibility, to obtain verbal and 
written informed consent and to start the study that took place between June 2017 and July 
2017. 
5.3.2 Participants 
The study aimed to recruit volunteers from the general public living in Newcastle. Forty 
healthy, non-smoking, normal weight and overweight (BMI: 20.0 – 29.9kg/m2) males and 
females were recruited. Participants were excluded if they had any of the following criteria: 
currently participating in other clinical study; vegetarianism (likely to have very high nitrate 
intake); high physical activity level (may have BMI in obese range but low fat mass), weight 
change more than 3.0 kg in the last two months (important influence on systemic metabolism 
and vascular function); active cancer and any diagnosis of malignant cancer in the last five 
years (likely to have systemic effects on study outcomes); chronic and acute metabolic and 
inflammatory conditions interfering with the study outcomes; previous diagnosis of type-1 or 
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type-2 diabetes treated with insulin and oral hypoglycaemic agents (modification of regulation 
of intermediate metabolism; weight loss medications (sibutramine, orlistat, rimonabant), 
history of bariatric surgery; drug use including: oral corticosteroids, anticoagulants, nitrate 
derived agents, anti-cholinergic; subjects on hormonal therapies (oestrogens, thyroxine, 
progesterone, oral hypoglycaemic agents), anti-hypertensive (diuretics, beta-blockers, calcium 
antagonists, ace-inhibitors and angiotensin receptors inhibitors), statins and any other anti-
dyslipidaemic agent and psychiatric drugs (antidepressants, sedatives, antipsychotics) - 
individuals will be excluded if dose for the drugs has been started/changed in the previous six 
months; alcohol intake >21 units/week for men and >14 units/week for women.  
5.3.3 Sample size 
Power calculations were based on differences in whole-body NO production seen in previous 
studies conducted by Siervo and colleagues using the same stable isotope method (Siervo et 
al., 2011b). Siervo estimated a normal production of NO as 0.63±0.25µmol*hr-1*kg-1. If we 
assign this reference value to the young healthy group, a 20% difference in whole-body NO 
production (with the same variability) between age groups will be detected with a total sample 
size of 40 subjects (20 subjects per age group, independent t-test) with an α-error probability 
of 0.05 and a 1-β error probability of 0.80. G Power 3.1 for Windows was used for the 
calculation of sample size. 
5.3.4 Ethical approval 
Prior to recruiting any participants, ethical approval was sought and gained from the Faculty 
of Medical Sciences, Newcastle University (1285/15004/2017) (Appendix 5.1). 
5.3.5 Recruitment 
Telephone interview 
Participants were provided with all the pertinent information regarding the study during the 
telephone interview. The participants were also asked for information about contact details, 
anthropometric measurement, health status, medication they consumed and smoking and 
drinking status. If they appeared to be eligible and agreed to participate in the study, an 
appointment was set up based on the availability of the participant to attend the study. 
Preparatory protocol (prior to study visit) 
An invitation email was sent to the potential participants confirming the date, time and venue 
of the study visit. The participant information sheet also was attached to the email. Participants 
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were also informed to refrain from eating and drinking caffeinated drinks at least four hours 
before the visit. They were also asked to minimise nitrate intake a day before the study visit 
and a detailed list of allowed and not allowed food items were emailed to the participants 
(Appendix 5.2). 
5.3.6 Clinical assessment 
The study was conducted at the NU Food research facilities between 8.30 am and 12.30 pm. 
After confirming the participant’s eligibility, samples of blood, urine and saliva were collected. 
Measurements of body weight and body composition (Bioelectrical Impedance Analysis) were 
performed. Resting blood pressure was measured in triplicate using an automated device. 
Vascular measurement (PWV) was performed to assess arterial stiffness. Participants were 
provided with eight pre-labelled 2 ml tubes for the collection of saliva samples at 5 pm (pre-
dose), 7.30 pm, 8.15 pm, 9.00 pm, 10.00 pm and the next morning at 7.00 am, 8.00 am and 
9.00 am. A dose of labelled sodium nitrate (Na15NO3, 99% Sigma Aldrich, UK) dissolved in 
100 ml of nitrate free water (Buxton water) was drunk by each participant immediately after 
the collection of the pre-dose saliva sample (at 5.00 pm).  
The participants were provided with a folder containing the questionnaires for the assessment 
of dietary intake (MEDE Food Frequency Questionnaire and nitrate intake questionnaire), 
lifestyle (IPAQ questionnaire) and saliva sample collection procedures (Appendix 5.3). The 
participants were instructed to collect saliva samples and to measure BP at home. A small meal 
(two packs of muesli bars) and nitrate free water were provided to be consumed by the 
participants during the study. After the collection of the last saliva sample (at 9.00 am), the 
study was completed (Figure 5.1). The participants were required to return the saliva samples, 
blood pressure device, study forms and questionnaires on the next day at the research centre. 
For those who having difficulties to go to the research centre, the investigators went to collect 
the materials at the participants’ home. 
 144 
 
 
Figure 5. 1: Overview of the protocol 
5.3.7 Measurement Protocols 
Questionnaires 
Participants were asked to complete a set of questionnaires on general health and lifestyle. In 
addition, each participant’s diet was assessed using a validated food frequency questionnaire 
and a nitrate intake questionnaire, and each participant was asked to complete a sun exposure 
questionnaire. 
Body composition 
Measurements were performed during the visit. Height and weight were measured with a 
standard stadiometer and weight scale, with participants wearing light clothing and barefooted. 
Weight was measured in kilograms to the nearest 100 g. Weight and height measurements were 
used to calculate BMI according to the following equation: 
BMI= weight (kg) 
             height (m)2 
 
Waist circumference was measured with a standard non-stretchable tape, in the standing 
position, at the minimum circumference between iliac crest and the rib cage. Body composition 
was measured using a leg-to-leg bioelectrical impedance device (TANITA 300 MA). 
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Resting blood pressure and pulse wave velocity 
Clinic: Blood pressure measurements were performed in triplicate at one minute intervals using 
an automated blood pressure monitor (model: Omron M3 [HEM-7200-E8(V)]). Before the 
measurement, participants were invited to rest in a sitting position for at least 15 minutes. An 
appropriate cuff size was utilised for the measurements. The average of the three measurements 
was used in the analysis. 
Home: Participants were provided with the same automated BP monitor to measure their resting 
BP at home immediately after the collection of the saliva samples as part of the ONT method 
(see below). In total, eight BP measurements were recorded by the participants (Appendix 
5.4). The average of the eight measurements was calculated for both SBP and DBP ad used in 
the analysis. 
Pulse wave velocity: Digital photoplethysmography (PTT) was used and details of the 
procedures are described in Chapter 4. Briefly, this measurement involved the attachment of 
five electrodes using small adhesive gel pads to the ear lobe, fingertip, chest and abdominal 
area. A series of two separate measurements were performed with different external cuff 
pressures (0 and 40 mmHg) applied to the whole right arm through the long cuff, with a minute 
rest interval between each measurement. The duration of this measurement was approximately 
15 minutes.  
Whole-body NO production 
A non-invasive method was used to assess whole-body NO production (ONT Method) (Siervo 
et al., 2011a). At the beginning of the ONT test, participants were asked to consume a meal 
with low nitrate content and the information was provided to them. Low nitrate bottled mineral 
water (0.1 mg/l) was provided to the participants. Subjects were received an oral dose of 
sodium nitrate (4 mg) in 100 ml distilled water (4 mg Na15NO3) and the isotopic decay of the 
tracer in saliva samples was used to derive estimates of NO production. Saliva samples were 
collected at predefined times over a period of 16 to 18 hours. Each participant was given a form 
for the saliva collection time and to write down the blood pressure measurements. 
The principle of the method is based on an isotopic dilution model. The oral dose of nitrate is 
rapidly assimilated into plasma (complete absorption in under two hours), which, on the 
timescale of the disposal kinetics, can be regarded as a bolus dose. Linear interpolation was 
used to estimate the 2-h changes in concentrations and tracer-to-tracee ratio (TTR) during the 
measurement period. The isotopic decay in saliva of an oral dose of labelled nitrate was 
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described by an exponential function for a single compartment. Data was described using a 
semi-logarithmic plot and the slope and intercept of the regression line was used to derive the 
rate of NO synthesis.  
All saliva samples were derivatised by nucleophilic substitution of mesitylene with 
trifluoroacetic acid anhydride (TFAA) as the catalyst to give a single product, nitromesitlylene 
(1, 3, 5-trimethyl nitrobenzene). Gas Chromatography Mass Spectrometry (GCMS) was used 
to determine the level of enrichment. The full description of the method was described in 
Chapter 3. All analyses were performed in duplicate in selected ion monitoring (SIM) of the 
molecular ion (MO) at m/z 165 and the M+1 ion at m/z 166 representing the unlabelled and 
labelled nitro-mesitlylene respectively. See also Chapter 3 for an example of typical unlabelled 
and labelled chromatograms and corresponding spectra.  
NO3
ˉ and NO2ˉ analyses  
Plasma and urinary concentrations of NO3ˉ and NO2ˉ were analysed using a Sievers gas-phase 
chemiluminescence NO analyser (Sievers NOA 280i, Analytix Ltd, Durham, UK). The Sievers 
NOA consists of two components, glass purge vessel and NO chemiluminescence analyser. 
The purge vessel contains either vanadium chloride or tri-iodide (I3) solutions. These solutions 
react with NO3ˉ and NO2ˉ (respectively) in the injected samples to produce NO. NO released 
from the above reactions are quantified by the chemiluminescence analyser. The concentrations 
of NO3ˉ and NO2ˉ were determined by plotting signal area (mV) against a calibration plot of a 
known concentration NO3ˉ and NO2ˉ standards. To analyse data from the injected samples, the 
Liquid Program (version 3.21) was used.  
Plasma NO3ˉ and NO2ˉ were processed to remove the protein from the plasma sample before 
the analysis. The plasma samples collected in lithium heparin vacutainer were used for the 
analysis. Details for the deproteination procedures were described in Chapter 3. Urine samples 
for the measurement of NO2ˉ required a 100-fold dilution (10 µl of urine samples + 990 µl of 
Milli-Q® water). A more detailed description of the protocol is provided in Chapter 3 and 
examples of calibration curves and sample analysis are provided in the Appendix 5.5.  
Venepuncture/blood samples   
Blood samples were collected after four hour fasting. Plasma samples were utilised to measure 
NO3ˉ, NO2ˉ and biomarkers of endothelial dysfunction. Serum plasma was used to measure 
25(OH)D concentration. Blood samples were collected using the following vacutainer tube: 
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Lithium heparin (5.0 ml), EDTA (5.0 ml), plain tube (5.0 ml). The samples were immediately 
centrifuged within five minutes after collection to preserve NO2ˉ. 
Asymmetric Dimetylarginine (ADMA) 
The measurement of ADMA in this PhD project was done using a commercial kit (CUSABIO 
ELISA kit CSB-E09298h) in a 96-well format. One hundred µl of plasma samples from EDTA 
tube was added per well. Details of the ADMA analysis procedures can be found in Chapter 3. 
Vitamin D concentration analysis 
Vitamin D concentrations analysis was done using commercial kit (25-Hydroxy Vitamin Ds 
Enzyme Immunoassay (EIA) from Immunodiagnosticsystems (IDS) AC-57SF1) in a 96-well 
format. Details of the 25(OH)D analysis procedures can be found in Appendix 5.6.  
Principle of assay 
The quantitative 25(OH)D ELISA kit uses a microtiter plate format. 25 µL of each calibrator, 
controls and serum samples were diluted with biotin labelled 25(OH)D. The diluted samples 
were incubated in microtiter wells with a fixed number of highly specific sheep 25(OH)D 
antibody at room temperature before aspiration and washing. Enzyme (horseradish peroxidase) 
labelled avidin was added and binds selectively to complexed biotin and the chromogenic 
substrate (TMB) was added to developed the colour. The stop solution was added to stop the 
reaction mixtures, and the fluorescent signal was monitored at 450 nm. The colour intensity 
developed is inversely proportional to the concentration of 25(OH)D. Therefore, the higher the 
sample 25(OH)D concentration, the weaker is the intensity of the signal. 
Saliva samples collection 
Saliva samples were obtained for the measurement of nitrate isotopic enrichments during the 
ONT method. Samples were collected by chewing a cotton ball for about two to three minutes 
and then using the 20 ml syringe to squeeze the saliva in the cotton ball into 1.5 ml Eppendorf 
tube. The tubes were containing 5 µL of 1M sodium hydroxide solution to prevent nitrate 
degradation. Samples were stored at -20ºC until further analyses. 
Urine Collection 
A spot urine sample was collected at the visit in urine plastic container. First void urine was 
discarded. Urine was then aliquoted in two Eppendorf tubes and stored at -20ºC for future 
analyses. Urine sample was used for the assessment of NO3ˉ concentrations using 
chemiluminescence. 
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Dietary assessment 
A food frequency questionnaire for the assessment of overall dietary and NO3ˉ intake was 
administered to evaluate typical energy and nutrient intake of each participant. The intakes of 
energy and nutrients were calculated using the MEDE FFQ Database. 
5.3.8 Sample storage 
Blood samples for serum or plasma collection were spun in a centrifuge (Jouan CR3i) at 3000 
rpm for 10 mins at 4°C. Plasma from lithium heparin tube and EDTA tube and serum from 
plain tube were transferred into the aliquot tubes and stored in the -80 C freezer at Human 
Nutrition Research Centre (HNRC) as quickly as possible for further analysis. Plasma from 
lithium heparin vacutainer tube was used for the measurement of NO3ˉ (deproteinised prior to 
the chemiluminescence analysis using ethanol- details on the procedure are described in 
Chapter 3). Serum from plain vacutainer tube was used for the measurement of serum 25(OH)D 
concentration, and plasma from EDTA vacutainer tube was used for the measurement of 
ADMA. 
5.3.9 Statistical analysis 
Baseline characteristics of the participants are presented as arithmetic means ± SDs for 
numerical variables and counts and percentages for categorical variables. The assumption of 
normality for all variables were tested by visual inspection of the histograms and evaluating 
the p-value for the Shapiro-Wilks test (if the p-value was < 0.05, the data were considered as 
not normally distributed). For non-normally distributed variables, logarithmic transformations 
were applied and data are presented as median (with 25th and 75th percentiles).  Two sided 
p<0.05 was considered statistically significant in all cases.  
Mean concentration of serum 25(OH)D concentration were categorised into two groups i.e. 
below and above the cut-off for adequacy (<30 nmol/L and ≥30 nmol/L). Independent sample 
t-test was used to compare differences between two groups. Univariate General Linear Model 
was used to compare differences for the main dependent variables between age (A) and gender 
(G) groups (Fixed factor) and also explore their interaction (A*G). Bivariate correlations were 
used to assess the association between serum 25(OH)D concentrations with age, 
anthropometric measurements, blood pressure, physical activity level, PWV, whole-body NO 
production and biomarkers of vascular health. Correlation analyses were also adjusted for 
physical activity level and vitamin D supplementation. The association between whole-body 
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NO production with age, anthropometric measurements, blood pressure, physical activity level, 
pulse wave velocity and biomarkers of vascular health were explored. The Bland-Altman 
method (see Chapter 3 for detailed description of this approach) was used to assess the 
agreement between home and clinic resting BP measurements. All statistical analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) 22.0 program for 
Windows (SPSS Inc., Chicago, IL).  
 
5.4 Results 
5.4.1 Recruitment and baseline characteristics of the participants 
Two hundred flyers containing the information of the study were sent out at Newcastle 
University targeting potential young male and female to participate in this study. The 
participants for the older group were sought from the volunteer database from previous studies 
conducted at the university. A total of 48 participants were contacted for the telephone 
screening interview. After screening, eight subjects did not meet the criteria (BMI >30 kg/m2: 
three subjects; reluctant to have their blood taken: two subjects; the date and time not suitable: 
three subjects). Hence, 40 participants in total were enrolled in the study (Figure 5.2). Visits 
were conducted between 8.45 am to 12.30 pm and the average visit duration was approximately 
40 minutes per participant. 
 
A total of 40 participants were recruited and completed the study {ten older male [68.5 years 
(60.7,70.0)], ten older female [62.0 years (55.7,68.2)], ten younger male [32.0 years 
(29.0,42.0)] and ten younger female [32.0 years (25.7,38.2)]. The study was well tolerated and 
100% compliance was received for the saliva collection and blood pressure measurement at 
home. A summary of the participants’ opinion and evaluation of the study are attached in 
Appendix 5.7.  
 
Baseline characteristics of the participants demonstrate that, except for height and DBP, the 
two age groups were significantly different for age, anthropometric variables, SBP and heart 
rate (P<0.05). On average, the older group had higher BMI, FM, SBP and lower heart rate 
compared with the younger group of participants. The results also revealed a significant 
difference between male and female participants for height, weight, FM, SBP and heart rate 
(Table 5.1). 
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Figure 5. 2: Recruitment flow chart
Disseminating of study information via: 
 Volunteer databases 
 Flyers: 200 pieces 
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Table 5. 1: Descriptive characteristics of the participants stratified by age and gender  
 All Younger 
(20 to 49 years old) 
Older 
(50 to 70 years old) 
P value 
 N = 40 Male (n=10) Female (n=10) Male (n=10) Female (n=10)  
 Mean (SD)  
Age 
(years) ¶ 
49.5 (31.0,66.5) 32.0 (29.0,42.0) 32.0 (25.7,38.2) 68.5 (60.7,70.0) 62.0 (55.7,68.2) A:< 0.001 
G: 0.21 
A*G: 0.94 
Height  
(cm) 
165.8 (9.1) 171.1 (8.87) 162.4 (4.2) 173.0 (6.3) 158.3 (7.6) A: 0.39 
G: <0.001 
A*G: 0.08 
Body weight  
(kg) 
69.8 (11.8) 69.5 (9.6) 61.6 (10.0) 81.8 (11.6) 66.7 (5.4)  A: 0.04 
G: <0.001 
A*G: 0.36 
BMI  
(kg/m2) 
25.0 (3.4) 23.7 (2.8) 23.4 (3.6) 25.9 (3.8) 26.7 (2.2) A: 0.04 
G: 0.67 
A*G: 0.08 
FM 
(kg) ¶ 
19.9 (10.9,23.3) 9.6 (8.6,15.3) 18.5 (13.1,21.2) 20.7 (13.2,23.4) 25.9 (21.4,26.6)  A:< 0.001 
G: <0.001 
A*G: 0.94 
Clinic SBP (mmHg) 127.4 (17.2) 123.1 (8.1) 110.2 (10.9) 141.7 (14.3) 133.6 (15.8) A: <0.001 
G: <0.001 
A*G: 0.48 
Clinic DBP  
(mmHg) 
74.9 (8.5) 76.2 (10.6) 68.7 (8.4) 78.3 (5.1) 76.4 (6.1) A: 0.05 
G: 0.07 
A*G: 0.25 
HR  
(bpm) 
69.9 (9.8) 72.4 (8.1) 78.2 (9.8) 60.3 (5.0) 68.3 (6.4)  A:< 0.001 
G: <0.001 
A*G: 0.56 
BMI, Body Mass Index; FM, Fat Mass; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HR, Heart Rate. ¶ Reported as median (25th, 75th percentiles). Significant p values are 
shown in bold. Univariate Analysis of Variance was used to test the effect of age and gender on selected outcomes. Age, Age; G, Gender; A*G, Age times Gender interaction. 
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5.4.2 Nutrient intake and physical activity of the participants 
The MEDE food frequency questionnaire was used to estimate the nutrient intake of the 
participants. Overall, we found that there was no significant difference in nutrient intakes 
between age and gender groups (Table 5.2). However, older female participants appeared to 
have a higher consumption of CHO, fat, calcium, iron, sodium, vitamin C and vitamin D 
compared with the other groups but none of the Age*Gender interactions was significant. The 
intake of CHO and proteins was found to be within acceptable macronutrient distribution 
ranges for adults (CHO: 45-65%, protein: 10-35%) (Bates et al., 2016) except for a slightly 
higher intake of energy from fat (36%).  
The comparison of mean nutrient intakes by participants in our study with results from the 
National Diet and Nutrition Survey (2016) (NDNS), showed that participants in this study had 
higher consumption of CHO (342 g/day), protein (111 g/day), fat (113 g/day) and energy (2714 
kcal/day) (total intake of these nutrients in NDNS for CHO, protein, fat and energy are 195 
g/day, 67.7 g/day 60.9 g/day and 1608 kcal/day, respectively.) The intakes of calcium (1019 
mg/day) and iron (18.5 mg/day) were also higher than the RNI (RNI for calcium and iron are 
700 mg and 8.7 mg respectively). The vitamin D intake (3.39 µg/day) in this study was found 
to be similar to the result reported in Chapter 4 (3.82 µg/day), which is considerably less than 
the recommended RNI (10 µg/day) (SACN, 2016). Participants in this study had a high 
consumption of vitamin C (136 mg/day), which is almost four fold higher than the RNI for 
vitamin C (40 mg/day) (British Nutrition Foundation, 2016), and older females had the highest 
consumption (207 mg/day). 
Total physical activity level (PAL) and walking PAL were highest in younger males (Table 
5.3) but there were no significant Age or Gender effects or Age*Gender interactions for any 
measured component of PAL due to the large variability of the results. 
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Table 5. 2: Dietary intakes (amounts /d) by participants stratified by age and gender 
 All Younger 
(20 to 49 years old) 
Older 
(50 to 70 years old) 
P value 
  Male Female Male Female  
N 40 10 10 10 10  
 Mean (SD)  
Carbohydrate (g) ¶ 
(% in kcal) 
 
342 (225,559) 
48 
261 (188,638) 
45 
432 (188,553) 
53 
277 (218,422) 
44 
346 (334,40) 
45 
A: 0.75 
G: 0.34 
A*G: 0.59 
Fat (g)  
(% in kcal) 
 
113 (59) 
36 
97 (68) 
39 
120 (72) 
33 
108 (51) 
39 
135 (51) 
40 
A: 0.65 
G: 0.28 
A*G: 0.88 
Protein (g)¶ 
(% in kcal) 
 
111 (79,153) 
16 
87.0 (52.4,162.3) 
16 
121.6 (75.6,175.8) 
15 
107.6 (72.2,135.5) 
17 
114.2 (98.4,150.1) 
15 
A: 0.83 
G: 0.19 
A*G: 0.95 
Energy 
(kJ/day) ¶ 
 
2714 (1910,4071) 2774 (1681,4209) 2774 (1681,2774) 2624 (1793,3490) 2971 (2655,3665) A: 0.65 
G: 0.25 
A*G: 0.84 
Calcium  
(mg) 
 
1019 (474) 822 (592) 1123 (443) 994 (473) 1215 (427) A: 0.53 
G: 0.14 
A*G: 0.60 
Iron  
(mg) 
 
18.5 (9.1) 17.0 (14.3) 19.9 (8.5) 16.5 (6.8) 22.3 (8.1) A: 0.99 
G: 0.26 
A*G: 0.86 
Sodium 
(mg) 
 
4250 (2201) 3172 (2390) 4616 (2501) 4695 (2285) 4869 (1794) A: 0.31 
G: 0.36 
A*G: 0.25 
Vitamin C  
(mg)¶ 
 
136 (84, 222) 89 (59,292) 151.1 (80.1,228.6) 116.9 (82.1,154.4) 207.0(163.7,252.9) A: 0.31 
G: 0.09 
A*G: 0.39 
Vitamin D  
(µg)¶ 
3.39 (2.13,4.95) 2.7 (1.83,5.59) 3.31 (2.46,5.57) 3.16 (2.1,4.9) 3.98 (1.68,4.39) A: 0.85 
G: 0.65 
A*G: 0.66 
Nitrate intake 
 (mg/day) ¶ 
 
140 (107, 254) 124 (110,188) 107.0 (50.6,272.7) 150 (93,268) 214 (141,344) A: 0.65 
G: 0.94 
A*G: 0.24 
Univariate Analysis of Variance was used to test the effect of age and gender on selected outcomes. A, Age; G, Gender. A*G, Age times Gender interaction; ¶ Reported as median 
(25th, 75th percentiles).  
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Table 5. 3: Physical Activity Level (PAL) of participants stratified by age and gender 
 All 
 
Younger 
(20 to 49 years old) 
Older 
(50 to 70 years old) 
P value 
  Male Female Male Female  
N 40 10 10 10 10  
 Mean (SD)  
PAL walking 
(METs/wk)¶ 
1097 (693,2079) 1386 (594,3118) 1039 (693,1493) 1017 (470,2598) 1155 (668,2829) A: 0.35 
G: 0.98 
A*G: 0.40 
PAL moderate 
METs/wk)¶ 
60 (0.0,570) 140 (0.0,1260) 0.00 (0.0,90) 480 (180,720) 0.00 (0.0,3570) A: 0.16 
G: 0.39 
A*G: 0.15 
PAL vigorous 
(METs/wk)¶ 
0.00 (0.0,720) 420.0 (0.0,1440) 0.00 (0.0,540) 600 (0.0,1080) 0.00 (0.0,120.0) A: 0.59 
G: 0.46 
A*G: 0.29 
PAL Total 
(METs/wk)¶ 
1872 (1025,4200) 3348 (1683,4776) 1249 (866,2145) 1854 (1520,4331) 2142 (668,7628) A: 0.33 
G: 0.32 
A*G:0.14 
PAL, Physical Activity Level; MET, Metabolic Equivalent of Task; wk, week; Univariate Analysis of Variance was used to test the effect of age and gender on selected 
outcomes.  A, Age; G, Gender; A*G, Age times Gender interaction. 
¶ Reported as median (25th, 75th percentiles). 
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5.4.3 Sunshine exposure and vitamin D status 
The relationships between habitual sunshine exposure and mean serum 25(OH)D concentration 
are summarised in Table 5.4. There was no relationship between time spent outdoors or time 
spent outdoors on weekdays and vitamin D status but serum 25(OH)D concentration were 
greater for those who spent more time outdoors (more than two hours) at the weekend. 
Participant’s ethnicity may have played a role in this study. The majority of the older 
participants were English (80 %; seven old female and nine old male), which have a fair skin 
type. The majority of younger participants were instead from Asia [15 participants (75%)], 
which were considered as having brown colour skin type. There was a different pattern of 
sunshine exposure between the older and younger groups. The younger group for both genders 
reported that they spend less time outdoors (between 15 to 30 minutes) especially during the 
weekdays. Older groups reported that they usually spend a longer time in outdoor activities 
(more than two hours). However, there were no significant associations between sunlight 
exposures, clothing, sunblock usage, skin type and serum 25(OH)D concentration. 
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Table 5. 4: Serum 25(OH)D concentrations by sunshine exposure variables as assessed by sunshine exposure questionnaire 
Characteristics Participants 
N (%) 
25(OH)D concentration 
(nmol/L) 
(mean ±SD) 
P value 
 
1. How often are you outdoors for at least half an hour between 10 am to 3 pm 
during the sunny months (April – September)? 
 Less than once a week 
 1 – 2 times a week 
 More than 2 times a week 
 Everyday 
 
 
5 (12.5) 
10 (25.0) 
9 (22.5) 
16 (40.0) 
 
 
 
46.1 (19.1) 
61.8 (20.2) 
58.5 (18.4) 
42.5 (16.7) 
 
 
 
 
0.11 
2. How much time would you spend outdoors on weekdays (Monday to Friday) 
during the sunny months (April – September)? 
 Less than 15 minutes 
 Between 15 and 30 minutes 
 Between 30 minutes and 2 hours 
 More than 2 hours 
 
 
5 (12.50) 
10 (25.0) 
9 (22.5) 
16 (40.0) 
 
 
 
40.9 (18.8) 
47.4 (20.8) 
48.0 (19.3) 
56.9 (17.6) 
 
 
 
0.33 
3. How much time would you spend outdoors on a weekend (Saturday - Sunday) 
during the sunny months (April-September)?  
 Less than 15 minutes        
 Between 15 and 30 minutes   
 Between 30 minutes and 2 hours         
 More than 2 hours   
 
 
2 (5.0) 
12 (30.0) 
20 (50.0) 
6 (15.00) 
 
 
 
54.7 (19.0) 
41.6 (19.1) 
49.9 (17.6) 
69.0 (13.5) 
 
 
 
0.03 
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Characteristics Participants 
N (%) 
25(OH)D concentration 
(nmol/L) 
(mean ±SD) 
P value 
 
5. How would you deliberately wear less clothing so as to get direct sunlight on 
your skin (e.g. sleeveless tops shorts)?  
 Never       
 Rarely      
 Sometimes       
 Usually      
               
 
 
13 (32.5) 
20 (50.0) 
6 (15.0) 
1(2.5) 
 
 
45.73 (21.0) 
49.58 (17.4) 
60.29 (18.4) 
73.9 
 
 
 
 
0.27 
6. Sunblock usage 
 Yes 
 No  
 
18 (45) 
22 (55) 
 
48.7 
52.2 
 
0.69 
 
7. Skin type 
 Burns easily, never tans (white, very fair) 
 Burns easily, tans minimally (white, fair) 
 Burns moderately, tans gradually (cream white, fair)  
 Burns minimally, tans well (brown, typical Mediterranean Caucasian skin) 
 Rarely burns, tans profusely (dark brown, mid-eastern skin types) 
 
 
 
1 (2.5) 
5 (12.5) 
13 (32.5) 
13 (32.5) 
8 (20.0) 
 
 
38.1 
43.4 (21.3) 
51.6 (21.0) 
54.5 (18.0) 
48.3 (19.1) 
 
 
 
 
0.78 
8. When you are outdoors during the sunny months (April – September), do you 
stay in the sun or do you seek the shade? 
 I try to avoid staying in direct sunshine 
 I sometimes stay in the sunshine 
 I enjoy staying in the sunshine  
 
 
13 (32.5) 
20 (50) 
7 (17.5) 
 
 
52.1 (23.2) 
49.3 (18.9) 
51.0 (12.4) 
 
 
 
0.91 
Significant p values are shown in bold. One-way ANOVA was used to  evaluate differences in 25(OH)D concentrations between groups.
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5.4.4 Measurement of blood pressure (at research facility and at home)  
Resting BP measurements were performed in two different locations; three measurements were 
recorded at the research facility and eight measurements were self-recorded at home by the 
participants (measured after each saliva collection). The average of the BP measurements was 
calculated and compared to evaluate the agreement between these two measurements protocols 
(Table 5.6). 
In general, the average SBP and DBP was within a normal range. A significant difference 
between age groups was found in SBP for the measurement recorded at the research facility 
(p<0.001). However, older participants had a higher SBP and DBP measured at the clinic and 
home compared to the younger group (seven older participants had a SBP greater than 140 
mmHg). BP measurements at the research facility were found to be higher compared that the 
measurements performed at home.  
These results are also illustrated in the scatterplots and B & A analysis (Figure 5.3). The 
regression analysis showed a good agreement between the two methods for SBP (n = 40, r = 
0.78, p<0.001, Figure 5.3 A) but slightly weaker association for DBP (n = 40, r = 0.64, 
p<0.001, Figure 5.3 C). The B & A analysis provided a visual representation of the agreement 
between the two BP methods. The mean differences for SBP and DBP between the two 
methods were small [mean bias = 3.08 mmHg (p=0.08) and 2.90 mmHg (p=0.01)], respectively 
(Table 5.5). The differences between the measurements were clustered within the 95% limits 
of agreement, with the exception for one point for SBP (Figure 5.3 B) and three points for 
DBP (Figure 5.3 D). The regression lines fitted to the B&A analysis were not significant and 
therefore indicated a lack of differential bias with increasing SBP and DBP readings. 
Table 5. 5: Correlation and agreement parameters of systolic (SBP, mmHg) and diastolic 
(DBP, mmHg) blood pressure measurements measured at the research facility and at 
home 
 N Mean 
Bias 
Regression 
equation 
 
r2 t-test (p) +2SD Min Max 
SBP 40 3.08 y=-19.34+ 0.18x 0.06 0.08 10.88 -17.88 32.38 
DBP 40 2.90 y=7.91-0.07x 0.005 0.01 7.35 -14.00 20.13 
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Table 5. 6: Measurement of blood pressure (at research facility and at home) stratified by age and gender 
 All Younger 
(20 to 49 years old) 
Older 
(50 to 70 years old)  
P value 
  Male Female Male Female  
N 40 10 10 10 10  
mmHg Mean (SD)  
Mean SBP measured at 
research facility  
(mmHg) 
127.4 (17.2) 123.1 (8.1) 110.2 (10.9) 141.70 (14.3) 134.60 (16.3) A: <0.001 
G: <0.001 
A*G:0.48 
Mean DBP measured at 
research facility  
(mmHg) 
74.9 (8.5) 76.2 (10.6) 68.70 (8.4) 78.30 (5.1) 76.60 (6.4) A: 0.05 
G: 0.07 
A*G: 0.25 
Mean SBP measured at 
home (mmHg) 
124.3 (14.7) 121.3 (12.9) 109.38 (10.7) 133.95 (11.8) 132.30 (9.4) A: <0.001 
G: 0.60 
A*G: 0.14 
Mean DBP measured at 
home (mmHg) 
72.0 (9.0) 74.5 (11.9) 67.23 (5.8) 73.62 (9.5) 72.72 (6.8) A: 0.42 
G: 0.15 
A*G: 0.25 
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; Univariate Analysis of Variance was used to test the effect of age and gender on selected outcomes. A, Age; G, Gender; A*G, Age 
times Gender interaction. Significant p values (p<0.05) are shown in bold.   
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(A) Regression analysis of average systolic blood pressure (SBP, mmHg) measured at home 
and at research facility 
 
 
(B) Bland-Altman analysis of mean systolic blood pressure (SBP, mmHg) measured at the 
clinic and at home 
 
(C) Regression analysis of average diastolic blood pressure (mmHg) measured at home and at 
research facility 
 
 
(D) Bland-Altman analysis of  mean diastolic blood pressure (DBP, mmHg) measured at the 
clinic and at home 
Figure 5. 3: Comparison of average systolic (SBP) and diastolic (DBP) blood pressure measured at the research facility and at home. (A) & (C): Linear regression analysis to evaluate 
the association between SBP and DBP measured at clinic and at home. (B) & (D): B&A plot to assess the agreement of BP measurements at the clinic and at home. Black horizontal 
line shows the mean difference (bold) and the ± 2S.D. range (fine, grey line). A regression line was fitted to the points (dashed black line) to evaluate differential bias.  
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5.4.5 Mean 25(OH)D concentrations  
Serum 25(OH)D concentrations were significantly higher in older participants (Figure 5.4). 
Mean serum 25(OH)D concentrations for the older group were 66.4 nmol/L in males and 55.3 
nmol/L in females, whilst in the younger group, the mean serum 25(OH)D concentrations were 
39.6 nmol/L for male and 40.7 nmol/L for female participants (Figure 5.4). In this study, we 
found that all older male participants had serum 25(OH)D concentrations of ≥ 30 nmol/L, and 
only one older female with less than 30 nmol/L. However, in the younger group, four females 
and one male participants had 25(OH)D concentrations <30 nmol/L (Table 5.7). The maximum 
serum 25(OH)D concentrations in the old group (male and female) were 89.5 nmol/L and 86.4 
nmol/L respectively, and the lowest for this group were 49.2 nmol/L and 29.8 nmol/L, 
respectively. For the young group, the maximum and minimum for young male were 65.8 
nmol/L and 27.3 nmol/L, and for young female were 68.2 nmol/L and 17.3 nmol/L, 
respectively. 
Eighteen (45%) participants in this study consumed vitamin D supplementation (Table 5.7 and 
Figure 5.5). The correlation between the vitamin D intake (from FFQ) with serum 25(OH)D 
concentrations was not significant in the total population (n= 40, r=-0.01, p=0.91) and after 
exclusion of participants taking vitamin D supplementation (n=22, r=-0.03, p=0.83).  
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Table 5. 7: Consumption of vitamin D supplementation stratified by age and gender 
 
Figure 5. 4: Mean serum 25(OH)D concentrations stratified by gender and age group. 
Univariate Analysis of Variance was used to test the effect of age and gender on selected outcomes. 
 (A, Age; G, Gender; A*G, Age times Gender interaction) 
 
 All Younger 
(20 to 49 years old) 
Older 
(50 to 70 years old)  
  Male Female Male Female 
N 40 (%) 10 (%) 10 (%) 10 (%) 10 (%) 
25(OH)D concentration 
 (< 30 nmol/L) 
6 (15) 1 (1) 4 (40) 0 1 
 Mean (SD) 
nmol/L 
24.83 (5.8) 27.34  22.96 
(6.42) 
- 29.80  
25(OH)D concentration  
(≥  30 nmol/L) 
34 (85) 9 (90) 6 (60) 10(100) 9 (90) 
 
 Mean (SD) 
nmol/L 
55.08 
(16.90) 
41.06 
(10.85) 
52.53 
(13.95) 
66.47 
(13.62) 
58.16 
(6.07) 
Vitamin D 
Supplementation Usage 
     
Yes 
 
 Mean 25(OH)D (SD) 
nmol/L 
18 (45) 
 
67.8 (11.5) 
2(20) 
 
57.6 (10.8) 
 
 
4(40) 
 
60.1 (9.6) 
 
7(70) 
 
73.4 (9.4) 
 
5 (50) 
 
70.3 (12.7) 
No 
 
 Mean 25(OH)D (SD) 
nmol/L 
 
22 (55) 
 
36.3 (10.1) 
8(20) 
 
35.2 (5.2) 
6(60) 
 
27.7 (8.9) 
 
3 (30) 
 
50.2 (0.9) 
5 (50) 
 
40.0 (10.9) 
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Figure 5. 5: Mean serum 25(OH)D concentrations in participants not taking vitamin D 
supplementation (n=22) stratified by age group. T-test for independent samples was used 
to compare the two groups. 
 
5.4.6 Mean NO production stratified by gender and age group 
Semi-logarithmic plots of saliva tracer/tracee ratio (TTR) were highly linear in both younger 
and older subjects (r > 0.96 in the period of 2 to 12 hours post dose). The younger group was 
characterised by a steeper slope of the regression line indicating a greater dilution of the tracer 
and hence a greater appearance of unlabelled nitrate compared with to the older group (Figure 
5.6 A). Male and female participants did not have a significantly different NO production rate 
(p=0.82). The values of NO synthesis ranged from 0.14 µmol.hr-1.kg-1 to 0.54 µmol.hr-1.kg-1 in 
the older group and 0.18 µmol.hr-1.kg-1 to 1.29 µmol.hr-1.kg-1 in the younger group. Mean NO 
production in younger people (0.61 µmol.hr-1.kg-1) was significantly higher than the older 
group (0.39 µmol.hr-1.kg-1) (p=0.03) (Figure 5.6 B).  
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(A)          (B) 
 
Figure 5. 6: Tracer-tracee ratio of labelled/unlabelled salivary nitrate measured during the ONT test and mean NO production stratified 
by gender and age group 
(A)Tracer-tracee ratio of labelled/unlabelled salivary nitrate measured during the ONT test and showed for younger (n=20, represented by blue line) and older 
(n=20, represented by orange line) participants. (B) Mean NO production stratified by gender and age group.  
Univariate Analysis of Variance was used to test the effect of age and gender. (A, Age; G, Gender; A*G, Age times Gender interaction) 
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5.4.7 Pulse Wave Velocity 
Mean PWV was higher in older (12.37 m/s) compared with younger (8.66 m/s) participants 
(p<0.001). Older men showed a mean PWV of 13.2 m/s, which is higher than the reference 
value for PWV (12 m/s), (Mancia et al., 2007).  The mean of PWV for old female subjects was 
11.47 m/s. Seventeen (85%) old participants and two (10%) young participants had a value of 
12 m/s or more for PWV measurements. 
Likewise, the younger group demonstrated a lower mean PWV (9.33 m/s for male and 8.0 m/s 
for female), which indicates a better vascular health (Figure 5.7). Overall, in this study, females 
had a lower value of PWV than males (p<0.05).  
 
Figure 5. 7: Mean Pulse Wave Velocity stratified by gender and age group 
Univariate Analysis of Variance was used to test the effect of age and gender. 
(A, Age; G, Gender; A*G, Age times Gender interaction) 
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5.4.8 Measurements of ADMA, nitrate (plasma and urine) and plasma nitrite  
There were no significant between-groups differences in plasma ADMA (p=0.50), plasma 
nitrate (p=0.42), urinary nitrate (p=0.86) and plasma nitrite (p=0.41) concentrations (Table 
5.8). The mean concentration of ADMA in this study was lower (89.01 ng/ml), compared to 
the previous cross sectional study reported in Chapter 4 (102.72 ng/ml). The same pattern was 
observed for plasma NO3ˉ and urinary NO3ˉ as the mean concentrations in this study were 14.5 
µmol/L and 0.64 mmol/L - respectively; mean concentrations for - plasma and urinary NO3ˉ 
were 34.67 µmol/L and 0.72 mmol/L in the previous cross sectional study measured in 
postmenopausal women. A large range of plasma NO2ˉ concentration was observed in this 
study (81.0 nmol/L to 768 nmol/L), and the mean concentration was 300 nmol/L.  
5.4.9 Age, anthropometric measurements, blood pressure, physical activity level, pulse wave 
velocity and biomarkers of vascular health stratified by 25(OH)D concentration 
The stratification of the sample by vitamin D status showed that six participants in this study 
had 25(OH)D concentration less than <30 nmol/L. The description of age, anthropometric 
measurements, BP, PAL, PWV and biomarkers of vascular health stratified according to 
vitamin D status (<30 nmo/L and ≥ 30 nmol/L) is presented in Table 5.9. No significant 
differences were found between the groups except for height, weight, 25(OH)D concentrations 
and PWV. PWV measurements were higher in ≥30 nmol/L group (p=0.03).  
5.4.10 Correlation between 25(OH)D with age, BMI, blood pressure, PWV, whole-body NO 
production and biomarkers of vascular health 
Table 5.10 shows the unadjusted and adjusted (vitamin D supplementation and PAL) 
correlation between 25(OH)D concentration with age, BMI, BP, PWV, NO production and 
biomarkers of vascular health. Overall, there were positive, significant correlations between 
25(OH)D concentrations (adjusted and unadjusted) with age (r=0.48, p<0.001), PWV (r=0.50, 
p<0.001) and negative, significant correlation with NO production (r=-0.37, p<0.001). 
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Table 5. 8: Measurements of ADMA, nitrate (plasma and urine) and plasma nitrite stratified by age and gender 
 
 All 
 
Younger 
(20 to 49 years old) 
Older 
(50 to 70 years old) 
P value 
  Male 
 
Female Male Female  
N 40 10 10 10 10  
 Mean (SD)  
ADMA  
(ng/mL) 
 
89.01 (45.0) 96.1 (47.2) 85.7 (49.4) 82.3 (39.9) 91.7 (48.7) A: 0.79 
G: 0.97 
A*G: 0.50 
 
NO3
-       
- Plasma 
(µmol/L)¶ 
14.5 (11.6,22.7) 15.90 (13.3,25.7) 13.81 (8.1,14.4) 18.64 (13.9,24.0) 12.1 (10.2,32.0) A: 0.56 
G: 0.18 
A*G:0.42 
 
- Urine 
(mmol/L)¶ 
 
0.64 (0.43,0.85) 0.84 (0.39,1.38) 0.70 (0.45,0.85) 0.58 (0.43,0.81) 0.55 (0.26,0.67) A:0.19 
G: 0.60 
A*G: 0.86 
 
Plasma NO2
-   
 (nmol/L)¶ 
 
256.5 (204, 377) 219 (156,528) 226 (152,345) 271 (227,361) 291 (248,399) A: 0.20 
G:0.79 
A*G:0.41 
 
PWV, Pulse Wave Velocity; ADMA, Asymmetric Dimethylarginine; NO, Nitric Oxide; Univariate Analysis of Variance was used to test the effect of age and gender on selected outcomes. A, 
Age; G, Gender; A*G, Age times Gender interaction.¶Reported as median (25th, 75th percentiles).  
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Table 5. 9: Age, anthropometric measurements, blood pressure, physical activity level, 
pulse wave velocity and biomarkers of vascular health stratified by 25(OH)D 
concentration status 
 
 25(OH)D concentration  
 <30nmol/L ≥30nmol P value 
N 6 34  
 
Age  
(years) ¶ 
 
38.5 (35.5,47.0) 
 
55.5 (30.0,68.0) 
 
0.49 
Height  
(cm) 
158.5 (7.2) 167.1 (8.9) 0.03 
Body weight  
(kg) ¶ 
62.8 (55.2,67.8) 69.3 (62.6,80.2) 0.04 
BMI  
(kg/m2) 
24.4 (3.3) 25.1 (3.3) 0.65 
FM  
(kg) ¶ 
19.7 (12.3,24.6) 19.9 (10.2,23.4) 0.77 
SBP  
(mmHg) 
122 (20.4) 128.3 (16.8) 0.41 
DBP  
(mmHg) 
73.8 (6.7) 75.1 (8.8) 0.73 
Home SBP  
(mmHg) 
119.10(13.3) 125.23(14.9) 0.35 
Home DBP  
(mmHg) 
72.77(8.37) 71.91 (9.21) 0.83 
25(OH)D concentration 
(nmol/L) 
24.83 (5.8) 55.0 (16.9) <0.001 
PWV  
(m/s) 
8.6 (1.20) 10.8 (2.3) 0.03 
ADMA 
(ng/ml) 
73.8 (46.8) 91.6 (44.8) 0.37 
NO3-  ¶    
- Plasma (µmol/L) 14.5 (12.2,26.1) 14.6 (11.3,22.3) 0.94 
- Urine (mmol/L) 0.76 (0.64,1.25) 0.59 (0.37,0.82) 0.14 
 
Plasma NO2-    
(nmol/L) ¶ 
226.5 (146.2,376.7) 262.5 (216.0,380.2) 0.34 
NO production  
(µmol.hr-1.kg-1) ¶ 
0.52 (0.39,0.72) 0.46 (0.35,0.54) 0.42 
PAL Total 
(METs/wk) ¶ 
1329 (1039,4326) 2012 (967,4238) 0.50 
¶Reported as median (25th, 75th percentiles) 
BMI, Body Mass Index; FM, Fat Mass; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; 25(OH)D, 25-
hydroxyvitamin-D; PAL, Physical Activity Level; MET, Metabolic Equivalent of Task; wk,, week; PWV, Pulse Wave 
Velocity; ADMA, Asymmetric Dimethylarginine; NO, Nitric Oxide; NO3- , nitrate; NO2-, nitrite. Significant p values are 
shown in bold.  Independent sample t-test was used to compare the two groups.
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Table 5. 10: Correlation between 25(OH)D concentration with age, BMI, blood 
pressure, PWV, whole-body NO production and biomarkers of vascular health 
 
Variables 25(OH)D concentration 
(unadjusted) 
25(OH)D concentration* 
(adjusted) 
Age  
(years) 
r = 0.48 
p <0.001 
r = 0.48 
p <0.001 
BMI 
(kg/m2) 
r = 0.22 
p = 0.17 
r = 0.05 
p = 0.73 
Clinic SBP  
(mmHg) 
r = 0.35 
p <0.05 
r = 0.31 
p = 0.06 
Clinic DBP  
(mmHg) 
r = 0.20 
p = 0.21 
r = 0.03 
p = 0.82 
PWV  
(m/s) 
r = 0.47 
p<0.001 
r = 0.50 
p <0.001 
NO production 
(µmol.hr-1.kg-1) 
r = -0.44 
p <0.001 
r = -0.37 
p <0.001 
Plasma NO3-   
(µmol/L) 
r =0.04 
p =0.77 
r = 0.02 
p = 0.88 
Urinary NO3-  
(mmol/L) 
r = -0.04 
p =0.77 
r = -0.15 
p = 0.35 
Plasma NO2-   
(nmol/L) 
r =-0.10 
p =0.95 
r =0.06 
p =0.71 
ADMA  
(ng/ml) 
r =0.09 
p =0.55 
r =-0.02 
p =0.86 
PWV, Pulse Wave Velocity; ADMA, Asymmetric Dimethylarginine; NO, Nitric Oxide; BMI, Body Mass Index; FM, Fat 
Mass; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; NO3- , nitrate; NO2-, nitrite 
*This correlation was adjusted for age, vitamin D supplementation and physical activity level. Significant p values are 
shown in bold. r, Pearson’s coefficient of correlation.
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5.4.11 Correlation between NO production and PWV with anthropometric, blood pressure 
and biomarkers of vascular health. 
There were positive, significant correlations between PWV with BMI, FM and home SBP 
(Table 5.11). However, negative significant correlations were observed between NO 
production with home SBP and age. ADMA which showed an almost significant, inverse 
correlation with NO production (r=-0.30, p=0.05) (Figure 5.8 A). There was also a significant, 
negative correlation between NO production and PWV (r=-0.37, p=0.01) (Figure 5.8 B). 
Table 5. 11: Correlation between NO production and PWV with anthropometric 
variables, blood pressure and biomarkers of vascular health 
 
Variables PWV NO production 
Age 
(years) 
r=0.80 
p<0.01 
r=-0.43 
p<0.01 
BMI 
(kg/m2) 
r= 0.54 
p<0.01 
r=-0.23 
p=0.14 
FM 
(kg) 
r=0.47 
p<0.01 
r=-0.22 
p=0.15 
Home SBP 
(mmHg) 
r=0.65 
p<0.01 
r=-0.41 
p<0.01 
Home DBP 
(mmHg) 
r=0.28 
p=0.07 
r=-0.12 
p=0.45 
Plasma NO3ˉ 
(µmol/L) 
r=0.14 
p=0.36 
r=0.15 
p=0.35 
Urinary NO3ˉ 
(mmol/L) 
r=-0.27 
p=0.85 
r=0.14 
p=0.35 
Plasma NO2ˉ 
(nmol/L) 
r=0.13 
p=0.42 
r=0.05 
p=0.72 
ADMA 
(ng/ml) 
r=-0.03 
p=0.84 
r=-0.30 
p=0.05 
PWV, Pulse Wave Velocity; ADMA, Asymmetric Dimethylarginine; NO, Nitric Oxide; BMI, Body Mass Index; FM, Fat 
Mass; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; NO3- , nitrate; NO2-, nitrite. Significant p values are 
shown in bold. r, Pearson’s coefficient of correlation. 
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Figure 5. 8: Regression analysis of (A) nitric oxide (NO) production with asymmetric 
dimethylarginine (ADMA) and (B) NO production with pulse wave velocity (PWV). 
r, Pearson’s coefficient of correlation. 
 
 
 
(A) NO production vs ADMA 
 
(B) NO production and PWV 
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 5.5 Discussion 
5.5.1 Summary of findings 
This study tested the hypothesis that ageing reduces whole-body NO production in normal and 
overweight, male and female participants. Additionally, we hypothesised that vitamin D may 
modify this association. We observed that NO production was significantly higher in the 
younger participants but no significant association was found with vitamin D concentrations.  
PWV was higher in the older group. There were no differences in whole-body NO production, 
nitrate, nitrite and ADMA for participants with or without adequate vitamin D status (25(OH)D 
concentration). However, there were positive, significant correlations between NO production 
and PWV with age, BMI, FM and SBP. These correlations were not explained by differences 
in 25(OH)D concentrations in either age groups. 
5.5.2 Ageing, NO production and vascular health 
NO is important to maintain vascular homeostasis, and lower production of NO has been 
associated with endothelial dysfunction. For example, in a study in a group of normal healthy 
volunteers aged between 20 and 79 years, PWV were significantly increased with age (Parikh 
et al., 2016). This was in line with a cross sectional study from a Swiss population of older 
adults that showed a significant association between age and arterial stiffness measured 
oscillometrically by pulse wave analysis (Endes et al., 2016). A study in Portugal observed a 
strong association between ‘large artery damage’ (defined as PWV >10 m/s) and older age in a 
cohort aged 60 to 70 years; 42% of these individuals had large artery damage (Cunha et al., 
2015). Lower NO production may explain these age-related functional and structural vascular 
modifications (El Assar et al., 2012). Several factors could contribute to the decrease in NO 
production and availability such as an increased oxidative stress, reduced availability of 
essential cofactors for eNOS, inhibition of eNOS by ADMA or accelerated  NO degradation 
(Borsa et al., 2012; Gradinaru et al., 2015). 
 
This is the first study in humans that quantified the impact of ageing on whole-body NO 
production measured using stable isotopic tracers. The rate of NO production in younger 
participants (0.61±0.3 µmol.hr-1.kg-1) was comparable with the aggregate rate of NO production 
in 18 healthy normal young people (mean age 34 ±13 years) subjects reported in previous 
studies using stable isotope tracers (0.63 ± 0.30 µmol.hr-1.kg-1) (Siervo et al., 2011b). This 
provides further support for a reference normal range of NO production in healthy young 
individuals measured in independent studies and using different isotopic methods. Forte et al 
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(1997) reported significantly higher NO production measured by stable isotopes in hypertensive 
women compared with men (Forte et al., 1997) but we found no evidence of a gender difference 
in whole-body NO production in this study. 
  
Estimates of whole-body NO production in this study was similar to NO production rates for 
healthy middle-aged and older obese individuals measured using the same ONT method several 
years ago. The estimation of NO production from different studies was summarised in Figure 
5.9. 
 
Figure 5. 9: Estimation of NO production rates from different studies using ONT 
method 
Data obtained from :(a):(Siervo et al., 2011c); (b)(Siervo et al., 2011b), (c) PhD thesis, Virginia Tomatis, 
Cambridge University 2015 (Personal communication from Dr Siervo). 
Mean age for study (a): Not reported, (b): Healthy 1 = 34 ±13 years; Healthy 2 = 27 ±11 years; Obese No MS = 
48 ±10 years (c): PCOS = 28 ±10 years 
MS, Metabolic syndrome; PCOS, Polycystic ovary syndrome 
 
 
This is the first study to report an inverse association between whole-body NO production 
(measured using stable isotopes) and PWV, which may provide further support for the 
hypothesis that lower NO is associated with structural modifications of the arterial wall. Whole-
body NO production was also inversely associated with SBP (measured in the clinic and at 
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home) which confirmed the results from two other studies using stable isotope tracers to 
measure NO production (Forte et al., 1997; Siervo et al., 2011b). Plasma ADMA concentrations 
showed a tendency to be associated with NO production in this study which confirmed the 
results of a previous study employing the same ONT method. These results may be explained 
by the characteristics of the population (overall healthy) and the associations with NO 
production should be tested in conditions with known increase in ADMA concentrations such 
as chronic kidney disease or heart failure. There was a non-significant trend for higher ADMA 
concentrations between the two age groups, which could be due to both groups being relatively 
healthy phenotype. However, a study by (Kielstein et al., 2003) revealed that plasma ADMA 
concentration (measured with high-performance liquid chromatography (HPLC)) was 
significantly higher (p<0.05) in older (2.77±0.20 μmol/L) than in young healthy subjects 
(1.30±0.11 μmol/L). The latter finding is in agreement with the significant positive correlation 
(r=0.54, p<0.0001) between age and ADMA observed in a random population sample in Tokyo 
(Miyazaki et al., 1999). 
5.5.3 Impact of vitamin D, NO production and vascular health 
Higher serum 25(OH)D concentration were found to be associated with lower NO production 
and greater systolic BP and PWV. In particular, those with 25(OH)D concentration ≥30 nmol/L 
have higher PWV compared with participants with lower 25(OH)D concentration. These results 
are contrary to our hypotheses and also to what reported in the previous cross sectional study 
reported in Chapter 4, where PWV was significantly higher in those with 25(OH)D less than 
30 nmol/L. Participants with an lower 25(OH)D concentrations were characterised by a slightly 
higher NO production (0.52 µmol.hr-1.kg-1) compared with participants with higher 25(OH)D 
concentrations (0.46 µmol.hr-1.kg-1). These differences and associations were maintained after 
the exclusion of participants taking vitamin D supplements or after adjustment of the analysis 
for vitamin D supplementation, age or physical activity levels. Similarly, ADMA 
concentrations were found to be lower in the insufficient compared to the higher 25(OH)D 
concentrations (73.8 vs 91.6 ng/ml). However, a recent cross sectional study conducted on 269 
men and 382 women Korean elderly population demonstrated that the mean ADMA 
concentration was significantly higher in the insufficient 25(OH)D group (17.92 ng/ml, 
p=0.001) compared with the sufficient 25(OH)D group (15.87 ng/ml) (Choi et al., 2017). In 
this study, they stratified the patients by 25(OH)D concentration into three groups according to 
serum 25(OH)D: sufficient (≥30 ng/mL, n=25), insufficient (10-<30 ng/mL, n=516), and 
deficient (<10 ng/mL, n=110). The measurement of ADMA concentration was assayed by 
HPLC. The mean ADMA concentration was significantly higher in the insufficient 25(OH)D 
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concentration (0.665 μmol/L, p=0.001) and the deficient 25(OH)D concentration (0.734 
μmol/L, p<0.001) compared with the sufficient 25(OH)D concentration (0.589 μmol/L). 
 
The hypotheses on a positive association between 25(OH)D concentration, NO production and 
measures of vascular health were mechanistically based on the results from animal or human 
studies linking multiple possible pathways through which 25(OH)D concentration potentially 
influence NO availability. For example, in diabetic mice lacking VDR study, vitamin D 
suppressed renin-angiotensin system (RAS) activity by suppression of renin gene transcription 
(Deb et al., 2009), which leads to reduced angiotensin II and also theoretically to greater NO 
production, less NO destruction, and increased NO availability. Similarly, a study done in mice 
with functionally inactive VDR reported that serum 25(OH)D concentration enhances the 
production of enzyme eNOS in the endothelium and enhanced NO production (Andrukhova et 
al., 2014). A study in 419 elderly in Ankara, Turkey by (Kutlay et al., 2014) showed an inverse 
association between PWV and 25(OH)D concentration. In their study, three cut of points for 
25(OH)D concentration were used [1st (< 20 ng/ml), 2nd (20–30 ng/ml) and 3rd (> 30 ng/ml)], 
and there were significant differences of 25(OH)D concentration between all the groups. 
Surprisingly, this study seems to have an opposite pattern of association with both NO 
production, blood pressure and PWV, which may suggest the existence of possible 
compensatory mechanisms that may sense the decrease in 25(OH)D concentration and 
potentially trigger positive feedback signals to enhance NO production. However, this 
alternative hypothesis remains highly speculative and needs to be tested in cellular and animal 
studies.  
 
In addition, no significant correlations were observed between serum 25(OH)D concentration 
and NO metabolites (plasma NO3ˉ (r=0.04; p=0.77), urinary NO3ˉ (r=-0.44; p=0.77), and 
plasma NO2ˉ (r=-0.10; p=0.95), even after adjustment for vitamin D supplementation and 
physical activity level. Similarly, a previous study conducted in  66 obese Caucasian children 
aged 7 to 14 years demonstrated no significant association of 25(OH)D concentration with 
plasma nitrite + nitrate and urinary nitrate concentrations (Codoner-Franch et al., 2012).  In this 
study, serum 25(OH)D concentration was quantified by electrochemiluminescence 
immunoassays, and NO3ˉ levels in plasma and urine were measured by spectrophotometrically 
using the Griess reaction. In contrast,  a significant association between 25(OH)D concentration 
with NO metabolites (NO3ˉ and NO2ˉ) was found in a cross sectional study in obese African-
Americans (Valiña-Tóth et al., 2012). In the study, serum 25(OH)D concentration was 
determined using liquid chromatography-tandem spectrometry, and NO3ˉ and NO2ˉ was 
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determined using Cayman's Nitrate/Nitrite colorimetric assay kit. Therefore, these discrepancy 
results between studies may be related to the study participants characteristic, method of 
measuring serum 25(OH)D concentration and NO metabolites. 
5.5.4 BP measurements and nitrite as a biomarker of NO production 
This study demonstrated a significant difference between the measurements of BP recorded at 
the clinic and at home. The measurement of SBP was found to be higher when measured at the 
clinic, especially in the older group. The difference may be simply explained by the 
psychological and emotional responses triggered by the measurement of BP in a clinical 
environment which defines the characteristics of the white-coat syndrome. BP methods that can 
minimise these effects are important from a diagnostic perspective and home monitoring of BP 
has been currently suggested as a valid and sensitive method to diagnose and monitor changes 
in BP (Franklin et al., 2016; Mancia et al., 2017). The measurement of BP proposed as part of 
the ONT protocol was easy to conduct and the lower BP readings were probably explained by 
the more comfortable and relaxed conditions experienced by each participant. A similar drop 
in BP readings was reported in a study conducted in 45 elderly patients (≥70 years), which 
revealed a significant difference between the BP measurements during hospital admission and 
home follow up (systolic from 133.5 ± 15.6 to 126.2 ± 14.4 mmHg, P = .008; diastolic from 
71.0 ± 9.0 to 68.3 ± 8.6 mmHg, P = .046) (Cappelleri, 2017). For our perspective, the significant 
association of the home BP readings with NO production and other measurements of vascular 
health provide further support on the feasibility of this BP method in future studies using the 
ONT method for the assessment of NO production.  
 
NO2
ˉ is widely accepted as a surrogate marker for NO, and has been shown to be a circulating 
storage pool for NO (Calvert and Lefer, 2010).  In addition, NO2
ˉ can be rapidly converted to 
NO under ischemic conditions (Sindler et al., 2014). However, it is not clear whether NO2
ˉ 
reflect regional endothelial function as assessed by brachial artery FMD. A study by Casey et 
al, 2007 demonstrates that systemic basal plasma levels of NO2
ˉ correlate with brachial FMD 
in young adults. This relationship suggests that brachial FMD and/or plasma NO2
ˉ may be used 
as markers of peripheral endothelial function in the young population (Casey et al., 2007).  In 
contrast, ADMA is an endogenous competitive inhibitor for the NO synthesis (Duygu et al., 
2006). Evidence indicates the inverse relationship between ADMA and NO2ˉ/NO3ˉ (Cevik et 
al., 2006; Eleuterio et al., 2013). This in in line with a study by (Haberka et al., 2009) that 
revealed the inversed association between ADMA with FMD (0.387; p = 0.012). 
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However, in this study, no association was found between NO2ˉ with biomarkers of vascular 
health, which may be due to several factors such as small sample size, general characteristics 
of the participants and methods of biomarkers measurement. The lack of associations in this 
study leaves room for further work and research regarding the relationship between NO 
metabolites and vascular health. 
5.5.5 Strength and limitations 
To my knowledge, this is the largest study using stable isotopes to investigate associations 
between vitamin D, ageing and whole body NO production. The compliance of participants 
with this study protocol was excellent and all participants completed the study. The saliva ONT 
method was well tolerated, feasible and, with further validation studies in clinically relevant 
populations, could potentially become a reference method for the quantitative assessment of 
NO production in humans. 
 
This study has a few limitations. The cross-sectional design is unable to provide information 
on the causality and direction of the associations between ageing, vitamin D status and NO 
production. Despite being the biggest study of its kind, the study had also a limited sample size 
(40 participants) and recruited a selected group of 20 healthy younger and 20 older participants. 
Therefore, the representativeness of the findings might be limited which may also be influenced 
by heterogeneous ethnic background of the participants. The limited sample size prevented 
from the exploration of a full interaction analysis between age with either gender or vitamin D 
levels which needs to be explored in future studies. In addition, the small number of participants 
with lower vitamin D status did not allow for a more detailed analysis on the interaction between 
age and vitamin D status. 
 
The number of participants with insufficient vitamin D status (assessed by 25(OH)D 
concentration) was small as the majority of the participants (85%) were in the higher 25(OH)D 
groups, which might potentially have contributed to the unexpected associations found in the 
study. Measurements of 25(OH)D concentrations in this study were performed using 
immunoassays. Unlike chromatographic methods, immunoassays do not measure vitamin D3 
and vitamin D2 independently, and this is a well-recognised limitation of immunoassays. The 
importance of being able to quantify both metabolites of vitamin D independently is becoming 
increasingly important with the evidence that vitamin D3 is more biologically active than 
vitamin D2 (Tripkovic et al., 2012).  
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The usage of vitamin D supplementation might have contributed to the confounding factor in 
this study as most of the older people in this study consumed vitamin D supplementation (60%), 
compared to only 30% in the younger group. This explained the discrepancy of 25(OH)D status 
between the two age groups. However, the exclusion of subjects taking vitamin D supplements 
did not modify the results. The study was conducted during the summer season and we can 
therefore disregard the seasonal variability in vitamin D exposure as a confounding factor. 
5.5.6 Conclusions 
In conclusion, we found that whole-body NO production is significantly lower in older people. 
In addition, the associations between NO production and systolic BP and PWV provide further 
support for the feasibility and sensitivity of the ONT stable isotopic method for the assessment 
of whole-body NO production in humans.  Unexpectedly, this study found significant lower 
NO production in participants with higher serum 25(OH)D concentrations. These results are 
contrary to the original hypotheses stipulated in this project and therefore further studies are 
needed to confirm these findings and to clarify the pathophysiological mechanisms underlying 
these associations. 
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Chapter 6: General Discussion and Conclusions 
 
6.1 Overview of the PhD work 
A low vitamin D status is a common public health problem worldwide and it is associated with 
both musculoskeletal and non-musculoskeletal effects (Palacios and Gonzalez, 2014). 
However, the association between vitamin D deficiency and non-musculoskeletal conditions is 
not adequately established and the effects of vitamin D supplementation remain debatable 
(Hossein-nezhad and Holick, 2013). Vitamin D influences vascular and metabolic processes 
including endothelial function (EF), a surrogate marker and predictor of cardiovascular disease 
risk. The evidence for a causal relationship between vitamin D and cardiovascular risk is 
inconsistent and inconclusive, and these discrepant results have raised further questions about 
the relationship between serum 25(OH)D concentration (the accepted marker of vitamin D 
status) and EF. 
Vitamin D has been suggested to have potential role in preventing CVD and type 2 diabetes 
mellitus (Danik and Manson, 2012). The individual RCTs have been designed following the 
report of significant associations between low vitamin D status and cardiovascular risk in cohort 
studies (Martins et al., 2007; Dobnig et al., 2008; Hintzpeter et al., 2008; Hypponen et al., 
2008) and mechanistic cellular and animal studies reporting a role of vitamin D in the regulation 
of NO production. However, the results of individual studies have been inconsistent and meta-
analysis of RCTs did not support the beneficial effects of vitamin D supplementation on CVD 
risk (Wang et al., 2010; Ford et al., 2014). Similarly, systematic review and meta-analysis 
evaluating the effects of vitamin D supplementation and endothelial function in RCTs did not 
support a protective role (Alyami et al., 2014; Hussin et al., 2017).  
The results from two independent observational studies carried out as part of this PhD project 
showed that serum 25(OH)D concentration had weak and inconsistent associations with 
physiological and biochemical markers of EF (i.e. PWV and ADMA). Perhaps, more 
importantly, the results presented in Chapter 5 show an inverse association between vitamin D 
status (serum 25(OH)D concentration) and whole-body NO production. While these cross-
sectional studies have significant limitations (discussed below), they have used a 
comprehensive panel of methods, including stable isotopes, to provide reliable measurements 
of EF and NO availability.  
This PhD project has investigated the association between vitamin D intake and status, EF and 
biomarkers of NO availability. First, a systematic review and meta-analysis was conducted to 
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evaluate the effects of vitamin D supplementation on markers of EF. A laboratory experiment 
also was conducted to improve the measurement of NO2ˉ and NO3ˉ using ozone-based 
chemiluminescence and to evaluate the agreement between circulating 25(OH)D concentrations 
measured in serum and using dry blood spots. Two independent cross-sectional studies were 
conducted to investigate whether serum 25(OH)D concentrations significantly associated with 
physiological and biochemical markers of EF in post-menopausal overweight and obese women 
(study 1) and to evaluate the association between age and whole body NO production measured 
using stable isotope tracers in healthy young and old individuals (study 2).  
6.1.1 Effects of vitamin D supplementation on Endothelial Function 
The first phase of the PhD included a systematic review and meta-analyses of RCT to assess 
the effects of vitamin D supplementation and serum 25(OH)D concentrations on EF (discussed 
in Chapter 2). The analyses also examined whether the effect size was modified by health status, 
study duration, dose, route of vitamin D administration, vitamin D status (baseline and post-
intervention), BMI, age and type of vitamin D (vitamin D2 or vitamin D3).  Overall, there was 
no evidence for an effect of vitamin D on EF. However, subgroup analysis showed a significant 
improvement of EF in diabetic subjects and in individuals with a higher BMI following vitamin 
D supplementation (daily doses varying from 1000 IU/day to 5000 IU/day). The significant 
benefit of vitamin D supplementation in diabetics and in those with higher BMI may indicate a 
role for the insulin pathway in modulating the effects of vitamin D on vascular function. 
6.1.2 Methods for measuring biomarkers of endothelial function and serum 25(OH)D 
concentration 
A summary of the methods and techniques for the measurement of NO production have been 
provided in Chapter 3. In this chapter, a detailed description of the different types of laboratory 
experiments has been provided for the measurement of NO2ˉ and NO3ˉ in plasma and urine 
samples. In particular, studies were conducted to investigate whether different deproteination 
procedures of plasma samples (using ethanol or methanol) influenced the measurement of 
plasma NO2ˉ and NO3ˉ concentration using ozone-based chemiluminescence. The finding 
showed that two deproteination methods had a negligible, non-significant influence on the 
measurement of NO3ˉ concentration in plasma samples. However, the procedure using 
methanol resulted in significantly higher NO2ˉ concentrations compared with use of ethanol. In 
Chapter 3, the agreement between two methods (conventional method using 
chemiluminescence immunoassay (CLIA) on liquid serum collected by venepuncture and dry 
blood spot (DBS) method) were investigated for the analysis of serum 25(OH)D concentrations. 
 181 
 
The collection and analysis of DBS represent a simple and efficient method that may facilitate 
the measurement of serum 25(OH)D concentrations in large population based studies. Several 
studies have reported significant agreement between serum 25(OH)D concentrations measured 
by the conventional method and DBS (Heath et al., 2014; Sakhi et al., 2015; Hoeller et al., 
2016). However, in this study, DBS has been found to be significantly over-estimate the serum 
25(OH)D concentration compared with the conventional method. The 25(OH)D concentration 
measured by DBS was found to be more than two-folds, which is doubtful. As these unusually 
high 25(OH)D result is atypical for North-East women (SACN, 2016), this study did not 
recommend the usage of DBS and it seems that the results from CLIA estimations are more 
precise. However, further validation studies are needed to establish the agreement between 
these two methods.  
The measurements of serum 25(OH)D concentration substantially varies depending on the 
methods of measurements and type of assay. There are two major types of assay, i.e. binding 
assay (CLIA, RIA and binding protein assay), which use a kit or an automated clinical 
chemistry platform, and chemical assay (HPLC and LC-MS/MS) and this method is able to 
separate the estimation of vitamin D3 and D2 concentrations (SACN, 2016). Significant 
differences in the results of 25(OH)D were observed among the various assays, and 
interpretation of the data from the study was also complicated by the fact that measurement of 
serum 25(OH)D concentration is affected by inter-assay differences. Standardization and 
harmonization of 25(OH)D measurements are therefore urgently needed. 
6.1.3 Association of serum 25(OH)D with physiological and biochemical markers of 
endothelial function 
This cross sectional study investigated the association of serum 25(OH)D concentration with 
physiological and biochemical markers of EF in overweight and obese post-menopausal 
women. Overall, the results showed no evidence for a significant association between serum 
25(OH)D concentration with biomarkers of endothelial function, blood pressure, age and BMI 
(discussed in Chapter 4). However, PWV was found to be higher in individuals with lower 
serum 25(OH)D concentration. In addition, ADMA concentration was higher in the lower 
serum 25(OH)D concentration group, but this difference was not quite statistically significant 
(p=0.07). Overall, these results provided a weak support for the hypothesis that serum 25(OH)D 
concentration is associated with vascular EF among overweight and obese, post-menopausal 
women. The initial plans for this study also included a comparison between two different 
methods of estimating 25(OH)D concentration using 1) the conventional method (based on 
venepuncture) and 2) a more novel method based on analysis of dry blood spots (DBS). 
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However, because the analyses of DBS were doubtful (see Chapter 3) in Chapter 4, only results 
from the conventional method has been used. 
This provided the basis for a more detailed study which was designed to explore the association 
between whole-body NO production measured by a non-invasive stable isotopic study and to 
evaluate the associations with PWV and ADMA concentrations in a population of younger and 
older healthy individuals (reported in Chapter 5 – see below).  
6.1.4 Ageing, NO production and serum 25(OH)D  
A second cross sectional study was performed on 40 healthy, normal weight and overweight 
males and females within two age brackets (20-50y, 50 - 65y) (discussed in Chapter 5). This 
final phase of the PhD project was done to investigate the associations between whole-body 
NO with PWV, ADMA, serum 25(OH)D and to investigate whether these associations are 
modified by age. The results revealed that whole-body NO production decreases with age and 
was also significantly associated with PWV and systolic blood pressure. Surprisingly, this study 
showed significant inverse associations between serum 25(OH)D concentrations and whole-
body NO production, PWV and systolic blood pressure. The results from this study provide no 
support for our primary hypothesis of a direct association between serum 25(OH)D 
concentration and NO production and call for further investigations to confirm these results in 
populations with larger samples size and more detailed assessment of cardiovascular 
phenotypes. Additional studies are therefore needed to clarify the supposed causal relationship 
between vitamin D and NO. 
6.2 Defining an appropriate 25(OH)D concentration 
There are ongoing discussions and debates concerning the serum 25(OH)D concentration cut 
off levels for defining vitamin D sufficiency/insufficiency. IOM concluded that the RDA for 
those aged 1–70 years were 600 IU/d whilst for those aged 71 years and older, the RDA is 
800IU/d. These were the intakes considered necessary to ensure that the corresponding serum 
25(OH)D concentration was at least 20 ng/ml (50 nmol/liter) which is the concentration 
required for good bone health in 97.5% of the population (Ross et al., 2011). On this basis, 
individuals with the serum 25(OH)D concentration <30 nmol/L are classified as deficient, and 
those with serum 25(OH)D concentration of 50 nmol/L and above are classified as sufficient. 
However, many researchers and expert groups including the Endocrine Society Task Force on 
Vitamin D and the International Osteoporosis Foundation do not accept this cut off point and 
higher intakes of vitamin D, between 800 to 2000 IU per day, achieved through supplementation 
or dietary intake have been recommended (Buck Institute for Research on Aging, 2016). The 
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Endocrine Society Task Force concluded that those with a cut-off level of 50nmol/L are 
identified as vitamin D deficient, and to maximise the effect of vitamin D on calcium, bone and 
muscle metabolism, serum 25(OH)D concentration ‘should exceed 75 nmol/L’ (Holick, 2011).  
SACN (2016) has established a RNI for vitamin D of 10 µg/day (with assumption of minimal 
sunshine exposure) which is based on the conclusion that serum 25(OH)D concentration below 
25 nmol/L lead to increased risk of poor musculoskeletal health (SACN, 2016). Most authorities 
base their cut off concentration for 25(OH)D on what is considered as the adequate 
concentration for protecting musculoskeletal health. SACN (2016) could not draw any 
inference about the relationship between serum 25(OH)D concentration and risk of developing 
CVD.  
Given the uncertainties about the appropriate cut off points for 25(OH)D concentration, 30 
nmol/L as the cut off point for vitamin D adequacy has been used in this cross sectional studies. 
The rationale behind this is that a serum concentration of 30 nmol/L was considered to be 
consistent with the lower end of requirements as reported by IOM (Ross et al., 2011). 
6.3 Strengths and limitations of the PhD work 
This PhD study has investigated for the first time, the association between whole-body NO 
production measured using a non-invasive stable isotopic method with PWV and ADMA 
concentrations. The measurements of NO2ˉ and NO3ˉ in this study used chemiluminescence, 
which is considered as the reference method of measuring of NO2ˉ and NO3ˉ in plasma 
(Pelletier et al., 2006). The measurement of whole body NO production was done using GCMS, 
which has been reported to be accurate, specific and highly sensitive for the determination of 
NO synthesis (Tsikas et al., 2000). 
However, there are some limitations associated with the study which need to be addressed in 
future studies. The two studies done in this PhD were designed as cross sectional studies based 
on recruitment of convenient samples, thereby making it difficult to determine the causal 
relationships. Furthermore, in the second cross sectional study, apart from the small sample 
size, the participants were recruited without the exclusion of vitamin D supplementation, which 
might have been a confounding of the associations between serum 25(OH)D concentrations and 
health outcomes. The participants in the studies were overall healthy and did not represent the 
total population in the UK. Lastly, the cross sectional studies in this PhD used single 
measurements of serum 25(OH)D concentrations as indicators of vitamin D status; thus this 
may not accurately reflect long term vitamin D status.  
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6.4 Conclusions and Future Work 
The objectives of the PhD programme have been achieved successfully by conducting a series 
of reviews, laboratory analyses and human studies to investigate whether serum 25(OH)D 
concentration is associated with EF and in vivo whole-body NO production. The results 
generated in this thesis have highlighted several further questions about the relationship of 
serum 25(OH)D concentration with EF in humans. New hypotheses to be explored in future 
work are detailed below. 
In the first cross sectional study, the target population was on overweight and obese 
postmenopausal women aged between 50 to 70 years old. The hypothesis that higher serum 
25(OH)D concentration may improve PWV and ADMA measurement remains to be tested in 
prospective studies. Such studies would benefit from recruiting a similar population group 
(overweight and obese postmenopausal women aged between 50 to 70 years old) with a wide 
range of 25(OH)D concentration in which those with low vitamin D status are well-matched in 
all other respects with those with higher vitamin D status. In the second cross sectional study, 
for the first time, the effects of ageing on whole body NO production using stable isotopes was 
investigated. This study revealed a surprising inverse association between serum 25(OH)D 
concentration and NO production. 
The results generated in this thesis have highlighted several potential of synergistic interaction 
of serum 25(OH)D concentration and EF that may have implications for future research. For 
example, there was evidence of positive effects of vitamin D supplementation in EF for obese 
individuals and in diabetic patients. Moreover, the first cross sectional study in this PhD 
revealed increased PWV and higher concentrations of ADMA in those with vitamin D 
concentrations < 30 nmol/L. Even though the second study of this PhD did not find a significant 
association of vitamin D with NO production, NO production was found to be significantly 
lower in older individuals and was significantly associated with systolic blood pressure and 
PWV. 
The public health implications in this study is minimal considering the pilot nature of the 
studies. However, the study has provided the basis for the condition of more detailed studies, 
based on some interesting findings observed in this study. The next step is to investigate the 
effects of serum 25(OH)D concentration on EF and whole body NO production in RCTs or in 
prospective studies. Longer duration of studies, using various doses of vitamin D, involving 
various population and age groups, using different techniques of EF measurements are the 
criteria that should be considered in planning the future studies. Furthermore, targeting 
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population groups with evidence of altered glucose homeostasis, e.g. those with diabetes may 
be particularly informative since my systematic review and meta-analysis suggested that 
vitamin D supplementation may be beneficial in this population group.  
In addition, there is a scope for further in vivo and in vitro in human and animal studies which 
investigate the mechanism through which 1,25(OH)2D3 may regulate EF. As 1,25(OH)2D3 
involved in the  upregulation of VEGF and its receptors in the endothelial cells (Zhong et al., 
2014), an in vivo study on the mechanism of  1,25(OH)2D3 in preventing hypoxia or oxidative 
stress condition might be worth explored in details. In addition, an animal study may be 
conducted to understand the mechanism of which 1,25(OH)2D3 involved in the alteration of 
basal tone of the endothelium, which normalised blood pressure, cardiac systolic function and 
renin-aldosterone level as reported by (Zhou et al., 2008). Such studies should focus on effects 
which are mediated by NO.  
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Appendix 2 1: Systematic review and meta-analysis published in the European Journal 
of Nutrition 
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Appendix 2. 2: BMI did not modify the association between type 2 diabetes and EF 
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Appendix 2 3: Studies in the review with different assays to measure 25-OHD concentrations 
Author Compliance Assay name, company Vit D/day 
(IU) 
Breslavsky et al. 2013 (Breslavsky et al., 2013) Not reported Not stated 1000 
Gepner et al. 2012 (Gepner et al., 2012) Not reported Not stated 2500 
Harris et al. 2011 (Harris et al., 2011a) Not reported Immunodiagnostic systems, Fountain Hills, AZ 2000 
Hewitt et al. 2013 (Hewitt et al., 2013) 100% compliance DiaSorin Inc, Stillwater, MN 7142 
Larsen et al. 2012 (Larsen et al., 2012) 99% compliance Liaison; DiaSorin, Saluggia, Italy 3000 
Longenecker et al. 2012(Longenecker et al., 2012) 99% compliance Immunodiagnostic Systems, Fountain Hills, AZ, USA 4000 
Marckmann et al. 2012 (Marckmann et al., 2012) 100% compliance LCMSMS 1, Applied Biosystems, Dionex, Sunnyvale, 
California, US 
5714 
Sokol et al. 2012 (Sokol et al., 2012) 99% compliance Quest Diagnostics, Teterboro, NJ, USA 7142 
Stricker et al. 2012 (Stricker et al., 2012) 100% compliance DiaSorin, Saluggia, Italy 3571 
Sugden et al. 2008 (Sugden et al., 2008) 100% compliance IDS, Tyne & Wear, UK 1785 
Witham et al. 2010 (Witham et al., 2010) 100% compliance IDS, Boldon, UK G1:892 
G2:1785 
Witham et al. 2012 (Witham et al., 2012) 100% compliance DiaSorin Ltd, Bracknell, UK 892 
Witham et al. 2013 (Beveridge and Witham, 2013) 100% compliance IDS Ltd UK 1785 
Witham et al. 2013 (Witham et al., 2013b) 100% compliance IDS, Bachem UK, Merseyside, UK 1785 
Witham et al.2013 (Witham et al., 2013c) 99% compliance Not stated 1190 
Yiu et al. 2012 (Yiu et al., 2013) Not reported I.D.S, (company not stated) 5000 
Dalan et al. 2016 (Dalan et al., 2016a) 94% compliance Electro-chemiluminescence immunoassay (ECLIA) 4000 
Pilz et al 2015 (Pilz et al., 2015) Not reported Chemiluminescence assay (IDS-iSYS 25-
hydroxyvitamin D assay; Immunodiagnostic Systems 
Ltd., Boldon, UK) 
2800 
Witham et al 2015 (Witham et al., 2015) 100% Immunodiagnostic systems (IDS) and 
radioimmunoassay (RIA) 
1666 
Borgi et al 2016 (Borgi et al., 2017) Not reported Radioimmunoassay (RIA),  Diasorin Corporation 7142 
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Appendix 3. 1: Performing ADMA analysis  
The measurement of ADMA in this PhD project was done using a commercial kit (CUSABIO 
ELISA kit CSB-E09298h). The following components were required to perform the 
analyses:1) Standard; 2) Biotin antibody; 3) HRP-avidin; 4) Biotin antibody Diluent; 5) HRP 
avidin diluent; 6) Sample diluent; 7) Wash buffer 8) TMB substrate and 9) Stop solution. 
Reagent preparation 
The plasma samples were collected in EDTA vacutainer tube. All reagents were brought to the 
room temperature (18 – 25ºc). The reagents, samples and standards were prepared as instructed; 
1) Fresh standard was prepared for wash assay and used within 4 hours after the 
preparation. 
2) Biotin antibody was centrifuged before opening. Biotin antibody requires 100-fold 
dilution (10 µl of Biotin-antibody + 990 µl of Biotin-antibody diluent). 
3) HRP –avidin was centrifuged before opening. HRP –avidin requires a 100-fold dilution 
((10 µl of HRP –avidin + 990 µl of HRP –avidin diluent). 
4) Twenty ml of Wash Buffer was diluted into deionized water to prepare 500 ml of wash 
buffer. 
5) Standard vial was centrifuged at 6000-10000rpm for 30s. Standard was then 
reconstituted with 1.0 ml of sample diluent. This reconstitution produced a stocl 
solution of 500 ng/ml. 
250 µl of sample diluent were pipetted into each tube (S0-S6) (Figure 3.1A). The stock 
solution was used to produces a 2-fold dilution series. Each tube was mixed thoroughly 
before the next transfer. The undiluted standard served as the high standard (500ng/ml). 
Sample diluent served as the zero standard (0ng/ml) 
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Figure 3.1A: The dilution procedures for ADMA standard 
Assay procedure 
In this procedure, all samples and standards were assayed in duplicate. A plate map was used 
to record the location of standards and samples. 
The following steps were followed to perform the assay: 
1) 100 μL of standard and sample were added per well. The plate was covered with 
adhesive strip and incubated for 2 hours at 37ºC.  
2) The liquid in each well were then removed, but not washed. 
3) 100 μL of Biotin-antibody were added to each well. The plate was covered with a new 
adhesive strip and incubated for 1 hour at 37ºC. 
4) Each well was then aspirated and washed. This process was repeated for two times for 
a total of three washes. Each well was filled with wash buffer (200 μL) using manifold 
dispenser and let it stand for 2 minutes. After the last wash, any remaining wash buffer 
was removed by aspiring or decanting. The plate was inverted and blotted against a 
clean paper towels. 
5) 100 μL of HRP-avidin was added to each well. The plate was covered with a new 
adhesive strip and incubated for 1 hour at 37ºC. 
6) The aspiration/wash process in step 4 was repeated. 
7) 90 μL of TMB Substrate was added to each well and incubated for 15 – 30 minutes at 
37ºC and protected from light. 
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8) 50 μL of stop solution was added to each well and the plate was gently tapped to ensure 
thoroughly mixed. 
9) The optical density in each well were determined within 5 minutes using a microplate 
reader set to 450 nm. 
 
Figure 3.1B: Standard curve ADMA 
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Appendix 3. 2: Performing 3NT analysis 
The measurement of 3-NT in this PhD project was done using a commercial kit (ABCAM 
ab113848). The following components were required to perform the analyses:1) 3NT BSA 
standard; 2) Extraction buffer; 3) Wash buffer; 4) Blocking solution; 5) HRP conjugated 3NT 
detector antibody and 6) Development solution 
Reagent preparation 
All reagents were brought to the room temperature (18 – 25ºc). The reagents, samples and 
standards were prepared as instructed; 
1) Wash buffer was prepared by adding 25mL 20X Wash Buffer to 475 Nano pure water. 
2) 2X Incubation Buffer were prepared by adding 10mL 10X Blocking Buffer to 40mL 
1X Wash Buffer. 
3) 2 X HRP-Detector antibodies were prepared immediately before use. 12µL 1000X 
Detector. 
4) By pipetting, the standard was reconstituted with 1 mL 1X Wash Buffer. It was then 
allowed to sit for 10 minutes before the pipetting were repeated to ensure thorough 
reconstitution. 
Standard preparation 
To create a 3-fold standard curve, seven tubes were labelled with #1-7. 600 µL from stock was 
transferred to tube #1. 600 µL of 1X Wash buffer were then added to each of tube #2 through 
#7. 300 µL from stock was transferred from tube #1 to tube #2 and were mixed thoroughly. 
300 µL was transferred from #2 to #3 using a fresh pipette tip and were mixed thoroughly. The 
procedures were repeated for tubes #4 through #7. 1X Wash buffer was used as the zero 
standard tube #8 (Figure 3.2A). 
 
Figure 3.2A: Dilution procedures for Nitrotyrosine standard 
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Assay procedure 
In this procedure, all samples and standards were assayed in duplicate. A plate map was used 
to record the location of standards and samples. 
The following steps were followed to perform the assay: 
1. 50 μL of each diluted standards was added to each of the sample wells in the plate. 
2.  50 μL of each samples were pipetted into individual wells. 
3. 50 μL of 2X HRP detector Antibody was pipetted into each well of the plate (for both 
standard and test samples) 
4. The plate was covered/sealed and incubated for 2 hours in room temperature, on a plate 
shaker at 300rpm. 
5. After the required incubation time, the plate was aspirated and washed for four times by 
using 300 μL 1X Wash Buffer into each well. The plate was inverted and blotted against clean 
paper towels to remove excess liquid. 
6. 100 μL HRP development Solution was pipetted to each empty well and the blue colour 
development was immediately recorded with time in the microplate reader with the following 
settings: 
Mode: Kinetic 
Wavelength: 600 nm 
Time: 15 min 
Interval: 20 sec – 1 min 
Shaking: Shake between readings 
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Figure 3.2B: Standard curve 3NT 
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Appendix 3. 3: Performing VEGF analysis 
The measurement of VEGF in this PhD project was done using a commercial kit from R&D 
Systems™ Quantikine® ELISA to measure VEGF. 
Reagent preparation  
All reagents were brought to the room temperature (18 – 25ºc). The reagents, samples and 
standards were prepared as instructed; 
Wash Buffer: 20mL of the Wash Buffer Concentrate were added to distilled water to prepare 
500mL of Wash Buffer. 
Substrate Solution: Colour Reagents A and B were mixed together in equal volumes within 15 
minutes of use. 200 μL of the resultant mixture was required per well. This solution should be 
protected from light. 
VEGF Standard: VEGF standard was reconstituted with Calibrator Diluent RD6U. This 
reconstitution produced a stock solution of 2000pg/mL. 
Plasma samples: 500 μL of Calibrator Diluent RD6U were pipetted into each tube (six 
polypropylene tubes were required for this preparation). Stock solution was used to produce 
the dilution series. Each tube was mixed thoroughly before the next transfer. 200 pg/mL 
standard were served as the high standard (Figure 3.6).  
 
Figure 3.3A: Dilution procedures for VEGF standard 
Assay procedure 
In this procedure, all samples and standards were assayed in duplicate. A plate map was used 
to record the location of standards and samples. 
The following steps were followed to perform the assay: 
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1. All reagents, working standards and samples were prepared as directed. 
2. 100 μL of Assay Diluent RD1W were added to each well. 
3. 100 μL of Standard, control and sample were added to each well. The plate was then 
covered with adhesive tape and were incubated for 2 hours at room temperature. 
4. Each well was then being washed and aspirated. The process was repeated twice for a 
total of three washes. 
5. 200 μL of VEGF Conjugate were added to each well and were incubated for 2 hours at 
room temperature. 
6. The aspiration/wash were repeated. 
7. 200 μL of Substrate Solution was added to each well. The well should be protected from 
light and incubated for 25 minutes at room temperature. 
8. 50 μL of stop solution was added to each well.  
9. The optical density in each well were determined within 30 minutes using a microplate 
reader set to 450 nm. 
 
Figure 3.3B: Standard curve VEGF 
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Appendix 3. 4: Performing ET-1 analysis 
The measurement of ET-1 in this PhD project was done using a commercial kit from Enzo Life 
Sciences, Inc (catalogue #ADI-900-020A). 
Principle of the assay 
Samples and standards were added to wells coated with a monoclonal antibody specific for ET-
1. The plate was then incubated for 30 minutes. Then, the plate was washed, leaving only bound 
ET-1 on the plate. A solution of HRP labelled monoclonal antibody to ET-1 was added. This 
binds the ET-1 captured on the plate. The plate was incubated again for 30 minutes. Then, the 
plate was washed to remove excess HRP labelled antibody and TMB substrate solution was 
added. The substrate generates a blue colour when catalysed by the HRP. Lastly, stop solution 
was added to stop the substrate reaction and the resulting yellow colour were read at 450 nm. 
 Reagent preparation  
The reagents, samples and standards were prepared as instructed; 
Wash Buffer: Wash buffer was prepared by diluting 50 mL of Wash Buffer Concentrate with 
950mL of deionized water. 
ET-1 standards: Eight 12 x 75mm polypropylene were labelled with tubes #1 through #8. 450 
μL of assay buffer were pipetted into tube #1. 250 μL of the assay buffer were pipetted into 
tubes #2 through #8. 50 μL of 1,000pg/mL standard stock were added into tube #1 and were 
vortex thoroughly. 250 μL of tube #1 were added to tube #2 and were vortex thoroughly. 250 
μL of tube #2 were added to tube #3 and were vortex thoroughly. This procedure was continued 
for tubes #4 through #8 (Figure 3.4A). 
 
Figure 3.4A: Dilution procedures for ET-1 standard 
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ET-1 Antibody: The antibody was prepared by diluting 10 μL of the supplied antibody 
concentrate with 1 ml of antibody diluent. 
Assay procedure 
In this procedure, all samples and standards were assayed in duplicate. A plate map was used 
to record the location of standards and samples. 
The following steps were followed to perform the assay: 
1. 100 μL of assay buffer was pipetted into S0 (0pg/mL standard) wells. 
2. 100 μL of standards #1 through #8 were pipetted to the bottom of the appropriate wells. 
3. 100 μL of the samples were pipetted to the bottom of the appropriate wells. 
4. The plate was sealed and incubated for 1 hour at room temperature. 
5. After the incubation period, the contents of the wells were emptied and washed by 
adding 400 μL of wash buffer to each well. This procedure was repeated for 4 more 
times for a total of 5 washes. After the final wash, the wells were aspirated and the plate 
was tapped firmly on a paper towel to remove any remaining wash buffer. 
6. 100 μL diluted antibody was pipetted into each well except the blank. 
7. The plate was sealed and incubated for 30 minutes at room temperature. 
8. Once again the plate was washed as in step 5. 
9. 100 μL substrate was pipetted into each well. 
10. The plate was incubated for 30 minutes at room temperature. 
11. 100 μL of stop solution was pipetted into each well. 
12. The optical densities in each well were determined using a microplate reader set to 450 
nm. 
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Figure 3.4B: Standard curve ET-1 
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Appendix 3. 5: Performing cGMP analysis 
The measurement of cGMP in this PhD project was done using a commercial kit from Enzo 
Life Sciences, Inc (catalogue #ADI-900-013). 
Reagent Preparation 
cGMP Standard: 5,000 pmol/ml cGMP standard solution were brought to the room temperature 
(18 – 25ºc). Six 12 x 75 mm glass tubes #1 to #6 were labelled. 900 μL standard diluent (assay 
buffer) was pipetted into tube #1 and 800 μL of standard diluent into tubes #2-6. 100 μL of the 
5,000 pmol/mL standard were added to tube #1 and were vortexed thoroughly. 200 μL of tube 
#1 were added to tube #2 and were vortexed thoroughly. These processes were continued for 
tubes #3 through #6. 
Wash Buffer: The wash buffer was prepared by diluting 5ml of the supplied concentrate with 
95ml of deionized water.  
Assay procedure 
In this procedure, all samples and standards were assayed in duplicate. A plate map was used 
to record the location of standards and samples. 
1. 100 μL of standard diluent (assay buffer) was pipetted into the NSB and the Bo (0 
pmol/mL standard) wells. 
2. 100 μL of standards were pipetted into the appropriate wells. 
3. 100 μL of samples were pipetted into the appropriate wells. 
4. 50 μL of standard diluent were pipetted into the NSB wells. 
5. 50 μL of blue conjugate were pipetted into each well, except the TA and Blank wells. 
6. 50 μL of yellow Antibody were pipetted into each well, except the Blank, TA and NSB 
wells. 
7. The plate was covered and incubated at room temperature for 2 hours on a plate shaker 
at ~500rpm. 
8. After the incubation period, the contents were emptied and washed by adding 400 μL 
of wash solution to every well. This procedure was repeated for 2 times for a total of 3 
washes. 
9. After the final wash, the wells were aspirated and the plate was tapped firmly on a lint 
free paper towel to remove any remaining wash buffer. 
10. 5 μL of blue conjugate was added to the TA wells. 
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11. 200 μL of the pNpp Substrate solution was added to every well and then incubated at 
room temperature for 1 hour without shaking. 
12. 50 μL of stop solution was added to every well. This stopped the reaction and the plate 
were read immediately. 
13. The optical density in each well were determined using a microplate reader set to 405 
nm. 
 
Figure 3.5A: Standard curve CGMP 
 
 
 
 
 
 
 
 
 
 
 
 211 
 
Appendix 3. 6: A standard curve for the calibration and examples of peak in analysing 
plasma and urinary nitrate using chemiluminescence 
 
Figure 3.6 A: Standard curve plotted for the calibration in nitrate analysis using 
chemiluminescence 
 
Figure 3.6 B: Example of plasma nitrate analysis using chemiluminescence 
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Figure 3.6 C: Example of urinary nitrate analysis using chemiluminescence 
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Appendix 3. 7: Performing NO3- analyses using chemiluminescence 
Preparation of Nitrate Standard solutions 
100mM NO3 was prepared as a standard/stock solution for conducting a serial dilution to obtain 
the standard curve. 
 85mg of NaNO3 was added in 10ml MiniQ H2O to make 100mM NO3 (standard 
solution). 
 Seven tubes (marked with the following: 10mM, 1mM, 100µM, 10µM, 1µM, 100nM, 
10nM) were arranged in a rack and 900µl MiniQ H20 was added to each tube. 
 Three tubes (marked with 50µM, 5µM, 50nM) were arranged in a rack and 300µl 
MiniQ H20 was added to each tube. 
 100µl of stock solution was added to 10nM tube and was mixed and vortexed 
thoroughly. A new pipette tip was used to transfer 100µl of the 10mM standard to 1mM 
tube. These processes were repeated to prepare 10nM.  
 300µl of the 100uM standard was transferred to the 50µM tube, mixed and vortexed 
thoroughly. 300µl of the 10µM standard was transferred to the 5µM, mixed and 
vortexed thoroughly. 300µl of the 100µM standard was transferred to the 50nM, mixed 
and vortexed thoroughly. 
 The most concentrated standards (10mM and 1mM) were discarded. 
 To produce the standard curve, 20µL standards were injected (in duplicate) into the 
purge vessels (the most diluted standard was injected first), and the peak area of each 
standard were measured to produce NO3 standard curves.  
Preparation of Nitrate Reducing Agent 
 160mg of VCL3 was weighted and resolved in 10ml MiniQ H2O, then 10ml HCL was 
added to mixed and solved the pellet. The solution should be blue. This procedure was 
done in the hood. The solution was filtered using filter paper (Whatman #1) 
 Antifoaming agent was diluted into 1:30. 100µL antifoaming agent was added into 3ml 
MiniQ H2O. 
 1ml NaOH was added to 19ml of MiniQ H2O to get 50% NaOH, then 15ml of this 
solution was added to the bubble base. This solution was used to prevent HCL vapors 
from entering the NOA. 
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General Operation Procedures 
 Gas supplies (N2 and O2) to the NOA were switched on. 
 NOA machine and PC were switched on. The machine was allowed to cool down to  
-12ºC. 
 Once the temperature reached -12ºC, the supply pressure was 6psig and the cell 
pressure is >300 torr, the ENTER was pressed to returned to the main menu. 
 The gas bubbler was opened to add 15ml of 1M NaOH to the bubble base. 
 The bubbler top was replaced and sealed the bubbler by pressing the bottom onto the 
top and twisting to achieve a tight seal. The bubbler piece was secured with the green 
plastic clamp and mounted on the ring stand using the clamp. 
 The IFD filter line was connected to the outlet of the bubbler. 
 The bubbler line tubing was connected from the outlet of the purge vessel to the inlet 
of the bubbler. 
 The gas inlet stopcock and the outlet stopcock on the purge vessel were closed and the 
needle valve was screwed on the purge vessel. 
 The drain stopcock on the purge vessel was closed. The screw cap on the top of the 
purge vessel was opened and 3ml of the filtered VCL3/HCL reagent was added.     
 200µl of the diluted antifoaming agent was added to the purge vessel and the screw 
cap was leaved off while adjusting the gas flow into the purge vessel. 
 The gas inlet stopcock on the purge vessel was opened and the needle valve was 
opened slowly to start the flow of gas into the purge vessel. A slow, gentle bubbling 
of gas was obtained through the reagent. 
 The screw cap was replaced, the outlet stopcock on the purge vessel was opened and 
the outlet stopcock on the gas bubbler was opened slowly while keeping an eye on the 
level of NaOH in the bubbler. 
 To adjust the Purge Gas Flow rate, the IFD filter line was connected to the NOA’s frit 
restrictor. The outlet stopcock on the purge vessel and on the gas bubbler was opened. 
The gas flow into the purge vessel was adjusted using the needle valve so that the cell 
pressure with the purge vessel were connected the same as recorded when the frit 
restrictor was open to the air (4 -7 torr). 
 All stopcocks, power for the water bath and chiller were turned off after the 
experiments finished. Finally, the gas supplies were turned off. 
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Appendix 3. 8: Performing NO2ˉ analyses using chemiluminescence  
Preparation of Nitrite Standard solutions 
100mM NO2 was prepared as a standard/stock solution for conducting a serial dilution to obtain 
the standard curve. 
 69 mg of NaNO2 was added in a 10mL MiniQ H2O to make 100mM NO3 (standard 
solution). 
 Seven tubes (marked with the following: 10mM, 1mM, 100µM, 10µM, 1µM, 100nM, 
10nM). 
 Three tubes (marked with 50µM, 5µM, 50nM) were arranged in a rack and 300µl 
MiniQ H20 was added to each tube. 
 100µl of stock solution was added to 10nM tube and was mixed and vortexed 
thoroughly. A new pipette tip was used to transfer 100µl of the 10mM standard to 1mM 
tube. These processes were repeated to prepare 10nM.  
 300µl of the 100uM standard was transferred to the 50µM tube, mixed and vortexed 
thoroughly. 300µl of the 10µM standard was transferred to the 5µM, mixed and 
vortexed thoroughly. 300µl of the 100nM standard was transferred to the 50nM, mixed 
and vortexed thoroughly. 
 The most concentrated and diluted standards (10mM, 1mM and10nM) were discarded. 
Preparation of Nitrite Reducing Agent 
 50mg of Nal was weighted and resolved in 2 ml MiniQ H2O. 
 2ml of acetic acid, 500µl of Nal and 100µl diluted antifoaming were added to the purge 
vessel. 
General Operation Procedures 
 Gas supplies (N2 and O2) to the NOA were switched on. 
 NOA machine and PC were switched on. The machine was allowed to cool down to  
-12ºC. 
 Once the temperature reached -12ºC, the supply pressure was 6psig and the cell 
pressure is >300 torr, the ENTER was pressed to returned to the main menu. 
 The drain stopcock, gas inlet stopcock and outlet stopcock on the purge vessel were 
closed. The septum and cap from the top of the purge vessel was removed. The needle 
valve on the purge vessel was screwed fully to stop the gas flow. 
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 2ml of concentrated acetic acid was added to the purge vessel. With the needle valve 
fully closed, the gas inlet stopcock on the purge vessel was opened. The needle valve 
was opened slowly to allow gas to flow into the acetic acid. A slow, gentle bubbling 
of gas was obtained through the acid and any dissolved oxygen was removed. 500µl 
Nal was added to the purge vessel. The screw cap and septum on the purge vessel 
were installed. 
 IFD filter line was connected to the frit restrictor and the nut was tighten finger tight. 
The outlet stopcock was opened and the gas flow into the purge vessel was adjusted 
using the needle valve to keep the cell pressure around 4 to 7 torr. 
 All stopcocks, power for the water bath and chiller were turned off after the 
experiments finished. Finally, the gas supplies were turned off. 
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Appendix 3. 9: Performing Nitrate Colorimetric Assay  
Performing the Griess Reaction 
A commercial kit (Nitrate/Nitrite Colorimetric Assay Kit, Cayman Chemical, Ann Arbor, MI, 
US) was used to measure NO3
-concentrations. The following components were required in 
order to perform the analysis: 1) Nitrate Assay Buffer; 2) Nitrate Reductase Enzyme 
Preparation; 3) Nitrate Reductase Cofactors Preparation; 4) Nitrate Standard and 5) Griess 
Reagent Reagents. 
Sample Preparation 
Plasma samples were filtered through 0.5mL centrifugal filters (Amicon ®Ultra, Merck 
Millipore, Cork, IRL). The filters were pre-rinsed with UltraPure water prior to ultrafiltration 
of the plasma (centrifudged at 14,000 rpm for 7 minutes). Plasma was diluted 1:2 in assay 
buffer.  
Plate set up 
At least two wells must be designated for absorbance blanks (containing 200 μL of Assay 
Buffer or water). The absorbance of these wells was then subtracted from the absorbance 
measured in all other wells. Standard curves for NO3
-  were obtained for the calculation of the 
concentrations.   
Measurement of Nitrate: Assay procedure 
In this procedure, all samples and standards were assayed in duplicate. A plate map was used 
to record the location of standards and samples. 
The following steps were followed to perform the assay: 
1) 200 μL of assay buffer were added to the blank wells. 
2) 80 μL of diluted samples was added to each of the sample wells. 
3) 10 μL of the enzyme cofactor and reductase mixture were added to each of the wells. 
4) The plate was covered and incubated at room temperature for one hour. 
5) After the required incubation time, 50 μL Griess reagents 1 and 2 were added to each 
well. The colour in the plate was allowed to developed for 10 minutes before the 
absorbance was read at 540 nm using plate reader (Multiskan Go Plate Reader, Thermo 
Scientific). 
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Determination of sample concentrations 
The calculation of nitrate concentrations involved the subtraction of the absorbance value of 
the blank wells from the absorbance values from all the other wells. A plot of absorbance at 
540-550 nm as a function of NO3
- concentration was made. The NO3
- standard curve was used 
for the determination of total nitrate + nitrite concentration. The following algorithm were used 
for determination of NO3
-. 
 
Sensitivity 
When using the maximum amount of sample for the nitrate assay (80 µl), the detection limit 
was 2.5 µM. The detection limit for the plasma was higher since only 40 µl of sample can be 
used. 
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Appendix 3. 10: Procedure of nitrate-derivatisation for GCMS analyses 
Chemicals and reagents 
Labelled sodium nitrate (15NaNO3, 98
+ atom %, Cambridge isotope laboratories, Inc., Andover, 
USA) was obtained from Sigma Aldrich Co, USA; unlabelled sodium nitrate (14NaNO3) was 
obtained from Fisher Scientific, Loughborough, UK; mesitylene, TFAA, sodium sulphate, 
sodium bicarbonate was all obtained from Sigma-Aldrich, UK. Deionised water was used for 
the aqueous solutions and during the dilution preparation. 
Safety 
The work has been done in biological safety cabinet due to some of the chemicals that are 
harmful as follows: 
1) Sodium Nitrate: Harmful if swallowed and can cause irritation to the skin, eye and 
respiratory tract. 
2) Mesitylene: Flammable liquid and harmful if swallowed or inhaled as it can be 
evaporated. Can cause irritation to skin and respiratory tract, toxic to aquatic life with 
long lasting effects. 
3) TFAA: Can cause severe skin burns and eye damage. Harmful if inhaled and it can 
react aggressively with water. 
Standards Preparation 
A series of experiments using different concentrations and enrichments of NaNO3ˉ was 
performed to investigate the accuracy of the methods and to gain proficiency of conducting the 
experiment before the real samples were analysed. 
The first experiment was performed to explore the linearity of measurements of Na14NO3ˉ   in 
aqueous solution across different range of concentrations. The concentrations range from 5 
mmol/l to 0.078 mmol/l. The volume of the samples was 500µl.  
The following formula was used to prepare the sample of Na14NO3ˉ (5mmol/L) and Na15NO3ˉ 
(5mmol/L) solution. 
[14N] Sodium Nitrate (NaNO3): molar mass is 84.99 g/mol 
[15N] Sodium Nitrate (NaNO3): molar mass is 85.99 g/mol 
Weight (mg) = 
(5𝑚𝑚𝑜𝑙/𝐿)∗𝑚𝑜𝑙𝑎𝑟 𝑚𝑎𝑠𝑠∗𝑉𝑜𝑙𝑢𝑚𝑒(100𝑚𝑙)
1000
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 42.5 mg of sodium nitrate (for 14N) / 43 mg of sodium nitrate ((for 15N) were weighted 
on the sensitive balance and transferred to a small beaker before being dissolved in a 
small amount of deionized water. 
 The solution was transferred into a clean 100mL volumetric flask and make up to 100 
mL with deionized water and mix thoroughly.  
The following steps were followed to perform the experiment.  
1. The samples were thawed at the room temperature.  
2. The samples were transferred to Agilent 1.5 mL GCMS vial (the volume of the samples 
may be varies). 
3. The samples were dried down under nitrogen at room temperature. This procedure took 
approximately 60 to 120 minutes- depending on the volume of the samples in the vials. 
4. After this procedure, 200µL TFAA and 1mL mesitylene were added to the dried 
samples. 
5. The samples were incubated at 70ºC for 1 hour in heating block, and then allowed to 
cool down at room temperature. 
6. Four clean disposable culture tubes were prepared (per sample) and labelled 
appropriately on the rack. 500mg of sodium sulphate (Na2SO4) was added in the fourth 
(last) culture tube for each sample. 
7. The samples in the vials (containing TFAA and mesitylene) were then transferred to 
the first culture tube. 
8. One ml de-ionised water was added (slowly) to the samples and vortex for 10 seconds. 
This procedure resulted the separation of 2 layers of solvent in the tube.  
9. The top solvent layer was transferred to the second culture tube. 
10. One ml of 1% aqueous sodium bicarbonate (MW 84; 84mg NaHCO3 in 100mL of 
deionised water) was added to the second culture tube, vortexed for 10 seconds and the 
top layer was transferred to the third culture tube. 
11. One ml de-ionised water was added to the third culture tube and vortex for 10 seconds 
and the top layer were transferred to the fourth culture tube (containing the sodium 
sulfate). 
12. Pre-plugged Pasteur pipettes were prepared by flushing through with 500µL 
mesitylene. 
13. The samples from the final culture tubes were removed and filtered through the 
prepared Pasteur pipette into a clean labelled 1.5 mL GCMS vials. 
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14. The solutions are now ready to be analysed by GCMS. 
 
The coefficient of determination showed good linearity of the method ((R2= 0.9911) which was 
maintained in the lowest concentrations (0.0078) (Figure 3.13). 
 
Figure 3.13: Regression analysis of peak areas of the ion 165 versus NO3 concentration in 
an unlabelled serial dilution of Na14NO3 standards. 
 
The second experiment was performed to investigate the performance of the nitro-mesitylene 
method in aqueous solution in different range of concentrations (5 mmol/l to 0.078 mmol/l). In 
a clean Agilent vials, 50 µl of each unlabelled Na14NO3ˉ was spiked with 50 µl of 15NO3ˉ to 
produce a range of enrichments. The total volume of the samples was 100 µl. The starting 
unlabelled and labelled baseline solutions of NaNO3
-  are described in Table 3.2.  
 
 
 
R² = 0.9911
0
200000
400000
600000
800000
1000000
1200000
1400000
0 0.5 1 1.5 2 2.5 3
A
b
u
n
d
an
ce
 
NO3 (mmol)
Peak Area m/z = 165
 222 
 
Table 3.2: Concentration (mmol/l) and total nitrate (NO3ˉ) content (mg/ml) of the 
labelled and unlabelled NO3ˉ aqueous solutions. 
 
 Sample Total Nitrate 
Content 
(mg/ml) 
Total Nitrate 
Content 
(mg/l) 
Concentration 
(mmol/l) 
Molecular 
mass (gr) 
Unlabelled, Na14NO3- A 0.425 42500 5 85 
Labelled, Na15NO3- B 0.025 2494 0.29 86 
 
The coefficient of determination (R2) was 0. 9966 as shown in Figure 3.14. 
 
APE vs Theoretical Enrichment 
 
Figure 3.14: Changes in isotopic enrichment in a serial dilution of unlabelled Na14NO3ˉ 
standards spiked with 0.29 mmol Na15NO3. 
 
The third experiment investigated the agreement between theoretical and measured 
enrichments in 15NO3ˉ using a range of enrichments in spiked standard aqueous solutions 
having the same concentration (5mmol/l). In this experiment, both 15NO3ˉ and 14NO3ˉ are 
5mmol/l. The samples had a total volume of 100 µl for each vials (Table 3.3). 
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Table 3.3: Isotopic enrichment in a 5 mmol aqueous solution of Na14NO3 spiked with 
different amounts of a 5 mmol solution of Na15NO3 
 
 Isotopic 
Enrichment (%) 
Na14NO3 
(5mmol) (µl) 
Na15NO3 
(5mmol) (µl) 
Na14NO3 
(5mmol) 
(µg/ml) 
Na15NO3 
(5mmol) 
(µg/ml) 
Final 
Concentration 
(mmol/l) 
1 100 0 100 0 0.43 5 
2 50 50 50 0.42 0.43 5 
3 10 90 10 0.42 0.43 5 
S
er
ia
l 
D
il
u
ti
o
n
 
5 100 100 (IE 10%) 0.42 0.43 5 
2.5 100 100 (IE 5%) 0.42 0.43 5 
1.25 100 100 (IE 2.5%) 0.42 0.43 5 
0.625 100 100 (IE 1.25%) 0.42 0.43 5 
0.313 100 100 (IE 0.625%) 0.42 0.43 5 
9 0 100 0 0.42 0 5 
 
The coefficient of determination (R2) was 1 as shown in Figure 3.15. 
APE vs Theoretical Enrichment 
 
Figure 3.15: Regression analysis of peak areas of the ion 165 versus NO3 concentration in 
an unlabelled serial dilution of Na14NO3 standards. 
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Appendix 3. 11: GCMS data analyses  
 
Figure 3.11A: Example of GCMS chromatogram and ion spectrum before the 
administration of the labelled nitrate dose 
 
 
 
Figure 3.11B: Example of integrated chromatogram for 165 and 166 ions 
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Figure 3.11C: Example of GCMS chromatogram and ion spectrum after the 
administration of the labelled nitrate dose 
 
 
 
 
Figure 3.11D: Example of integrated chromatogram for 165 and 166 ions 
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Appendix 3. 12: Comparison of CL for deproteination method using ETH and MTH 
(after removal of the outliers). 
 
(B) Regression analysis of plasma nitrate concentration (µM) estimated by CL after 
deproteination using the ETH and MTH methods (after the removal of the outliers)  
 
 
(B) Bland-Altman analysis of estimates of plasma nitrate concentration after deproteination 
using the ETH and MTH methods (after the removal of the outliers) 
 
Figure 3.9A: Comparison of CL for deproteination method using ETH and MTH (after 
removal of the outliers). (A) Linear regression analysis between plasma nitrate concentration 
observed by the ETH and MTH. (B) Plotting according the method of B & A agreement 
between the difference in the nitrate concentrations measured by the ETH and MTH. Black 
horizontal lines (bold) show the mean difference between ETH and MTH and the fine, grey 
line, are the limits of agreement (± 2SD). 
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Appendix 3. 13: Comparison of CL and Griess methods for the measurements of 
plasma concentrations 
 
(A) Regression analysis of plasma nitrate concentration (µM) estimated by Griess and 
MTH 
   
 
(B) Bland-Altman analysis of estimates of  mean plasma nitrate concentration 
using Griess and MTH methods 
Figure 3.10A: Comparison of CL and Griess methods for the measurements of plasma concentrations in 
80 subjects. (A), Linear regression analysis to evaluate the association between plasma nitrate 
concentration measured by the Griess and CL methods. (B), Agreement and differential bias between 
the two methods was evaluated by the Bland-Altman method. Black horizontal lines (bold) show the 
mean difference between CL and Griess methods and the fine, grey line are the limits of agreement (± 
2SD). A regression line was fitted to the points (dashed black line) to evaluate differential bias. Plasma 
samples measured by CL were processed using the MTH method.   
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Appendix 3. 14: Comparison of plasma nitrite measured by CL in untreated samples 
and using the MTH deproteination method 
 
 
(A) Regression analysis of plasma nitrite concentration (µM) estimated by CL 
(untreated vs  MTH) 
 
        (B) Bland-Altman analysis of estimates of mean plasma nitrite concentration using 
CL (untreated vs MTH) 
 
Figure 3.11A: Comparison of plasma nitrite measured by CL in untreated samples and using 
the MTH deproteination method. (A), Linear regression analysis to evaluate the association 
between the two processing methods. (B), B & A to assess agreement between the two methods 
and evaluate presence of differential bias. Black horizontal line shows the mean difference 
(bold) and the ± 2S.D. range (fine, grey line). A regression line was fitted to the points (dashed 
black line) to evaluate differential bias. 
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Appendix 3. 15: Procedure of analysing of 25(OH)D concentration using conventional 
method 
 
It involved three phases of incubation. In the first incubation, 15uL of sample was incubated 
with pretreatment reagent 1 and 2, resulted in the releasing bound 25OH vitamin D from the 
vitamin D binding protein. In the second incubation, the pretreated sample was incubated 
with ruthenium labelled vitamin D binding protein which leads to the formation of a complex 
between the vitamin D and the ruthenylated vitamin D binding protein. In the third 
incubation, the addition of streptavidin-coated microparticles and 25(OH)D labelled with 
biotin and the unbound ruthenium labelled vitamin D binding proteins become occupied. A 
complex consisting of the ruthenylated vitamin D binding protein and the biotinylated 25-
OH vitamin D was formed and became bounded to the solid phase via interaction of biotin 
and streptavidin. 
 
The reaction mixture was then aspirated into the measuring cell where the microparticles 
were magnetically captured onto the surface of the electrode. The unbound substances were 
then removed. The application of a voltage to the electrode then induces chemiluminescent 
emission which is measured by a photomultiplier. 
 
After separation, the samples stability was depending on the temperature where it was kept. 
The analytical range of CLIA method were between 7.50 to 175 nmol/L and samples with 
the concentration outside these limits are reported as <10nmol/L or >174nmol/L. Coefficient 
of Variability (CV) for inter-assay analyses is 18.4% at a 25(OH)D level of 39.5 nmol/L and 
11.7% at 121.25 nmol/L. 
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Appendix 3. 16: Procedures of analysing 25(OH)D using dry blood spot (DBS) method 
 
Technical Service Information Sheet 
Determination of 25-Hydroxyvitamin D3 & D2 in Dried Blood Spots 
by LC-MS/MS 
 
Samples 
Suitable collection kits and blood spot devices are supplied as part of the testing process.  
Samples show good stability and may be sent via the postal system using the envelope 
provided in the kit. 
The blood spot method involved taking a 3mm punch from a dried blood spot. The punches 
were extracted and the 25-hydroxyvitamin D were derivatived with 4-Phenyl-1,2,4- 
triazoline-3,5-dione (PTAD), which increased the sensitivity during MS-detection. After 
some further sample preparation, the samples were loaded onto liquid chromatography–mass 
spectrometry (LC/MS/MS) analyser (Waters i-Class UPLC and Waters Xevo TQ-S triple 
quad mass spectrometer). Multiple reaction monitoring (MRM) mass spectrometry was used 
to analyse the samples for 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and these total 
were added to report total 25-hydroxyvitamin D. 
 
The precision and accuracy of this method were reported by City Assay as below: 
Parameter Blood spot vitamin D 
Linearity r2 > 0.98 
Limit of quantitation (CV <20%) < 7.1 nmol/L 
Intra assay variation <10 % 
Inter assay variation <11 % 
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Method 
A liquid chromatography-
tandem mass spectrometry 
(LC-MS/MS) method is 
applied to dried blood spot 
samples, utilising blood spot 
calibrators.  The method is 
standardised against our 
conventional 25-
hydroxyvitamin D3 and D2 
LC-MS/MS service for 
plasma/serum.  The 
laboratory participates in the 
DEQAS external quality 
assurance scheme.  Blood 
spot results show good 
comparability to serum/plasma results. 
 
Figure 1: Comparison of total 25-hydroxyvitamin D results for capillary blood spots with conventional LC-
MS/MS method for paired serum or plasma samples (n = 36), data for samples from October 2012 until May 2015 
 
Reference ranges 
Total 25-Hydroxyvitamin D 
status 
Concentration (nmol/L) 
Severe deficiency <15 
Deficiency 15 – 30 
Insufficiency 30.1 – 50 
Adequate 50.1-220 
High to toxic 220.1-500 
Toxic >500 
 
The individual values for 25-hydroxyvitamin D3 and D2 are reported as well as the total in 
nmol/L. Target turnaround time is 2-3 days. Results are reported with a clear interpretation and 
sent via first class post or a PDF report is emailed to the specified email address. 
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Appendix 4. 1: Summary findings of observational studies on vitamin D and cardiovascular disease 
No Author Study design Country Main Outcome 
1. Michal L. Melamed (Melamed et al., 
2008) 
Cross sectional US 25(OH)D levels were inversely associated with 
hypertension, diabetes mellitus, hypertriglyceridemia, and 
obesity 
2. Harald Dobnig (Dobnig et al., 2008) Prospective cohort Germany Low 25(OH)D levels correlated inversely with markers of 
inflammation (C-reactive protein and interleukin-6), 
oxidative burden (serum phospholipid and glutathione), 
and cell adhesion (vascular cell adhesion molecule-1 and 
intercellular adhesion molecule-1) 
3. Jeffrey L. Anderson (Anderson et al., 
2010) 
Prospective study US Serum 25(OH)D levels <30 ng/ml were associated with 
highly significant increases in the prevalence of diabetes, 
hypertension, hyperlipidemia, and peripheral vascular 
disease. Serum 25(OH)D levels were also highly associated 
with coronary artery disease, myocardial infarction, heart 
failure and stroke 
4. Suzanne E Judd (Judd et al., 2008) Cross sectional US 25(OH)D levels were inversely associated with 
hypertension, diabetes mellitus, hypertriglyceridemia, and 
obesity 
5. Edward Giovannucci (Giovannucci 
et al., 2008) 
Prospective Study US Men deficient in 25(OH)D (<15 ng/ml) were at increased 
risk for myocardial infarction compared with those 
considered to be vitamin D sufficient (>30 ng/ml)  
6. Archna Bajaj (Bajaj et al., 2014) Follow up study US Significant association between circulating 25(OH) vitamin 
D and risk of CVD events 
7. Lu Wang (Wang et al., 2013) 
 
Prospective study US Inverse relationship between vitamin D levels and 
development of hypertension  
8. Yakup Alsancak (Alsancak et al., 
2015) 
Prospective cohort  Turkey  Failed to demonstrate significant relationship between 
serum vitamin D levels and the severity and extent of 
coronary artery disease 
9. Thomas J. Wang (Wang et al., 2008) Longitudinal study US Vitamin D deficiency is associated with incident 
cardiovascular disease.  
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No Author Study design Country Main Outcome 
10. Scragg, R (Scragg et al., 2007) Cross sectional US Vitamin D status was associated inversely with BP. 
11. Judd, S,E (Judd et al., 2008) Cross sectional US 25(OH)D levels inversely associated with hypertension, 
diabetes mellitus, hypertriglyceridemia, and obesity 
12. Martins, D (Martins et al., 2007) Prospective cohort US Serum 25(OH)D levels are associated with important 
cardiovascular disease risk factors 
13. Hintzpeter, B (Hintzpeter et al., 
2008) 
Prospective cohort German The results demonstrate that moderate and mild vitamin D 
deficiency affects a large proportion of the adult population 
in Germany 
14. Hypponen, E (Hypponen et al., 
2008) 
Prospective cohort UK Serum 25(OH)D is inversely associated with metabolic 
syndrome, whereas the inverse association with IGF-1 was 
found only among those without hypovitaminosis D. These 
results suggest that metabolic syndrome prevalence is the 
lowest when both 25(OH)D and IGF-1 are high. 
15. Forouhi, N.G (Forouhi et al., 2008) Prospective study UK Inverse associations between baseline serum 25(OH)D and 
glycemia and insulin resistance 
16. Reis, J.P (Reis et al., 2007) Prospective cohort US An increased risk of metabolic syndrome with elevated 
PTH levels in older men 
17. Gannage-Yared, M.H (Gannage-
Yared et al., 2009) 
Cross sectional Lebanon There are relationships between 25(OH)D and several 
metabolic risk factors and adiponectin 
18. Pasco, J.A (Pasco et al., 2009) Cross sectional Australia Women with high vitamin D were less likely to have 
elevated PTH, hypertension or bone deficits than women 
with poor levels. 
19. Rueda, S (Rueda et al., 2008) Cross sectional Spain The findings did not support an independent contribution 
of 25(OH)D or PTH in the pathogenesis of the metabolic 
syndrome in severely obese subjects 
20. Chan, R (Chan et al., 2012) Cross sectional China The findings support an association between serum PTH 
and blood pressure, but not for serum 25(OH)D in older 
Chinese men whose vitamin D status is optimal. 
21. Williams, D.M (Williams et al., 
2011) 
Cross sectional US Higher calcium levels might be a more important predictor 
of increased cardiovascular risk in adolescents than lower 
25(OH)D levels or PTH levels 
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No Author Study design Country Main Outcome 
 
22. Dorjgochoo, T (Dorjgochoo et al., 
2012) 
Cross sectional China Circulating 25(OH)D levels were inversely related to levels 
of individual BP parameters and hypertension among 
middle-aged and elderly men but not in women 
23. Snijder, M.B (Snijder et al., 2007) Cohort study Netherlands Serum 25(OH)D was not associated with blood pressure, 
24. Jablonski, K.L. (Jablonski et al., 
2011) 
Cross sectional US Inadequate serum 25(OH)D is associated with vascular 
endothelial dysfunction among healthy middle-aged/older 
adults and this is mediated in part by NFκB-related 
inflammation.  
25. Yiu, Y.F (Yiu et al., 2011) Cross sectional China Serum 25(OH)D status was significantly associated with 
brachial artery FMD 
26. Codoner-Franch, P. (Codoner-Franch 
et al., 2012) 
Cross sectional Spain Insufficient 25(OH)D levels were detected in severely 
obese children with increased markers of 
oxidative/nitrosative stress, inflammation, and endothelial 
activation. 
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Appendix 4. 2: Study sponsorship 
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Appendix 4. 3: Ethical approval 
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Appendix 4. 4: Substantial amendment 
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Appendix 4. 5: Physical Activity Questionnaire 
  
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives.  The questions will ask you about the time you spent being physically 
active in the last 7 days.  Please answer each question even if you do not consider yourself to 
be an active person.  Please think about the activities you do at work, as part of your house 
and yard work, to get from place to place, and in your spare time for recreation, exercise or 
sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous physical 
activities refer to activities that take hard physical effort and make you breathe much harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on one of 
those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not 
include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
 
4. How much time did you usually spend doing moderate physical activities on one of 
those days? 
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_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you have done solely 
for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time?   
 
_____ days per week 
  
   No walking    Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 7 days.  
Include time spent at work, at home, while doing course work and during leisure time.  This 
may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to 
watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
This is the end of the questionnaire, thank you for participating. 
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Appendix 4. 6: Food Frequency Questionnaire 
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Appendix 4. 7: Sunshine Exposure Questionnaire 
Sunshine Exposure Questionnaire 
This section will help me to understand your personal sun exposure habits while in the UK.  
1. How much time would you spend outdoors on a weekday during the sunny months? 
⃝Less than 15 minutes 
⃝Between 15 and 30 minutes 
⃝Between 30 minutes and 1 hour 
⃝Between 1 hour and 2 hours 
⃝More than 2 hours 
 
2. How much time would you spend outdoors on a weekend day during the sunny months?  
⃝Less than 15 minutes 
⃝Between 15 and 30 minutes 
⃝Between 30 minutes and 1 hour 
⃝Between 1 hour and 2 hours 
⃝More than 2 hours 
 
3. When you are outdoors during the sunny months, do you mostly wear… 
(List 1-4 in order of priority, no. 1 being the one you would do the most and no. 4 being the one 
you would do the least) 
 Order of Priority 
Long sleeves and long trousers or stockings  
Short sleeves and long trousers/skirt  
Short Sleeves and Short skirt/shorts  
Swimwear or light beach clothes  
 
4. Do you veil, and if so to what extent of your body is covered? 
 
⃝ Not applicable (I do not veil) 
⃝ Fully covered (eyes exposed) 
⃝ Partially covered 
 
5. During the sunny months, how often would you apply sunscreen? (In the UK- not on holiday) 
 
Please tick or circle your answer 
Never  Rarely  Sometimes  Usually  Always  Other 
 
6. What sun protection factor do you usually apply? _______  
 
7. What environment does your occupation expose you to? 
 
⃝Indoors 
⃝Outdoors 
⃝Mixture 
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Appendix 5. 1: Ethics Approval 
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Appendix 5. 2: Standarized low NO3ˉ Diet 
Standardized low NO3- Diet 
In order to increase the precision and validity of our measurements during the study, we need 
to control the amount of nitrate in your diet and you should try to follow the dietary guidelines 
provided below. The dietary plan will be thoroughly explained to you and if you have any other 
questions about the diet during the study please let us know and we will be very happy to clarify 
them to you. 
A list of food allowed and food to avoid is shown below. 
Food to avoid Food allowed 
 Rocket 
 Beet 
 Beetroot 
 Broccoli 
 Brussels 
sprouts 
 Cabbage 
 Canned 
asparagus 
 Canned 
beans 
 Canned corn 
 Canned peas 
 Canned 
pumpkin 
 Canned 
spinach 
 Canned 
tomatoes 
 Cauliflower 
 Celery 
 Chard 
 Chicory 
 Chinese Leaf 
 Chives 
 Coriander 
 Cured beef 
 Dill 
 Endive 
 Fennel 
 Ham 
 Kale 
 Apples 
 Apricots 
 Artichoke 
 Asparagus 
 Avocados 
 Bacon 
 Bananas 
 Basil 
 Beans 
 Beans 
(French) 
 Beans 
(Runner) 
 Blackberries 
 Barley 
 Beans 
(Broad) 
 Beansprout 
 Blueberries 
 Blue Cheese 
 Bread 
 Butter 
 Camembert 
 Cantaloupe 
 Cereal 
 Cheese Soft 
 Cheese 
Spread 
 Cherries 
 Chicken 
 Corn 
 Corn oil 
 
 
 Cured Turkey 
 Currants 
 Dried Beef 
 Frankfurt 
 Hot peppers 
 Egg 
 Eggplant 
 Fresh Pepper 
 Feta Cheese 
 Flour 
 Fresh Cheese 
 Fresh 
Sausage 
 Fresh Tomato 
 Grapefruit 
 Garlic 
 Grapes 
 Ketchup 
 Kiwi 
 Mayonnaise 
 Meat Fresh 
 Milk 
 Minced Meat 
 Mushrooms 
 Mandarin 
Oranges 
 Mango 
 Melon 
 Mustard and 
Cress 
 Onion 
(Spring) 
 
 Pumpkin 
 Parsnip 
 Pasta 
 Peach 
 Peas 
 Pineapples 
 Plums 
 Potatoes 
 Poultry 
 Prickly Pears 
 Radish 
 Raspberries 
 Red and yellow 
peppers 
 Quinces 
 Strawberries, 
blueberries 
 String beans 
 Summer squash 
 Sunflower oil 
 Sweet almond oil 
 Rice 
 Ricotta 
 Soybean oil 
 Sweet corn 
 Sweet potato 
 Watermelon 
 Wheat 
 Wheat flour 
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Food to avoid Food allowed 
 Green Beans 
 Leek 
 Lettuce 
 Meat Cured 
 Rhubarb 
 Spinach 
 Turnip 
 Watercress 
 Courgette 
 Cucumber 
 Cured Pork 
 Cured Salami 
 Peanuts 
 White bread 
 Winter melon 
 Wheat germ oil 
 Yogurt 
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Appendix 5. 3: Saliva collection procedures 
 
 256 
 
 257 
 
Appendix 5. 4: Participant’s checklist 
Participant’s checklist 
No Task Remarks 
Day 1 
1. 5.00pm 
• 1st collection of saliva sample  
 
• Drink the sodium nitrate solution 
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
 
 
 
 
 
2. 7.00pm – 7.10pm 
• Have snacks and drink 
 
 
 
2. 7.30pm 
• 2nd collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
 
 
 
3. 8.15pm 
• 3rd collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
4. 9.00pm 
• 4th collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
5. 10.00pm 
• 5th collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
 
 
: 
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Day 2 
6. 7.00am or specify time: ________am 
 
• 6th collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
 
7. 8.00am or specify time: _______am 
 
• 7th collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
 
8. 9.00am or specify time: _______am 
 
• 8th collection of saliva sample  
 
• Blood pressure measurement 
 
Blood pressure reading 
SBP: 
DBP: 
 
 
 
 
 
 
 
9. Questionnaires 
1. Physical activity questionnaire (IPAQ)  
 
2. Food Frequency questionnaire (FFQ)  
 
3. Sun exposure questionnaire 
 
4. Nitrate intake questionnaire 
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Appendix 5. 5: Examples of nitrate/nitrite calibration curves and examples of 
plasma nitrate/nitrite and urinary nitrate analysis  
 
Figure 5.5 A: Examples of nitrate calibration curves.   
 
 
Figure 5.5 B: Examples of nitrite calibration curves. 
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Figure 5.5 C: Examples of plasma nitrate sample analysis 
 
Figure 5.5 D: Examples of plasma nitrite sample analysis 
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Figure 5.5 E: Examples of urinary nitrate sample analysis 
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Appendix 5. 6: Performing 25(OH)D analysis  
The measurement of 25(OH)D concentrations in this PhD project was done using a 
commercial kit (25-Hydroxy Vitamin Ds Enzyme Immunoassay (EIA) from 
Immunodiagnosticsystems (IDS) AC-57SF1) in a 96-well format. The following 
components were required to perform the analyses: 1) Calibrators; 2) Controls; 3) Antibody 
coated plate; 4) 25-D Biotin concentrate; 5) Enzyme conjugate; 6) TMB substrate; 7) Stop 
solution 8) and wash concentrate. 
Reagent preparation 
The serum samples were collected in plain vacutainer tube. All reagents were brought to 
the room temperature (18 – 25ºc) at least 90 minutes before use. The reagents, samples and 
standards were prepared as instructed; 
25-D Biotin solution (supplied in lyophilised condition) 
i. 3ml of buffer was added to the bottle of lyophilised 25-D Concentrate and stand for 
10-15 minutes at room temperature. The solution was inverted several times to 
ensure complete reconstitution. 
ii. The reconstituted 25-D Biotin Concentrate was added back into the bottle 
containing the remaining buffer and mixed well. 
Wash solution 
i. The content of the bottle of Wash Concentrate was added to 950 mL of distilled 
water and mixed. 
Assay procedure 
6) Borosilicate glass were labelled, one for each Calibrator, Control and Sample. 
7) 25µL of each Calibrator, Control or samples were added to the appropriately labelled 
tubes. 
8) 1 ml of 25-D Biotin Solution was added to all tubes. 
9) Each of the tubes was vortexed thoroughly for 10 seconds. 
10) 200µL of each diluted calibrator, Control or Sample were added in duplicate to the 
appropriate well. The plate was covered with the adhesive plate sealer and incubated at 
room temperature (18c -25c) for 2 hours. 
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11) The plate was aspirated and washed. This process was repeated for two times for a total 
of three washes. Each well was filled with wash buffer (250μL) using manifold 
dispenser. After the last wash, any remaining wash buffer was removed by aspiring or 
decanting. The plate was inverted and blotted against a clean paper towels. 
12) Using multichannel pipette, 200µL of Enzyme Conjugate were added to each of the 
wells. The plate was covered with a new adhesive strip and incubated for 30 minutes at 
room temperature. 
13) The aspiration/wash process in step 6 was repeated. Using multichannel pipette, 200µL 
of substrate was added to each well. The plate was covered with a new adhesive strip 
and incubated for 30 minutes at room temperature. 
14) After 30 minutes, by using multichannel pipette, 100µL of stop solution was added to 
each well.  
15) The absorbance in each well was determined within 30 minutes using a microplate 
reader set to 450 nm. 
 
Figure 5.5A: Standard curve 25(OH)D 
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Appendix 5. 7: Participant’s evaluation form 
Evaluation Form 
At the end of the study on Ageing, Vitamin D and NO production, each participant was asked to complete 
an anonymous evaluation form to provide feedback on some aspects of the study protocols. Seventeen 
volunteers out of forty provided their feedback and their answers are reported below. 
Question 1: What do you like about the AVIDNO Study? 
A1: Checking my blood pressure. Might buy a blood pressure monitor. The researchers were very friendly. 
A2: The participant’s information sheets were very comprehensive. 
A3: It was easy to do at home. 
A4: Checking my blood pressure discovering very high. 
A5: Well organised and easy instructions. 
A6: Like contributing to the future. 
A7: The potential outcome. 
A8: Instructions were very comprehensive and checklist was helpful. 
A9: The information and rationale provided. 
A10: Measure my blood pressure and heart rate. 
A11: The relaxed way it's carried out. 
A12: Study protocol. 
A13: Its precision. 
A14: I have the results from my healthcare. 
A15: Being checked and advised about healthy lifestyle. 
A16: I find it very interesting. 
A17: No comment 
 
Question 2: Is there anything that you disliked about the AVIDNO Study? 
A1: No 
A2: No 
A3: The first cotton ball to chew. 
A4: None 
A5: Cotton ball chewing. 
A6: Have a limited dinner. 
A7: The blood monitor was difficult to set to work. 
A8: Not really. 
A9: No 
A10: No 
A11: No 
A12: None 
A13: No 
A14: No 
A15: No 
A16: No 
A17: No 
 
Question 3: If a similar study was conducted in the future, would you be likely to participate? 
A1: Yes, if I am still in Newcastle 
A2: Yes 
A3: Yes 
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A4: Yes 
A5: Yes 
A6: Not really sure at this moment. 
A7: Yes 
A8: Yes 
A9: Yes 
A10: Yes 
A11: Yes 
A12: Yes 
A13: Yes 
A14: Yes 
A15: Yes 
A16: Yes 
A17: Yes 
 
Question 4: Would you add any additional tests or measurements to the ones we took as part of this 
study? 
A1: No 
A2: No 
A3: Not qualified to suggest any. 
A4: Provide extra cotton balls. 
A5: Do not know 
A6: Not sure 
A7: No 
A8: No 
A9: No 
A10: No 
A11: I think it would be better to do it over two days 
A12: No 
A13: No 
A14: No 
A15: No 
A16: No 
A17: No 
 
Question 5: What do you think is an appropriate length of time for a study visit?  
A1: 1 hour 
A2: 2 hours 
A3: 1 hour 
A4: 1 hour 
A5: Less than 2 hours is ok. 
A6: About 1 hour 
A7: 1 hour and half 
A8: 1 hour 
A9: 2 hours 
A10: Whatever is necessary 
A11: 1 hour 
A12: 90 minutes 
A13: Just nice 
A14: 1 and half hour 
A15: There is no time limit 
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A16: No comment 
A17: 1 hour 
Question 6: What is the maximum time you would be willing to attend a study visit? 
 
A1: 2 hour 
A2: 4 hours 
A3: 2 hour 
A4: 1 hour 
A5: No limit. 
A6: Whatever was needed 
A7: 1 hour and half 
A8: 1 hour 
A9: 2 hours 
A10: As long as necessary 
A11: 1 hour 
A12: 90 minutes 
A13: Just nice 
A14: 1 and half hour 
A15: There is no time limit 
A16: Depends what the study was 
A17: 1 hour 
 
Question 7: Are there any improvements that could be made to the study? 
A1: No 
A2: No 
A3: Not that I am aware of 
A4: None 
A5: Not enough information to comment. 
A6: No 
A7: Feedback on results. 
A8: Not sure 
A9: No 
A10: No 
A11: No 
A12: No 
A13: No comments 
A14: No 
A15: No 
A16: No 
A17: No 
 
Question 8: Do you think the incentive we offer to the participants is sufficient? 
A1: Yes 
A2: Yes 
A3: Yes, generous 
A4: Yes 
A5: Yes 
A6: Yes 
A7: Yes 
A8: Yes 
A9: Yes 
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A10: Yes 
A11: Yes 
A12: Yes 
A13: Yes 
A14: Yes 
A15: Yes 
A16: Yes 
A17: No, because the time that a person does to help this study is quite a while. 
 
Question 9: Do you have any additional comments? 
 
A1: No 
A2: No 
A3: No 
A4: No 
A5: Would like to hear about the study outcome 
A6: Glad to be involved 
A7: The FFQ and Q39 no option for baking roasting which is how I often cook vegetables 
A8: No 
A9: No 
A10: No 
A11: Nil 
A12: No 
A13: No 
A14: No 
A15: No 
A16: The only thing I found that it was not attending the university it was ongoing at home therefore I think 
participant should be offered more. 
A17: No 
 
 
 
 
 
 
 
 
 
 
 
 
 268 
 
 
References 
 
Agapitov, A.V. and Haynes, W.G. (2002) 'Role of endothelin in cardiovascular disease', J 
Renin Angiotensin Aldosterone Syst, 3(1), pp. 1-15. 
 
Ahmed, S., Ratanapo, S., Kittanamongkolchai, W., Cheungpasitporn, W., Suksaranjit, P. 
and Chongnarungsin, D. (2013) 'Vitamin D deficiency and cardiovascular disease', Swiss 
medical weekly, 143. 
 
Ahren, C., Jungersten, L. and Sandberg, T. (1999) 'Plasma nitrate as an index of nitric oxide 
formation in patients with acute infectious diseases', Scand J Infect Dis, 31(4), pp. 405-7. 
 
Aihara, K., Azuma, H. and Matsumoto, T. (2006) '[Vitamin D-vitamin D receptor system 
regulates antithrombogenicity in vivo]', Clinical Calcium, 16(7), pp. 1173-79. 
 
Al-Qaisi, M., Kharbanda, R.K., Mittal, T.K. and Donald, A.E. (2008) 'Measurement of 
endothelial function and its clinical utility for cardiovascular risk', Vasc Health Risk 
Manag, 4(3), pp. 647-52. 
 
Al-Shoumer, K.A.S. and Al-Essa, T.M. (2015) 'Is there a relationship between vitamin D 
with insulin resistance and diabetes mellitus?', World Journal of Diabetes, 6(8), pp. 1057-
1064. 
 
Al Mheid, I., Patel, R., Murrow, J., Morris, A., Rahman, A., Fike, L., Kavtaradze, N., 
Uphoff, I., Hooper, C., Tangpricha, V., Alexander, R.W., Brigham, K. and Quyyumi, A.A. 
(2011) 'Vitamin D status is associated with arterial stiffness and vascular dysfunction in 
healthy humans', J Am Coll Cardiol, 58(2), pp. 186-92. 
 
Alberts, B., Johnson, A. and Lewis, J., et al. (2002) 'Blood Vessels and Endothelial Cells', 
in  Molecular Biology of the Cell. 4th edn. 
 
Almirall, J., Vaqueiro, M., Bare, M.L. and Anton, E. (2010) 'Association of low serum 25-
hydroxyvitamin D levels and high arterial blood pressure in the elderly', Nephrology 
Dialysis Transplantation, 25(2), pp. 503-9. 
 
Alsancak, Y., Cengel, A., Akyel, A., Ozkan, S., Sezenoz, B., Unlu, S., Kiziltunc, E., 
Akboga, M.K., Alsancak, A.D., Elbeg, S., Sahinarslan, A. and Yalcın, M.R. (2015) 
'Relationship between serum vitamin D levels and angiographic severity and extent of 
coronary artery disease', European Journal of Clinical Investigation, 45(9), pp. 940-948. 
 
Alyahya, K.O. (2017) Vitamin D levels in schoolchildren: a cross-sectional study in Kuwait 
BMC Pediatrics. 17:213 
 
Alyami, A., Soares, M.J., Sherriff, J.L. and Mamo, J.C. (2014) 'Vitamin D & endothelial 
function', The Indian Journal of Medical Research, 140(4), pp. 483-490. 
 
 269 
 
Anderson, E.A. and Mark, A.L. (1989) 'Flow-mediated and reflex changes in large 
peripheral artery tone in humans', Circulation, 79(1), pp. 93-100. 
 
Anderson, J.L., May, H.T., Horne, B.D., Bair, T.L., Hall, N.L., Carlquist, J.F., Lappe, D.L. 
and Muhlestein, J.B. (2010) 'Relation of vitamin D deficiency to cardiovascular risk factors, 
disease status, and incident events in a general healthcare population', Am J Cardiol, 106(7), 
pp. 963-8. 
 
Andrukhova, O., Slavic, S., Zeitz, U., Riesen, S.C., Heppelmann, M.S., Ambrisko, T.D., 
Markovic, M., Kuebler, W.M. and Erben, R.G. (2014) 'Vitamin D is a regulator of 
endothelial nitric oxide synthase and arterial stiffness in mice', Molecular Endocrinology, 
28(1), pp. 53-64. 
 
Ardawi, M.S.M., Sibiany, A.M., Bakhsh, T.M., Qari, M.H. and Maimani, A.A. (2012) 
'High prevalence of vitamin D deficiency among healthy Saudi Arabian men: relationship 
to bone mineral density, parathyroid hormone, bone turnover markers, and lifestyle factors', 
Osteoporosis International, 23(2), pp. 675-686. 
 
Ashwell, M., Stone, E.M., Stolte, H., Cashman, K.D., Macdonald, H., Lanham-New, S., 
Hiom, S., Webb, A. and Fraser, D. (2010) 'UK Food Standards Agency Workshop Report: 
an investigation of the relative contributions of diet and sunlight to vitamin D status', Br J 
Nutr, 104(4), pp. 603-11. 
 
Asmar, R., Benetos, A., Topouchian, J., Laurent, P., Pannier, B., Brisac, A.M., Target, R. 
and Levy, B.I. (1995) 'Assessment of arterial distensibility by automatic pulse wave 
velocity measurement. Validation and clinical application studies', Hypertension, 26(3), pp. 
485-90. 
 
Avogaro, A., Toffolo, G., Kiwanuka, E., de Kreutzenberg, S.V., Tessari, P. and Cobelli, C. 
(2003) 'L-arginine-nitric oxide kinetics in normal and type 2 diabetic subjects: a stable-
labelled 15N arginine approach', Diabetes, 52(3), pp. 795-802. 
 
Bajaj, A., Stone, K.L., Peters, K., Parimi, N., Barrett-Connor, E., Bauer, D., Cawthon, P.M., 
Ensrud, K.E., Hoffman, A.R., Orwoll, E. and Schernhammer, E.S. (2014) 'Circulating 
Vitamin D, Supplement Use, and Cardiovascular Disease Risk: The MrOS Sleep Study', 
The Journal of Clinical Endocrinology & Metabolism, 99(9), pp. 3256-3262. 
 
Bassil, D., Rahme, M., Hoteit, M. and Fuleihan, G.E.-H. (2013) 'Hypovitaminosis D in the 
Middle East and North Africa: Prevalence, risk factors and impact on outcomes', Dermato-
endocrinology, 5(2), pp. 274-298. 
 
Bates, B., Cox, L., Nicholson, S., Page, P., Prentice, A., Steer, T. and Swan, G. (2016) 
National Diet and Nutrition Survey Results from Years 5 and 6 (combined) of the Rolling 
Programme (2012/2013 – 2013/2014) https://www.gov.uk/government/statistics/ndns-
results-from-years-5-and-6-combined. 
 
Bednarski, R., Donderski, R. and Manitius, J. (2007) '[Role of vitamin D3 in arterial blood 
pressure control]', Polski Merkuriusz Lekarski, 23(136), pp. 307-10. 
 
 270 
 
Beveridge, L.A. and Witham, M.D. (2013) 'Vitamin D and the cardiovascular system', 
Osteoporosis International, 24(8), pp. 2167-2180. 
 
Bhan, I. (2014) 'Vitamin D Binding Protein and Bone Health', International Journal of 
Endocrinology, Volume 2014, Article ID 561214,, p. 5 pages. 
 
Bikle, Daniel D. (2014) 'Vitamin D Metabolism, Mechanism of Action, and Clinical 
Applications', Chemistry & Biology, 21(3), pp. 319-329. 
 
Bland, J.M. and Altman, D.G. (1986) 'Statistical methods for assessing agreement between 
two methods of clinical measurement', Lancet, 1(8476), pp. 307-10. 
 
Blum, M., Dolnikowski, G., Seyoum, E., Harris, S.S., Booth, S.L., Peterson, J., Saltzman, 
E. and Dawson-Hughes, B. (2008) 'Vitamin D 3 in fat tissue', Endocrine, 33(1), pp. 90-94. 
 
Boger, R.H. (2004) 'Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide 
synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor', 
J Nutr, 134(10 Suppl), pp. 2842S-2847S; discussion 2853S. 
 
Böger, R.H., Bode-Böger, S.M., Szuba, A., Tsao, P.S., Chan, J.R., Tangphao, O., Blaschke, 
T.F. and Cooke, J.P. (1998) 'Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor 
for Endothelial Dysfunction', Its Role in Hypercholesterolemia, 98(18), pp. 1842-1847. 
 
Böhm, F. and Pernow, J. (2007) 'The importance of endothelin-1 for vascular dysfunction 
in cardiovascular disease', Cardiovascular Research, 76(1), pp. 8-18. 
 
Bondonno, C.P., Croft, K.D. and Hodgson, J.M. (2016) 'Dietary Nitrate, Nitric Oxide, and 
Cardiovascular Health', Crit Rev Food Sci Nutr, 56(12), pp. 2036-52. 
 
Bonilla, C., Ness, A.R., Wills, A.K., Lawlor, D.A., Lewis, S.J. and Davey Smith, G. (2014) 
'Skin pigmentation, sun exposure and vitamin D levels in children of the Avon Longitudinal 
Study of Parents and Children', BMC Public Health, 14, p. 597. 
 
Borgi, L., McMullan, C., Wohlhueter, A., Curhan, G.C., Fisher, N.D. and Forman, J.P. 
(2017) 'Effect of Vitamin D on Endothelial Function: A Randomized, Double-Blind, 
Placebo-Controlled Trial', Am J Hypertens, 30(2), pp. 124-129. 
 
Borissova, A.M., Tankova, T., Kirilov, G., Dakovska, L. and Kovacheva, R. (2003) 'The 
effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic 
patients', Int J Clin Pract, 57(4), pp. 258-61. 
 
Borsa, C., Ionescu, C. and Gradinaru, D. (2012) Oxidized LDL and NO Synthesis as 
Biomarkers of Atherogenesis - Correlations with Metabolic Profile in Elderly. 
 
Bouillon, R., Carmeliet, G., Verlinden, L., Van Etten, E., Verstuyf, A., Luderer, H.F., 
Lieben, L., Mathieu, C. and Demay, M. (2008) 'Vitamin D and human health: Lessons from 
vitamin D receptor null mice', Endocrine Reviews, 29(6), pp. 726-776. 
 
Bourque, S.L., Davidge, S.T. and Adams, M.A. (2011) 'The interaction between 
endothelin-1 and nitric oxide in the vasculature: new perspectives', American Journal of 
 271 
 
Physiology - Regulatory, Integrative and Comparative Physiology, 300(6), pp. R1288-
R1295. 
 
Boutens, L. and Stienstra, R. (2016) 'Adipose tissue macrophages: going off track during 
obesity', Diabetologia, 59, pp. 879-894. 
Brandenburg, V.M., Vervloet, M.G. and Marx, N. (2012) 'The role of vitamin D in 
cardiovascular disease: From present evidence to future perspectives', Atherosclerosis, 
225(2), pp. 253-263. 
 
Breslavsky, A., Frand, J., Matas, Z., Boaz, M., Barnea, Z. and Shargorodsky, M. (2013) 
'Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose 
homeostasis in type 2 diabetic patients', Clinical Nutrition, 32(6), pp. 970-975. 
 
British Heart Foundation (2015) Cardiovascular Disease Statistics,  2015. 
 
British Nutrition Foundation (2016) 'Nutrition Requirements'. 
 
Bruckdorfer, R. (2005) 'The basics about nitric oxide', Mol Aspects Med, 26(1-2), pp. 3-31. 
Bryan, N.S. and Grisham, M.B. (2007) 'Methods to Detect Nitric Oxide and its Metabolites 
in Biological Samples', Free radical biology & medicine, 43(5), pp. 645-657. 
 
Buck Institute for Research on Aging (2016) 'A new look at vitamin D challenges the 
current view of its benefits'. 
 
Calvert, J.W. and Lefer, D.J. (2010) 'Clinical translation of nitrite therapy for 
cardiovascular diseases', Nitric Oxide, 22(2), pp. 91-7. 
 
Campos-Outcalt, D. (2013) 'Vitamin D: When it helps, when it harms', Journal of Family 
Practice, 62(7), pp. 368-370. 
 
Cancello, R., Tordjman, J., Poitou, C., Guilhem, G., Bouillot, J.L., Hugol, D., Coussieu, 
C., Basdevant, A., Hen, A.B., Bedossa, P., Guerre-Millo, M. and Clément, K. (2006) 
'Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With 
Marked Hepatic Lesions in Morbid Human Obesity', Diabetes, 55(6), pp. 1554-1561. 
 
Cannon, B. (2013) 'Cardiovascular disease: Biochemistry to behaviour', Nature, 493(7434), 
pp. S2-S3. 
 
Casey, D.P., Beck, D.T. and Braith, R.W. (2007) 'Systemic Plasma Levels Of 
Nitrite/Nitrate (Nox) Reflect Brachial Flow-Mediated Dilation Responses In Young Men 
And Women', Clinical and Experimental Pharmacology and Physiology, 34(12), pp. 1291-
1293. 
 
Castillo, L., Beaumier, L., Ajami, A.M. and Young, V.R. (1996) 'Whole body nitric oxide 
synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling', 
Proceedings of the National Academy of Sciences of the United States of America, 93(21), 
pp. 11460-11465. 
 
 272 
 
Celermajer, D.S., Sorensen, K.E., Spiegelhalter, D.J., Georgakopoulos, D., Robinson, J. 
and Deanfield, J.E. (1994) 'Aging is associated with endothelial dysfunction in healthy men 
years before the age-related decline in women', J Am Coll Cardiol, 24(2), pp. 471-6. 
 
Cevik, D., Unay, O., Durmusoglu, F., Yurdun, T. and Bilsel, A.S. (2006) 'Plasma markers 
of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on 
ADMA', Vasc Med, 11(1), pp. 7-12. 
Chai, W., Cooney, R.V., Franke, A.A. and Bostick, R.M. (2013) 'Effects of calcium and 
vitamin D supplementation on blood pressure and serumlipids and carotenoids: A 
randomized, double-blind, placebo-controlled, clinicaltrial', Annals of Epidemiology, 
23(9), pp. 564-570. 
 
Chan, R., Chan, D., Woo, J., Ohlsson, C., Mellstrom, D., Kwok, T. and Leung, P. (2012) 
'Serum 25-hydroxyvitamin D and parathyroid hormone levels in relation to blood pressure 
in a cross-sectional study in older Chinese men', J Hum Hypertens, 26(1), pp. 20-7. 
 
Cho, S.W., Kim, B.K., Kim, J.H., Byun, Y.S., Goh, C.W., Rhee, K.J., Ahn, H.S., Lee, B.K. 
and Kim, B.O. (2013) 'Non-invasively measured aortic wave reflection and pulse pressure 
amplification are related to the severity of coronary artery disease', J Cardiol, 62(2), pp. 
131-7. 
 
Choi, H.R., Lee, S.W., Yeom, H., Jeon, D.H., Kim, H.C. and Youm, Y. (2017) 'Association 
between vitamin D status and asymmetric dimethylarginine (ADMA) concentration in the 
Korean elderly population', Maturitas, 102, pp. 13-17. 
 
Christakos, S., Ajibade, D.V., Dhawan, P., Fechner, A.J. and Mady, L.J. (2012) 'Vitamin 
D: metabolism', Rheum Dis Clin North Am, 38(1), pp. 1-11, vii. 
 
Christakos, S., Dhawan, P., Porta, A., Mady, L.J. and Seth, T. (2011) 'Vitamin D and 
Intestinal Calcium Absorption', Molecular and Cellular Endocrinology, 347(1-2), pp. 25-
29. 
 
Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B. and Graham, I. 
(1991) 'Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease', New 
England Journal of Medicine, 324(17), pp. 1149-1155. 
 
Codoner-Franch, P., Tavarez-Alonso, S., Simo-Jorda, R., Laporta-Martin, P., Carratala-
Calvo, A. and Alonso-Iglesias, E. (2012) 'Vitamin D status is linked to biomarkers of 
oxidative stress, inflammation, and endothelial activation in obese children', J Pediatr, 
161(5), pp. 848-54. 
 
Corretti, M.C., Anderson, T.J., Benjamin, E.J., Celermajer, D., Charbonneau, F., Creager, 
M.A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., Vallance, P., Vita, 
J. and Vogel, R. (2002) 'Guidelines for the ultrasound assessment of endothelial-dependent 
flow-mediated vasodilation of the brachial artery: a report of the International Brachial 
Artery Reactivity Task Force', J Am Coll Cardiol, 39(2), pp. 257-65. 
 
Cosenso-Martin, L.N. and Vilela-Martin, J.F. (2011) 'Is there an association between 
vitamin D and hypertension?', Recent Patents on Cardiovascular Drug Discovery, 6(2), pp. 
140-7. 
 273 
 
 
Crowther, M., Lim, W. and Crowther, M.A. (2010) 'Systematic review and meta-analysis 
methodology', Blood, 116(17), pp. 3140-6. 
 
Csonka, C., Páli, T., Bencsik, P., Görbe, A., Ferdinandy, P. and Csont, T. (2015) 
'Measurement of NO in biological samples', British Journal of Pharmacology, 172(6), pp. 
1620-1632. 
 
Cui, R., Iso, H., Pi, J., Kumagai, Y., Yamagishi, K., Tanigawa, T. and Shimamoto, T. 
(2007) 'Metabolic syndrome and urinary cGMP excretion in general population', 
Atherosclerosis, 190(2), pp. 423-8. 
 
Cummings, P. (2011) 'Arguments for and against standardized mean differences (effect 
sizes)', Arch Pediatr Adolesc Med, 165(7), pp. 592-6. 
 
Dahlof, B. (2010) 'Cardiovascular disease risk factors: epidemiology and risk assessment', 
Am J Cardiol, 105(1 Suppl), pp. 3a-9a. 
 
Dalan, R., Liew, H., Assam, P.N., Chan, E.S., Siddiqui, F.J., Tan, A.W., Chew, D.E., 
Boehm, B.O. and Leow, M.K. (2016a) 'A randomised controlled trial evaluating the impact 
of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: 
The DIMENSION trial', Diab Vasc Dis Res, 13(3), pp. 192-200. 
 
Dalan, R., Liew, H., Assam, P.N., Chan, E.S.Y., Siddiqui, F.J., Tan, A.W.K., Chew, 
D.E.K., Boehm, B.O. and Leow, M.K.S. (2016b) 'A randomised controlled trial evaluating 
the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes 
mellitus: The DIMENSION trial', Diabetes & Vascular Disease Research, 13(3), pp. 192-
200. 
 
Dalan, R., Liew, H., Tan, W.K.A., Chew, D.E.K. and Leow, M.K.-S. (2014) 'Vitamin D 
and the endothelium: basic, translational and clinical research updates', IJC Metabolic & 
Endocrine, 4, pp. 4-17. 
 
Dalen, J.E., Alpert, J.S., Goldberg, R.J. and Weinstein, R.S. (2014) 'The Epidemic of the 
20th Century: Coronary Heart Disease', The American Journal of Medicine, 127(9), pp. 
807-812. 
 
Danik, J.S. and Manson, J.E. (2012) 'Vitamin D and Cardiovascular Disease', Current 
treatment options in cardiovascular medicine, 14(4), pp. 414-424. 
 
Davis, J.S., Darcy, C.J., Yeo, T.W., Jones, C., McNeil, Y.R., Stephens, D.P., Celermajer, 
D.S. and Anstey, N.M. (2011) 'Asymmetric dimethylarginine, endothelial nitric oxide 
bioavailability and mortality in sepsis', PLoS One, 6(2), p. e17260. 
 
Dawodu, A. and Wagner, C.L. (2007) 'Mother-child vitamin D deficiency: an international 
perspective', Arch Dis Child, 92(9), pp. 737-40. 
 
de Boer, I.H., Tinker, L.F., Connelly, S., Curb, J.D., Howard, B.V., Kestenbaum, B., 
Larson, J.C., Manson, J.E., Margolis, K.L., Siscovick, D.S. and Weiss, N.S. (2008) 
 274 
 
'Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's 
Health Initiative', Diabetes Care, 31(4), pp. 701-7. 
 
Deleskog, A., Piksasova, O., Silveira, A., Gertow, K., Baldassarre, D., Veglia, F., Sennblad, 
B., Strawbridge, R.J., Larsson, M., Leander, K., Gigante, B., Kauhanen, J., Rauramaa, R., 
Smit, A.J., Mannarino, E., Giral, P., Gustafsson, S., Östenson, C.-G., Humphries, S.E., 
Tremoli, E., de Faire, U., Öhrvik, J. and Hamsten, A. (2013) 'Serum 25-Hydroxyvitamin D 
Concentration in Subclinical Carotid Atherosclerosis', Arteriosclerosis, Thrombosis, and 
Vascular Biology, 33(11), pp. 2633-2638. 
Dessein, P.H., Joffe, B.I. and Singh, S. (2005) 'Biomarkers of endothelial dysfunction, 
cardiovascular risk factors and atherosclerosis in rheumatoid arthritis', Arthritis Research 
& Therapy, 7(3), pp. R634-R643. 
 
Dietary Reference Intakes for Calcium and Vitamin D (2011). The National Academies 
Press. 
Dobnig, H., Pilz, S., Scharnagl, H. and et al. (2008) 'Independent association of low serum 
25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular 
mortality', Archives of Internal Medicine, 168(12), pp. 1340-1349. 
 
Dorjgochoo, T., Shu, X.O., Xiang, Y.-B., Yang, G., Cai, Q., Li, H., Ji, B.-T., Cai, H., Gao, 
Y.-T. and Zheng, W. (2012) 'Circulating 25-hydroxyvitamin D levels in relation to blood 
pressure parameters and hypertension in the Shanghai Women’s and Men’s Health Studies', 
The British journal of nutrition, 108(3), pp. 449-458. 
 
Drincic, A.T., Armas, L.A., Van Diest, E.E. and Heaney, R.P. (2012) 'Volumetric dilution, 
rather than sequestration best explains the low vitamin D status of obesity', Obesity (Silver 
Spring), 20(7), pp. 1444-8. 
 
Dua, S., Bhuker, M., Sharma, P., Dhall, M. and Kapoor, S. (2014) 'Body Mass Index 
Relates to Blood Pressure Among Adults', North American Journal of Medical Sciences, 
6(2), pp. 89-95. 
 
Duckles, S.P. and Miller, V.M. (2010) 'Hormonal modulation of endothelial NO 
production', Pflugers Archiv : European journal of physiology, 459(6), pp. 841-851. 
 
Duygu, Ç., Özlem, U., Fatih, D., Türkan, Y. and Bilsel, A.S. (2006) 'Plasma markers of 
NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on 
ADMA', Vascular Medicine, 11(1), pp. 7-12. 
 
Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) 'Bias in meta-analysis 
detected by a simple, graphical test', Bmj, 315(7109), pp. 629-34. 
 
Eisman, J.A., Shepard, R.M. and DeLuca, H.F. (1977) 'Determination of 25-
hydroxyvitamin D2 and 25-hydroxyvitamin D3 in human plasma using high-pressure 
liquid chromatography', Analytical Biochemistry, 80(1), pp. 298-305. 
 
El Assar, M., Angulo, J., Vallejo, S., Peiró, C., Sánchez-Ferrer, C.F. and Rodríguez-Mañas, 
L. (2012) 'Mechanisms Involved in the Aging-Induced Vascular Dysfunction', Frontiers in 
Physiology, 3, p. 132. 
 
 275 
 
Elamin, M.B., Abu Elnour, N.O., Elamin, K.B., Fatourechi, M.M., Alkatib, A.A., 
Almandoz, J.P., Liu, H., Lane, M.A., Mullan, R.J., Hazem, A., Erwin, P.J., Hensrud, D.D., 
Murad, M.H. and Montori, V.M. (2011) 'Vitamin D and cardiovascular outcomes: A 
systematic review and meta-analysis', Journal of Clinical Endocrinology and Metabolism, 
96(7), pp. 1931-1942. 
Elesber, A.A., Bonetti, P.O. and Lerman, A. (2006) 'Endothelial function and 
cerebrovascular disease: implications for diagnosis and treatment', Curr Treat Options 
Cardiovasc Med, 8(3), pp. 213-9. 
 
Eleuterio, N.M., Palei, A.C.T., Rangel Machado, J.S., Tanus-Santos, J.E., Cavalli, R.C. and 
Sandrim, V.C. (2013) 'Relationship between adiponectin and nitrite in healthy and 
preeclampsia pregnancies', Clinica Chimica Acta, 423, pp. 112-115. 
 
Endemann, D.H. and Schiffrin, E.L. (2004) 'Endothelial Dysfunction', Journal of the 
American Society of Nephrology, 15(8), pp. 1983-1992. 
 
Ertek, S., Akgül, E., Cicero, A.F., Kütük, U., Demirtaş, S., Çehreli, S. and Erdoğan, G. 
(2012) '25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive 
women', Archives of Medical Science : AMS, 8(1), pp. 47-52. 
 
Eyles, D., Anderson, C., Ko, P., Jones, A., Thomas, A., Burne, T., Mortensen, P.B., 
Norgaard-Pedersen, B., Hougaard, D.M. and McGrath, J. (2009) 'A sensitive LC/MS/MS 
assay of 25OH vitamin D3 and 25OH vitamin D2 in dried blood spots', Clin Chim Acta, 
403(1-2), pp. 145-51. 
 
Felber, J.P. and Golay, A. (2002) 'Pathways from obesity to diabetes', Int J Obes Relat 
Metab Disord, 26 Suppl 2, pp. S39-45. 
 
Ferder, M., Inserra, F., Manucha, W. and Ferder, L. (2013) 'The world pandemic of vitamin 
D deficiency could possibly be explained by cellular inflammatory response activity 
induced by the renin-angiotensin system', American Journal of Physiology - Cell 
Physiology, 304(11), pp. C1027-C1039. 
 
Flammer, A.J., Anderson, T., Celermajer, D.S., Creager, M.A., Deanfield, J., Ganz, P., 
Hamburg, N.M., Lüscher, T.F., Shechter, M., Taddei, S., Vita, J.A. and Lerman, A. (2012) 
'The Assessment of Endothelial Function', From Research Into Clinical Practice, 126(6), 
pp. 753-767. 
 
Ford, J.A., MacLennan, G.S., Avenell, A., Bolland, M., Grey, A. and Witham, M. (2014) 
'Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, 
and meta-analysis', Am J Clin Nutr, 100(3), pp. 746-55. 
 
Forman, J.P., Giovannucci, E., Holmes, M.D., Bischoff-Ferrari, H.A., Tworoger, S.S., 
Willett, W.C. and Curhan, G.C. (2007) 'Plasma 25-hydroxyvitamin D levels and risk of 
incident hypertension', Hypertension, 49(5), pp. 1063-9. 
 
Forouhi, N.G., Luan, J.a., Cooper, A., Boucher, B.J. and Wareham, N.J. (2008) 'Baseline 
Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin 
Resistance : The Medical Research Council Ely Prospective Study 1990–2000', Diabetes, 
57(10), pp. 2619-2625. 
 276 
 
 
Forstermann, U. (2010) 'Nitric oxide and oxidative stress in vascular disease', Pflugers 
Arch, 459(6), pp. 923-39. 
 
Forstermann, U. and Sessa, W.C. (2012) 'Nitric oxide synthases: regulation and function', 
Eur Heart J, 33(7), pp. 829-37, 837a-837d. 
 
Forte, P., Copland, M., Smith, L.M., Milne, E., Sutherland, J. and Benjamin, N. (1997) 
'Basal nitric oxide synthesis in essential hypertension', Lancet, 349(9055), pp. 837-42. 
 
Forte, P., Ogborn, M.R. and Lilley-Chan, T. (2006) 'A Noninvasive, Sensitive, Specific, 
and Reliable Approach to Assess Whole-Body Nitric Oxide Synthesis in Children', Pediatr 
Res, 59(5), pp. 736-741. 
 
Francis, S.H., Busch, J.L. and Corbin, J.D. (2010) 'cGMP-Dependent Protein Kinases and 
cGMP Phosphodiesterases in Nitric Oxide and cGMP Action', Pharmacological Reviews, 
62(3), pp. 525-563. 
 
Franklin, S.S., Thijs, L., Asayama, K., Li, Y., Hansen, T.W., Boggia, J., Jacobs, L., Zhang, 
Z., Kikuya, M., Bjorklund-Bodegard, K., Ohkubo, T., Yang, W.Y., Jeppesen, J., Dolan, E., 
Kuznetsova, T., Stolarz-Skrzypek, K., Tikhonoff, V., Malyutina, S., Casiglia, E., Nikitin, 
Y., Lind, L., Sandoya, E., Kawecka-Jaszcz, K., Filipovsky, J., Imai, Y., Wang, J.G., 
O'Brien, E. and Staessen, J.A. (2016) 'The Cardiovascular Risk of White-Coat 
Hypertension', J Am Coll Cardiol, 68(19), pp. 2033-2043. 
 
Frayn, K. and Stanner, S. (2008) 'The Aetiology and Epidemiology of Cardiovascular 
Disease', in Frayn, K. and Stanner, S. (eds.) Cardiovascular Disease. Blackwell Publishing 
Ltd, pp. 1-21. 
 
Gallagher, J.C. (2013) 'Vitamin D and Aging', Endocrinology and metabolism clinics of 
North America, 42(2), pp. 319-332. 
 
Gannage-Yared, M.H., Chedid, R., Khalife, S., Azzi, E., Zoghbi, F. and Halaby, G. (2009) 
'Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a 
young Middle-Eastern population', Eur J Endocrinol, 160(6), pp. 965-71. 
 
Gepner, A.D., Haller, I.V., Krueger, D.C., Korcarz, C.E., Binkley, N. and Stein, J.H. (2015) 
'A Randomized Controlled Trial of the Effects of Vitamin D Supplementation on Arterial 
Stiffness and Aortic Blood Pressure in Native American Women', Atherosclerosis, 240(2), 
pp. 526-528. 
 
Gepner, A.D., Ramamurthy, R., Krueger, D.C., Korcarz, C.E., Binkley, N. and Stein, J.H. 
(2012) 'A prospective randomized controlled trial of the effects of vitamin D 
supplementation on cardiovascular disease risk', PLoS ONE [Electronic Resource], 7(5), 
p. e36617. 
 
Giallauria, F., Milaneschi, Y., Tanaka, T., Maggio, M., Canepa, M., Elango, P., Vigorito, 
C., Lakatta, E.G., Ferrucci, L. and Strait, J. (2012) 'Arterial stiffness and vitamin D levels: 
the Baltimore longitudinal study of aging', J Clin Endocrinol Metab, 97(10), pp. 3717-23. 
 
 277 
 
Gilchrist, M., Shore, A.C. and Benjamin, N. (2011) 'Inorganic nitrate and nitrite and control 
of blood pressure', Cardiovasc Res, 89(3), pp. 492-8. 
 
Gillespie, L.D., Robertson, M.C., Gillespie, W.J., Sherrington, C., Gates, S., Clemson, 
L.M. and Lamb, S.E. (2012) 'Interventions for preventing falls in older people living in the 
community', Cochrane Database Syst Rev, (9), p. Cd007146. 
 
Giovannucci, E. (2005) 'The epidemiology of vitamin D and cancer incidence and 
mortality: a review (United States)', Cancer Causes Control, 16(2), pp. 83-95. 
 
Giovannucci, E., Liu, Y., Hollis, B.W. and Rimm, E.B. (2008) '25-hydroxyvitamin d and 
risk of myocardial infarction in men: A prospective study', Archives of Internal Medicine, 
168(11), pp. 1174-1180. 
 
Gloth (1995) 'Vitamin D Deficiency in Homebound Elderly Persons', Journal of the 
American Medical Association. , 274(21), pp. 1683-1686. 
 
Gradinaru, D., Borsa, C., Ionescu, C. and Prada, G.I. (2015) 'Oxidized LDL and NO 
synthesis—Biomarkers of endothelial dysfunction and ageing', Mechanisms of Ageing and 
Development, 151, pp. 101-113. 
 
Grandi, N.C., Breitling, L.P. and Brenner, H. (2010) 'Vitamin D and cardiovascular disease: 
systematic review and meta-analysis of prospective studies', Prev Med, 51(3-4), pp. 228-
33. 
 
Green, L.C., Ruiz de Luzuriaga, K., Wagner, D.A., Rand, W., Istfan, N., Young, V.R. and 
Tannenbaum, S.R. (1981) 'Nitrate biosynthesis in man', Proc Natl Acad Sci U S A, 78(12), 
pp. 7764-8. 
 
Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S. and Tannenbaum, 
S.R. (1982) 'Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids', Analytical 
Biochemistry, 126(1), pp. 131-138. 
 
Greene-Finestone, L.S et al. (2017) Pediatr. Child Health 22: 439 -444. 
 
Greenberg, S.S., Xie, J., Spitzer, J.J., Wang, J.F., Lancaster, J., Grisham, M.B., Powers, 
D.R. and Giles, T.D. (1995) 'Nitro containing L-arginine analogs interfere with assays for 
nitrate and nitrite', Life Sci, 57(21), pp. 1949-61. 
 
Gulseth, H.L., Wium, C., Angel, K., Eriksen, E.F. and Birkeland, K.I. (2017) 'Effects of 
Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With 
Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial', Diabetes 
Care, 40(7), pp. 872-878. 
 
Gutzki, F.M., Tsikas, D., Alheid, U. and Frolich, J.C. (1992) 'Determination of 
endothelium-derived nitrite/nitrate by gas chromatography/tandem mass spectrometry 
using (15N)NaNO2 as internal standard', Biol Mass Spectrom, 21(2), pp. 97-102. 
 
Haberka, M., Mizia-Stec, K., Gąsior, Z., Mizia, M., Janowska, J., Holecki, M. and 
Zahorska-Markiewicz, B. (2009) 'Serum ADMA concentration – an independent factor 
 278 
 
determining FMD impairment in cardiac syndrome X', Upsala Journal of Medical 
Sciences, 114(4), pp. 221-227. 
 
Habib, S. and Ali, A. (2011) 'Biochemistry of Nitric Oxide', Indian Journal of Clinical 
Biochemistry, 26(1), pp. 3-17. 
Haddad, J.G. (1995) 'Plasma vitamin D-binding protein (Gc-globulin): multiple tasks', J 
Steroid Biochem Mol Biol, 53(1-6), pp. 579-82. 
 
Haddad, J.G., Matsuoka, L.Y., Hollis, B.W., Hu, Y.Z. and Wortsman, J. (1993) 'Human 
plasma transport of vitamin D after its endogenous synthesis', J Clin Invest, 91(6), pp. 2552-
5. 
 
Hakim, T.S., Sugimori, K., Camporesi, E.M. and Anderson, G. (1996) 'Half-life of nitric 
oxide in aqueous solutions with and without haemoglobin', Physiol Meas, 17(4), pp. 267-
77. 
 
Halliwell, B. (1997) 'What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of 
peroxynitrite formation in vivo?', FEBS Letters, 411(2–3), pp. 157-160. 
 
Hansson, G.K. (2005) 'Inflammation, atherosclerosis, and coronary artery disease', N Engl 
J Med, 352(16), pp. 1685-95. 
 
Harris, R.A., Nishiyama, S.K., Wray, D.W. and Richardson, R.S. (2010) 'Ultrasound 
Assessment of Flow-Mediated Dilation', Hypertension, 55(5), pp. 1075-1085. 
 
Harris, R.A., Pedersen-White, J., Guo, D.H., Stallmann-Jorgensen, I.S., Keeton, D., Huang, 
Y., Shah, Y., Zhu, H. and Dong, Y. (2011a) 'Vitamin D3 supplementation for 16 weeks 
improves flow-mediated dilation in overweight African-American adults', American 
Journal of Hypertension, 24(5), pp. 557-62. 
 
Harris, R.A., Pedersen-White, J., Guo, D.H., Stallmann-Jorgensen, I.S., Keeton, D., Huang, 
Y., Zhu, H., Shah, Y. and Dong, Y. (2011b) 'Vitamin D improves flow-mediated dilation 
in African American adults', FASEB Journal, 25. 
 
Harris, S.S. (2005) 'Vitamin D in type 1 diabetes prevention', J Nutr, 135(2), pp. 323-5. 
 
Hashikabe, Y., Suzuki, K., Jojima, T., Uchida, K. and Hattori, Y. (2006) 'Aldosterone 
impairs vascular endothelial cell function', J Cardiovasc Pharmacol, 47(4), pp. 609-13. 
 
Haussler, M.R., Jurutka, P.W., Hsieh, J.C., Thompson, P.D., Selznick, S.H., Haussler, C.A. 
and Whitfield, G.K. (1995) 'New understanding of the molecular mechanism of receptor-
mediated genomic actions of the vitamin D hormone', Bone, 17(2), pp. S33-S38. 
 
Haussler, M.R., Jurutka, P.W., Mizwicki, M. and Norman, A.W. (2011) 'Vitamin D 
receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-
genomic mechanisms', Best Pract Res Clin Endocrinol Metab, 25(4), pp. 543-59. 
 
Hayashi, T., Yamada, K., Esaki, T., Kuzuya, M., Satake, S., Ishikawa, T., Hidaka, H. and 
Iguchi, A. (1995) 'Estrogen increases endothelial nitric oxide by a receptor-mediated 
system', Biochem Biophys Res Commun, 214(3), pp. 847-55. 
 279 
 
 
Heath, A.K., Williamson, E.J., Ebeling, P.R., Kvaskoff, D., Eyles, D.W. and English, D.R. 
(2014) 'Measurements of 25-hydroxyvitamin D concentrations in archived dried blood 
spots are reliable and accurately reflect those in plasma', J Clin Endocrinol Metab, 99(9), 
pp. 3319-24. 
Hetrick, E.M. and Schoenfisch, M.H. (2009) 'Analytical chemistry of nitric oxide', Annu 
Rev Anal Chem (Palo Alto Calif), 2, pp. 409-33. 
 
Hewitt, N.A., O'Connor, A.A., O'Shaughnessy, D.V. and Elder, G.J. (2013) 'Effects of 
cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in 
hemodialysis patients', Clinical Journal of The American Society of Nephrology: CJASN, 
8(7), pp. 1143-9. 
 
Higashi, Y., Noma, K., Yoshizumi, M. and Kihara, Y. (2009) 'Endothelial Function and 
Oxidative Stress in Cardiovascular Diseases', Circulation Journal, 73(3), pp. 411-418. 
 
Higgins, J.P.T. and Green, S. (2008) 'Guide to the Contents of a Cochrane Protocol and 
Review', in  Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & 
Sons, Ltd, pp. 51-79. 
 
Higgins, J.P.T., Thompson, S.G., Deeks, J.J. and Altman, D.G. (2003) Measuring 
inconsistency in meta-analyses. 
 
Hill, T.R., Granic, A., Davies, K., Collerton, J., Martin-Ruiz, C., Siervo, M., Mathers, J.C., 
Adamson, A.J., Francis, R.M., Pearce, S.H., Razvi, S., Kirkwood, T.B.L. and Jagger, C. 
(2016) 'Serum 25-hydroxyvitamin D concentration and its determinants in the very old: the 
Newcastle 85+ Study', Osteoporosis International, 27(3), pp. 1199-1208. 
 
Hintzpeter, B., Mensink, G.B., Thierfelder, W., Muller, M.J. and Scheidt-Nave, C. (2008) 
'Vitamin D status and health correlates among German adults', Eur J Clin Nutr, 62(9), pp. 
1079-89. 
 
Holick, M. (2011) Vitamin D: Evolutionary, Physiological and Health Perspectives. 
 
Holick, M.F. (1996) 'Vitamin D and bone health', J Nutr, 126(4 Suppl), pp. 1159s-64s. 
 
Holick, M.F. (1998) 'Vitamin D requirements for humans of all ages: new increased 
requirements for women and men 50 years and older', Osteoporos Int, 8 Suppl 2, pp. S24-
9. 
 
Holick, M.F. (2007) 'Vitamin D Deficiency', New England Journal of Medicine, 357(3), 
pp. 266-281. 
 
Holick, M.F. (2008) 'The vitamin D deficiency pandemic and consequences for nonskeletal 
health: Mechanisms of action', Molecular Aspects of Medicine, 29(6), pp. 361-368. 
 
Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, 
R.P., Murad, M.H. and Weaver, C.M. (2011) 'Evaluation, treatment, and prevention of 
vitamin D deficiency: an Endocrine Society clinical practice guideline', J Clin Endocrinol 
Metab, 96(7), pp. 1911-30. 
 280 
 
 
Holick, M.F., MacLaughlin, J.A., Clark, M.B., Holick, S.A., Potts, J.T., Jr., Anderson, 
R.R., Blank, I.H., Parrish, J.A. and Elias, P. (1980) 'Photosynthesis of previtamin D3 in 
human skin and the physiologic consequences', Science, 210(4466), pp. 203-5. 
Hollis, B.W., Kamerud, J.Q., Kurkowski, A., Beaulieu, J. and Napoli, J.L. (1996) 
'Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-
labeled tracer', Clin Chem, 42(4), pp. 586-92. 
 
Hord, N.G., Tang, Y. and Bryan, N.S. (2009) 'Food sources of nitrates and nitrites: the 
physiologic context for potential health benefits', Am J Clin Nutr, 90(1), pp. 1-10. 
 
Hossein-nezhad, A. and Holick, M.F. (2013) 'Vitamin D for Health: A Global Perspective', 
Mayo Clinic proceedings. Mayo Clinic, 88(7), pp. 720-755. 
 
Hosseinpanah, F., pour, S.H., Heibatollahi, M., Moghbel, N., Asefzade, S. and Azizi, F. 
(2010) 'The effects of air pollution on vitamin D status in healthy women: A cross sectional 
study', BMC Public Health, 10, pp. 519-519. 
 
Houghton, L.A. and Vieth, R. (2006) 'The case against ergocalciferol (vitamin D2) as a 
vitamin supplement', Am J Clin Nutr, 84(4), pp. 694-7. 
 
Hsia, J., Heiss, G., Ren, H., Allison, M., Dolan, N.C., Greenland, P., Heckbert, S.R., 
Johnson, K.C., Manson, J.E., Sidney, S. and Trevisan, M. (2007) 'Calcium/vitamin D 
supplementation and cardiovascular events', Circulation, 115(7), pp. 846-54. 
 
Hsieh, H.-J., Liu, C.-A., Huang, B., Tseng, A.H.H. and Wang, D.L. (2014) 'Shear-induced 
endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) 
and nitric oxide (NO) and the pathophysiological implications', Journal of Biomedical 
Science, 21(1), p. 3. 
 
Hunter, R.A., Storm, W.L., Coneski, P.N. and Schoenfisch, M.H. (2013) 'Inaccuracies of 
nitric oxide measurement methods in biological media', Analytical chemistry, 85(3), pp. 
1957-1963. 
 
Hussin, A.M., Ashor, A.W., Schoenmakers, I., Hill, T., Mathers, J.C. and Siervo, M. (2017) 
'Effects of vitamin D supplementation on endothelial function: a systematic review and 
meta-analysis of randomised clinical trials', European Journal of Nutrition, 56(3), pp. 
1095-1104. 
 
Hypponen, E., Boucher, B.J., Berry, D.J. and Power, C. (2008) '25-hydroxyvitamin D, IGF-
1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British 
Birth Cohort', Diabetes, 57(2), pp. 298-305. 
 
Hypponen, E. and Power, C. (2007) 'Hypovitaminosis D in British adults at age 45 y: 
nationwide cohort study of dietary and lifestyle predictors', Am J Clin Nutr, 85(3), pp. 860-
8. 
 
Ignarro, L.J., Adams, J.B., Horwitz, P.M. and Wood, K.S. (1986) 'Activation of soluble 
guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of 
heme-containing and heme-deficient enzyme forms', J Biol Chem, 261(11), pp. 4997-5002. 
 281 
 
 
Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin, D. and 
Calcium (2011) 'The National Academies Collection: Reports funded by National Institutes 
of Health', in Ross, A.C., Taylor, C.L., Yaktine, A.L. and Del Valle, H.B. (eds.) Dietary 
Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies 
Press (US) 
National Academy of Sciences. 
 
Jablonski, K.L., Chonchol, M., Pierce, G.L., Walker, A.E. and Seals, D.R. (2011) '25-
Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial 
dysfunction in middle-aged and older adults', Hypertension, 57(1), pp. 63-9. 
 
Jackson, S.J., Siervo, M., Persson, E., McKenna, L.M. and Bluck, L.J.C. (2008) 'A novel 
derivative for the assessment of urinary and salivary nitrate using gas chromatography mass 
spectrometry', Rapid communications in mass spectrometry : RCM, 22(24), pp. 4158-4164. 
 
Janssen, H.C.J.P., Samson, M.M. and Verhaar, H.J.J. (2002) 'Vitamin D deficiency, muscle 
function, and falls in elderly people', The American Journal of Clinical Nutrition, 75(4), 
pp. 611-615. 
 
Jenkins, D.J., Kendall, C.W., Nguyen, T.H., Teitel, J., Marchie, A., Chiu, M., Taha, A.Y., 
Faulkner, D.A., Kemp, T., Wong, J.M., de Souza, R., Emam, A., Trautwein, E.A., Lapsley, 
K.G., Holmes, C., Josse, R.G., Leiter, L.A. and Singer, W. (2007) 'Effect on hematologic 
risk factors for coronary heart disease of a cholesterol reducing diet', Eur J Clin Nutr, 61(4), 
pp. 483-92. 
 
Jorde, R. and Figenschau, Y. (2009) 'Supplementation with cholecalciferol does not 
improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D 
levels', Eur J Nutr, 48(6), pp. 349-54. 
 
Judd, S.E., Nanes, M.S., Ziegler, T.R., Wilson, P.W. and Tangpricha, V. (2008) 'Optimal 
vitamin D status attenuates the age-associated increase in systolic blood pressure in white 
Americans: results from the third National Health and Nutrition Examination Survey', Am 
J Clin Nutr, 87(1), pp. 136-41. 
 
Jurutka, P.W., Whitfield, G.K., Hsieh, J.C., Thompson, P.D., Haussler, C.A. and Haussler, 
M.R. (2001) 'Molecular nature of the vitamin D receptor and its role in regulation of gene 
expression', Rev Endocr Metab Disord, 2(2), pp. 203-16. 
 
Kamen, D.L. and Tangpricha, V. (2010) 'Vitamin D and molecular actions on the immune 
system: modulation of innate and autoimmunity', Journal of molecular medicine (Berlin, 
Germany), 88(5), pp. 441-450. 
 
Kannel, W.B. and McGee, D.L. (1979) 'Diabetes and cardiovascular disease. The 
Framingham study', Jama, 241(19), pp. 2035-8. 
 
Kassi, E., Adamopoulos, C., Basdra, E.K. and Papavassiliou, A.G. (2013) 'Role of Vitamin 
D in Atherosclerosis', Circulation, 128(23), pp. 2517-2531. 
 
 282 
 
Katusic, Z.S. (1996) 'Superoxide anion and endothelial regulation of arterial tone', Free 
Radic Biol Med, 20(3), pp. 443-8. 
 
Kaur, H. and Halliwell, B. (1994) 'Evidence for nitric oxide-mediated oxidative damage in 
chronic inflammation Nitrotyrosine in serum and synovial fluid from rheumatoid patients', 
FEBS Letters, 350(1), pp. 9-12. 
Kelm, M. (1999) 'Nitric oxide metabolism and breakdown', Biochimica et Biophysica Acta 
(BBA) - Bioenergetics, 1411(2–3), pp. 273-289. 
 
Kelm, M. (2002) 'Flow-mediated dilatation in human circulation: diagnostic and 
therapeutic aspects', American Journal of Physiology - Heart and Circulatory Physiology, 
282(1), pp. H1-H5. 
 
Kevin McKinney (2008) 'Association of race, body fat and season with vitamin D status 
among young women: a cross-sectional study', Clinical Endocrinology, 69(4), pp. 535-541. 
 
Kharitonov, S., Alving, K. and Barnes, P.J. (1997) 'Exhaled and nasal nitric oxide 
measurements: recommendations. The European Respiratory Society Task Force', 
European Respiratory Journal, 10(7), pp. 1683-1693. 
 
Khurana, R., Simons, M., Martin, J.F. and Zachary, I.C. (2005) 'Role of Angiogenesis in 
Cardiovascular Disease', A Critical Appraisal, 112(12), pp. 1813-1824. 
 
Kimlin, M.G. (2008) 'Geographic location and vitamin D synthesis', Molecular Aspects of 
Medicine, 29(6), pp. 453-461. 
 
Kinyamu, H.K., Gallagher, J.C., Prahl, J.M., DeLuca, H.F., Petranick, K.M. and Lanspa, 
S.J. (1997a) 'Association between intestinal vitamin D receptor, calcium absorption, and 
serum 1,25 dihydroxyvitamin D in normal young and elderly women', J Bone Miner Res, 
12(6), pp. 922-8. 
 
Kinyamu, H.K., Gallagher, J.C., Prahl, J.M., Deluca, H.F., Petranick, K.M. and Lanspa, 
S.J. (1997b) 'Association Between Intestinal Vitamin D Receptor, Calcium Absorption, and 
Serum 1,25 Dihydroxyvitamin D in Normal Young and Elderly Women', Journal of Bone 
and Mineral Research, 12(6), pp. 922-928. 
 
Kleinbongard, P., Dejam, A., Lauer, T., Jax, T., Kerber, S., Gharini, P., Balzer, J., Zotz, 
R.B., Scharf, R.E., Willers, R., Schechter, A.N., Feelisch, M. and Kelm, M. (2006) 'Plasma 
nitrite concentrations reflect the degree of endothelial dysfunction in humans', Free Radical 
Biology and Medicine, 40(2), pp. 295-302. 
 
Kliche, S. and Waltenberger, J. (2001) 'VEGF receptor signaling and endothelial function', 
IUBMB Life, 52(1-2), pp. 61-6. 
 
Knekt, P., Laaksonen, M., Mattila, C., Harkanen, T., Marniemi, J., Heliovaara, M., 
Rissanen, H., Montonen, J. and Reunanen, A. (2008) 'Serum vitamin D and subsequent 
occurrence of type 2 diabetes', Epidemiology, 19(5), pp. 666-71. 
 
Kook, H., Itoh, H., Choi, B.S., Sawada, N., Doi, K., Hwang, T.J., Kim, K.K., Arai, H., 
Baik, Y.H. and Nakao, K. (2003) 'Physiological concentration of atrial natriuretic peptide 
 283 
 
induces endothelial regeneration in vitro', American Journal of Physiology - Heart and 
Circulatory Physiology, 284(4), pp. H1388-H1397. 
 
Kubli, S., Waeber, B., Dalle-Ave, A. and Feihl, F. (2000) 'Reproducibility of laser Doppler 
imaging of skin blood flow as a tool to assess endothelial function', J Cardiovasc 
Pharmacol, 36(5), pp. 640-8. 
Kuwai, T. and Hayashi, J. (2006) 'Nitric Oxide Pathway Activation and Impaired Red 
Blood Cell Deformability with Hypercholesterolemia', Journal of Atherosclerosis and 
Thrombosis, 13(6), pp. 286-294. 
 
Laclaustra, M., Frangi, A.F., Garcia, D., Boisrobert, L., Frangi, A.G. and Pascual, I. (2007) 
'Detailed exploration of the endothelium: parameterization of flow-mediated dilation 
through principal component analysis', Physiol Meas, 28(3), pp. 301-20. 
 
Lai, W.K. and Kan, M.Y. (2015) 'Homocysteine-Induced Endothelial Dysfunction', Ann 
Nutr Metab, 67(1), pp. 1-12. 
 
Lakoski, S.G., Cushman, M., Siscovick, D.S., Blumenthal, R.S., Palmas, W., Burke, G. and 
Herrington, D.M. (2011) 'The relationship between inflammation, obesity and risk for 
hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA)', Journal of human 
hypertension, 25(2), pp. 73-79. 
 
Landim, M.B.P., Filho, A.C. and Chagas, A.C.P. (2009) 'Asymmetric Dimethylarginine 
(ADMA) and Endothelial Dysfunction: Implications for Atherogenesis', Clinics (Sao 
Paulo, Brazil), 64(5), pp. 471-478. 
 
Larkin, E.K., Gebretsadik, T., Koestner, N., Newman, M.S., Liu, Z., Carroll, K.N., Minton, 
P., Woodward, K. and Hartert, T.V. (2011) 'Agreement of blood spot card measurements 
of vitamin D levels with serum, whole blood specimen types and a dietary recall 
instrument', PLoS One, 6(1), p. e16602. 
 
Larsen, T., Mose, F.H., Bech, J.N., Hansen, A.B. and Pedersen, E.B. (2012) 'Effect of 
cholecalciferol supplementation during winter months in patients with hypertension: a 
randomized, placebo-controlled trial', American Journal of Hypertension, 25(11), pp. 1215-
22. 
 
Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C., Hayoz, D., 
Pannier, B., Vlachopoulos, C., Wilkinson, I. and Struijker-Boudier, H. (2006) 'Expert 
consensus document on arterial stiffness: methodological issues and clinical applications', 
Eur Heart J, 27(21), pp. 2588-605. 
 
Lavie, C.J., Dinicolantonio, J.J., Milani, R.V. and O'Keefe, J.H. (2013) 'Vitamin D and 
cardiovascular health', Circulation, 128(22), pp. 2404-2406. 
 
Leaf, C.D., Wishnok, J.S. and Tannenbaum, S.R. (1989) 'L-Arginine is a precursor for 
nitrate biosynthesis in humans', Biochemical and Biophysical Research Communications, 
163(2), pp. 1032-1037. 
 
 284 
 
Lee, J.H., O'Keefe, J.H., Bell, D., Hensrud, D.D. and Holick, M.F. (2008) 'Vitamin D 
Deficiency: An Important, Common, and Easily Treatable Cardiovascular Risk Factor?', 
Journal of the American College of Cardiology, 52(24), pp. 1949-1956. 
 
Lee, J.H. and Suh, H.S. (2017) 'Association of Serum 25-hydroxy-vitamin D Concentration 
and Arterial Stiffness among Korean Adults in Single Center', Journal of Bone Metabolism, 
24(1), pp. 51-58. 
Libby, P., Ridker, P.M. and Hansson, G.K. (2011) 'Progress and challenges in translating 
the biology of atherosclerosis', Nature, 473(7347), pp. 317-325. 
 
Libby, P., Ridker, P.M. and Maseri, A. (2002) 'Inflammation and Atherosclerosis', 
Circulation, 105(9), pp. 1135-1143. 
 
Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., 
Clarke, M., Devereaux, P.J., Kleijnen, J. and Moher, D. (2009) The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that evaluate healthcare 
interventions: explanation and elaboration. 
 
Lim, S., Shin, H., Kim, M.J., Ahn, H.Y., Kang, S.M., Yoon, J.W., Choi, S.H., Kim, K.W., 
Song, J.H., Choi, S.I., Chun, E.J., Shin, C.S., Park, K.S. and Jang, H.C. (2012) 'Vitamin D 
Inadequacy Is Associated with Significant Coronary Artery Stenosis in a Community-
Based Elderly Cohort: The Korean Longitudinal Study on Health and Aging', The Journal 
of Clinical Endocrinology & Metabolism, 97(1), pp. 169-178. 
 
Lin, M.I. and Sessa, W.C. (2006) 'Vascular Endothelial Growth Factor Signaling to 
Endothelial Nitric Oxide Synthase', More than a FLeeTing Moment, 99(7), pp. 666-668. 
 
Lips, P. (2006) 'Vitamin D physiology', Progress in Biophysics and Molecular Biology, 
92(1), pp. 4-8. 
 
Lips, P. (2012) 'Interaction between vitamin D and calcium', Scand J Clin Lab Invest Suppl, 
243, pp. 60-4. 
 
Liu, S., Song, Y., Ford, E.S., Manson, J.E., Buring, J.E. and Ridker, P.M. (2005) 'Dietary 
calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older 
U.S. women', Diabetes Care, 28(12), pp. 2926-32. 
 
Liu, Z.-M., Woo, J., Wu, S.-H. and Ho, S.C. (2013) 'The Role of Vitamin D in Blood 
Pressure, Endothelial and Renal Function in Postmenopausal Women', Nutrients, 5(7), pp. 
2590-2610. 
 
Longenecker, C.T., Hileman, C.O., Carman, T.L., Ross, A.C., Seydafkan, S., Brown, T.T., 
Labbato, D.E., Storer, N., Tangpricha, V. and McComsey, G.A. (2012) 'Vitamin D 
supplementation and endothelial function in vitamin D deficient HIV-infected patients: a 
randomized placebo-controlled trial', Antiviral Therapy, 17(4), pp. 613-21. 
 
Lundberg, J.O., Weitzberg, E. and Gladwin, M.T. (2008) 'The nitrate-nitrite-nitric oxide 
pathway in physiology and therapeutics', Nat Rev Drug Discov, 7(2), pp. 156-167. 
 
 285 
 
Mackay-Sim, A., Feron, F., Eyles, D., Burne, T. and McGrath, J. (2004) 'Schizophrenia, 
vitamin D, and brain development', Int Rev Neurobiol, 59, pp. 351-80. 
 
MacLaughlin, J. and Holick, M.F. (1985) 'Aging decreases the capacity of human skin to 
produce vitamin D3', Journal of Clinical Investigation, 76(4), pp. 1536-1538. 
 
Maestro, B., Campion, J., Davila, N. and Calle, C. (2000) 'Stimulation by 1,25-
dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose 
transport in U-937 human promonocytic cells', Endocr J, 47(4), pp. 383-91. 
 
Maestro, B., Molero, S., Bajo, S., Dávila, N. and Calle, C. (2002) 'Transcriptional activation 
of the human insulin receptor gene by 1,25-dihydroxyvitamin D3', Cell Biochemistry and 
Function, 20(3), pp. 227-232. 
 
Mair, J. and Puschendorf, B. (1998) 'Is Measurement of Cyclic Guanosine Monophosphate 
in Plasma or Urine Suitable for Assessing In Vivo Nitric Oxide Production?', Circulation, 
97(12), pp. 1209-1210. 
 
Majid Molla, A., Badawi, M.H., al-Yaish, S., Sharma, P., el-Salam, R.S. and Molla, A.M. 
(2000) 'Risk factors for nutritional rickets among children in Kuwait', Pediatr Int, 42(3), 
pp. 280-4. 
 
Mancia, G., Bombelli, M., Cuspidi, C., Facchetti, R. and Grassi, G. (2017) 'Cardiovascular 
Risk Associated With White Coat Hypertension', Pro Side of the Argument. 
 
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, 
G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, 
A., Schmieder, R.E., Struijker Boudier, H.A.J. and Zanchetti, A. (2007) '†2007 Guidelines 
for the management of arterial hypertension1 The Task Force for the Management of 
Arterial Hypertension of the European Society of Hypertension (ESH) and of the European 
Society of Cardiology (ESC)', European Heart Journal, 28(12), pp. 1462-1536. 
 
Manicourt, D.H. and Devogelaer, J.P. (2008) 'Urban tropospheric ozone increases the 
prevalence of vitamin D deficiency among Belgian postmenopausal women with outdoor 
activities during summer', J Clin Endocrinol Metab, 93(10), pp. 3893-9. 
 
Marckmann, P., Agerskov, H., Thineshkumar, S., Bladbjerg, E.M., Sidelmann, J.J., 
Jespersen, J., Nybo, M., Rasmussen, L.M., Hansen, D. and Scholze, A. (2012) 'Randomized 
controlled trial of cholecalciferol supplementation in chronic kidney disease patients with 
hypovitaminosis D', Nephrology Dialysis Transplantation, 27(9), pp. 3523-31. 
 
Margolis, K.L., Ray, R.M., Van Horn, L., Manson, J.E., Allison, M.A., Black, H.R., 
Beresford, S.A., Connelly, S.A., Curb, J.D., Grimm, R.H., Jr., Kotchen, T.A., Kuller, L.H., 
Wassertheil-Smoller, S., Thomson, C.A. and Torner, J.C. (2008) 'Effect of calcium and 
vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized 
Trial', Hypertension, 52(5), pp. 847-55. 
 
Martineau, A.R., Jolliffe, D.A., Hooper, R.L., Greenberg, L., Aloia, J.F., Bergman, P., 
Dubnov-Raz, G., Esposito, S., Ganmaa, D., Ginde, A.A., Goodall, E.C., Grant, C.C., 
Griffiths, C.J., Janssens, W., Laaksi, I., Manaseki-Holland, S., Mauger, D., Murdoch, D.R., 
 286 
 
Neale, R., Rees, J.R., Simpson, S., Stelmach, I., Kumar, G.T., Urashima, M. and Camargo, 
C.A. (2017) 'Vitamin D supplementation to prevent acute respiratory tract infections: 
systematic review and meta-analysis of individual participant data', BMJ, 356. 
 
Martins, D., Wolf, M., Pan, D., Zadshir, A., Tareen, N., Thadhani, R., Felsenfeld, A., 
Levine, B., Mehrotra, R. and Norris, K. (2007) 'Prevalence of cardiovascular risk factors 
and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third 
National Health and Nutrition Examination Survey', Arch Intern Med, 167(11), pp. 1159-
65. 
 
Mattila, C., Knekt, P., Mannisto, S., Rissanen, H., Laaksonen, M.A., Montonen, J. and 
Reunanen, A. (2007) 'Serum 25-hydroxyvitamin D concentration and subsequent risk of 
type 2 diabetes', Diabetes Care, 30(10), pp. 2569-70. 
 
Mazidi, M., Karimi, E., Rezaie, P. and Vatanparast, H. (2017) 'The impact of vitamin D 
supplement intake on vascular endothelial function; a systematic review and meta-analysis 
of randomized controlled trials', Food Nutr Res, 61(1), p. 1273574. 
 
Melamed, M.L., Michos, E.D., Post, W. and Astor, B. (2008) '25-hydroxyvitamin D levels 
and the risk of mortality in the general population', Arch Intern Med, 168(15), pp. 1629-37. 
Mertens, I.L. and van Gaal, L.F. (2000) 'Overweight, Obesity, and Blood Pressure: The 
Effects of Modest Weight Reduction', Obesity Research, 8(3), pp. 270-278. 
 
Metzger, I.F., Sertorio, J.T. and Tanus-Santos, J.E. (2006) 'Relationship between systemic 
nitric oxide metabolites and cyclic GMP in healthy male volunteers', Acta Physiol (Oxf), 
188(2), pp. 123-7. 
 
Michiels, C. (2003) 'Endothelial cell functions', J Cell Physiol, 196(3), pp. 430-43. 
 
Min, B. (2013) 'Effects of Vitamin D on Blood Pressure and Endothelial Function', The 
Korean Journal of Physiology & Pharmacology : Official Journal of the Korean 
Physiological Society and the Korean Society of Pharmacology, 17(5), pp. 385-392. 
 
Mishra, V.A., Harbada, R. and Sharma, A. (2015) 'Vitamin B12 and Vitamin D 
Deficiencies: An Unusual Cause of Fever, Severe Hemolytic Anemia and 
Thrombocytopenia', Journal of Family Medicine and Primary Care, 4(1), pp. 145-148. 
 
Mithal, A., Wahl, D.A., Bonjour, J.P., Burckhardt, P., Dawson-Hughes, B., Eisman, J.A., 
El-Hajj Fuleihan, G., Josse, R.G., Lips, P. and Morales-Torres, J. (2009) 'Global vitamin D 
status and determinants of hypovitaminosis D', Osteoporos Int, 20(11), pp. 1807-20. 
 
Miyazaki, H., Matsuoka, H., Cooke, J.P., Usui, M., Ueda, S., Okuda, S. and Imaizumi, T. 
(1999) 'Endogenous Nitric Oxide Synthase Inhibitor', A Novel Marker of Atherosclerosis, 
99(9), pp. 1141-1146. 
 
Molinari, C., Uberti, F., Grossini, E., Vacca, G., Carda, S., Invernizzi, M. and Cisari, C. 
(2011) '1alpha,25-dihydroxycholecalciferol induces nitric oxide production in cultured 
endothelial cells', Cellular Physiology & Biochemistry, 27(6), pp. 661-8. 
 
 287 
 
Monaco, C. (2016) 'The Effects of Dietary Nitrate Supplementation on Contractile 
Function and Mitochondrial Bioenergetics in the Heart '. 
Moore, C.E. and Ruppe, M. (2017) 'Vitamin D Supplementation Does Not Reduce Blood 
Pressure of Premenopausal African American Women', The FASEB Journal, 31(1 
Supplement), p. 800.7. 
 
Mosekilde, L. (2005) 'Vitamin D and the elderly', Clinical Endocrinology, 62(3), pp. 265-
281. 
 
Nadir, M.A., Szwejkowski, B.R. and Witham, M.D. (2010) 'Vitamin D and cardiovascular 
prevention', Cardiovasc Ther, 28(4), pp. e5-12. 
 
Nagpal, J., Pande, J.N. and Bhartia, A. (2009) 'A double-blind, randomized, placebo-
controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity 
in apparently healthy, middle-aged, centrally obese men', Diabet Med, 26(1), pp. 19-27. 
 
Nagpal, S., Na, S. and Rathnachalam, R. (2005) 'Noncalcemic actions of vitamin D receptor 
ligands', Endocrine Reviews, 26(5), pp. 662-687. 
 
Nair, S. (2010) 'Vitamin D Deficiency and Liver Disease', Gastroenterology & Hepatology, 
6(8), pp. 491-493. 
 
National Diet and Nutrition Survey (2011) 'Headline results from Years 1 and 2 (combined) 
of the Rolling Programme (2008/2009 – 2009/10) '. 
 
National Heart and Lung and Blood Institute (2016a) 'What is Coronary Heart Disease', 
National Institute of Health. 
 
National Heart and Lung and Blood Institute (2016b) 'What Is Peripheral Artery Disease?', 
National Institute of Health. 
 
Nemerovski, C.W., Dorsch, M.P., Simpson, R.U., Bone, H.G., Aaronson, K.D. and Bleske, 
B.E. (2009) 'Vitamin D and cardiovascular disease', Pharmacotherapy, 29(6), pp. 691-708. 
 
Nemirovskiy, O.V., Radabaugh, M.R., Aggarwal, P., Funckes-Shippy, C.L., Mnich, S.J., 
Meyer, D.M., Sunyer, T., Rodney Mathews, W. and Misko, T.P. (2009) 'Plasma 3-
nitrotyrosine is a biomarker in animal models of arthritis: Pharmacological dissection of 
iNOS’ role in disease', Nitric Oxide, 20(3), pp. 150-156. 
 
Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999) 'Vascular endothelial 
growth factor (VEGF) and its receptors', The FASEB Journal, 13(1), pp. 9-22. 
 
Ngim, C.A., Abdul Rahman, A.R. and Ibrahim, A. (1999) 'Pulse wave velocity as an index 
of arterial stiffness: a comparison between newly diagnosed (untreated) hypertensive and 
normotensive middle-aged Malay men and its relationship with fasting insulin', Acta 
Cardiol, 54(5), pp. 277-82. 
 
NICE (2016) 'Sunshine Exposure: Risks and Benefits', National Institute for Health and 
Care Excellence. 
 288 
 
 
Norman, A.W. (2008) 'From vitamin D to hormone D: fundamentals of the vitamin D 
endocrine system essential for good health', Am J Clin Nutr, 88(2), pp. 491s-499s. 
 
Norman, P.E. and Powell, J.T. (2014) 'Vitamin d and cardiovascular disease', Circ Res, 
114(2), pp. 379-93. 
North, B.J. and Sinclair, D.A. (2012) 'The Intersection Between Aging and Cardiovascular 
Disease', Circulation Research, 110(8), pp. 1097-1108. 
 
O'Connor (2011) 'An update on UK Vitamin D intakes and status, and issues for food 
fortification and supplementation', British Nutrition Foundation, 36(3), pp. 390-396. 
 
O’Leary, F. and Samman, S. (2010) 'Vitamin B(12) in Health and Disease', Nutrients, 2(3), 
pp. 299-316. 
 
Oberhelman, S.S., Meekins, M.E., Fischer, P.R., Lee, B.R., Singh, R.J., Cha, S.S., Gardner, 
B.M., Pettifor, J.M., Croghan, I.T. and Thacher, T.D. (2013) 'Maternal vitamin D 
supplementation to improve the vitamin D status of breast-fed infants: a randomized 
controlled trial', Mayo Clin Proc, 88(12), pp. 1378-87. 
 
Oliver, J.J. and Webb, D.J. (2003) 'Noninvasive Assessment of Arterial Stiffness and Risk 
of Atherosclerotic Events', Arteriosclerosis, Thrombosis, and Vascular Biology, 23(4), pp. 
554-566. 
 
Palacios, C. and Gonzalez, L. (2014) 'Is vitamin D deficiency a major global public health 
problem?', The Journal of steroid biochemistry and molecular biology, 144PA, pp. 138-
145. 
Palmer, R.M.J., Ashton, D.S. and Moncada, S. (1988) 'Vascular endothelial cells synthesize 
nitric oxide from L-arginine', Nature, 333(6174), pp. 664-666. 
 
Pasco, J.A., Henry, M.J., Nicholson, G.C., Brennan, S.L. and Kotowicz, M.A. (2009) 
'Behavioural and physical characteristics associated with vitamin D status in women', Bone, 
44(6), pp. 1085-1091. 
 
Pelletier, M.M., Kleinbongard, P., Ringwood, L., Hito, R., Hunter, C.J., Schechter, A.N., 
Gladwin, M.T. and Dejam, A. (2006) 'The measurement of blood and plasma nitrite by 
chemiluminescence: pitfalls and solutions', Free Radic Biol Med, 41(4), pp. 541-8. 
 
Perrault, L.P., Mahlberg, F., Breugnot, C., Bidouard, J.-P., Villeneuve, N., Vilaine, J.-P. 
and Vanhoutte, P.M. (2000) 'Hypercholesterolemia Increases Coronary Endothelial 
Dysfunction, Lipid Content, and Accelerated Atherosclerosis After Heart Transplantation', 
Arteriosclerosis, Thrombosis, and Vascular Biology, 20(3), pp. 728-736. 
 
Pettifor, J.M. (2004) 'Nutritional rickets: deficiency of vitamin D, calcium, or both?', Am J 
Clin Nutr, 80(6 Suppl), pp. 1725s-9s. 
 
Piknova, B., Park, J.W., Cassel, K.S., Gilliard, C.N. and Schechter, A.N. (2016) 'Measuring 
Nitrite and Nitrate, Metabolites in the Nitric Oxide Pathway, in Biological Materials using 
the Chemiluminescence Method', (118), p. e54879. 
 
 289 
 
Pilz, S., Gaksch, M., Kienreich, K., Grubler, M., Verheyen, N., Fahrleitner-Pammer, A., 
Treiber, G., Drechsler, C., B, O.H., Obermayer-Pietsch, B., Schwetz, V., Aberer, F., Mader, 
J., Scharnagl, H., Meinitzer, A., Lerchbaum, E., Dekker, J.M., Zittermann, A., Marz, W. 
and Tomaschitz, A. (2015) 'Effects of vitamin D on blood pressure and cardiovascular risk 
factors: a randomized controlled trial', Hypertension, 65(6), pp. 1195-201. 
 
Pilz, S., Tomaschitz, A., Ritz, E. and Pieber, T.R. (2009) 'Vitamin D status and arterial 
hypertension: a systematic review', Nat Rev Cardiol, 6(10), pp. 621-30. 
 
Pinder, A.G., Rogers, S.C., Khalatbari, A., Ingram, T.E. and James, P.E. (2008) 'The 
measurement of nitric oxide and its metabolites in biological samples by ozone-based 
chemiluminescence', Methods Mol Biol, 476, pp. 11-28. 
 
Pittas, A.G., Chung, M., Trikalinos, T., Mitri, J., Brendel, M., Patel, K., Lichtenstein, A.H., 
Lau, J. and Balk, E.M. (2010) 'Systematic review: Vitamin D and cardiometabolic 
outcomes', Annals of Internal Medicine, 152(5), pp. 307-314. 
 
Pittas, A.G., Dawson-Hughes, B., Li, T., Van Dam, R.M., Willett, W.C., Manson, J.E. and 
Hu, F.B. (2006) 'Vitamin D and calcium intake in relation to type 2 diabetes in women', 
Diabetes Care, 29(3), pp. 650-6. 
 
Pittas, A.G., Harris, S.S., Stark, P.C. and Dawson-Hughes, B. (2007a) 'The effects of 
calcium and vitamin D supplementation on blood glucose and markers of inflammation in 
nondiabetic adults', Diabetes Care, 30(4), pp. 980-6. 
 
Pittas, A.G., Lau, J., Hu, F.B. and Dawson-Hughes, B. (2007b) 'The role of vitamin D and 
calcium in type 2 diabetes. A systematic review and meta-analysis', J Clin Endocrinol 
Metab, 92(6), pp. 2017-29. 
 
Polly, P. and Tan, T.C. (2014) 'The role of vitamin D in skeletal and cardiac muscle 
function', Frontiers in Physiology, 5, p. 145. 
 
Pourshahidi, L.K. (2015) 'Vitamin D and obesity: current perspectives and future 
directions', The Nutrition Society, https://doi.org/10.1017/S0029665114001578.  
 
Pries, A.R., Secomb, T.W. and Gaehtgens, P. (2000) 'The endothelial surface layer', 
Pflugers Arch- Eur J Physiol, 440, pp. 653-666. 
 
Puddu, P., Puddu, G.M., Zaca, F. and Muscari, A. (2000) 'Endothelial dysfunction in 
hypertension', Acta Cardiol, 55(4), pp. 221-32. 
 
Pusceddu, I., Farrell, C.J., Di Pierro, A.M., Jani, E., Herrmann, W. and Herrmann, M. 
(2015) 'The role of telomeres and vitamin D in cellular aging and age-related diseases', Clin 
Chem Lab Med, 53(11), pp. 1661-78. 
 
Pushpakumar, S., Kundu, S. and Sen, U. (2014) 'Endothelial dysfunction: the link between 
homocysteine and hydrogen sulfide', Curr Med Chem, 21(32), pp. 3662-72. 
 
Putz-Bankuti, C., Pilz, S., Stojakovic, T., Scharnagl, H., Pieber, T.R., Trauner, M., 
Obermayer-Pietsch, B. and Stauber, R.E. (2012) 'Association of 25-hydroxyvitamin D 
 290 
 
levels with liver dysfunction and mortality in chronic liver disease', Liver Int, 32(5), pp. 
845-51. 
 
Pyke, K.E. and Tschakovsky, M.E. (2005) 'The relationship between shear stress and flow-
mediated dilatation: implications for the assessment of endothelial function', The Journal 
of Physiology, 568(Pt 2), pp. 357-369. 
 
Queisser, N. and Schupp, N. (2012) 'Aldosterone, oxidative stress, and NF-kappaB 
activation in hypertension-related cardiovascular and renal diseases', Free Radic Biol Med, 
53(2), pp. 314-27. 
Quyyumi, A.A. and Patel, R.S. (2010) 'Endothelial dysfunction and hypertension: cause or 
effect?', Hypertension, 55(5), pp. 1092-4. 
 
Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakthisekaran, D., Sethi, G. 
and Nishigaki, I. (2013) 'The Vascular Endothelium and Human Diseases', International 
Journal of Biological Sciences, 9(10), pp. 1057-1069. 
 
Rapoport, R.M. and Murad, F. (1983) 'Endothelium-dependent and nitrovasodilator-
induced relaxation of vascular smooth muscle: role of cyclic GMP', J Cyclic Nucleotide 
Protein Phosphor Res, 9(4-5), pp. 281-96. 
 
Rassaf, T., Feelisch, M. and Kelm, M. (2004) 'Circulating NO pool: assessment of nitrite 
and nitroso species in blood and tissues', Free Radic Biol Med, 36(4), pp. 413-22. 
 
Reis, J.P., von Muhlen, D., Kritz-Silverstein, D., Wingard, D.L. and Barrett-Connor, E. 
(2007) 'Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome 
in community-dwelling older adults', Diabetes Care, 30(6), pp. 1549-55. 
 
Rhodes, P.M., Leone, A.M., Francis, P.L., Struthers, A.D. and Moncada, S. (1995) 'The L-
Arginine: Nitric Oxide Pathway Is the Major Source of Plasma Nitrite in Fasted Humans', 
Biochemical and Biophysical Research Communications, 209(2), pp. 590-596. 
 
Ridker, P.M., Brown, N.J., Vaughan, D.E., Harrison, D.G. and Mehta, J.L. (2004) 
'Established and emerging plasma biomarkers in the prediction of first atherothrombotic 
events', Circulation, 109(25 Suppl 1), pp. Iv6-19. 
 
Rockett, K.A., Brookes, R., Udalova, I., Vidal, V., Hill, A.V. and Kwiatkowski, D. (1998) 
'1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of 
Mycobacterium tuberculosis in a human macrophage-like cell line', Infect Immun, 66(11), 
pp. 5314-21. 
 
Rodríguez-Rodríguez, E., Navia, B., López-Sobaler, A.M. and Ortega, R.M. (2009) 
'Vitamin D in Overweight/Obese Women and Its Relationship With Dietetic and 
Anthropometric Variables', Obesity, 17(4), pp. 778-782. 
 
Rodríguez, A.J., Scott, D., Srikanth, V. and Ebeling, P. (2016) 'Effect of vitamin D 
supplementation on measures of arterial stiffness: a systematic review and meta-analysis 
of randomized controlled trials', Clinical Endocrinology, 84(5), pp. 645-657. 
 
 291 
 
Romitelli, F., Santini, S.A., Chierici, E., Pitocco, D., Tavazzi, B., Amorini, A.M., 
Lazzarino, G. and Di Stasio, E. (2007) 'Comparison of nitrite/nitrate concentration in 
human plasma and serum samples measured by the enzymatic batch Griess assay, ion-
pairing HPLC and ion-trap GC-MS: the importance of a correct removal of proteins in the 
Griess assay', J Chromatogr B Analyt Technol Biomed Life Sci, 851(1-2), pp. 257-67. 
 
Rosenfeld, M.E. (2013) 'Inflammation and atherosclerosis: direct versus indirect 
mechanisms', Curr Opin Pharmacol, 13(2), pp. 154-60. 
 
Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., Durazo-
Arvizu, R.A., Gallagher, J.C., Gallo, R.L., Jones, G., Kovacs, C.S., Mayne, S.T., Rosen, 
C.J. and Shapses, S.A. (2011) 'The 2011 Report on Dietary Reference Intakes for Calcium 
and Vitamin D from the Institute of Medicine: What Clinicians Need to Know', The Journal 
of Clinical Endocrinology and Metabolism, 96(1), pp. 53-58. 
 
Rueda, S., Fernández-Fernández, C., Romero, F., Martínez de Osaba, M.J. and Vidal, J. 
(2008) 'Vitamin D, PTH, and the Metabolic Syndrome in Severely Obese Subjects', Obesity 
Surgery, 18(2), pp. 151-154. 
 
Ruggiero, M. and Pacini, S. (2009) 'Chronic kidney disease and vitamin D: how much is 
adequate?', Kidney Int, 76(9), pp. 931-3. 
 
Rybalkin, S.D., Yan, C., Bornfeldt, K.E. and Beavo, J.A. (2003) 'Cyclic GMP 
Phosphodiesterases and Regulation of Smooth Muscle Function', Circulation Research, 
93(4), pp. 280-291. 
 
SACN (2016) 'Scientific Advisory Committee of Nutrition (SACN) - Vitamin D and 
Health'. 
 
Sakhi, A.K., Bastani, N.E., Ellingjord-Dale, M., Gundersen, T.E., Blomhoff, R. and Ursin, 
G. (2015) 'Feasibility of self-sampled dried blood spot and saliva samples sent by mail in a 
population-based study', BMC Cancer, 15, p. 265. 
 
Sakinis, A., Jungersten, L. and Wennmalm, Å. (1999) 'An 18oxygen inhalation method for 
determination of total body formation of nitric oxide in humans', Clinical Physiology, 
19(6), pp. 504-509. 
 
Samuel, L. and Borrell, L.N. (2013) 'The effect of body mass index on optimal vitamin D 
status in U.S. adults: The National Health and Nutrition Examination Survey 2001–2006', 
Annals of Epidemiology, 23(7), pp. 409-414. 
 
Šantak, B., Radermacher, P., Iber, T., Adler, J., Wachter, U., Vassilev, D., Georgieff, M. 
and Vogt, J. (1997) 'In vivo quantification of endotoxin-induced nitric oxide production in 
pigs from Na15NO3-infusion', British Journal of Pharmacology, 122(8), pp. 1605-1610. 
 
Schächinger, V., Britten, M.B. and Zeiher, A.M. (2000) 'Prognostic Impact of Coronary 
Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease', 
Circulation, 101(16), pp. 1899-1906. 
 
 292 
 
Schoenenberger, A.W., Urbanek, N., Bergner, M., Toggweiler, S., Resink, T.J. and Erne, 
P. (2012) 'Associations of reactive hyperemia index and intravascular ultrasound-assessed 
coronary plaque morphology in patients with coronary artery disease', Am J Cardiol, 
109(12), pp. 1711-6. 
 
Schoenmakers, I., Gousias, P., Jones, K.S. and Prentice, A. (2016) 'Prediction of winter 
vitamin D status and requirements in the UK population based on 25(OH) vitamin D half-
life and dietary intake data', The Journal of Steroid Biochemistry and Molecular Biology, 
164, pp. 218-222. 
 
Schulz, E., Gori, T. and Munzel, T. (2011) 'Oxidative stress and endothelial dysfunction in 
hypertension', Hypertens Res, 34(6), pp. 665-73. 
Scragg, R., Sowers, M. and Bell, C. (2007) 'Serum 25-hydroxyvitamin D, ethnicity, and 
blood pressure in the Third National Health and Nutrition Examination Survey', Am J 
Hypertens, 20(7), pp. 713-9. 
 
Seals, D.R., Jablonski, K.L. and Donato, A.J. (2011) 'Aging and vascular endothelial 
function in humans', Clinical science (London, England : 1979), 120(9), pp. 357-375. 
 
Sena, C.M., Pereira, A.M. and Seica, R. (2013) 'Endothelial dysfunction - A major mediator 
of diabetic vascular disease', Biochim Biophys Acta, 1832(12), pp. 2216-31. 
 
Sena, L.A. and Chandel, N.S. (2012) 'Physiological roles of mitochondrial reactive oxygen 
species', Molecular cell, 48(2), pp. 158-167. 
 
Sharwood-Smith, G., Bruce, J. and Drummond, G. (2006) 'Assessment of pulse transit time 
to indicate cardiovascular changes during obstetric spinal anaesthesia†', BJA: British 
Journal of Anaesthesia, 96(1), pp. 100-105. 
 
Shibuya, M. (2011) 'Vascular Endothelial Growth Factor (VEGF) and Its Receptor 
(VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic 
Therapies', Genes & Cancer, 2(12), pp. 1097-1105. 
 
Shimokawa, H. (2000) 'Clinical Assessment of Endothelial Function', Japanese 
Circulation Society. 
 
Sibal, L., Agarwal, S.C., Home, P.D. and Boger, R.H. (2010) 'The Role of Asymmetric 
Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease', 
Current Cardiology Reviews, 6(2), pp. 82-90. 
 
Siervo, M., Corander, M., Stranges, S. and Bluck, L. (2011a) 'Post-challenge 
hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of 
asymmetric dimethylarginine (ADMA)', Nutr Metab Cardiovasc Dis, 21(1), pp. 1-10. 
 
Siervo, M., Jackson, S.J. and Bluck, L.J. (2011b) 'In-vivo nitric oxide synthesis is reduced 
in obese patients with metabolic syndrome: application of a novel stable isotopic method', 
J Hypertens, 29(8), pp. 1515-27. 
 
 293 
 
Siervo, M., Stephan, B.C.M., Feelisch, M. and Bluck, L.J.C. (2011c) 'Measurement of in 
vivo nitric oxide synthesis in humans using stable isotopic methods: a systematic review', 
Free Radical Biology and Medicine, 51(4), pp. 795-804. 
 
Sindler, A.L., DeVan, A.E., Fleenor, B.S. and Seals, D.R. (2014) 'Inorganic nitrite 
supplementation for healthy arterial aging', Journal of Applied Physiology, 116(5), pp. 463-
477. 
 
Smithers, G., Gregory, J.R., Bates, C.J., Prentice, A., Jackson, L.V. and Wenlock, R. (2000) 
'The National Diet and Nutrition Survey: young people aged 4–18 years', Nutrition Bulletin, 
25(2), pp. 105-111. 
 
Smolenski, A., Poller, W., Walter, U. and Lohmann, S.M. (2000) 'Regulation of Human 
Endothelial Cell Focal Adhesion Sites and Migration by cGMP-dependent Protein Kinase 
I', Journal of Biological Chemistry, 275(33), pp. 25723-25732. 
 
Snijder, M.B., Lips, P., Seidell, J.C., Visser, M., Deeg, D.J., Dekker, J.M. and van Dam, 
R.M. (2007) 'Vitamin D status and parathyroid hormone levels in relation to blood pressure: 
a population-based study in older men and women', J Intern Med, 261(6), pp. 558-65. 
 
Snijder, M.B., van Dam, R.M., Visser, M., Deeg, D.J., Dekker, J.M., Bouter, L.M., Seidell, 
J.C. and Lips, P. (2005) 'Adiposity in relation to vitamin D status and parathyroid hormone 
levels: a population-based study in older men and women', J Clin Endocrinol Metab, 90(7), 
pp. 4119-23. 
 
Sokol, S.I., Srinivas, V., Crandall, J.P., Kim, M., Tellides, G., Lebastchi, A., Yu, Y., Gupta, 
A.K. and Alderman, M.H. (2012) 'The effects of vitamin D repletion on endothelial 
function and inflammation in patients with coronary artery disease', Vascular Medicine 
(United Kingdom), 17(6), pp. 394-404. 
 
Sollid, S.T., Hutchinson, M.Y.S., Fuskevåg, O.M., Figenschau, Y., Joakimsen, R.M., 
Schirmer, H., Njølstad, I., Svartberg, J., Kamycheva, E. and Jorde, R. (2014) 'No Effect of 
High-Dose Vitamin D Supplementation on Glycemic Status or Cardiovascular Risk Factors 
in Subjects With Prediabetes', Diabetes Care. 
 
Somjen, D., Kohen, F., Amir-Zaltsman, Y., Knoll, E. and Stern, N. (2000) 'Vitamin D 
analogs modulate the action of gonadal steroids in human vascular cells in vitro', American 
Journal of Hypertension, 13(4 Pt 1), pp. 396-403. 
 
Song, Y., Wang, L., Pittas, A.G., Del Gobbo, L.C., Zhang, C., Manson, J.E. and Hu, F.B. 
(2013) 'Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis 
of prospective studies', Diabetes Care, 36(5), pp. 1422-8. 
 
Spiro, A. and Buttriss, J.L. (2014) 'Vitamin D: An overview of vitamin D status and intake 
in Europe', Nutrition Bulletin / Bnf, 39(4), pp. 322-350. 
 
Springbett, P., Buglass, S. and Young, A.R. (2010) 'Photoprotection and vitamin D status', 
J Photochem Photobiol B, 101(2), pp. 160-8. 
 
 294 
 
Stojanovic, M. and Radenkovic, M. (2015) 'Vitamin D versus placebo in improvement of 
endothelial dysfunction: a meta-analysis of randomized clinical trials', Cardiovasc Ther, 
33(3), pp. 145-54. 
 
Strasser, B., Arvandi, M., Pasha, E.P., Haley, A.P., Stanforth, P. and Tanaka, H. (2015) 
'Abdominal obesity is associated with arterial stiffness in middle-aged adults', Nutrition, 
Metabolism and Cardiovascular Diseases, 25(5), pp. 495-502. 
 
Stricker, H., Tosi Bianda, F., Guidicelli-Nicolosi, S., Limoni, C. and Colucci, G. (2012) 
'Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in 
patients with peripheral arterial disease: a randomised controlled pilot study', European 
Journal of Vascular & Endovascular Surgery, 44(3), pp. 307-12. 
 
Stuehr, D., Pou, S. and Rosen, G.M. (2001) 'Oxygen reduction by nitric-oxide synthases', 
J Biol Chem, 276(18), pp. 14533-6. 
 
Sugden, J.A., Davies, J.I., Witham, M.D., Morris, A.D. and Struthers, A.D. (2008) 'Vitamin 
D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin 
D levels', Diabet Med, 25(3), pp. 320-5. 
 
Sumpio, B.E., Riley, J.T. and Dardik, A. (2002) 'Cells in focus: endothelial cell', Int J 
Biochem Cell Biol, 34(12), pp. 1508-12. 
 
Surks, H.K. (2007) 'cGMP-Dependent Protein Kinase I and Smooth Muscle Relaxation', A 
Tale of Two Isoforms, 101(11), pp. 1078-1080. 
 
Sutton-Tyrrell, K., Mackey, R.H., Holubkov, R., Vaitkevicius, P.V., Spurgeon, H.A. and 
Lakatta, E.G. (2001) 'Measurement variation of aortic pulse wave velocity in the elderly', 
American Journal of Hypertension, 14(5), pp. 463-468. 
 
Sydow, K. and Böger, R.H. (2012) 'Reloaded: ADMA and oxidative stress are responsible 
for endothelial dysfunction in hyperhomocyst(e)inaemia: effects of l-arginine and B 
vitaminsAUTHORS' RETROSPECTIVE', Cardiovascular Research, 96(2), pp. 167-171. 
 
Syvänen, K., Korhonen, P., Partanen, A. and Aarnio, P. (2011) 'Endothelial function in a 
cardiovascular risk population with borderline ankle–brachial index', Vascular Health and 
Risk Management, 7, pp. 97-101. 
 
Talaei, A., Mohamadi, M. and Adgi, Z. (2013) 'The effect of vitamin D on insulin resistance 
in patients with type 2 diabetes', Diabetology & Metabolic Syndrome, 5(1), p. 8. 
 
Tang, E.H. and Vanhoutte, P.M. (2010) 'Endothelial dysfunction: a strategic target in the 
treatment of hypertension?', Pflugers Arch, 459(6), pp. 995-1004. 
 
Tarcin, O., Yavuz, D.G., Ozben, B., Telli, A., Ogunc, A.V., Yuksel, M., Toprak, A., Yazici, 
D., Sancak, S., Deyneli, O. and Akalin, S. (2009) 'Effect of vitamin D deficiency and 
replacement on endothelial function in asymptomatic subjects', J Clin Endocrinol Metab, 
94(10), pp. 4023-30. 
 
 295 
 
Teixeira, B.C., Lopes, A.L., Macedo, R.C.O., Correa, C.S., Ramis, T.R., Ribeiro, J.L. and 
Reischak-Oliveira, A. (2014) 'Inflammatory markers, endothelial function and 
cardiovascular risk', Jornal Vascular Brasileiro, 13, pp. 108-115. 
 
Theodoratou, E., Tzoulaki, I., Zgaga, L. and Ioannidis, J.P.A. (2014) 'Vitamin D and 
multiple health outcomes: umbrella review of systematic reviews and meta-analyses of 
observational studies and randomised trials', BMJ : British Medical Journal, 348. 
 
Toda, N. and Okamura, T. (2013) 'Obesity impairs vasodilatation and blood flow increase 
mediated by endothelial nitric oxide: An overview', J Clin Pharmacol, 53(12), pp. 1228-
39. 
Toda, N. and Toda, H. (2010) 'Nitric oxide-mediated blood flow regulation as affected by 
smoking and nicotine', Eur J Pharmacol, 649(1-3), pp. 1-13. 
Toprakçı, M., Özmen, D., Mutaf, I., Turgan, N., Parıldar, Z., Habif, S., Güner, İ. and 
Bayındır, O. (2000) 'Age-associated changes in nitric oxide metabolites nitrite and nitrate', 
International Journal of Clinical and Laboratory Research, 30(2), p. 83. 
 
Tousoulis, D., Antoniades, C. and Stefanadis, C. (2005) 'Evaluating endothelial function in 
humans: a guide to invasive and non-invasive techniques', Heart, 91(4), pp. 553-558. 
 
Tousoulis, D., Davies, G., Crake, T., Lerman, A., Hasdai, D. and Holmes, D. (1998) 
'Acetylcholine and endothelial function', Circulation, 98(15), pp. 1587a-1590. 
 
Tousoulis, D., Kampoli, A.M., Tentolouris, C., Papageorgiou, N. and Stefanadis, C. (2012) 
'The role of nitric oxide on endothelial function', Curr Vasc Pharmacol, 10(1), pp. 4-18. 
 
Tripkovic, L. (2013) 'Vitamin D2 vs. vitamin D3: Are they one and the same?', Nutrition 
Bulletin, 38(2), pp. 243-248. 
 
Tripkovic, L., Lambert, H., Hart, K., Smith, C.P., Bucca, G., Penson, S., Chope, G., 
Hyppönen, E., Berry, J., Vieth, R. and Lanham-New, S. (2012) 'Comparison of vitamin 
D(2) and vitamin D(3) supplementation in raising serum 25-hydroxyvitamin D status: a 
systematic review and meta-analysis', The American Journal of Clinical Nutrition, 95(6), 
pp. 1357-1364. 
Trochoutsou, A.I., Kloukina, V., Samitas, K. and Xanthou, G. (2015) 'Vitamin-D in the 
Immune System: Genomic and Non-Genomic Actions', Mini Rev Med Chem, 15(11), pp. 
953-63. 
 
Tsikas, D. (2005a) 'Methods of quantitative analysis of the nitric oxide metabolites nitrite 
and nitrate in human biological fluids', Free Radic Res, 39(8), pp. 797-815. 
 
Tsikas, D. (2005b) 'ReviewMethods of quantitative analysis of the nitric oxide metabolites 
nitrite and nitrate in human biological fluids', Free Radical Research, 39(8), pp. 797-815. 
 
Tsikas, D. (2007) 'Analysis of nitrite and nitrate in biological fluids by assays based on the 
Griess reaction: Appraisal of the Griess reaction in the l-arginine/nitric oxide area of 
research', Journal of Chromatography B, 851(1–2), pp. 51-70. 
 
Tsikas, D., Fuchs, I., Gutzki, F.M. and Frolich, J.C. (1998) 'Measurement of nitrite and 
nitrate in plasma, serum and urine of humans by high-performance liquid chromatography, 
 296 
 
the Griess assay, chemiluminescence and gas chromatography-mass spectrometry: 
interferences by biogenic amines and N(G)-nitro-L-arginine analogs', J Chromatogr B 
Biomed Sci Appl, 715(2), pp. 441-4; discussion 445-8. 
 
Tsikas, D., Gutzki, F.M., Rossa, S., Bauer, H., Neumann, C., Dockendorff, K., Sandmann, 
J. and Frolich, J.C. (1997) 'Measurement of nitrite and nitrate in biological fluids by gas 
chromatography-mass spectrometry and by the Griess assay: problems with the Griess 
assay--solutions by gas chromatography-mass spectrometry', Anal Biochem, 244(2), pp. 
208-20. 
 
Tsikas, D., Sandmann, J., Savva, A., Lueßen, P., Böger, R.H., Gutzki, F.-M., Mayer, B. 
and Frölich, J.C. (2000) 'Assessment of nitric oxide synthase activity in vitro and in vivo 
by gas chromatography–mass spectrometry', Journal of Chromatography B: Biomedical 
Sciences and Applications, 742(1), pp. 143-153. 
 
UK Department of Health (1998) 'Dietary Reference Values for food energy and nutrients 
for the United Kingdom. Report of the Panel on Dietary Reference Values of the Committee 
on Medical Aspects of Food Policy. Report on Health and Social Subjects 41'. 
 
Vaidya, A. and Forman, J.P. (2012) 'Vitamin D and Vascular Disease: The Current and 
Future Status of Vitamin D Therapy in Hypertension and Kidney Disease', Current 
hypertension reports, 14(2), pp. 111-119 
. 
Valiña-Tóth, A.L., Lai, Z., Zhang, S. and Flack, J.M. (2012) 'Vitamin D and Parathyroid 
Hormone Relationships with Urinary Nitric Oxide Metabolites and Plasma Isoprostanes in 
African-Americans', Cardiorenal Medicine, 2(3), pp. 234-242. 
 
Vallance, P. and Leiper, J. (2004) 'Cardiovascular biology of the asymmetric 
dimethylarginine:dimethylarginine dimethylaminohydrolase pathway', Arterioscler 
Thromb Vasc Biol, 24(6), pp. 1023-30. 
 
Vallance, P., Patton, S., Bhagat, K., MacAllister, R., Radomski, M., Moncada, S. and 
Malinski, T. (1995) 'Direct measurement of nitric oxide in human beings', Lancet, 
346(8968), pp. 153-4. 
 
van den Ouweland, J.M.W. (2016) 'Analysis of vitamin D metabolites by liquid 
chromatography-tandem mass spectrometry', TrAC Trends in Analytical Chemistry, 84, pp. 
117-130. 
 
van Eijk, H.M.H., Luiking, Y.C. and Deutz, N.E.P. (2007) 'Methods using stable isotopes 
to measure nitric oxide (NO) synthesis in the l-arginine/NO pathway in health and disease', 
Journal of Chromatography B, 851(1–2), pp. 172-185. 
 
Vanhoutte, P.M., Shimokawa, H., Tang, E.H. and Feletou, M. (2009) 'Endothelial 
dysfunction and vascular disease', Acta Physiol (Oxf), 196(2), pp. 193-222. 
 
Vilarrasa, N., Maravall, J., Estepa, A., Sanchez, R., Masdevall, C., Navarro, M.A., Alia, P., 
Soler, J. and Gomez, J.M. (2007) 'Low 25-hydroxyvitamin D concentrations in obese 
women: their clinical significance and relationship with anthropometric and body 
composition variables', J Endocrinol Invest, 30(8), pp. 653-8. 
 297 
 
 
Virdis, A., Ghiadoni, L., Cardinal, H., Favilla, S., Duranti, P., Birindelli, R., Magagna, A., 
Bernini, G., Salvetti, G., Taddei, S. and Salvetti, A. (2001) 'Mechanisms responsible for 
endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects 
and patients with essential hypertension', J Am Coll Cardiol, 38(4), pp. 1106-15. 
 
von Hurst, P.R., Stonehouse, W. and Coad, J. (2010) 'Vitamin D supplementation reduces 
insulin resistance in South Asian women living in New Zealand who are insulin resistant 
and vitamin D deficient - a randomised, placebo-controlled trial', Br J Nutr, 103(4), pp. 
549-55. 
 
Wagner, C.L. and Greer, F.R. (2008) 'Prevention of Rickets and Vitamin D Deficiency in 
Infants, Children, and Adolescents', Pediatrics, 122(5), pp. 1142-1152. 
 
Wagner, D., Hanwell, H.E.C. and Vieth, R. (2009) 'An evaluation of automated methods 
for measurement of serum 25-hydroxyvitamin D', Clinical Biochemistry, 42(15), pp. 1549-
1556. 
Wahl, D.A., Cooper, C., Ebeling, P.R., Eggersdorfer, M., Hilger, J., Hoffmann, K., Josse, 
R., Kanis, J.A., Mithal, A., Pierroz, D.D., Stenmark, J., Stöcklin, E. and Dawson-Hughes, 
B. (2012) 'A global representation of vitamin D status in healthy populations', Archives of 
Osteoporosis, 7(1), pp. 155-172. 
 
Walsh, J.S., Evans, A.L., Bowles, S., Naylor, K.E. and Jones, K.S. (2016) 'Free 25-
hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health', 
103(6), pp. 1465-71. 
 
Wang, L., Ma, J., Manson, J.E., Buring, J.E., Gaziano, J.M. and Sesso, H.D. (2013) 'A 
prospective study of plasma vitamin D metabolites, vitamin D receptor gene 
polymorphisms, and risk of hypertension in men', European Journal of Nutrition, 52(7), 
pp. 1771-1779. 
 
Wang, L., Manson, J.E., Song, Y. and Sesso, H.D. (2010) 'Systematic review: Vitamin D 
and calcium supplementation in prevention of cardiovascular events', Ann Intern Med, 
152(5), pp. 315-23. 
 
Wang, T.J., Pencina, M.J., Booth, S.L., Jacques, P.F., Ingelsson, E., Lanier, K., Benjamin, 
E.J., D’Agostino, R.B., Wolf, M. and Vasan, R.S. (2008) 'Vitamin D Deficiency and Risk 
of Cardiovascular Disease', Circulation, 117(4), pp. 503-511. 
 
Wanner, M., Richard, A., Martin, B., Linseisen, J. and Rohrmann, S. (2015) 'Associations 
between objective and self-reported physical activity and vitamin D serum levels in the US 
population', Cancer Causes & Control, 26(6), pp. 881-891. 
 
Webb, L.K., and M.F. Holick, (2009) 'Influence of Season and Latitude on the Cutaneous 
Synthesis of Vitamin D3: Exposure to Winter Sunlight in Boston and Edmonton Will Not 
Promote Vitamin D3 Synthesis in Human Skin - See more at: 
http://press.endocrine.org/doi/abs/10.1210/jcem-67-2-373#sthash.PbMDcO1O.dpuf', The 
Journal of Endocrinology and Metabolism, 67(2), pp. 373-378. 
 
 298 
 
Weber, C. and Noels, H. (2011) 'Atherosclerosis: current pathogenesis and therapeutic 
options', Nat Med, 17(11), pp. 1410-22. 
 
Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L. and Ferrante, A.W. 
(2003) 'Obesity is associated with macrophage accumulation in adipose tissue', Journal of 
Clinical Investigation, 112(12), pp. 1796-1808. 
 
Whayne, T.F. (2011) 'Atherosclerosis: Current status of prevention and treatment', 
International Journal of Angiology, 20(4), pp. 213-222. 
 
Widmer, R.J. and Lerman, A. (2014) 'Endothelial dysfunction and cardiovascular disease', 
Global Cardiology Science & Practice, 2014(3), pp. 291-308. 
 
Wilkinson, I.B., Fuchs, S.A., Jansen, I.M., Spratt, J.C., Murray, G.D., Cockcroft, J.R. and 
Webb, D.J. (1998) 'Reproducibility of pulse wave velocity and augmentation index 
measured by pulse wave analysis', Journal of Hypertension, 16(12), pp. 2079-2084. 
 
Wilkinson, I.B., Hall, I.R., MacCallum, H., Mackenzie, I.S., McEniery, C.M., van der 
Arend, B.J., Shu, Y.E., MacKay, L.S., Webb, D.J. and Cockcroft, J.R. (2002) 'Pulse-wave 
analysis: clinical evaluation of a noninvasive, widely applicable method for assessing 
endothelial function', Arterioscler Thromb Vasc Biol, 22(1), pp. 147-52. 
 
Wilkinson, I.B. and Webb, D.J. (2001) 'Venous occlusion plethysmography in 
cardiovascular research: methodology and clinical applications', British Journal of Clinical 
Pharmacology, 52(6), pp. 631-646. 
 
Williams, D.M., Fraser, A. and Lawlor, D.A. (2011) 'Associations of vitamin D, 
parathyroid hormone and calcium with cardiovascular risk factors in US adolescents', 
Heart, 97(4), pp. 315-320. 
 
Williams, S., Malatesta, K. and Norris, K. (2009) 'Vitamin D and Chronic Kidney Disease', 
Ethnicity & disease, 19(4 Suppl 5), pp. S5-8-11. 
 
Wilson, P.W.F. (2004) 'The epidemiology of atherosclerotic disease', in Loscalzo, J. (ed.) 
Molecular Mechanisms of Atherosclerosis. London: Taylor & Francis. 
 
Witham, M.D., Adams, F., Kabir, G., Kennedy, G., Belch, J.J. and Khan, F. (2013a) 'Effect 
of short-term vitamin D supplementation on markers of vascular health in South Asian 
women living in the UK--a randomised controlled trial', Atherosclerosis, 230(2), pp. 293-
9. 
 
Witham, M.D., Adams, F., McSwiggan, S., Kennedy, G., Kabir, G., Belch, J.J.F. and Khan, 
F. (2015) 'Effect of intermittent vitamin D3 on vascular function and symptoms in chronic 
fatigue syndrome – A randomised controlled trial', Nutrition, Metabolism and 
Cardiovascular Diseases, 25(3), pp. 287-294. 
 
Witham, M.D., Dove, F.J., Dryburgh, M., Sugden, J.A., Morris, A.D. and Struthers, A.D. 
(2010) 'The effect of different doses of vitamin D(3) on markers of vascular health in 
patients with type 2 diabetes: a randomised controlled trial', Diabetologia, 53(10), pp. 
2112-9. 
 299 
 
 
Witham, M.D., Dove, F.J., Khan, F., Lang, C.C., Belch, J.J. and Struthers, A.D. (2013b) 
'Effects of vitamin D supplementation on markers of vascular function after myocardial 
infarction--a randomised controlled trial', International Journal of Cardiology, 167(3), pp. 
745-9. 
 
Witham, M.D., Dove, F.J., Sugden, J.A., Doney, A.S. and Struthers, A.D. (2012) 'The 
effect of vitamin D replacement on markers of vascular health in stroke patients - a 
randomised controlled trial', Nutrition Metabolism & Cardiovascular Diseases, 22(10), pp. 
864-70. 
 
Witham, M.D., Price, R.J., Struthers, A.D., Donnan, P.T., Messow, C.M., Ford, I. and 
McMurdo, M.E. (2013c) 'Cholecalciferol treatment to reduce blood pressure in older 
patients with isolated systolic hypertension: the VitDISH randomized controlled trial', 
JAMA Internal Medicine, 173(18), pp. 1672-9. 
 
World Health Organization (2016a) 'Global Atlas on Cardiovaascular Disease Prevention 
and Control'. 
 
World Health Organization (2016b) 'WHO Fact Sheet: Cardiovascular diseases (CVDs)'. 
 
Worrall, D.S. and Olefsky, J.M. (2002) 'The effects of intracellular calcium depletion on 
insulin signaling in 3T3-L1 adipocytes', Mol Endocrinol, 16(2), pp. 378-89. 
 
Wortsman, J., Matsuoka, L.Y., Chen, T.C., Lu, Z. and Holick, M.F. (2000) 'Decreased 
bioavailability of vitamin D in obesity', The American Journal of Clinical Nutrition, 72(3), 
pp. 690-693. 
 
Wu, S.H., Ho, S.C. and Zhong, L. (2010) 'Effects of vitamin D supplementation on blood 
pressure', Southern Medical Journal, 103(8), pp. 729-737. 
 
Yilmaz, M.I., Sonmez, A., Saglam, M., Qureshi, A.R., Carrero, J.J., Caglar, K., Eyileten, 
T., Cakir, E., Oguz, Y., Vural, A., Yenicesu, M., Lindholm, B., Stenvinkel, P. and 
Axelsson, J. (2008) 'ADMA Levels Correlate with Proteinuria, Secondary Amyloidosis, 
and Endothelial Dysfunction', Journal of the American Society of Nephrology : JASN, 
19(2), pp. 388-395. 
 
Yiu, Y.F., Chan, Y.H., Yiu, K.H., Siu, C.W., Li, S.W., Wong, L.Y., Lee, S.W., Tam, S., 
Wong, E.W., Cheung, B.M. and Tse, H.F. (2011) 'Vitamin D deficiency is associated with 
depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients 
with type 2 diabetes', J Clin Endocrinol Metab, 96(5), pp. E830-5. 
 
Yiu, Y.F., Yiu, K.H., Siu, C.W., Chan, Y.H., Li, S.W., Wong, L.Y., Lee, S.W.L., Tam, S., 
Wong, E.W.K., Lau, C.P., Cheung, B.M.Y. and Tse, H.F. (2013) 'Randomized controlled 
trial of vitamin D supplement on endothelial function in patients with type 2 diabetes', 
Atherosclerosis, 227(1), pp. 140-146. 
 
Yudkin, J.S., Stehouwer, C.D., Emeis, J.J. and Coppack, S.W. (1999) 'C-reactive protein 
in healthy subjects: associations with obesity, insulin resistance, and endothelial 
 300 
 
dysfunction: a potential role for cytokines originating from adipose tissue?', Arterioscler 
Thromb Vasc Biol, 19(4), pp. 972-8. 
 
Zhong, W., Gu, B., Gu, Y., Groome, L.J., Sun, J. and Wang, Y. (2014) 'Activation of 
vitamin D receptor promotes VEGF and CuZn-SOD expression in endothelial cells', J 
Steroid Biochem Mol Biol, 140, pp. 56-62. 
 
Zhou, C., Lu, F., Cao, K., Xu, D., Goltzman, D. and Miao, D. (2008) 'Calcium-independent 
and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-
hydroxylase knockout mice', Kidney Int, 74(2), pp. 170-9. 
 
Zittermann, A., Frisch, S., Berthold, H.K., Gotting, C., Kuhn, J., Kleesiek, K., Stehle, P., 
Koertke, H. and Koerfer, R. (2009) 'Vitamin D supplementation enhances the beneficial 
effects of weight loss on cardiovascular disease risk markers', Am J Clin Nutr, 89(5), pp. 
1321-7. 
 
